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I. Abstract 
It is now accepted that there is a link between obesity and several diseases such 
as cardiovascular disease (CVD), diabetes, rheumatoid arthritis (RA), and 
atherosclerosis with the common initiating factor in pathogenesis being a state 
of low grade, chronic inflammation.  This state, characterised by elevated levels 
of pro-inflammatory cytokines such as interleukin (IL) 6, leads to sustained 
activation of inflammatory signalling pathways such as the Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) pathway and 
subsequently pathogenesis. Suppressor of cytokine signalling (SOCS) 3 is 
inducible by several stimuli including IL6 and 3'-5'-cyclic adenosine 
monophosphate (cAMP), and via these routes has been demonstrated to 
terminate IL6 signalling thus quenching JAK/STAT signalling and an inflammatory 
response.  
 
While SOCS3 was primarily characterised as a competitive inhibitor of 
intracellular signalling, it also functions as specificity factor for an elongin-
cullin-SOCS (ECS)-type E3 ubiquitin ligase. In this role, it has been demonstrated 
to direct ubiquitin-mediated proteasomal degradation of several substrates and 
lysosomal routing. However, the full spectrum of SOCS3-dependently 
ubiquitinated substrates is unknown. Given that JAK/STAT signalling is critical in 
the development of chronic inflammatory disorders, delineating the role of 
SOCS3 as an E3 ligase might be therapeutically beneficial.  However, given the 
broad range of SOCS3 stimuli, the availability of certain SOCS3 substrates might 
be conditional on the route of SOCS3 induction. Using a global proteomics 
approach, this study aimed to identify SOCS3-dependently ubiquitinated 
substrates in response to cAMP and thus elaborate on the already well-
established role of cAMP in inflammation.   
 
Differentially stable isotope labelling of amino acids in cell culture (SILAC)-
labelled, tandem affinity purified ubiquitinomes of wild type (WT) murine 
embryonic fibroblasts (MEFs) and SOCS3-/- MEFs, each expressing epitope-tagged 
forms of ubiquitin, were compared using mass spectrometry (MS) following 
cAMP-mediated SOCS3 induction. Using this approach, proteins modified by 
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SOCS3 with the epitope-tagged form of ubiquitin should be enriched in WT MEFs 
but not SOCS3-/- MEFs.  
 
MaxQuant analysis of raw mass spectromeric data identified several candidate 
SOCS3 substrates. Of these, SOCS3 was found to interact with PTRF/cavin-1, a 
regulator of caveolae formation and stability. Other substrates were tested but 
with limited success. Co-immunoprecipitation studies showed that SOCS3 could 
precipitate cavin-1 however the interaction was reduced following the inhibition 
of protein tyrosine phosphatases (PTPs) using sodium orthovanadate and 
hydrogen peroxide. This was surprising since all known SOCS3 substrates are 
tyrosine-phosphorylated prior to interacting with SOCS3 via its Src-homology (SH) 
2 domain. Consistent with this finding, SOCS3 did not interact with known cavin-
1 tyrosine-phosphorylated peptides spotted on a peptide array. However, a full-
length cavin-1 peptide array spotted with non-tyrosine-phosphorylated peptides 
showed specific interactions at multiple sites. It is proposed that this interaction 
might influence the localisation and stability of either protein.    
 
While SOCS3 was demonstrated to impact cavin-1 ubiquitination, the mechanism 
by which it does so or the functional consequence is still not clear. 
Immunoprecipitation of cavin-1 following the introduction of SOCS3 was 
accompanied by a shift in the polyubiquitin signal from a high molecular weight, 
seen with cavin-1 alone, to a low molecular weight. Furthermore, an enhanced 
K48-polyubiquitin signal was detectable in this low molecular weight fraction, 
which was focused around the molecular weight of cavin-1. It is not known if this 
ubiquitin signal is SOCS3-dependent.    
 
In conclusion, the project has identified and validated a novel substrate of 
SOCS3. However, the mechanism by which SOCS3 regulates cavin-1 
ubiquitination or the biological function of the interaction is currently unknown.  
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1.0 Introduction 
Spiralling levels of obesity has seen a concomitant increase in the cases of 
inflammatory-related diseases (1). The common initiating factor is a state of low 
grade, chronic inflammation induced by the elevated secretion of adipocytokines 
and the subsequent infiltration, into fat tissue, of immune cells that amplify and 
sustain the effect (2-4).  Metabolic and immune systems have a complex 
relationship being linked by array of pleiotropic signalling molecules. While 
many adipocytokines might be classified as either protective e.g. adiponectin or 
damaging e.g. IL6, it is more likely that a balance is necessary for homeostasis. 
As such, an imbalance created by increased adiposity may result in a local and 
systemic response leading to the progressive development of several disorders. 
Adipocytokines up-regulated in obesity such as IL6 (5) can elicit cell and tissue 
specific responses through activating common intracellular signalling pathways 
i.e. the JAK/STAT pathway (6). Furthermore, activation of this pathway by 
multiple stimuli is critical in the development of CVD (7). Therefore, 
understanding this basic signalling unit and the complex milieu of cell-specific 
crosstalk may enable specific targeting for therapeutic benefit.  
 
Here, I will introduce the immune system and the interplay between it and the 
metabolic system, which can result in pathogenesis. I will then introduce the 
JAK/STAT pathway, its regulation, and consequences of dysregulation. Moreover, 
I will show how understanding of the negative regulation of the JAK/STAT 
pathway might be therapeutically beneficial. I aim to show that by targeting 
SOCS3, a specificity factor for an E3 ubiquitin ligase, it might be possible to 
elicit a precise response. While several ubiquitinated substrates of SOCS3 are 
known (8-12), the full spectrum has yet to be identified. As such, I aim to 
introduce an experimental rational for identifying SOCS3-dependently 
ubiquitinated substrates. By doing so, it may be possible to therapeutically 
target specific events while reducing adverse effects.        
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1.1 Project basis: the immune system and disease  
1.1.1 The immune system and endothelial cell activation 
Multicellular organisms are constantly exposed to a wide variety of pathogens 
and foreign particles but evade infection via inflammation initiated by the 
innate immune system. A tightly coordinated system of fast-acting response 
combined with a slower, long-term response provides an efficient mechanism of 
detection and removal of potentially damaging infectious agents. These 
responses, defined as the innate and adaptive immune system respectively, 
coordinate humoral and cell-mediated defence mechanisms against infectious 
agents that evade physical barriers e.g. skin, saliva, mucus, and hair. Each 
system induces an inflammatory response, mediated by a set of soluble proteins 
such as cytokines and chemo-attractants, which aids the clearance of the 
infection via phagocytosis and destruction of pathogens and infected cells. 
Inflammatory mediators are usually secreted at the site of infection over periods 
of hours to days and correlate with negative effects of illness (13). These effects 
can become exaggerated upon prolonged exposure requiring the inflammatory 
response to be tightly controlled. 
 
The innate immune response is a rapid and non-specific reaction activated at the 
site of infection. The elimination of invading agents is mediated by system of 
conserved circulating proteins, antibodies, and phagocytic cells such as 
macrophages that recognise pathogen associated molecular patterns (PAMPs) on 
foreign particles (glycoproteins, lipids, and DNA) via conserved, germline-
encoded pattern recognition receptors (PRRs). The most well studied PRRs 
include toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like 
receptors (RLRs) (14). Activation can elicit multiple effects that aid the 
destruction and phagocytosis of foreign particles and pathogens e.g. 
complement, activation of inflammatory signalling pathways, and apoptosis (15). 
For example, TLR4 detects the gram negative bacterial component LPS which 
leads to activation of the pro-inflammatory nuclear factor kappa B (NFκB) 
pathway (16) resulting in the secretion of multiple pro-inflammatory cytokines 
such as tumour necrosis factor α  (TNFα), IL1, and IL6, that initiate the 
clearance of the infection (17). 
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Adaptive immunity (13) is a slower, antigen-specific response mediated by B- 
and T-lymphocytes that detect foreign particles via a highly diverse set 
antibodies and T-cell receptors (TCRs) respectively (15). Such diversity enables 
detection of existing and as yet un-encountered antigens and as such, negative 
screening of lymphocyte reactivity is necessary to prevent autoimmunity (14). 
An adaptive response is initiated either via the detection of antigen by naïve B-
cells or by antigen-presenting cell (APC)-dependent activation of naïve T-cells. 
APCs express a form of major histocompatibility complex (MHC) molecule on its 
surface that enables the presentation of internalised, non-self peptides at the 
plasma membrane. Two forms of MHC, MHCI and MHCII are defined, while MHCI 
is present on all nucleated cells i.e. all cells with the exception of red blood 
cells, MHCII is only present on APCs i.e. dendritic cells, macrophages, and B-
lymphocytes (13). APCs locally activated by a PAMP/PRR interaction 
subsequently internalise foreign particles via phagocytosis and present them at 
the surface on MHCII. Directed by chemokines, APCs then move to peripheral 
lymphoid organs e.g. spleen and lymph nodes where they deliver the foreign 
cargo to induce an adaptive immune response (13). Activated B- and T-
lymphocytes are drawn to sites of infection by chemokines via interactions 
between cell-surface receptors i.e. selectins and integrins, and endothelial cells 
(13). T-cells are activated by APCs following an MHCII-TCR interaction aided by 
co-stimulatory molecules which cause them to undergo clonal expansion 
producing a set of naïve, effector, and memory cells (13). Naïve T-cells 
differentiate to helper T-cells (Th cells, CD4+) or cytotoxic T-cells (CD8+), the 
latter of which induces apoptosis of infected cells upon stimulation with MHCI-
bound peptide. MHCII-bound peptides activate CD4+ T-cells to secrete cytokines 
which amplify the response of specific lymphocyte compartments i.e. Th1 elicits 
a T-cell-mediated response against intracellular bacteria and virus whereas Th2 
induces a B-cell-mediated humoral response against extracellular pathogens 
(18). APCs therefore act as the bridge between innate and adaptive systems. 
Furthermore, Th cells also differentiate to regulatory (Tregs) T-cells that suppress 
T-cell-induced chronic inflammation and autoimmunity i.e. peripheral tolerance 
via a cytokine-directed mechanism (14). Naïve B-cells also undergo clonal 
expansion, upon detection of antigen or following activation by Th cells they 
differentiate to effector plasma cells that secrete cytokine, chemokine, and 
antibodies that contribute to complement and phagocytosis (13). Finally, the 
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generation of both B- and T-cell memory cells preserve the proven antigen 
detection machinery to enable a quick secondary response to future infection.  
 
The immune system works intimately with the endothelium to enable clearance 
of infection (19). Healthy vascular endothelial cells (ECs) form an interface 
between luminal components of the circulatory system and surrounding organs. 
It functions as a barrier to solutes and cells while maintaining an anti-thrombotic 
environment. Activation of the immune system results in a cytokine/chemokine-
mediated cascade of events where ECs undergo morphological and phenotypic 
changes enabling them to participate (19). This presents as the common signs of 
inflammation which includes redness, heat, swelling, pain, increased blood flow, 
and loss of vascular integrity (20). Vasoconstriction increases blood pressure, 
producing redness and heat via engorgement of the capillary network. Vascular 
permeability aids infiltration of phagocytic cells but also contributes to swelling 
from fluid accumulation (20). EC activation causes a reduction in vascular 
integrity, expression of leukocyte adhesion molecules, increased 
cytokine/chemokine secretion, up-regulation of human leukocyte antigen (HLA), 
and generation of reactive oxygen species (ROS) (21,22).  These changes enable 
the recruitment and infiltration of leukocytes to the sub-endothelial space, a 
process that is promoted by additional cytokine/chemokine secretion from the 
recruited immune cells. Since such events can be destructive, inflammation 
must be tightly controlled. EC activation is a graded, tightly regulated response 
but persistent, increased basal conditions of activating molecules can have a 
cumulative effect. It is under these conditions that EC activation can result in 
pathogenesis (23).  
1.1.2 Chronic inflammation and the immune system 
Adipocytes were initially regarded as a simple lipid store but are now accepted 
as an endocrine organ. The discovery of leptin provided a mechanism by which 
adipocytes could communicate the energy status of the organism and thus 
control body mass (24). Leptin is now considered a pleiotropic signalling 
molecule involved in energy homeostasis, angiogenesis, and immunity (25). 
Adipocytes are now accepted to secrete multiple adipocytokines, including 
leptin, that regulate metabolically active systems including liver, skeletal 
muscle, and endothelium. Adipocytokines include many pro-inflammatory 
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signalling molecules such as IL6 and TNFα, which enables cross-talk between 
metabolic and immune systems (26). For example, IL6 carries out multiple 
functions such as differentiation of B-cells, T-cell activation and proliferation of 
vascular smooth muscle cells (VSMCs) (7). IL6 can also induce monocyte 
chemotactic protein (MCP) 1, a chemokine that recruits monocytes to sites of 
infection (27). Furthermore, both TNFα and IL6 induce the expression of 
adhesion molecules such as selectins, vascular cell adhesion molecule (VCAM) 1, 
and intercellular adhesion molecule (ICAM) 1 which are necessary for transport, 
adherence, and infiltration of the endothelium (28,29). Importantly, the 
secretion of pro-inflammatory adipocytokines correlates with adiposity and as 
such, IL6 (5) and TNFα (30) are both elevated during obesity. Furthermore, 
enhanced levels of these adipocytokines are specifically associated with 
increased visceral fat, as opposed to subcutaneous fat levels (31,32). However, 
secretion of anti-inflammatory adipocytokines such as adiponectin are reduced 
under the same condition (26). In support of the involvement of the immune 
system in obesity, macrophages (4) are sequestered by chemoattractants such as 
MCP1 and infiltrate adipose tissue to perpetuate and enhance adipocytokine 
secretion (2). Furthermore, this condition is supported by an imbalance in T-cell 
compartments (33). An increase in Th1 and decrease in Th2 and Treg T-cells 
promotes a pro-inflammatory, macrophage-dependent response which escalates 
the effect in a vicious feedback cycle (33). In effect, during obesity, adipose 
tissue enters a nutrient-induced inflammatory state. While this is a simplistic 
view, it is evident that a complex relationship exists between adipocytes and the 
immune system, which left unattended, can promote systemic inflammation and 
via EC activation, can promote inflammatory events and pathogenesis (19,23).    
1.1.3 Inflammatory disease 
It is been discussed how metabolic and immune systems are interrelated and 
that prolonged high calorie diets and subsequent excess adiposity provoke 
chronic activation of the immune system. Obesity contributes to a state of 
systemic low grade inflammation via the elevated secretion of adipocytokines 
(34). An obesity induced imbalance of the metabolic and immune system can 
lead to a condition referred to as the metabolic syndrome, a state of insulin 
resistance, high plasma triglyceride, low high-density lipoprotein cholesterol, 
and hypertension (21). This primes the individual for several inflammatory 
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related disorders such as type-2 diabetes and atherosclerosis (21,35) and it is of 
note that the prevalence of these disorders is increasing with rates of obesity 
(36,37). The link between metabolic and immune systems has enabled the 
molecular mechanisms of disease to be investigated. However, given the 
complexity of the relationship between these systems and that disease 
progression is often multifactorial, involving both genetic and environmental 
effects, these mechanisms have yet to be fully elucidated. 
 
Insulin resistance and subsequently type-2 diabetes can be induced by several 
events.  Adipose tissue is a source of free fatty acids (FFAs) that are released 
following lipolysis that can be stimulated by IL6 and TNFα (38). Increased 
lipolysis during obesity provides elevated levels of circulating FFAs that can 
activate TLR4 in adipocytes and induce a state of insulin resistance (38) via 
activation of the NFκB pathway which has well-accepted links to insulin 
resistance (39). Furthermore, an elevated level of TNFα is associated with 
insulin resistance in obese mice while genetic impairment of TNFα signalling 
increases insulin sensitivity with a concomitant decrease in FFAs (40). Both FFA 
and TNFα can activate one of the pro-inflammatory mitogen-activated protein 
kinase (MAPK) pathways, the c-Jun N-terminal kinase (JNK) pathway, which is 
hyperactive in obese mice (35).  Subsequently, activation of JNK1 was found to 
result in an inhibitory phosphorylation on the insulin receptor substrate (IRS) 1 
(S307) blocking its interaction with the insulin receptor and thus downstream 
signalling (35). In contrast, deletion of JNK1 is protective against insulin 
resistance (35).  
 
It is now well established that obesity-related increases in adipocytokine 
secretion contributes to the development of atherosclerosis-induced 
cardiovascular disease which is one of the leading causes of deaths worldwide 
(41). It has been recognised for years that high fat/cholesterol diets are 
associated with cardiovascular disease (42). Combining knowledge from a wide 
variety of inflammation-related events, the progression of atherosclerotic lesion 
development has been described. It is likely initiated by hyperlipidaemia, 
hypertension, and elevated cytokine release. The systemic nature of these 
events combines, resulting in uncontrolled EC activated and pathogenesis.   
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Atherosclerosis is the formation of lesions within the arterial intima due to the 
accumulation of lipid, connective tissue, leukocytes, and the proliferation and 
infiltration of smooth muscle cells (Figure 1.0). Narrowing of the artery precedes 
plaque rupture that can cause coronary thrombosis (43). Lesions do not always 
precede pathogenesis since stable lesions can be formed that are compensated 
for by arterial wall dilation (18).  Lesions preferentially localise to areas of 
haemodynamic strain such as arterial bifurcations, branch ostia, and curvatures 
(43). Oscillating shear stresses in these regions tends to be accompanied by 
expression of leukocyte adhesion molecules, pro-inflammatory genes including 
multiple cytokines, and angiotensin-II which itself promotes a vasoconstriction 
and a pro-thrombotic environment (23). Increased circulating pro-inflammatory 
cytokines and accumulation of ROS tend to further activate ECs allowing lipids 
such as LDL to be oxidised (ox-LDL) upon infiltration into the sub-endothelial 
space. Sequestered macrophages phagocytose ox-LDL via scavenger receptors 
and develop into foam cells producing a fatty streak, characteristic of early 
stage atherosclerosis (44). Foam cells, macrophages, and APCs then contribute 
to the increased production of pro-inflammatory factors that accelerate 
formation of unstable lesions (Figure 1.0). For example, necrosis and 
destabilisation of the lesion by macrophage-derived matrix metalloproteinases 
(MMPs) can lead to rupture and potentially thrombosis, arterial blockage, and 
myocardial infarction or stroke (44). Furthermore, while high haemodynamic 
stress induces the release of nitric oxide (NO) and vasodilatation which can 
compensate for lesion formation, increased flow can also contribute to plaque 
damage (23).    
 
Chronic inflammatory disorders can be differentiated by individual phenotypes 
due to tissue specific responses although the underlining cause remains common. 
For example, atherosclerosis and cirrhosis involve the same leukocyte 
compartments but whereas cirrhosis is defined by parenchymal-cell injury 
producing fibrotic scarring, atherosclerosis is induced by endothelial-cell injury 
that causes fibrosis and smooth muscle proliferation resulting in stenosis, 
rupture, and thrombosis (45). Chronic inflammatory diseases might therefore be 
treated by understanding and targeting of common regulatory mechanisms of the 
immuno-inflammatory response.  
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Figure 1.0: Development of atherosclerotic lesions 
Atherogenesis is initiated by endothelial cell inflammation, activation, and dysfunction. 
Loss of vascular integrity allows access to monocytes and the diffusion of solutes such as 
LDL into the arterial intima. LDL is acted upon by oxidative and enzymatic modification 
which initiates EC activation. Expression of adhesion molecules, production of reactive 
oxygen species (ROS), and the secretion of cytokines and chemokines contributes to 
attraction, activation, and infiltration of macrophages that form foam cells upon uptake 
of ROS-modified lipids via scavenger receptors. Lesions mature following foam cell 
breakdown and accumulation of cholesterol, calcium, and collagen. Necrosis and 
destabilisation of the lesion by macrophage-derived matrix metalloproteinases can lead 
to rupture and potentially thrombosis, arterial blockage, myocardial infarction or 
stroke. Image adapted with permission from (44).  
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1.1.4 Targeting inflammatory disorders 
It is clear that pathogenesis results due to the sustained, uncontrolled elevation 
of adipocytokine levels that activate the ECs. Furthermore, via positive feedback 
loops these molecules can interact with the immune system to sustain a pro-
inflammatory state that drives pathogenesis. While multiple stimuli are involved, 
the intracellular signalling pathways activated are often common. It has been 
described how both FFA and TNFα can stimulate the NFκB pathway to promote 
insulin resistance (35). NFκB also drives transcription of matrix 
metalloproteinases (MMP1, 3, 9), pro-inflammatory cytokines (TNF-α, IL6), 
chemokines (IL8), leukocyte adhesion molecules, and growth factors (18,22). It 
is thus not surprising that numerous other studies have implicated NFκB in the 
development inflammatory diseases (39). However, the NFκB pathway also 
provides protective, anti-apoptotic effects required for clearance of pathogens 
(18).   
 
Several events in the progression of atherosclerosis have been shown to be 
regulated directly or indirectly by the JAK/STAT pathway including vascular 
tone, mechanical and oxidative stress, and pro-inflammatory gene expression 
(7). Most notably of course is the direct activation of the JAK/STAT pathway by 
IL6, a pleiotropic adipocytokine elevated in the obese (5), that can induce acute 
phase proteins, cytokines, chemokines, activate T-cells and the proliferation of 
smooth muscle cells (7,27-29). Furthermore dysregulation of the JAK/STAT 
pathway is also integral to the development of other chronic inflammatory 
disorders such as Crohn’s disease (46) and certain cancers (47).   
 
Targeting of these pleiotropic signalling molecules might therefore be 
therapeutically beneficial. Several disorders have been targeted using anti-TNFα 
inhibitors including Crohn’s disease (infliximab) and rheumatoid arthritis 
(etanercept, adalimumab) (48). Treatments that mop-up and inhibit the action 
of pro-inflammatory cytokines such as anti-IL6 mAbs e.g. elsilimomab, and anti-
IL6R mAbs e.g. tocilizumab, have also been successful in reducing disease 
progression (47).  
 
                                                                                                                                                                                                                                                      10
Inhibition of IL6 signalling might be beneficial in certain cases i.e. to prevent the 
progression of cancer. However, global inhibition of IL6 signalling might be 
detrimental since minimum activation might be necessary for protection. For 
example, Schieffer et al found that atherosclerotic lesion formation was greater 
in Apoe-/- IL6-/- mice and was accompanied by a reduction in levels IL10 
compared to Apoe-/- mice (49). This suggested that lesion formation is 
dependent on the balance of anti- (IL10) and pro-inflammatory (IL6) cytokines 
and that IL6 is require to maintain IL10 levels. As such, it would be better to 
therapeutically target downstream IL6 signalling events, while preserving its 
protective effects.     
 
This study aims to investigate SOCS3, which was initially described as a cytokine-
inducible negative regulator of JAK/STAT signalling (50). At present, inducers of 
SOCS3 include, but are not limited to, cytokines (IL1, IL6, LIF, OSM, IFNγ, TNFα, 
EPO, and prolactin), chemo-attractants (IL8, N-formyl-Met-Leu-Phe), bacterial 
components (LPS, unmethylated CpG DNA), leptin, insulin, and the intracellular 
second-messenger cyclic AMP. SOCS3 can suppress signalling from a diverse set 
of receptors either by directly binding the receptor itself or by initiating 
ubiquitin-mediated proteasomal degradation (51). In the case of the latter, 
SOCS3 acts as a specificity factor for an ECS-type of E3 ubiquitin ligase of which 
only a few targets are known (8-12). While the ubiquitin-proteasome pathway 
consists of only a few E1 activation and E2 conjugation proteins (Section 1.2.5), 
several hundred E3 ligases have been defined (52). Thus, it may be 
therapeutically beneficial to specifically target SOCS3 in this role.        
1.2 Cytokine-mediated JAK/STAT signalling 
The following sections review current knowledge on the JAK/STAT pathway and 
its regulation. The JAK/STAT pathway can be activated by multiple stimuli, 
however the emphasis here will be on cytokine signalling, specifically IL6.  
1.2.1 Cytokines  
Cytokines are extracellular proteins secreted by many cells types that function 
as autocrine, paracrine, juxtacrine, and endocrine hormones. They act 
pleiotropically and synergistically to regulate survival, proliferation, 
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differentiation, and the function of many cell types (18). Importantly they are 
transiently expressed (hours to days) to elicit a pro- or anti-inflammatory 
response in a cell-specific fashion to activate/amplify the action of specific 
leukocyte compartments (18). They have the positive effect of co-ordinating the 
clearance of infection but are also responsible for the negative effects of illness 
such as fever, lethargy, sleep, allergy, and anorexia. Persistent cytokine 
generation can result in several chronic inflammatory disease states such as CVD 
(46).  
 
To date around 50 cytokines have been defined including interleukins (IL), 
tumour necrosis factors (TNF), interferons (IFN), colony stimulating factors 
(CSF), and transforming growth factors (TGF) (18). More than 70 further 
candidates have been identified via sequence comparisons (53). Cytokines are 
characterised by the structure of the receptors that they activate and include: 
hematopoietin/type 1, interferon/type 2, TNF, and IL1/TLR. IL6 mediates its 
effects by targeting the largest family of cytokine receptors, the 
haematopoietin/type 1 receptors, of which the membrane-bound receptor gp130 
is the most common signalling unit (54).  
1.2.2 The IL6 family of cytokines and their receptors  
The IL6 family of four-α-helical cytokines includes IL6, IL11, leukaemia inhibitory 
factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), ciliary neurotrophic 
factor (CNTF), and cardiotrophin-like cytokine (CLC) (55). Most IL6 family 
members transduce signals via gp130 either as a homodimer, as in the case of 
IL6, or as a heterodimer of gp130 and a second signalling receptor protein 
(Figure 1.1). Although each ligand-receptor partnership imparts a specific 
response, in common is the activation of the JAK/STAT and extracellular signal-
regulated kinase (ERK) pathways (Figure 1.2). Increased signalling diversity is 
achieved from their interaction with membrane-bound, soluble and associated 
isoforms of both IL6Rα and gp130 subunits. As well as binding and interacting 
with membrane-localised IL6Rα to trigger signalling via gp130, termed 
“classical” IL6 signalling, IL6 is unique in that it can also function via a so-called 
trans-signalling mechanism. This is achieved because gp130 does not recognise 
IL6 directly. Instead, IL6 must first form a low affinity complex with the 80kDa 
non-signalling α-receptor, IL6Rα (CD126), which then forms a high affinity 
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tetramer with a homodimer of gp130. Gp130 is ubiquitously and constitutively 
expressed whereas membrane bound/non-signalling IL6Rα is restricted to 
hepatocytes, leukocytes, and lymphocytes. However soluble IL6R (sIL6R) variants 
can also be generated either via alternate splicing of the IL6Rα primary 
transcript (56) or by limited proteolysis of the membrane-localised IL6Rα protein 
by metalloproteases ADAM10 or ADAM17, resulting in soluble IL6Rα (sIL6Rα) 
being shed from hepatocytes or macrophages (57). This enables signalling in non-
IL6Rα-expressing cells, thus increasing the repertoire of IL6-responsive cells 
during an inflammatory response (55).  
 
IL6 is a 22-28 kDa protein, depending on its glycosylation state, secreted by 
leukocytes, fibroblasts, endothelial cells, keratinocytes, hepatocytes, and bone 
marrow cells. Five isoforms exist in humans (IL6, IL6alt, IL6Q2, IL6Q2,4, and 
IL6Q4) due to alternative splicing (58,59). IL6 is a multifunctional mediator of 
numerous complex biological responses, including hepatic induction of acute 
phase proteins, differentiation of B cells, as well as T-cell activation, growth, 
and differentiation. In a pro-inflammatory role, IL6 initiates inflammation via 
the activation of endothelial cells by upregulating expression of the adhesion 
molecules ICAM1, E-selectin, and VCAM1, chemokine MCP1/CCL2, and by 
induction of smooth muscle cell proliferation and migration (27-29). IL6 is also 
involved in the generation of Th17 cells from naïve T-cells and the inhibition of 
Treg development (60). Th17 cells provide protection against fungi and 
extracellular bacteria, while Tregs limit this response. In a state of sustained, 
elevated levels of IL6, the fine balance between Th17 cells and Tregs is lost. 
Through this disruption, Th17 cells are critical in the development of 
inflammatory disorders such as rheumatoid arthritis (60).  IL6 also mediates anti-
inflammatory responses including the negative regulation of IL1 and TNFα 
synthesis as well as quenching of the pro-inflammatory effects of IL1 by up-
regulation of IL1R antagonist IL1ra (61) and maintenance of IL10 (49).  
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Figure 1.1: IL6 cytokine family share receptor subunits 
Gp130, a 130 kDa glycoprotein, forms homo- or hetero-dimers with the IL6 cytokine 
family of receptors. IL6 and IL11 both require a gp130 homodimer whereas others 
require hetero-dimers. OSM can bind two forms of heterodimer whereas LIF, CT-1, CNTF 
and CLC all require a LIFR-gp130 complex, a further non-signalling receptor might also 
be necessary. Slight structural differences within the α-helical domains of each cytokine 
might determine the receptor-dimer format. Gp130 does not recognise IL6 directly. IL6 
first forms a low affinity complex with the 80kDa, non-signalling α-receptor, IL6Rα, 
which then binds gp130 with high affinity. A similar series of events also applies to IL11, 
CNTF, CLC and possibly CT-1. IL6 receptor (IL6-R), IL11 receptor (IL11R), leukaemia 
inhibitory factor receptor (LIFR), oncostatin M receptor (OSMR), ciliary neurotrophic 
factor receptor (CNTF-R). Adapted with permission from (55).  
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1.2.3 IL6-mediated JAK/STAT signalling and its regulation 
The gp130 signalling receptor lacks intrinsic kinase activity but is constitutively 
associated with JAK family tyrosine kinases (Figure 1.2). Cytokine-receptor 
ligation brings gp130-JAK into close proximity allowing trans-phosphorylation and 
activation of JAKs which then tyrosine phosphorylate gp130 producing docking 
sites for the SH2-domain-containing signalling mediators STATs and SH2 domain-
containing protein-tyrosine phosphatase 2 (SHP2). IL6-family cytokines 
predominantly signal from gp130 through JAK1/STAT3 and to a lesser extent 
JAK2/STAT1 (55). JAK1-mediated phosphorylation of gp130 at Y767, Y814, Y905 and 
Y915 at a pYXXQ consensus sequence enables binding of STAT3 that competes 
with STAT1 binding at Y905 and Y915 at a more constrained pYXLQ consensus 
sequence (55,62). This could account for the more potent activation and dimer 
formation of transcriptionally active STAT3 compared to STAT1. Docked STATs 
are tyrosine-phosphorylated by JAKs within their SH2 domains (STAT1, Y701 and 
STAT3, Y705) which enables receptor dissociation and formation of homo- or 
hetero- dimers, via their SH2 domain, or trimers with DNA-binding adapter 
proteins such as the IFN regulatory factors (IRFs) before translocating to the 
nucleus where they drive cytokine-inducible gene transcription from palindromic 
DNA elements with a TTN4–6AA consensus sequence (63) as well as IFN-stimulated 
response elements (ISRE sites, AGTTTN3TTTC) and IFNγ-activated sequence (GAS 
sites, TTCN3GAA). The exact preference depends on STAT dimer composition, 
adapter protein interaction, IFN type as well as STAT-specific sequence 
variations (64). Formation of dimers and trimers further increases the functional 
capacity of STATs to modulate gene expression patterns in a cytokine dependent 
fashion. JAKs also activate SHP2 via tyrosine phosphorylation of Y542 and Y580 and 
at Y759 on gp130, all of which overcome the auto-inhibitory mechanism of the 
internal SH2 domains within SHP2. JAK-phosphorylated SHP2 then induces ERK-
mediated gene transcription via the recruitment of the Growth factor receptor-
bound 2-Son of sevenless (Grb2-Sos) complex via pY
542 and pY
580 (55). Grb2 
functions as an adaptor protein for Sos, a Ras guanine nucleotide exchange 
factor (GEF). Co-localisation of Sos with Ras at the plasma membrane enables 
activation of Ras and initiation of the ERK signalling pathway (55). 
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Figure 1.2: IL6 family cytokine signalling 
IL6-family cytokine signalling. IL6-family cytokines activate JAK/STAT and ERK 
pathways. IL6 binds either soluble or membrane-associated IL6 receptor alpha chains 
followed by binding a gp130 receptor which itself lacks kinase activity but is 
constitutively associated with JAKs. Cytokine-receptor ligation forms receptor dimers 
which brings JAKs into close proximity. Following trans-phosphorylation and activation 
of JAKs, the receptor subunits are phosphorylated producing docking sites for SH2-
domain containing proteins, STATs and SHP2. Activation of STATs by JAKs results in 
receptor dissociation, dimerisation, and translocation to the nucleus where they drive 
cytokine-induced gene transcription. STAT-induced SOCS3 negatively regulates cytokine 
signalling either by direct inhibition of JAKs or via the degradation of signalling 
intermediates in its role as a specificity factor for the ECS family of E3 ubiquitin ligases. 
In a similar fashion to STATs, bound, phosphorylated SHP2 induces gene transcription by 
activation of the MAPK pathway via the recruitment of the Growth factor receptor 
bound protein 2-Son of sevenless (Grb2-Sos) complex via phosphorylated tyrosine 
residues pY
542 and pY
580. Grb2 is an adaptor protein required for SHP2 association and Sos 
is a Ras guanine nucleotide exchange factor (GEF). SHP2 is a phosphatase so might act 
on gp130 and associated factors to negatively regulate signalling. 
                                                                                                                                                                                                                                                      16
1.2.4 Negative regulation of the JAK/STAT pathway 
Chronic activation of the JAK/STAT pathway can initiate and perpetuate chronic 
inflammatory diseases such as rheumatoid arthritis and Crohn’s disease as well 
as certain forms of cancer (46,47,65,66). Negative regulation occurs through 
multiple routes within both extracellular and intracellular domains via inhibitory 
and degradative mechanisms. For example, soluble gp130 (sgp130) can trap 
circulating sIL6Rα/IL6 complexes and thus quench trans-signalling. Furthermore, 
active phagocytic cells, such as neutrophils at sites of inflammation, secrete 
proteases that degrade cytokines including IL6 (65,67). Intracellular signalling 
intermediates can be made functionally mute by protein tyrosine phosphatases 
such as SHP2, and also by direct inhibition by protein inhibitors of activated 
STAT (PIAS) (68,69) and suppressor of cytokine signalling (SOCS) proteins (70), 
the latter of which can also drive ubiquitin-directed proteasomal degradation 
(10).  
1.2.4.1 Extracellular regulation of cytokine signalling  
Cytokine-dependent signalling can be suppressed by inhibition or degradation of 
cytokines. Soluble forms of IL6R (sIL6R) is shed from macrophages and is 
essential for IL6 trans-signalling through gp130 (57). However, sIL6R and soluble 
gp130 (sgp130) is detectable in human serum (67). As such, sgp130 can 
antagonise IL6-IL6R-induced signalling and modulate the effects of circulating 
IL6 (67,71).  
 
Elevated levels of IL6 present during inflammation are also removed following 
degradation by serine proteases elastase, proteinase 3, and cathepsin G secreted 
from neutrophils (65). However, it is not clear if these are expressed in response 
to IL6 i.e. as a regulatory feedback loop. It is also possible that other cells are 
involved including those of the invading pathogen which might secrete proteases 
as a protective mechanism (65).   
1.2.4.2 Protein tyrosine phosphatases (PTPs) 
While SHP2 can activate the ERK pathway, it can also negatively regulate the 
JAK/STAT pathway via its protein tyrosine phosphatase activity against gp130, 
JAK, and STAT proteins. SHP2 is ubiquitously expressed and consists of two N-
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terminal SH2 domains and a C-terminal catalytic phosphatase domain. In its 
inactive state, the SH2 domains bind to the phosphatase domain to block 
substrate interaction. This inhibitory action is removed upon tyrosine 
phosphorylation by cytokine-activated JAKs (see above). Other phosphatases 
might also have roles in JAK/STAT regulation such as PTPεC, PTP1B, CD45, SHP1 
and nuclear-localised phosphatase TCPTP (55). 
1.2.4.3 Protein inhibitors of activated STAT 
Protein inhibitors of activated STAT (PIAS), as their name suggests, block the 
function of active/phosphorylated STATs but they also interact with a wide 
range of non-STAT proteins, most of which are transcription factors such as 
NFκB, and so have wider actions as transcriptional regulators (69). Five PIAS 
family members (PIAS1, PIAS3, PIASxα, PIASxβ, and PIASy) have been defined. All 
PIAS bind to active/tyrosine-phosphorylated, nuclear-localised STAT proteins 
although the inhibitory mechanism appears to be PIAS-specific. All PIAS proteins 
also have E3 SUMO ligase activity enabling the reversible covalent attachment of 
“small ubiquitin-related modifier” (SUMO) to the ε-amino groups of lysine 
residues residing within a Ψ-K-x-D/E consensus sequence for SUMOylation on 
target proteins (Ψ=hydrophobic residue) (69). This post-translational 
modification modulates cellular localisation, function, and protein-protein 
interactions, thus altering the composition and activity of transcription factor 
complexes. IFNγ-induced STAT1 and IL6-induced STAT3-dependent gene 
transcription are suppressed by PIAS1 and PIAS3 respectively via inhibition of 
transcription factor-DNA binding. Furthermore, STAT1-dependent gene 
transcription is also inhibited via SUMOylation at K703 (72). In contrast, PIASx and 
PIASy inhibit gene transcription by acting as transcriptional co-repressors. 
Regulation by PIAS proteins is complex with certain regulatory roles being 
SUMOylation independent and others relying on specific PIAS domains(68). 
1.2.4.4 Suppressors of cytokine signalling 
SOCS proteins negatively regulate multiple pathways involved in immune, 
growth, and metabolic responses. Eight SOCS family members are defined 
(SOCS1-7 and cytokine-inducible SH2 domain-containing protein (CIS)) of which 
CIS and SOCS1-3 are best characterised (73). SOCS proteins were discovered 
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following a search for early cytokine-induced genes in haematopoietic cells (74). 
In general, SOCS proteins have low basal expression levels that are rapidly 
elevated by several inflammatory mediators. In a classical negative feedback 
loop, STAT-induced SOCS proteins ablate intracellular pro-inflammatory 
signalling by either direct inhibition of signalling components or by ubiquitin-
mediated receptor internalisation and proteasomal degradation of signalling 
intermediates via its action as the specificity factor for E3 ubiquitin ligases 
(62,75). However, sequence deviations between family members bring about 
different mechanisms of action, and combined with differential expression 
kinetics, suggest that SOCS family members might each provide non-redundant 
functionality.  
 
Induction of SOCS proteins occurs via multiple routes and the variety of SOCS-
regulated pathways is becoming more diverse. Moreover, differing expression 
kinetics and the potential for cross-regulation within the SOCS family adds a 
further layer of complexity.  At present, inducers of SOCS include, but are not 
limited to, cytokines (IL1, IL6, LIF, OSM, IL3, IFNγ, TNFα, EPO, prolactin), 
chemo-attractants (IL8, formyl-Met-Leu-Phe), bacteria-derived components 
(LPS, unmethylated CpG DNA), hormones (leptin, insulin), and the second-
messenger cAMP. Receptor tyrosine kinases (RTK) such as EGFR and PDGFR 
activated by their cognate ligands might also induce and be regulated by SOCS 
proteins (51). SOCS proteins bind tyrosine-phosphorylated receptors that have 
immunoreceptor tyrosine-based inhibitory motif (ITIM)-like sites such as gp130, 
EpoR, ObR, and others such as CD33 of the SIGLEC glycoprotein family (12). Due 
to the requirement for tyrosine phosphorylation, it is possible that in certain 
circumstances inhibition of signalling by SOCS might be indirect i.e. cross-talk 
between related signalling pathways (51). 
 
Structurally, each SOCS family member consists of a conserved central SH2 
domain, an extended SH2 subdomain (ESS), a variable-length, non-conserved N-
terminal domain, and a 40 amino acid C-terminal domain SOCS-box (Figure 1.3, 
panel A). The SOCS-box is considered a multi-functional region. It can regulate 
stability and the cross-regulation of SOCS proteins as well as SH2-dependent 
SOCS/substrate recognition and regulation i.e. CIS/ERK regulation. In its role as 
an E3 ligase, the SOCS-box is required for interaction with the ubiquitin 
                                                                                                                                                                                                                                                      19
machinery (cullin5, elonginB, and elonginC) via cullin-binding and B/C-box 
subdomains while tyrosine-phosphorylated substrates are specifically targeted 
via the SH2 domain (Figure 1.3 and 1.4). SOCS1 and SOCS3 are unique in that 
they also contain an N-terminal kinase inhibitory region (KIR) that shares 
homology with the pseudosubstrate domain of JAKs. SOCS4-7 also have extended 
C-terminal domains that have no known functional motifs.  
 
Crystal structures of elongin-bound SOCS2 and SOCS4 suggest that extended N- 
and C-terminal regions might function to stabilise the tertiary structure (75). 
SOCS2 has a conserved C-terminus that is predicted to stabilise the SH2-SOCS-
box interaction allowing exposure of the N-terminal ESS and KIR. The SOCS4 SH2-
SOCS-box interaction is stabilised by the extended N-terminal domain, the 
extended C-terminus then interacts with the N-terminal domain to further 
stabilise the structure (75). These structural characteristics are thought to apply 
to similar SOCS family members i.e. SOCS1, SOCS3, CIS, and SOCS5-7 
respectively. Over the full length of the protein, SOCS family members have 
sequence homology with SOCS4-5 being most similar (92%) followed by SOCS6-7 
(57%), CIS and SOCS2 (45%), and finally SOCS1 and SOCS3 (35%) although certain 
domains are more conserved than others (76) (Figure 1.3, panel B). For instance, 
the elongin binding site is the most conserved site on all SOCS proteins which 
points to its importance (75). Consistent with this, mutation of a single leucine 
within the B/C-box has been demonstrated to completely block elongin 
interaction and substrate degradation (77). 
 
Direct inhibition of substrates requires the SH2 domain, ESS, and KIR, but 
uniquely, CIS also requires the SOCS-box and pY
253 (75). Furthermore, interaction 
of the CIS-SH2 domain with pY
253 is hypothesised to regulate CIS by keeping it in 
an inactive a state until tyrosine-phosphorylated substrates are available. SOCS1 
and SOCS3 are the only family members that can inhibit IL6-gp130 signalling via 
a SOCS-box independent route. Both inhibit JAK catalytic activity by acting as 
pseudosubstrates and thus blocking STAT1 and STAT3 activation. SOCS1 binds to 
the tyrosine-phosphorylated activation loop of JAK2 via its KIR, SH2, and ESS. 
SOCS3 similarly binds JAK1 but its interaction is weaker and requires further 
interaction with tyrosine-phosphorylated receptors such as gp130 at pY759 via its    
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Figure 1.3: Elongin-Cullin-SOCS-box (ECS) family of E3 ubiquitin ligases  
A. Organisation of domains within the SOCS protein family, see text for description. B. 
Sequence alignment of the SOCS-box for all SOCS family members. The alignment was 
performed using the clustalW2 multiple sequence alignment tool available at 
http://www.ebi.ac.uk/Tools/msa/clustalw2/. Highlighted sections indicate the BC-box 
and Cul5-box.  
 
 
 
                  BC-box                    Cul5-box   
                       
CIS     VQPFVRRSSARSLQHLCRLVINRLVA--DVDCLPLPRRMADYLRQYPFQL 
SOCS1   LGAPLRQRRVRPLQELCRQRIVAAVGRENLARIPLNPVLRDYLSSFPFQI 
SOCS2   TKPLY--TSAPSLQHLCRLTINKCTG--AIWGLPLPTRLKDYLEEYKFQV 
SOCS3   VLSRPLSSNVATLQHLCRKTVNGHLDS-YEKVTQLPGPIREFLDQYDAPL 
SOCS4   LSTPLIRTFPFSLQHICRTVICNCTTYDGIDALPIPSSMKLYLKEYHYKS 
SOCS5   LTISLNRTFPFSLQYICRAVICRCTTYDGIDGLPLPSMLQDFLKEYHYKQ 
SOCS6   TNPVSRFMQVRSLQYLCRFVIRQYTRIDLIQKLPLPNKMKDYLQEKHY-- 
SOCS7   LYPVSRFSNVKSLQHLCRFRIRQLVRIDHIPDLPLPKPLISYIRKFYYYD 
B 
A 
                                                                                                                                                                                                                                                      21
 
 
 
 
 
 
Figure 1.4: Structural model of the SOCS3-containing ECS-type E3 ubiquitin 
ligase 
A. The central cullin5 scaffold protein positions the E2 conjugating enzyme in close 
proximity to SOCS3, which binds a target substrate (not shown) via its SH2 domain. 
SOCS3 is attached to cullin5 via a complex of elonginB and elonginC. The triple α-helix 
structure of the C-terminal domain SOCS-box forms a 4-helix bundle with a single helix, 
helix 4, of elonginC. Diagram reproduced with permission from (75). B. Basic E3 
ubiquitin ligase architecture. VHL and SOCS proteins act as specificity units for the ECS 
family of E3 ubiquitin ligases. SOCS proteins bind specific tyrosine-phosphorylated 
substrates or phosphodegrons via an SH2 domain. The SOCS-box motif enables 
interaction with components an E3 ubiquitin ligase. SOCS binds to the N-terminal of the 
cullin5 scaffold protein via the adaptor proteins elonginB, elonginC. Cullin5, via its C-
terminus, also binds the RING finger-containing protein Rbx2 that enables interaction 
with the E2 conjugation protein. In complex with the E3 ligase scaffold, the substrate 
and E2-bound ubiquitin are in close proximity thus facilitating the transfer of ubiquitin 
to the substrate.  
 
 
A 
B 
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SH2 domain and as such, mutation of Y759 (Y757 on murine gp130) reduces the 
inhibitory effect of SOCS3 but not SOCS1 (51,78). This is thought to explain why 
SOCS1 is a more potent inhibitor of JAK/STAT signalling. IL6 and IFNγ both 
induce SOCS1 and SOCS3 in a STAT-dependent fashion.  Furthermore, 
overexpression of SOCS1 or SOCS3 is sufficient to terminate JAK/STAT signalling. 
In contrast, in vivo studies indicate that SOCS1 specifically targets IFNγ-
dependent JAK2/STAT1 signalling whereas SOCS3 targets IL6-dependent 
JAK1/STAT3 signalling. Interestingly, in conditional SOCS3 knockout mice, IL6 
has a similar response and gene expression profile as IFNγ due to prolonged 
STAT1 signalling suggesting that SOCS3 might be required prevent generation of 
a IFNγ-type response by IL6 (51).  
 
The SOCS3 SH2 domain shares 41% homology with that of SHP2 (12). 
Furthermore, SOCS3 binds at an overlapping sequence and as such can compete 
with SHP2 to ablate SHP2-induced ERK activation by gp130. SHP2 itself might 
also contribute to signal suppression via the dephosphorylation of receptor 
tyrosine residues or receptor-bound substrates such as JAK. SOCS3 can also 
prolong ERK signalling by binding, and thus inhibiting, the Ras inhibitor p120 
RasGAP. Upon SOCS3 induction by IL2, IL6, Epo, insulin, EGF, and PDGF, SOCS3 is 
tyrosine-phosphorylated within the SOCS-box domain enabling binding to p120 
RasGAP. This function does not affect SOCS3-dependent inhibitory effects such 
as its ability of block STAT5 activation. Unregulated Ras-mediated ERK activation 
is an initiator of tumourigenesis and Ras is mutationally activated in over 15% of 
all cancers (79). Since IL6 activates ERK signalling but also maintains ERK 
activation via SOCS3, sustained JAK/STAT signalling due to chronic inflammation 
might also contribute to tumourigenesis.  
 
CIS is thought to compete with STAT5 for phosphotyrosine residues on active 
erythropoietin (Epo) and growth hormone (GH) receptors (51,74). However, this 
is disputed in the case of GHR due to non-overlapping binding sites of STAT5 and 
CIS (75). However, CIS may disrupt STAT5 binding via steric hindrance (80). A 
degradation-dependent regulatory mechanism is now preferred since CIS can 
only bind its substrates when in complex with elonginB/C.  SOCS2, being most 
similar to CIS with which it shares 35% identity, has been shown to function by 
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inhibiting GH-stimulated STAT5 activation in a SOCS-box dependent fashion. 
Furthermore, SOCS2-/- mice have an overgrown phenotype (75,81) which 
indicates its importance in GH regulation. Inhibitory mechanisms and functional 
relevance of SOCS4-7 are as yet undefined. However, both SOCS4 and SOCS5 
have been reported to increase EGF-dependent EGFR degradation (75) while 
SOCS5, being specifically expressed in Th1 but not Th2 cells, might affect T-helper 
cell equilibrium by repressing Th2 cell differentiation (51). This is relevant in the 
study of allergic diseases such as asthma where Th cell imbalance, specifically an 
increase in the Th2 compartment due to atopic SOCS protein expression, is 
thought to be an initiating factor (82).  Furthermore, SOCS5 might also regulate 
IL4 signalling by inhibiting IL4R-bound JAK1 (80). SOCS6 and SOCS7 are most 
similar in relation to SH2 and SOCS-box domains and both bind tyrosine-
phosphorylated insulin receptors to suppress signalling following insulin 
treatment, suggesting similar or redundant functions. 
 
Suggestions of E3 ligase functionality resulted from analysis of SOCS3 which 
identified a conserved C-terminal domain, the SOCS-box, also present in a known 
E3 ligase Von-Hippel-Lindau (VHL) and others MUF-1, and elonginA (51). SOCS-
box domains have been identified within over 70 human proteins conjugated to a 
variety of protein-protein interaction domains including SH2 domains, WD-40 
repeats, SPRY domains, leucine rich repeats, and ankyrin repeats that are 
thought to add target specificity and diversity (75,83).  
 
Most SOCS members form ECS-type E3 ligases and as such specifically bind E3 
ligase components elonginB/C, cullin5 and the RING finger-containing protein 
Rbx2 via the SOCS-box (Figure 1.4, panel B). SOCS binds the cullin5 scaffold 
protein via the elonginB/C dimer that binds the N-terminal region of cullin5. 
Cullin5 also binds Rbx2 via its C-terminus and enables interaction with the E2 
conjugation protein. SOCS1 has also been found in complex with cullin5/Rbx1 
(51). Both Rbx1 and Rbx2 bind cullin2 and cullin5 when overexpressed but under 
physiological conditions preferentially binds cullin2 and cullin5 respectively (84). 
Interestingly, SOCS6 might regulate proteasomal degradation via a non-ECS E3 
ubiquitin ligase since it has been reported in complex with haem-oxidized IRP2 
ubiquitin ligase1 (HOIL1) (85).  
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Unbound SOCS-box exists in a disordered state and only becomes organised upon 
binding elonginB/C, requiring that this interaction precede the binding of cullin5 
and E3 ligase complex formation (77). This was initially hypothesised from 
observations of crystal structures of VHL, SOCS2 and SOCS4 that were found to 
interact with elongins through mainly (+70%) hydrophobic interactions. 
Uncoupling of these proteins vastly increases exposure of non-polar residues and  
as such was expected to contribute to unfolding and also increase the difficulty 
in producing unbound crystal structures (75).  Two subclasses of SOCS proteins 
can be defined based on their differing affinity for cullin5 (86). SOCS1 and SOCS3 
binds elonginB/C-cullin5-Rbx2 weakly (Kd=10
-6 M (SOCS1), 10-7 M (SOCS3)) 
compared to all other family members (Kd=10
-8 M) due to slower off rates and 
they also have shorter half-lives. As such, it is thought that SOCS2, SOCS4-7 and 
CIS regulate signalling via a solely ubiquitin dependent pathway.  
 
E3 ligase functionality has been demonstrated for SOCS1 and SOCS3 but has yet 
to be confirmed for other SOCS family members (86). As such, studies on mice 
that have been genetically manipulated to remove the SOCS3 SOCS-box i.e. 
SOCS3 SOCS-box knockout mice, have immunological defects suggesting 
important proteasome-dependent regulatory roles (see below). The SOCS 
proteins act as a specificity unit within the elonginBC-cullin5-Rbx2 E3 ligase 
complex. Binding to the E3 ligase scaffold is via the SOCS box domain. SOCS 
proteins associate with tyrosine-phosphorylated substrates via a conserved 
central SH2 domain. It is currently regarded as a multifunctional domain 
implicated in SOCS stability, adaptor protein interaction, proteasomal 
degradation, receptor binding, and regulation of MAPK pathway. In relation to 
JAK/STAT signalling, SOCS1 has been shown to direct proteasomal degradation of 
active/tyrosine-phosphorylated JAK2 (87). JAK2 is monoubiquitinated in 
unstimulated cells but becomes polyubiquitinated following tyrosine 
phosphorylation (Y1007) and subsequent association with SOCS1. It is possible that 
SOCS3 similarly regulates JAK1 (73) but this has yet to be demonstrated. The full 
spectrum of ubiquitin-regulated SOCS substrates is unknown; those indentified so 
far are shown in Table 1.0. 
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Table 1.0: Ubiquitin-regulated SOCS substrates 
Table of proteins known to be targeted for ubiquitin-mediated proteasomal degradation 
by SOCS family members.  
Substrate Reference SOCS Family Member 
CD33 (11) 
SOCS3 Siglec-7 (12) 
IRS-1/2 (9) 
JAK2 (87) 
SOCS1 
Tel-JAK2 (88) 
Vav (89) 
NFκB subunit p65/Rel A (90) 
Mal (91) 
HPV, E7 (92) 
FAK (10) SOCS1, SOCS3 
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The importance of the SOCS-box component of individual SOCS proteins has been 
demonstrated using animal models. Zhang et al (2001) showed SOCS1-SOCS-box-
deleted (SOCS1∆SB/∆SB) knock-in mice developed a less severe phenotype than 
SOCS1 knockout mice suggesting an essential role for the SOCS-box domain (93). 
The severity of phenotype has been linked to prolonged hyper-responsiveness to 
IFNγ that prolongs STAT1 signalling in SOCS1∆SB/∆SB, but intermediate to that 
observed for the WT and conditional SOCS1-/- mice. Similarly, SOCS3∆SB/∆SB mice, 
although viable, have prolonged STAT3 signalling that is intermediate to that of 
conditional SOCS3-/- and WT mice. Hyper-responsiveness to G-CSF, in 
SOCS3∆SB/∆SB mice, resulted in enhanced granulopoiesis, tissue infiltration, and 
arthritis, although the phenotype was reduced compared to the conditional 
SOCS3-/- mice (94). The increased half-life of active pJAK1 found in SOCS3∆SB/∆SB 
embryonic stem cells (ES) suggests that SOCS3 can regulate JAK1 via ubiquitin 
ligase activity (73). Furthermore, comparison of WT, SOCS3-/- and SOCS3∆SB/∆SB ES 
cells has shown that the SOCS-box is specifically required to target LIF-induced 
pJAK for proteasomal degradation. These results indicated that in ES cells, pJAK 
dissociates from gp130 and is cleared via proteasomal degradation by SOCS3 and 
not simply inhibited by the KIR domain (73).   
 
SOCS3 negatively regulates IL6-induced JAK/STAT signalling in vitro and in vivo 
(95). This is supported from the finding that IL6-activated STAT1 and STAT3 
signalling is prolonged in conditional SOCS3-/- mice. In vitro studies have found 
that over-expressed SOCS1, SOCS3, or CIS can inhibit JAK/STAT signalling 
although in vivo function is more specific. If over-expressed, SOCS1 and SOCS3 
inhibits IL6 and IFNγ signalling although in conditional SOCS3-/- mice IL6 signalling 
is prolonged whereas IFNγ is unaffected. The opposite occurs in SOCS1-/- mice 
i.e. IFNγ signalling is prolonged whereas IL6 is unaffected suggesting that SOCS1 
and SOCS3 have reciprocal roles.   Interestingly, IL6-induced gene products from 
SOCS3-/- mice matched that of IFNγ-induced genes. This observation might be 
explained by the extended activation period of the STAT1, since it is potently 
activated by IFNγ but minimally activated by IL6 in the presence of SOCS3. 
Suppression of the IL6-activated JAK/STAT pathway by SOCS3 might therefore 
prevent an IFNγ-induced response by IL6 (95).    
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Tyrosine residues within the SOCS-box (70%) are conserved across all SOCS family 
member and are thought to regulate substrate binding, SOCS protein stability, 
ERK pathway regulation or auto-regulation in complex with the ESS or SH2 
domains (75). The interaction of the CIS SH2 domain with pY253 has already been 
mentioned with regard to the potential for auto-regulation. Furthermore, SOCS3 
SOCS-box-dependent maintenance of ERK signalling has also been discussed. 
Other phosphorylation events are thought to regulate the interaction of SOCS 
with the ubiquitination machinery and also modulate SOCS stability. In these 
cases, phosphorylation is thought to affect auto-ubiquitination or interaction 
with other E3 ligase complexes including those constructed from other SOCS 
family members. A complete list of protein kinases responsible for SOCS 
phosphorylation has yet to be documented although cytokine-induced kinases 
such as the Pim serine/threonine family kinases are thought to stabilise SOCS1 
(96). In support of this, all Pim family members (Pim1-Pim3) interact and 
phosphorylate SOCS1, while reduced SOCS1 levels were detected in Pim1/2 
knockout mice. It should be noted that not all phosphorylation events are 
sufficient to affect stability since hyperphosphorylation of SOCS3 by a 
constitutively active JAK2 mutant (V617F) is insufficient to cause destabilisation 
(8,73).   
 
Ubiquitin-directed proteasomal degradation of SOCS proteins, which is 
intimately linked to phosphorylation, might occur in an auto-regulatory fashion 
or via another SOCS protein or E3 ligase. Ubiquitination occurs within non-
conserved sequences at specific lysine residues on target proteins. As such, 
SOCS3 stability was increased, following an N-terminal domain truncation that 
resulted in the loss of Lys6 (97). Furthermore SOCS2, 6 and 7 can bind all other 
SOCS proteins and have been implicated in their regulation via proteasomal 
degradation (75). Ubiquitin-dependent SOCS regulation is yet to be resolved, 
with literature painting a complex picture of both auto- and cross-regulation, 
mainly from the finding that formation of SOCS E3 ligases, specifically the SOCS-
elongin interaction, has been shown to both stabilise and destabilise SOCS 
proteins. Furthermore, RING E3 ligases often perform auto-ubiquitination but are 
also found in complex with other E3 ligases (98) and so both mechanisms of 
regulation are equally possible. For example, concomitant degradation of CIS 
and SOCS3 with their target proteins, GHR and SIGLEC 7 respectively (75) as well 
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as the observation that disruption of the elonginB/C interaction leads to 
stabilisation, suggests that CIS/SOCS3-E3 ligases perform auto-ubiquitination. 
Conversely, a similar disruption to SOCS1 has been reported to destabilise the 
protein (99) suggesting that the elonginB/C interaction is protective. 
Additionally, SOCS3 is phosphorylated within the SOCS-box at Y204 and Y221 upon 
induction in response to IL2, IL3, Epo, EGF, PDGF, and IL6. Such phosphorylation 
events fail to block binding to gp130 or JAK inhibition but blocks binding to 
elonginB/C and reduce protein stability (100). In MEFs, IL6-induced SOCS3 is 
phosphorylated independently from IL6 stimulation, gp130 recruitment, and 
JAKs. Src receptor tyrosine kinases (RTK) were shown to be involved although 
residual SOCS3 phosphorylation suggested the involvement of additional kinases. 
It might therefore be speculated that SOCS3 could be regulated via crosstalk 
from other signalling pathways (62). Furthermore, SOCS3 was found to be 
stabilised in SOCS3∆SB/∆SB cells suggesting that SOCS-box or SOCS-box 
phosphorylation is necessary for its degradation (94).  
 
Different expression kinetics of SOCS proteins suggests the potential for 
additional regulation. SOCS1, 3, and CIS are rapidly and transiently induced, 
whereas SOCS2, 6, and 7 are expressed later and, in the case of SOCS2, 
expression in more prolonged (75). For example, Tannahill et al (2005) (55) 
showed that SOCS3 is induced after 30 minutes in IL2-treated peripheral blood 
mononuclear cells (PBMC) whereas SOCS2 was only detectable after 4 hours. 
Furthermore, whereas SOCS3 expression is transient and undetectable after 4 
hours, SOCS2 could still be detected after 24 hours (55).  All SOCS proteins 
interact with E3 ubiquitin machinery although SOCS1 and SOCS3 do so more 
weakly (101). Thus a situation is possible where stronger interacting members 
could potentially out-complete weaker members for the ubiquitin machinery and 
thus induce their proteasomal degradation. For example, SOCS2 is expressed 
later than SOCS1/3, and overexpression was found to have the unexpected 
effect of restoring JAK/STAT signalling following GH stimulation (51). This would 
suggest a role for SOCS2 in the negative regulation of SOCS1/3. Although new 
data dispute such a mechanism (102), SOCS2 has been demonstrated to regulate 
CIS in this fashion (75).  Furthermore, different expression kinetics might allow 
temporal regulation of signalling. For example, delayed expression of SOCS 
proteins would prolong the action of target signalling intermediates by delaying 
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their inhibition/degradation. SOCS2-mediated regulation is further complicated 
since low levels of SOCS2 can suppress GH signalling indicating a dual function 
(103). As well as ubiquitination, specific regions such as PEST (proline, 
glutamate, serine, and threonine-rich) motifs are also associated with the 
regulation of stability via proteasomal degradation. An unstructured PEST motif 
is found within the SH2 domain of SOCS3. Mutation of the PEST motif does not 
impact SH2 binding of phospho-tyrosine residues and complete removal of the 
motif does not prevent STAT3 inhibition. However, it does seem to impact 
stability since removal of the domain increases the half-life of SOCS3, suggesting 
a destabilising role (77). 
 
1.3 SOCS3: the first cAMP-inducible E3 ubiquitin ligase 
1.3.1 Cyclic AMP: generation and effectors 
Cyclic-AMP is a second messenger produced following the activation of Gαs-
coupled GPCRs e.g. activation of EP2 and EP4 receptors by prostaglandin E2 or by 
direct activation the Gαs effector protein adenylyl cyclase by forskolin (70). 
Adenylyl cyclase generates cAMP from cellular ATP, which rapidly diffuses 
throughout the cell. Efficient cAMP-dependent signalling is achieved by co-
localisation of cAMP effectors at typically at A-kinase anchoring proteins (AKAPs) 
(104). Furthermore, compartmentalisation and negative regulation of cAMP 
signalling is mediated by a family of phosphodiesterases (PDEs) such as the 
cAMP-specific PDE4 family which catalyses the hydrolysis of cAMP to AMP (104).  
Four cAMP effectors are defined namely cyclic nucleotide-gated (CNG) ion 
channels  (105), protein kinase A/cAMP-dependent protein kinase (PKA) (106), 
exchange protein directly activated by cAMP (EPAC) (107,108), and potentially 
CNRASGEF1 (109,110). The latter is controversial since the direct binding of 
cNMP has yet to be confirmed. While CNG ion channels are well characterised 
for photoreceptor, olfactory, and neuronal cells (105), functions within other 
cells types are not well characterised. As such, CNRASGEF1 and CNG ion 
channels will not be considered further.  
 
PKA, a serine/threonine kinase, is a multi-subunit protein consisting two 
regulatory (R) and two catalytic (C) units (Figure 1.5). Genes encoding four R 
                                                                                                                                                                                                                                                      30
units RIα, RIβ, RIIα, and RIIβ and three C units Cα, β, and γ are defined. PKA can 
be targeted to specific substrates by precise cellular localisation by AKAPs that 
bind PKA preferentially via the RII subunit although some also interact with RI 
subunits (111,112). Classically, cAMP drives gene transcription in a PKA/cAMP 
response element-binding protein (CREB)-dependent manner (113). Activation of 
PKA follows threonine phosphorylation at Thr197 within the activation loop of the 
catalytic unit and cAMP binding at two locations on each regulatory unit at the 
C-terminal cAMP-binding domain (CBD)(112). Conformational changes induced by 
cAMP binding allow dissociation of catalytic units and translocation to the 
nucleus. Within the nucleus, PKA catalytic domains phosphorylate CREB at S133, 
which enables association with CREB-binding protein (CBP) and gene 
transcription from cAMP-response elements (CREs) (113).  
 
Exchange protein directly activated by cAMP (EPAC) is a second form of cAMP 
sensor that changed the landscape of cAMP-mediated signalling (Figure 1.5). 
Until their discovery, PKA was the only accepted cAMP-activated protein 
(107,108)  EPACs are cAMP-activated guanine nucleotide exchange factors (GEF) 
for the Rap family of GTPases (107).  Two isoforms of EPAC are defined; EPAC1 is 
ubiquitously expressed while EPAC2 is restricted to brain tissue and adrenal 
glands (107,108). EPACs have diverse functions including cell adhesion, 
exocytosis, cell differentiation and proliferation, gene expression, and apoptosis 
(114). Cyclic AMP is a well defined anti-inflammatory mediator (115) and several 
of its responses are elicited via EPAC. For example, cAMP/EPAC-mediated SOCS3 
induction is sufficient to terminate IL6 signalling (70). Furthermore, to protect 
against infiltration of pro-inflammatory mediators, vascular permeability is 
reduced following EPAC1 activation by vascular endothelial (VE)-cadherin-
dependent cell junction formation and actin remodelling (116). The 
development of cAMP analogues that selectively activate EPACs such as 8CPT-
2’O-Me-cAMP(007) has enabled PKA- and EPAC-specific pathways to be 
delineated (116).    
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Figure 1.5: PKA and EPAC domain structure 
PKA is a cAMP-activated serine/threonine protein kinase. It exists as a complex of two 
regulatory (R) and two catalytic (C) units when inactivate. Binding of cAMP at two 
cAMP-binding domains (CBD) on each regulatory unit leads to activation and dissociation 
of catalytic units and phosphorylation of multiple substrates at serine and threonine 
residues.  EPACs are GEFs for the Rap family of small GTPases. They share a conserved 
central CBD with PKA although EPAC2 also has an additional low affinity N-terminus CBD 
of unknown function. The Dishevelled/Egl-10/Pleckstrin (DEP) domain mediates 
membrane attachment while the Ras exchange motif (REM), found in all known Rap 
GEFs, is important for structural stability (107).  GEF activity is provided by the CDC25 
homology domain (CDC25HD) aided by the REM and the Ras association domain (RA). 
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1.3.2 SOCS3 and cAMP 
As previously stated, SOCS proteins are each induced by a variety of stimuli but 
importantly, SOCS3 is also inducible by cAMP (117). How cAMP leads to SOCS3 
induction is yet to be fully described. Unlike IL6 which induces SOCS3 via the 
JAK/STAT pathway, cAMP-induced SOCS3 is via an EPAC/CAATT enhancer binding 
protein (C/EBP) (70) and a PKA-independent ERK-mediated route (118). Whereas 
the former is dependent on STAT-mediated gene transcription the latter is 
dependent on the C/EBP transcription factor family, specifically the C/EBPβ and 
C/EBPδ isoforms (119). Sustained cAMP elevation is thought to result in at least 
two distinct events leading to SOCS3 induction: EPAC1 activation and transient 
PKA-independent ERK activation (118). EPAC1 activation increases recruitment 
of C/EBP at the SOCS3 promoter (119) whereas ERK-dependent phosphorylation 
of C/EBPβ at Thr235 fully activates SOCS3 expression (70). While downstream 
events following EPAC activation are unclear, it has been shown that SOCS3 
induction is Rap1-dependent (119), via the activation of its downstream effector 
PKCα through PLCε (120). Activation of PKC by the sn-1,2-diacylglycerol (DAG) 
analogue phorbol myristate acetate (PMA) leads to ERK-dependent 
phosphorylation of the transcription factors STAT3 (S727), SP3 (S73), and the 
component of the AP-1 complex c-Jun (S63) within their transactivation domains 
in HUVECs (121). Furthermore, AP-1, STAT, and SP1/SP3 consensus sites within 
SOCS3 promoter (-107 nucleotides from the transcription start site) are 
necessary for PMA and cAMP-mediated SOCS3 induction. Inhibition of ERK 
signalling using the MEK inhibitor U0126 does not completely ablate SOCS3 
induction in COS1 cells suggesting the involvement of another MAPK such as JNK 
(121). Indeed, JNK inhibition blocks PMA-dependent phosphorylation of c-Jun 
and cAMP-mediated induction of SOCS3 (121).  A further study by the same group 
also showed that the p38 MAPK pathway is also involved in the maintenance of 
basal activity of the SOCS3 promoter (122).  
 
It has been demonstrated that EPAC1 activation is sufficient to terminate IL6 
signalling following SOCS3 induction (70). The SOCS3 SH2 and KIR domains have 
been shown to be essential for this inhibitory role (123). However, the increased 
half-life of active pJAK1 found in SOCS3∆SB/∆SB embryonic stem cells (ES) suggests 
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that SOCS3 can regulate JAK1 via ubiquitin ligase activity (73). The identification 
of several SOCS3 ubiquitin-regulated substrates has marked SOCS3 as the first 
cAMP-inducible E3 ubiquitin ligase (8-12). However, the full spectrum of SOCS3-
dependently ubiquitinated substrates has yet to be identified necessitating this 
study.    
1.3.3 SOCS3 and inflammation 
The importance of STAT3/SOCS3 signalling has been demonstrated in several 
chronic inflammatory disorders such as atherosclerosis (66) and Crohn’s disease 
(46,124). SOCS3 inhibits pro-inflammatory IL6-stimulated signalling in ECs 
(70,118). Furthermore, prolonged IL6 signalling is detected in macrophages and 
liver cells from conditional SOCS3-/- mice (95). Moreover, while IL6 can inhibit 
macrophage colony-stimulating factor (M-CSF)-mediated proliferation of bone 
marrow-derived macrophages, IL6 has a greater inhibitory effect on SOCS3-/- 
macrophages (95). Sustained IL6 signalling in the absence of SOCS3 led to an 
IFNγ-type response, probably due to extended STAT1 signalling, suggesting that 
SOCS3 is required to direct the appropriate cytokine response (95). Together, 
these data not only demonstrate the ability SOCS3 to suppress and regulate the 
duration of cytokine signalling but also to regulate macrophage proliferation.  
Furthermore, the specific loss of SOCS3 in macrophages has been shown to 
produce an IL6-mediated IL10-like anti-inflammatory response (125). Similar to 
IL10-treated WT macrophages, treating SOCS3-/- macrophages with LPS plus IL6 
resulted in sustained STAT3 activation that suppressed secretion of the pro-
inflammatory cytokines TNFα and IL12 (125).    
 
Chronic IL6 signalling contributes to the onset of atherosclerosis, which is 
associated with the upregulation of adhesion molecules, chemokines, and 
proliferation of vascular smooth muscle cells (VSMCs) (Section 1.1.3). 
Furthermore, SOCS3 is found to be elevated in the shoulder regions of 
atherosclerotic plaques (66). The shoulders are weak, vulnerable regions 
associated with inflammatory gene expression, macrophage infiltration, and 
strong haemodynamic stress, it is here where rupture frequently occurs (66,126). 
Overexpression of SOCS3 has been demonstrated to negatively regulate IL6-
mediated STAT3 signalling and reduce proliferation of VSMCs and monocytes 
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(66). Furthermore, this was accompanied by a reduction in ICAM1 and MCP1 
expression thus supporting its role as a negative regulator of inflammation (66).  
SOCS3 is also a negative regulator of G-CSF mediated granulopoiesis, the 
development of progenitor stems cells to granulocytes such as neutrophils. A 
targeted, conditional deletion of SOCS3 in haematopoietic cells resulted in 
splenomegaly and neutrophil leukocytosis followed by inflammation of the plural 
and peritoneal cavities (127). Increase response to G-CSF was linked to sustained 
STAT3 activation but not STAT1, STAT5, or ERK1/2, which are also G-CSFR 
effectors. This study showed that SOCS3 could inhibit STAT3 signalling via 
inhibition of JAK, which was dependent on G-CSFR pY
729 (pY
728 in mouse). 
However, a more recent study found that negative regulation of G-CSFR might 
also be dependent on the E3 ligase functionality of SOCS3. A specific SOCS3 
SOCS-box deletion (SOCS3∆SB/∆SB) in mice produced a similar but milder 
phenotype compared to the conditional SOCS3-/- mice (94). Furthermore, 
SOCS3∆SB/∆SB mice had prolonged STAT3 signalling that was intermediate to that 
of conditional SOCS3-/- and WT mice (94). Furthermore, SOCS3 has been shown 
to target G-CSFR for SOCS-box-dependent ubiquitination and lysosomal 
degradation (8). As such, SOCS3 regulates this pathway via both SOCS-box 
dependent and independent mechanisms. As an E3 ligase, SOCS3 might more 
broadly impact inflammatory signalling by targeting effectors of JAK/STAT 
signalling. A SOCS3∆SB/∆SB in embryonic stem cells (ES) resulted in an increased 
half-life of active pJAK1 suggests that SOCS3 can regulate JAK1 via ubiquitin 
ligase activity (73). Furthermore, comparison of WT, SOCS3-/-, and SOCS3∆SB/∆SB 
ES cells has shown that the SOCS-box is specifically required to target LIF-
induced pJAK for proteasomal degradation. These results indicated that in ES 
cells, pJAK dissociates from gp130 and is cleared via proteasomal degradation by 
SOCS3 and not simply inhibited by the KIR domain (73).   
 
The role of SOCS3 in adaptive immunity is less well understood. However, SOCS3 
has been shown to be important in the development and maintenance of allergy 
(82) and the development of autoimmune disorders such as multiple sclerosis 
(128). SOCS3 is differentially expressed in naïve CD4+ T-cells following 
differentiation to Th cells with SOCS3 being exclusively expressed in Th2 cells. 
Elevated SOCS3 expression during differentiation, which is dependent on 
IL4/STAT6 signalling, correlates with the development and severity of atopic 
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dermatitis and asthma (82). SOCS3 transgenic mice, which constitutively express 
elevated levels of SOCS3 in T-cell subsets, have an increased Th2 response (82). 
SOCS3 expression was found to inhibit IL12-mediated STAT4 signalling thus 
inhibiting Th1 differentiation. As such, increase SOCS3 levels leads to 
pathogenesis due to an excessive Th2-activated granulocyte response (82). 
Increased levels of SOCS3 seem to be driven by IL4 which is also is secreted by 
Th2 cells and in a positive feedback loop maintains SOCS3 expression. A further 
study implicated SOCS3 in the development of Th17 cells (129). Th17 cells provide 
protection against fungi and extracellular bacteria, while Tregs limit this 
response. Sustained IL6 signalling disrupts the Th17/Treg balance leading to Th17 
cell-mediated development of inflammatory disorders such as rheumatoid 
arthritis (60). In the absence of SOCS3, IL23-mediated STAT3 signalling is 
enhanced which drives STAT3 mediated IL17A/F gene expression and subsequent 
generation of Th17 cells; this effect is enhanced in the presence of IL6 (129).  
 
The effects of SOCS3 therefore seem to be cell/context specific and thus 
therapeutic benefits might require precise targeting of SOCS3. For example, in 
the case of G-CSFR signalling, inhibition of SOCS3 might aid recovery from 
neutropenia such as following chemotherapy while activation of SOCS3 might aid 
treatment of chronic inflammation associated with neutrophil accumulation such 
as inflammatory bowel disease (IBD) (127). Furthermore, while upregulation of 
SOCS3 might be anti-inflammatory by reducing atherosclerotic lesion formation 
(66), upregulation in macrophages might be pro-inflammatory (125).   
 
Exogenous delivery of recombinant SOCS3 through various routes has been used 
to reduce the severity of phenotype of several chronic inflammatory disorders 
such as rheumatoid arthritis (130) and acute systemic inflammatory responses 
such as endotoxic shock (131). Adenoviral delivery of SOCS3 cDNA into joints of 
arthritic mouse models (antigen/collagen-induced arthritis) suppressed 
proliferation of synovial fibroblasts, pannus formation, monocyte infiltration, 
secretion of IL6, and a generally milder arthritic phenotype (130).  Furthermore, 
liposomal delivery of SOCS3 cDNA into mice peritoneum prior to challenge with 
LPS increased mouse survival and reduced serum TNFα levels (131). Moreover, a 
cell penetrating (CP) form of SOCS3 has been produced that strongly targets 
leukocyte and lymphocyte subsets in blood, spleen, and liver but also kidney and 
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liver cells and to a lesser degree lung, spleen, and heart (132). Intraperitoneal 
delivery of CP-SOCS3 has been demonstrated to reduce IL6, TNFα, and MCP1 
expression. CP-SOCS3 also reduced MHCII induction possibly via inhibition if 
IFNγ/STAT1 signalling. Interestingly, a CP-SOCS3 mutant lacking a SOCS-box had 
an impaired ability to inhibit STAT1 signalling thus demonstrating the 
importance this region of SOCS3 to negatively regulate inflammatory signalling. 
Additionally, CP-SOCS3 administered to a mouse model of acute liver injury 
(staphylococcal enterotoxin B + D-galactosamine) resulted in a 100% survival rate 
with no visible liver injury (132).  
 
Recently, statins have been used to combat multiple sclerosis, an autoimmune 
disease associated autoreactive T-cells, likely Th17 cells, which migrate to the 
central nervous system (CNS) and cause neuronal demyelination and 
conductional dysfunction amongst many other things (128).  Statins have lots of 
anti-inflammatory effects outwith their ability to lower cholesterol such as 
reducing expression of adhesion molecules (ICAM, VCAM), cytokines (TNFα, IL6), 
chemokines (MCP1), and inhibition of the NFκB pathway (133,134). With regards 
to T-cell response, the anti-inflammatory effects of statins are thought to stem 
from manipulation of SOCS3 expression (128). For example, simvastatin is 
thought to activate STAT3 in dendritic cells to induce SOCS3 which blocks IL23 
production thus inhibiting Th17 cell differentiation (128). However, this might 
also be accompanied by several other anti-inflammatory effects of statins such 
as reducing Th1 pro-inflammatory cytokines (TNFα, IFNγ) and elevating Th2 anti-
inflammatory cytokines (IL10) (128). 
 
It can be seen that SOCS3 is integral to the regulation of both innate and 
adaptive immune systems. Furthermore, manipulation of SOCS3 has been shown 
to be successful in the treatment of chronic inflammatory disorders. However, 
the involvement of SOCS3 as an E3 ubiquitin ligase in the regulation of these 
disorders is incompletely understood. Given that the disruption of E3 ligases are 
expected to have specific effects (Section 1.4), targeting of SOCS3 in this 
capacity might be therapeutically beneficial.      
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1.4 Ubiquitin-proteasome pathway 
1.4.1 Ubiquitination: formation and function 
Ubiquitination is a reversible post-translational modification that parallels the 
phosphorylation system by modulating location, activity and protein interactions 
(98). Ubiquitin is a 76 amino-acid protein which is thought to be involved in the 
regulation of most cellular events (98). Covalent attachment of mono-, multi-, 
or polyubiquitin chains provides a diverse set of signals from which signalling 
pathways can be fine-tuned. Ubiquitination typically involves the formation of 
an isopeptide bond between the ε-amino-group on an internal lysine residue 
within the target protein and the C-terminal glycine residue (G76) of ubiquitin. A 
modification of the N-terminal methionine residue of ubiquitin has also been 
reported (135). Attachment of ubiquitin is mediated by the individual actions of 
E1 activating, E2 conjugating, and E3 ligase proteins where substrate specificity 
is determined by the latter (Figure 1.6). Furthermore, an additional protein 
termed the E4 enzyme (ubiquitin chain elongation factor) has also been reported 
that serves to elongate mono- or oligoubiquitin chains (136). By doing so, 
proteins activated by monoubiquitination might be targeted for polyubiquitin-
dependent degradation. E3 ubiquitin ligases comprise two main forms, the 
homologous to E6-AP COOH-terminus (HECT)-domain and really interesting new 
gene (RING)-finger-motif. RING-finger E3s are the largest family of ubiquitin 
ligases and include the elongin-cullin-SOCS family (52). The main functional 
difference being that, while RING-finger E3s indirectly bind ubiquitin via an E2 
conjugation enzyme, HECT-domain E3s become covalently attached to ubiquitin 
at conserved a cysteine residue via a thiol-ester bond and are therefore directly 
involved in ubiquitin transfer (Figure 1.6). 
 
Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) (98) 
and all can be used to form polyubiquitin chains although most is known about 
the K48- and K63-linked moieties. K48-linked chains are the most understood 
and direct proteasomal degradation (137) (Figure 1.8) whereas K63-linked chains 
can function as scaffolds and activators of ubiquitin-interacting domain-bound 
complexes (16).  
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While the functions of chains produced using non-K48/K63 lysine residues are not 
well understood (see figure 1.6 for examples), recent studies suggest that all 
non-K63-polyubiquitin chains might have a role in targeting proteins to the 
proteasome (138). SOCS3 has been shown to direct ubiquitin-mediated 
proteasomal degradation and lysosomal routing of its substrates and so it is 
predicted to form K48-polyubiquitin chains (8-12). A difference in structure of 
polyubiquitin chains has been suggested to be responsible for the functional 
variation. NMR has been used to show that K48-polyubiquitin produces a closed 
conformation whereas K63-linked chains produce a more extended linear 
structure (98). Adding to the complexity of the ubiquitin signal, chains can have 
mixed linkages and branches although their significance has not yet been 
explained(138). Furthermore, proteasomal degradation has also been reported 
following generation of novel linear ubiquitin chains i.e. C-terminal glycine of 
ubiquitin to the N-terminal methionine of ubiquitin (85).   
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A.       B. 
 
 
Figure 1.6: Ubiquitination  
Ubiquitin is a 76-residue protein that is covalently bound to a target protein to direct 
multiple functions (5). A. Attachment of ubiquitin is via a three-step hierarchical 
process of activation (E1), conjugation (E2), and ligation (E3). In human, two E1, 50 E2 
and over 600 E3 ubiquitin ligases have been defined along with 90 DUBs and 20 UBDs 
(14). In an ATP dependent step, ubiquitin is attached to an E1 activating enzyme via a 
high energy thio-ester bond. This charged complex then transfers ubiquitin to another 
cysteine in the active site of the E2 conjugating enzyme.  Finally, ubiquitin is 
transferred to a substrate lysine residue via an isopeptide bond between the ε-amino 
group of the lysine within the substrate and the C-terminal carboxyl of ubiquitin via the 
E2-E3 interaction. The E3 ligase, itself a multi-subunit protein complex, brings together 
the E2 linked ubiquitin and the target protein and so acts as a specificity unit. The 
mechanism of ubiquitin ligation differs between E3 ligase families. HECT E3 ligases are 
directly covalently attached to ubiquitin whereas E3 RING ligases indirectly bind 
ubiquitin via the E2 conjugation enzyme. B. Ubiquitin has seven lysine residues and 
chains can be produced from each of them. Variations direct different functions as 
shown although not all possible ubiquitin combinations have defined functions. 
Reproduced with permission from (98). 
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Ubiquitin is not alone in its ability to modulate the proteome. Ubiquitin-like 
proteins (ULP) have also been characterised which include small ubiquitin-like 
modifier (SUMO) and neural precursor cell expressed, developmentally down-
regulated 8 (NEDD8). They are structurally similar in that they have a conserved 
‘ubiquitin fold’. In a similar three-step fashion to ubiquitin, they are covalently 
attached to target proteins to facilitate a number of functions such as regulating 
protein interactions, localisation, activity, and stability. SUMOylation might be 
more specific than ubiquitination due to the use of a single E2 conjugation 
enzyme, Ubc9 (69). Furthermore, unlike ubiquitination SUMOylation takes place 
at ΨKxE (Ψ is I, L or V; x is any residue) consensus motif (69). Mono- and poly-
SUMOylation are possible where mono-SUMOylation regulates interaction, 
activity, and localisation whereas poly-SUMOylation is thought to initiate 
polyubiquitination and proteasomal degradation thus linking the SUMO and 
ubiquitin systems (69). PIAS members are thought to be regulated by 
SUMOylation and that they themselves have SUMO-E3 ligase function (69). All 
known cullins are mono-neddylated at a internal lysine residue within the 
consensus sequence IVRIMKMR (139). Neddylation is thought to be essential for 
E3 ligase formation and increased catalytic activity (52,98). Both modifications 
occur via an isopeptide bond with the C-terminal G76 of the ULP and are 
therefore indistinguishable from ubiquitin following trypsin digestion i.e. both 
modification leave a GlyGly remnant important for determining the modified 
lysine residues via mass spectrometry.    
 
Ubiquitination is reversible via the action of deubiquitinases (DUBs). Around 100 
DUBs have been identified, however their substrates have not been fully 
described (140). DUBs regulate signalling events by cleaving and disassembling 
ubiquitin and polyubiquitin chains from affected substrates and so aid the 
recycling of free ubiquitin (141). Specificity is conveyed by protein-protein 
interaction motifs that enable binding to proteins with specific ubiquitin 
modifications e.g. K63/K48 polyubiquitin chains. DUBs like A20 and CYLD are 
integral to the regulation of the innate immune response by ablating NFκB 
signalling (141). CYLD also regulates the adaptive immune response via its role in 
the development, tolerance, and activation of T-Cells (142). As such, DUBs are 
associated with several immune-related disorders (see below).  
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Covalent attachment of ubiquitin can modulate protein function and localisation 
but other proteins can also interact non-covalently with ubiquitin with similar 
results. For example, the K63-polyubiquitination is essential for the localisation 
of activation of NFκB essential modulator (NEMO/IKKγ) during NFκB signalling 
(16). Around 16 UBDs have been characterised which enable a weak (Kd>100µM) 
interaction with monoubiquitin which is strengthened by several mechanisms 
such as cooperative binding with other proteins/lipids and by having multiple 
UBDs (143). Different UBDs interact with ubiquitin at different sites resulting in a 
diverse range of proteins and protein folds that interact with ubiquitin. 
Furthermore, the diversity of linkages/branching of polyubiquitin chains has 
complicated the characterisation of the UBDs (143). As such, delineating 
ubiquitin-binding code is in its infancy. For instance, NEMO binds to  
polyubiquitin chains via a novel UBD termed NEMO-ubiquitin-binding (NUB) 
domain that partly includes a coiled-coiled domain and leucine zipper motif and 
the intermediate linker region (16). 
1.4.2 The canonical NFκB pathway: a ubiquitin dependent pathway 
Ubiquitination is recognised as a regulator of the immune system where it plays 
a central role in the activation, amplification, and termination of the innate and 
adaptive immune system (14). Ubiquitination is central to the regulation of the 
pro-inflammatory NFκB pathway and requires functional K48- and K63-
polyubiquitin chains (16). Different stimuli initiate distinct sequences of events 
that eventually activate NFκB, although in each case several ubiquitin-mediated 
events such as protein localisation, activation, and proteasomal degradation are 
shared (16). Lipopolysaccharide (LPS) activates toll-like receptor 4 (TLR4) 
resulting in the recruitment of adaptor proteins myeloid differentiation primary 
response protein 88 (MyD88) and interleukin-1 receptor-associated kinase 1 
(IRAK1) to its cytoplasmic face (Figure 1.7). The activated E3 ubiquitin ligase, 
TNF receptor associated factor 6 (TRAF6), catalyses the formation of K63-
polyubiquitin chains which binds multiple factors via their ubiquitin-interacting 
domains. The K63-polyubiquitin-dependent localisation of kinase regulatory unit 
TAK1 binding protein 2 (TAB2) binds and enables the autophosphorylation and 
activation of transforming growth factor-β-activated kinase-1 (TAK1).  
Subsequently, a further K63-polyubiquitin-bound kinase complex IκB kinase (IKK) 
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is activated following the phosphorylation of IKKβ by TAK1. IKK consists of the 
catalytic subunits IκB kinase α (IKKα) and IκB kinase β (IKKβ) which are bound to 
the K63-polyubiquitin chains via the regulatory subunit NEMO/IKKγ. This 
phosphorylation cascade concludes with the phosphorylation of IκBα by IKKα at 
S32 and S36.  Phosphorylated IκBα is then recognised and K48-polyubiquitinated 
by its cognate E3 ubiquitin ligase (SCFβ-TRCP, not shown). IκBα is subsequently 
degraded via the 26S proteasome allowing the p65 (REL-A)/p50 subunits of NFκB 
to translocate to the nucleus to drive gene transcription. Other PRRs (RLRs, 
NLRs) can also activate the NFκB pathway via distinct receptor-activated 
ubiquitin-dependent mechanisms (144).   
 
The NFκB pathway is negatively regulated via several mechanisms. IκBα is a 
gene target of NFκB and so acts as part of a classical feedback loop to suppress 
NFκB-directed gene transcription via its sequestration back to the cytoplasm. In 
addition to nuclear export, REL-A is also targeted for ubiquitin-mediated 
proteasomal degradation via a COMMD1/ECSSOCS1 complex within the nucleus 
(145). This pathway is also negatively regulated by the DUBs CYLD and A20 that 
degrade K63-polyubiquitin chains thus blocking downstream signalling events 
(146). CYLD is inducible by LPS after which it depolymerises K63-polyubiquitin 
chains on NEMO to ablate NFκB signalling (147). A20, a TNFα-inducible DUB, 
targets receptor interacting protein (RIP), part of the TNF receptor 1 (TNFR1) 
signalling complex, to ablate NFκB signalling. However, A20 is unique in that it 
has both DUB and E3 ligase domains and following K63-specific deubiquitination 
of RIP, A20 ubiquitinates RIP with a K48 polyubiquitin chain thus targeting it for 
degradation (146).     
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Figure 1.7: The canonical NFκB pathway is dependent on K48- and K63-
polyubiquitin chain formation 
Briefly, lipopolysaccharide (LPS) activates toll-like receptor 4 (TLR4) resulting in the 
binding and activation of multiple signalling mediators to its cytoplasmic face. The 
activated E3 ubiquitin ligase, TNF receptor associated factor 6 (TRAF6), catalyses the 
formation of K63-polyubiquitin chains which binds multiple factors via their ubiquitin-
interacting domains. These factors initiate a phosphorylation cascade that leads to the 
phosphorylation of IκBα by IKKα. This phosphorylation event allows IκBα to be 
recognised and K48-polyubiquitinated by its E3 ubiquitin ligase (SCFβ-TRCP, not shown). 
IκBα is subsequently degraded via the 26S proteasome allowing the p65 (REL-A)/p50 
subunits of NFκB to translocate to the nucleus to drive gene transcription. IκBα is a 
gene target of NFκB and so acts in a classical feedback loop to suppress NFκB-directed 
gene transcription. Image adapted with permission from (16). 
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                                                                                                                                                                                                                                                      44
NFκB signalling is integral to the activation of the innate immune response such 
as the TLR4-mediated activation of macrophages which then secrete pro-
inflammatory cytokines to amplify/maintain the innate response but also 
activate an adaptive T-Cell response (39). Given the importance of ubiquitin in 
NFκB signalling it is not surprising that dysregulation is associated with severe 
inflammatory and immunological disorders. For example, a mutation within the 
NUB domain of NEMO, which impairs the binding of K63-polyubiquitin chains and 
thus localisation and activation of the IKK complex, is associated X-linked 
recessive syndrome anhidrotic ectodermal dysplasia with immunodeficiency 
(EDA-ID). Patients with EDA-ID have poor inflammatory response, impaired NFκB 
signalling such as in response to LPS, and die prematurely from multiple 
infections (148). Dysregulation of DUBs or mutations of ubiquitin attachment 
sites in target proteins also cause dysfunction. Mouse models lacking the DUB 
A20 die prematurely from severe inflammation due to hyperactive NFκB 
signalling (146,149). However, mice lacking CYLD, while having normal TNFα-
mediated NFκB signalling in bone-marrow-derived macrophages, have impaired 
levels of CD4+ and CD8+ T-Cells (142).   
 
In a similar way to LPS, TNFα also activates the canonical NFκB pathway (Figure 
1.8). However, full activation is conditional on the recruitment of the E3 ligase 
linear ubiquitin chain assembly complex (LUBAC), a trimeric complex consisting 
of HOIL1, HOIL-1-interacting protein (HOIP), and SHANK-associated RH domain 
interacting protein (SHARPIN). LUBAC catalyses the formation of linear (M1-) 
polyubiquitin chains on RIP1 and NEMO, which is thought to result in a more 
stable IKK complex (136,150,151). In the absence of LUBAC, NFκB signalling is 
impaired leading to TNFα-induced cell death (150). Furthermore, mice deficient 
in SHARPIN develop chronic proliferative dermatitis (CPDM), a multi-organ 
inflammatory disorder (150).   
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Figure 1.8: The canonical TNFα-activated NFκB pathway is dependent on 
linear (M1-), K48- and K63-polyubiquitin chain formation 
Briefly, a trimer of tumour necrosis factor alpha (TNFα) cross-links and activates the 
TNF-receptor 1 (TNFR1) monomers resulting in the binding and activation of multiple 
signalling mediators to its cytoplasmic face. The adaptor protein TNF receptor 1-
associated death domain protein (TRADD) recruits the E3 ubiquitin ligases, TNF receptor 
associated factor 2 (TRAF2) and cellular inhibitor of apoptosis 1/2 (cIAP1/2) which 
catalyses the formation of K63-polyubiquitin chains on receptor-interacting protein 
kinase 1 (RIP1). Multiple factors are then recruited via their ubiquitin-interacting 
domains. These factors initiate a phosphorylation cascade that leads to the 
phosphorylation, ubiquitination, and degradation of IκBα allowing NFκB to translocate 
to the nucleus to drive gene transcription. Full activation of the NFκB is conditional on 
the recruitment of the E3 ligase linear ubiquitin chain assembly complex (LUBAC), a 
trimeric complex consisting of HOIP, SHARPIN, and HOIL-1. LUBAC catalyses the 
formation of linear (M1) polyubiquitin chains on RIP1 and NEMO (not shown) which is 
thought to result in a more stable IKK complex. Image adapted with permission from 
(151). 
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Together it seems that ubiquitination and canonical NFκB signalling is critical for 
protection against infection due to its role in the activation and development of 
the immune system but dysregulation can result in severe inflammation. As such, 
tight control is necessary to maintain homeostasis.  
1.4.3 Therapeutically targeting the ubiquitin-proteasome pathway   
The ubiquitin proteasome pathway has been therapeutically exploited by 
targeting both the ubiquitin protein cascade and the proteasome. With 
structural knowledge of the ubiquitin cascade proteins (E1, E2, and E3), it might 
be possible to disrupt the interaction of these proteins with each other or their 
substrates. In human, two E1, 50 E2s, and over 600 E3 ubiquitin ligases have 
been defined (14). As such, disruption of E1 function might be valuable where a 
global effect might be achievable. However, targeting at the level of the E3, 
which determines the specificity of ubiquitination, would be more precise with 
potentially less adverse effects. However, a potential problem with disruption of 
E3 ligases is the lack of knowledge of E3 targets. Inhibition of a single E3 could 
affect multiple unknown targets and pathways. If this could be overcome, 
targeting of substrate-E3 complex would allow a highly specific functional 
inhibition via selective targeting of substrates. So far, small molecule disruption 
of E3-E2 has not been reported. Targeting of a RING-finger based E3-substrate 
interaction has been successful such as in the case of MDM2-p53 with the MDM2 
antagonist Nutlin, which targets the p53-binding pocket on MDM2 (52,152). This 
strategy might also be possible in treatment of inflammation. It is known that β-
transducin repeat-containing protein (β-TRCP), the specificity factor for a 
further RING-finger based E3 ligase, SCFβ-TRCP, targets NFκB signalling via 
ubiquitination of its inhibitor IκBα (153). Inhibition could have potential anti-
inflammatory effects. However, since SCFβ-TRCP also regulates the pro-oncogenic 
transcription factor β-catenin, inhibition of SCFβ-TRCP might result in 
tumourigenesis (52). Interestingly, a small molecule inhibitor of IκBα 
ubiquitination, Ro106–9920, has been identified (154). This novel, but yet 
unidentified E3 is distinct from SCFβ-TRCP and inhibits NFκB signalling without 
affecting levels of β-catenin (154).  
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Figure 1.9: Structure and function of the 26S proteasome 
The 26S proteasome is a 2000 kDa multi-subunit protein that performs ATP-dependent, 
ubiquitin-dependent degradation of a vast range of cellular proteins. A. The 26S 
proteasome is constructed from two 19S regulator units and one 20S catalytic unit. Only 
the structure of the 20S unit has been determined (155). Ubiquitinated proteins are 
recognised by the 19S units which deubiquitinate and denature the proteins before 
feeding them into a cylindrical chamber of the 20S subunit. Three broad-spectrum 
proteolytic sites within the 20S core, chymotrypsin-like, trypsin-like, and post-glutamyl 
peptide hydrolase-like (PGPH), cleave the peptides at C-terminal hydrophobic, basic, 
and acidic residues respectively as it is fed through producing 3-26 residue 
peptides(156). The 20S subunit can exist in a latent form but requires additional units to 
aid entry of the peptide into the catalytic core i.e. 19S subunit. B. The β catalytic rings 
are made of 7 subunits with β1, β2, and β5 having catalytic activity. Chymotrypsin-like, 
trypsin-like, and capsase-like/post-glutamyl peptide hydrolase-like (PGPH), cleave the 
peptides at C-terminal hydrophobic, basic, and acidic residues. Inhibition of the 
chymotrypsin-like domain by the drug Bortezomib is a successful anti-cancer treatment.  
RP, regulatory protein; CP, catalytic protein. Adapted with permission from (155,156). 
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Neddylation is important in the construction and regulation of catalytic activity 
of E3 ligases including cullin5, a component of the elongin-cullin-SOCS3 type E3. 
Inhibition of neddylation is a further potential strategy that could be 
implemented to sustain the functional effects of ubiquitinated proteins. 
Inhibition of this process might be therapeutically beneficial although non-
specific effects are expected since it regulates all cullins (157). 
 
Inhibition of the proteasome (Figure 1.9) has been exploited in cancer 
treatments. The chymotrypsin-like inhibitor Bortezomib specifically targets 
cancer cells possibly since these cells have higher rates of protein expression 
and so are more sensitive to proteasome inhibition. However, the mechanism of 
growth inhibition and cell death of cancer cell lines due to proteasome inhibition 
is unknown (156). 
 
Currently there is a lack of knowledge of structure and protein interaction that 
make the design of a specific E3-substrate disruptors challenging, although some 
progress has been made via functional screening programs (152). In the case of 
SOCS3, few substrates are known. By performing a global screen for SOCS3-
dependently ubiquitinated substrates, it is hoped that the impact of SOCS3 on 
inflammation can be better understood. Discovery of new SOCS3 substrates 
through this study might therefore provide targets that when correctly targeted 
produce specific therapeutically beneficial effects.          
1.5 Project rationale and experimental approach 
1.5.1 Project rationale 
Currently, it is accepted that there is a link between obesity and several 
diseases such as CVD, diabetes, RA, and atherosclerosis with the common 
initiating factor in pathogenesis being a state of low grade, chronic inflammation 
(1,3). Such a state is characterised by elevated levels of pro-inflammatory 
cytokines such as IL6 (5). Sustained activation of inflammatory signalling 
pathways following ligand-cytokine-receptor ligation can result in pathogenesis 
if not properly regulated (46). One such pathway, the JAK-STAT pathway, is 
found to be hyperactive in several chronic inflammatory disorders (46,66,130). 
An IL6-inducible protein, SOCS3, has been demonstrated to terminate IL6-
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mediated STAT signalling thus suppressing an inflammatory response (Section 
1.3.3) (118). Furthermore, SOCS3 is induced by, and regulates several signalling 
pathways including, but not limited to, IL6 (Figure 1.2) (70), LPS (158), TNFα 
(159), and insulin (160). As such, SOCS3 might simultaneously control a diverse 
set of intracellular signalling events. Supporting its role as an anti-inflammatory 
mediator, SOCS3 is also inducible via cAMP (70), an accepted global anti-
inflammatory agent (Figure 1.10) (115).  
 
While SOCS3 was primarily characterised as a competitive inhibitor of 
intracellular signalling (70,158,159), it also functions as specificity factor for an 
ECS-type E3 ubiquitin ligase. In this role it has been demonstrated to direct 
ubiquitin-mediated proteasomal degradation of several substrates (9-12) and 
lysosomal routing (8). However, the full spectrum of SOCS3-dependently 
ubiquitinated substrates is unknown. It is possible that SOCS3 might regulate 
cytokine signalling via the targeted degradation of specific pro-inflammatory 
mediators. Indeed, SOCS1 has been shown to target JAK2 for proteasomal 
degradation (87). Moreover, the increased half-life of active pJAK1 following 
genetic impairment of SOCS3 E3 ligase functionality in embryonic stem cells (ES) 
suggests that SOCS3 might similarly regulate JAK1 (73). Interestingly, JAK3 is 
also downregulated following elevation of cAMP levels in antigen-primed T-
lymphocytes, however the mechanism of how this occurs is unclear (161).  Given 
that JAK/STAT signalling is critical in the development of inflammatory 
disorders, delineating the role of SOCS3 as an E3 ligase might be therapeutically 
beneficial.  However, given the broad range of SOCS3 stimuli, the availability of 
certain SOCS3 substrates might be conditional on the route of SOCS3 induction 
and target phosphorylation. Using a global proteomics approach, this study 
aimed to identify SOCS3-dependently ubiquitinated substrates in response to 
cAMP and thus elaborate on the already well-established role of cAMP in 
inflammation.   
 
Differentially SILAC-labelled, tandem affinity purified ubiquitinomes of WT MEFs 
and SOCS3-/- MEFs each expressing epitope-tagged forms of ubiquitin were 
compared using mass spectrometry following cAMP-mediated SOCS3 induction 
(Figure 1.11). Using this approach, proteins modified by SOCS3 with the epitope-
tagged form of ubiquitin should be enriched in WT MEFs but not SOCS3-/- MEFs.  
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1.5.2 Experimental approach  
SOCS3 regulates several pathways in part by acting as a specificity factor for an 
ECS-type E3 ubiquitin ligase (9-12). E3 ligases do not recognise a consensus 
ubiquitinylated sequence. Furthermore, SOCS3 does not ubiquitinate all its 
binding partners (162). Therefore, analysis of SOCS3 protein-protein interactions 
via microarray, immunoprecipitation, or GST pull-down is insufficient for 
identification of SOCS3-dependently ubiquitinated substrates. Direct analysis of 
the ubiquitinome is necessary. Identification of substrates of cAMP-dependent, 
SOCS3-specific ubiquitination will instead be performed via a comparison of 
purified ubiquitinomes from WT and SOCS3-/- MEFs (Figure 1.11). As such, SOCS3-
dependently ubiquitinated proteins should be detectable in WT but not SOCS3-/- 
MEFs.  
 
Currently, all known SOCS3-dependently ubiquitinated targets are tyrosine-
phosphorylation prior to binding SOCS3 and ubiquitination (9-12). While it is 
understood that the impact of ubiquitination on cell signalling events is growing 
ever more important, the ubiquitinome might still only make up only a small 
fraction of the proteome. As such, detection of potentially low abundance 
signalling intermediates with transient, labile PTMs are not without their 
challenges. The probability of detecting SOCS3-dependently ubiquitinated 
substrates might be improved by preserving tyrosine-phosphorylated, 
ubiquitinated proteins via the inhibition of PTPs, the proteasome, and by 
blocking the action of DUBs. As such, the pool of tyrosine-phosphorylated 
proteins will be enriched by the use of PTP inhibitors Na3VO4 and H2O2 while the 
ubiquitinome will be preserved via the use of the proteasome inhibitor MG132. 
Furthermore, the use of highly denaturing conditions during ubiquitinome 
isolation will contribute to the preservation of ubiquitinated proteins by 
denaturing and deactivating DUBs. Forskolin, the direct activator of adenylyl 
cyclase, will facilitate the elevation of intracellular cAMP levels and SOCS3 
induction.   
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Figure 1.10: SOCS3 induction and function 
SOCS3 is rapidly induced upon sustained, elevated levels cAMP via EPAC1 activation and 
transient PKA-independent ERK activation. SOCS3 is induced via C/EBPβ-dependent 
gene transcription. EPAC1 activation increases recruitment of C/EBP at the SOCS3 
promoter (119) whereas ERK-dependent phosphorylation of C/EBPβ at Thr235 fully 
activates SOCS3 expression (70). SOCS3 induction is sufficient to terminate IL6 signalling 
(70). SOCS3 has also been identified as a component of E3 ligases that direct ubiquitin-
dependent protein degradation via the 26S proteasome(9-12). SOCS3 might further 
regulate the inflammatory response via this mechanism.   
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Figure 1.11: Experimental strategy 
The aim of this study was to identify SOCS3-dependently ubiquitinated substrates from 
differentially SILAC-labelled ubiquitinomes, tandem affinity purified from WT and 
SOCS3-/- MEFs aided by (His)6+biotin-tagged ubiquitin (HBUb). SILAC ratios of C-terminal 
arginine- or lysine-labelled peptides were assessed following mass spectrometry. 
Peptides from SOCS3-specific HBUb-modified proteins should only be detectable in WT 
HBUb but not SOCS3-/-HBUb MEFs. See text for details. 
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I have chosen SILAC to enable the discrimination of WT HBUb and SOCS3-/- HBUb 
MEF-isolated ubiquitinomes. SILAC is an efficient, reproducible, metabolic 
process of incorporating stable isotopes of amino acids into the proteome. 
Labelling coverage is dependent on the purity and composition of the SILAC 
media as well as the incubation period. It has been shown that it is possible to 
achieve almost 100% coverage of even low abundance proteins over five cell 
doublings (163). Owing to a low level of the natural, light amino acid that is 
usually present in SILAC media, 98.5% incorporation is typical (verbal 
communication, Biochemical Society conference). Here, SILAC media (Dundee 
Cell Products) with a purity >99% is used thus establishing the limit of maximum 
incorporation. Furthermore, growth media supplements may contribute to 
contamination from the natural amino acid. As such, the use of dialysed serum is 
necessary, although its use could potentially impact on cell proliferation (163). 
There is no chemical difference between the natural amino acid and its isotope 
and so cells can be grown and handled as normal. Since labelling occurs within 
live cells, samples can be differentiated¸ mixed, and treated as one sample 
directly following cell harvesting. As such, the chance of introducing handling 
errors is reduced. In contrast, other chemical incorporation techniques such as 
isotope coded affinity tags (ICAT) are multi-step, require post-harvest 
processing, and do not achieve complete incorporation (163,164).  
 
Standard mass spectrometry protocols begin with digestion of proteins to 
peptides of manageable size (8-20 amino acids). Liquid chromatography (LC) 
then focuses peptides into bands of similar mass prior to ionisation and MS. This 
not only reduces the complexity of the peptide mixture but also enables 
accurate quantitation of the co-eluting peptides. Sequencing of peptides is 
achieved via mass analysis of fragmented, ionised peptides. As such, the choice 
of amino acid(s) and isotope are important considerations for mass 
spectrometric analysis. The most frequently used stable isotopes include 2H, 13C, 
and 15N. While deuterium is the cheaper isotope, it is problematic in that it 
resolves from its light-labelled counterpart during reverse phase liquid 
chromatography and as such affects quantitation (165). To achieve maximum 
coverage, common essential amino acids such as lysine, leucine, and arginine 
are used. Arginine is non-essential in vivo but has been demonstrated to be 
essential under cell-culture conditions (166). Trypsin, a commonly used protease 
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for MS-based studies, cleaves C-terminally to arginine and lysine and thus all 
tryptic peptides, apart from C-terminal fragments, will be labelled (167). 
Furthermore, due to the frequency and abundance of these amino acids within 
the proteome (~5%)(165), trypsin produces several peptides around 8-10 amino 
acids in length per protein. Such peptides are small enough to be accurately 
sequenced via MS but large enough to be unique which is important for protein 
identification. Moreover, the detection of several peptides from a single protein 
will improve protein assignment and calculation of a SILAC ratio. Additionally, 
since lysine and arginine have basic side-chains, they retain a positive charge, 
which is a prerequisite for ionisation and detection by mass spectrometry. 
Differential-SILAC labelling (168) using these amino acids effectively produces 
two separate proteomes distinguishable via a mass shift imparted by the heavy 
isotope. Heavy 13C6-arginine and 
13C6-lysine will produce a mass difference of 
6Da (6 carbons per amino acid) compared to the natural 12C6 species, for each 
arginine or lysine residue replaced. This shift is sufficient to discriminate 
between differentially labelled peptides (165) and thus enable further 
processing by data analysis software. Taken together, these qualities make 
arginine and lysine well suited to this project.  
 
The disadvantage of using arginine is that it can be metabolised from 13C6-
arginine to an isotope of the non-essential amino acid 13C5-proline via the 
arginase pathway (169). Incorporation of the heavy proline isotope will result in 
a second set of peaks shifted by 5Da from the unaffected, heavy-labelled species 
for each proline present. Although this makes quantitation difficult, it can be 
corrected for by the addition of the different MS peak clusters using software 
such as MaxQuant (Section 2.2.10.2) (170). However, since mathematical 
corrections can be time consuming and inaccurate, several non-computer-based 
solutions have been suggested. These include modifications of the SILAC media 
to either reduce (171), prevent (169), or compensate (172) for arginine 
metabolism or to genetically modify cells (173) to prevent arginine conversion. 
Of these, the most simplistic approach was suggested by Bendall et al (169). In 
this system, successfully implemented in ECs, HeLa, and MCF7 cell lines, media 
was merely supplemented with L-proline (200mg/L). The L-arginine metabolic 
pathway is bidirectional and dependent on the bioavailability of precursors 
(169). As such, the presence of proline, an essential amino acid usually omitted 
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from DMEM or present in reduced concentrations, prevents conversion of 
arginine to proline. Although proline can be metabolised back to arginine, no 
significant back-conversion was detected, probably due to its presence in the 
media. Given its simplicity, this method was favoured for this project. 
 
Mass spectrometry is very sensitive (peptide detection limit ~10-15 mol) and thus 
commonly used for the detection of low abundant proteins. However, a high 
background of contaminant e.g. keratin, can mask weak signals. Preparation of 
samples is therefore a limiting factor in MS-based studies (Section 2.2.9.4) (174). 
Importantly, detection of low abundant proteins can be improved following the 
isolation of the relevant subproteome i.e. the ubiquitinome. Tandem affinity 
purification (TAP) strategy is relatively quick and achieves high levels of purity 
necessary for MS. General TAP strategies involve the production of a fusion 
protein where a TAP tag is conjugated to the N- or C-terminus of the protein of 
interest. Employing multiple structurally distinct tags theoretically allows for 
the selection of specific complexes and the removal of others. TAP strategies 
typically involve two purification stages allowing reduction of non-specifically 
bound proteins and contaminants. Since most approaches are performed under 
native/non-denaturing conditions, post-translational modifications can be 
vulnerable. I have chosen to perform TAP under fully denaturing conditions as 
doing so might protect PTMs such as ubiquitinated proteins from DUBs. Such 
conditions would also reduce background from non-specifically bound proteins 
and ubiquitin binding proteins that bind ubiquitin but are not ubiquitinated 
themselves.  
 
This study employs the (His)6+biotin (HBUb) tag to isolate proteins following 
sequential application of nickel and streptavidin affinity chromatography. The 
HBUb tag (168,175) (Figure 1.12) is able to facilitate purification under extreme 
denaturing conditions (8M urea/6M guanidinium chloride) and consists of a 
hexahistidine domain that reversibly binds nickel, and a biotinylation signal 
peptide. The latter is a 75 amino-acid region from the Propioni-bacterium 
shermanii 1.3S transcarboxylase subunit which can be covalently linked via Lys41 
to the carboxyl group of biotin by endogenous biotin ligases (176).  
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Figure 1.12: The hexahistidine-biotin tag 
The (His)6+biotin-tagged Ub (HBUb) allows purification under highly denaturing 
conditions. This accommodates the preservation of ubiquitinated proteins via the 
inactivation of DUBs and prevents purification of ubiquitin binding proteins (UBP), 
proteins that bind ubiquitin but are not ubiquitinated themselves. HBUb-tagged proteins 
are first purified using the hexahistidine domain that reversibly binds nickel (Ni2+). The 
second round of purification involves the BIO domain that irreversibly binds (Kd = 10
-15 M) 
streptavidin. The BIO domain has been shown to be biotinylated at K41 in yeast and 
mammalian cells. 
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The first stage of TAP, Ni2+ affinity chromatography, removes non-specifically 
bound proteins along with endogenously biotinylated proteins that might 
otherwise be purified in the following stage. The tight binding of biotin to 
streptavidin (Kd = 10
-15M) during streptavidin affinity chromatography allows very 
stringent wash conditions and enables the removal of most non-specifically and 
non-covalently associated proteins. However, a low level of background should 
always be expected. Using the HBUb system the second purification step can 
achieve a 6-fold reduction in non-specific purification over the first (175). Since 
ubiquitin is N-terminally tagged, linear (M1) polyubiquitin chains cannot be 
constructed (151). While SOCS3 has not been shown to be able to form this type 
of polyubiquitin chain, it cannot be ruled-out. However, if this is the case then 
this strategy would be limited to the identification of non-M1 polyubiquitinated 
substrates.   
 
Mass spectromeric analysis combines the several systems to fractionate, ionise, 
fragment, and analyse the mass of peptides (177). The choice of system depends 
on requirements of cost, speed, sensitivity, resolution, and mass accuracy etc. A 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) was used 
for optimisation experiments such as SILAC-label incorporation (Section 4.3.2). 
MALDI ionises dried peptides from a solid matrix using several laser pulses (177). 
Given that peptides of various sizes are ionised simultaneously, this system is 
limited to simple peptide mixtures. Furthermore, mass analysis is dependent on 
the time-of-flight (t ∝ m/z) over a known distance where smaller molecules take 
less time than larger molecules to reach a detector module (177). The device-
dependent distance is a major limiting factor of the resolution of the mass 
spectrometer. In contrast, a linear trap quadrupole (LTQ)-Orbitrap system 
incorporating an electrospray ionisation (ESI) technique was used to identify 
SOCS3 substrates (Section 5.0). ESI involves ionising samples out of solution, a 
milder method to MALDI that reduces the possibility of peptide fragmentation. 
As such, samples can be pre-fractionated by liquid chromatography, enabling the 
analysis of more complex peptide mixtures. Furthermore, by using an LTQ-
Orbitrap, distance is not limiting since ions are trapped within an 
electromagnetic field and allowed to oscillate repeatedly around a central axis 
(177,178). Here, peptides are not separated by their mass-dependent velocity, 
the mass is now dependent on the frequency of axial oscillations (ω, where ω ∝ 
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1/m/z) and gives the Orbitrap superior mass accuracy (sub ppm vs. 10s ppm) and 
resolution (100,000s vs. 1000s, full width half maximum (FWHM)) over the TOF 
(177). Both systems employ tandem mass spectrometry (MS/MS) where two mass 
spectrometers are coupled. While the first measures the mass and abundance of 
the primary peptide, the second measures the mass and abundance of peptides 
that have been fragmented by collision with an inert gas i.e. collision-induced 
dissociation (CID). Fragmentation, occurs at the weakest point in the peptide 
and most commonly at the peptide bond (179). Fragmentation of multiple copies 
of the same peptide produces a sequence of daughter ions differing by a single 
amino acid i.e. a known mass, and as such, the peptide sequence can be 
predicted. Fragmentation can occur leaving the C-terminal (y-ions) or the N-
terminal (b-ions) intact. The former are most common and are therefore more 
likely to produce a complete sequence of daughter y-ions (167). As such, it is 
advantageous to analyse trypsin-digested, C-terminally SILAC-labelled peptides. 
Furthermore, y-ions from heavy labelled peptides are less likely to be confused 
with those of the unlabelled moiety (167). Loss of low abundant proteins during 
TAP or loss of peptides during ionisation may lead to partial sequence coverage. 
Moreover, CID favours and thus fragments at the weakest bond, thus PTMs 
including phosphorylation are frequently lost (179). This information would be of 
value since known SOCS3-ubiquitinated substrates are tyrosine-phosphorylated 
before binding SOCS3 (9-12). However, it is not the focus of the project and so 
not critical to its success. 
 
A major disadvantage of MS is the amount of data that is generated. While 
manual analysis of the mass spectra must be performed to asses the quality of 
the data, the most analysis can be performed automatically. For this study, 
post-MS data analysis will performed using the free quantitative proteomics 
software MaxQuant (Section 2.2.10.2) (170) but also using the commercially 
available Mascot search engine(180) (Section 2.2.10.1).  
 
Using a strategy that combines SILAC, TAP, MS, and subsequent MaxQuant data 
analysis will be exploited for the identification of SOCS3-dependently 
ubiquitinated substrates. 
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2.0 Materials, methods, and external services 
2.1 Materials 
Abcam, UK: 
Anti-PTRF antibody      (cat. no. ab48824) 
 
Agilent, UK: 
Quikchange II Site-Directed Mutagenesis kit   (cat. no. 200523) 
 
Bio-Rad Laboratories Ltd, UK:  
Precision Plus Protein Kaleidoscope Standards   (cat. no. 161-0375) 
 
Cell Signaling Technology, US: 
Anti-poly-His, rabbit polyclonal IgG   (cat. no. 2365) 
Anti-IκBα, (44D4) rabbit monoclonal IgG  (cat. no. 4812) 
Anti-pIκBα, (ser32/36) (5A5) mouse monoclonal IgG (cat. no. 9246) 
 
Corning 
15cm diameter TC treated culture dish    (cat. no. 430599) 
 
Dundee Cell Products, UK: 
Ready to use SILAC DMEM media containing   (cat. no. LM010) 
13C labelled arginine and lysine amino acids (R6K6) 
 
Control SILAC DMEM media containing unlabelled  (cat. no. LM014) 
arginine and lysine amino acids (R0K0) 
 
SILAC dialysed calf serum     (cat. no. DS1003) 
 
Expedeon:  
InstantBlue single step Coomassie based gel stain  (cat. no. ISB1L) 
 
GE Healthcare:  
Ni-Sepharose beads, 6 Fast Flow     (cat. no. 17-5318-01) 
Streptavidin-Sepharose beads, High Performance (cat. no. 17-5113-01) 
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Inverclyde Biologicals, UK:  
Whatman Protran Nitrocellulose Membrane  (cat. no. 10401396) 
 
Invitrogen, UK:  
D-biotin 50mM aqueous solution    (cat. no. B-20656) 
Cell Dissociation Buffer, enzyme free, PBS-based (cat. no. 13151-014) 
Endotoxin-free phosphate buffered saline (PBS) (cat. no. 14140-094) 
Dulbecco’s Modified Eagle Medium (DMEM)   (cat. no. D6546) 
NuPAGE 4-12% Bis-Tris Gel (1.0mm x 10 well)  (cat. no. NP0321BOX) 
NuPAGE MOPs SDS Running Buffer(20x)   (cat. no. NP0001) 
NuPAGE LDS Sample Buffer(4x)    (cat. no. NP0007) 
XCell SureLock Mini-Cell     (cat. no. EI0001) 
 
Jencons, UK: 
Sleeve Protectors, PP/PE     (cat. no. 114-3437)  
 
Merck Biosciences, UK: 
MG-132                     (cat. no. 474790)  
Forskolin                     (cat. no. 344270)  
 
Millipore,UK: 
Anti-Ub, Lys48-specific, (Apu2),     (cat. no. 05-1307) 
rabbit monoclonal IgG 
Anti-Phosphotyrosine, clone 4G10    (cat. no. 05-321X) 
Amicon Ultra Pre-Launch Centrifugal Filter Devices (cat. no. UFC201024PL)  
 
Kodak, UK:   
Medical X-ray Film General Purpose Blue   (cat. no. 8143059) 
 
Perkin-Elmer Life Sciences, UK:  
Enhanced chemiluminescence (ECL) reagents      (cat. no. NEL 104)  
 
Pierce Thermo Scientific:  
High sensitivity streptavidin-HRP    (cat. no. 21130)  
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Promega:  
Wizard Plus SV minipreps      (cat. no. A1330) 
 
Qiagen, UK:  
Endofree plasmid Maxi kit      (cat. no. 12362)  
 
Roche Applied Science, UK:   
Complete, EDTA-free protease     (cat. no. 11836170001) 
inhibitor cocktail tablets 
 
Santa Cruz Biotechnology, US: 
Anti-SOCS3, (M-20) goat polyclonal IgG   (cat. no. sc-7009) 
Anti-Ub, (P4D1), mouse monoclonal IgG   (cat. no. sc-8017) 
 
Sartorius Stedim Biotech, DL: 
Minisart syringe end filter, 0.45µm   (cat. no. 16555) 
Minisart syringe end filter, 0.20µm   (cat. no. 16534) 
 
Sigma-Aldrich, UK:  
Anti-FLAG M2 agarose from mouse       (cat. no. A2220)  
Protein G-Sepharose 4B Fast Flow    (cat. no. P3296)  
recombinant protein 
 
Trypsin, Proteomics grade     (cat. no. T6567) 
Sterile filtered cell culture water            (cat. no. W3500)  
Trypsin – EDTA                  (cat. no. T4299)  
Tween – 20                    (cat. no. P5927)  
30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide    (cat. no. A3699)  
L-glutamine                    (cat. no. G7513)  
Penicillin-streptomycin              (cat. no. P0781)  
Anti-mouse IgG (peroxidase-conjugated)      (cat. no. A4416)  
Anti-rabbit IgG (peroxidase-conjugated)        (cat. no. A6154)  
Anti-Goat IgG (peroxidase-conjugated)        (cat. no. A5420) 
Anti-poly-His, (HIS-1), mouse monoclonal IgG  (cat. no. H1029) 
Soybean trypsin inhibitor              (cat. no. T9003)  
Benzamidine                  (cat. no. 12072)  
Bovine serum albumin              (cat. no. A7030)  
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Bromophenol blue                 (cat. no. B7021)  
Ampicillin                    (cat. no. A9393)  
N, N, N’,N’-tetramethylethylenediamine (TEMED)   (cat. no. T9281)  
Phenylmethylsulphonyl fluoride (PMSF)        (cat. no. P7626)  
Nonidet P-40                   (cat. no. N6507)  
Tissue culture bovine serum albumin        (cat. no. A1595) 
Puromycin       (cat. no. P8833) 
L-Proline BioUltra, ≥99.5%     (cat. no. 81709) 
Imidazole       (cat. no. I5513) 
Monoclonal anti-HA agarose conjugated clone HA-7 (cat. no. A2095) 
 
Sino Biological Inc.: 
Recombinant Human SOCS3 / CIS3    (cat. no. 11315-H30E) 
 
Sarstedt: 
Tissue culture cell scraper 25cm    (cat. no. 83.183) 
 
Thermo-Scientific: 
Rectangular Dishes 4-well dishes     (cat. no. 267061) 
 
Cell lines:  
MEFs:  WT (SOCS3+/+) and SOCS3-/- (Kawaguchi et al., 2004, (9)), initially 
provided by Prof. Akihiko Yoshimura (Kyushu University, Japan) were available 
as liquid nitrogen-frozen laboratory stocks. 
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Table 2.0:  Constructs 
Donor cDNA Vector Tag A
R
 Reference 
Peter Kaiser University of California HBUb pQCXIP - P (168) 
Merry 
Mclaird 
Stowers Institute for  
Medical Research 
Elongin B pCDNA3 Myc-5xHis A (181) 
Elongin C pCDNA3-HSV - A (181) 
Cullin 5 pCDNA3 - A (181) 
Rbx1 pRSETB Myc A (181) 
Stephen 
Yarwood 
University of Glasgow FAK1 - Myc A - 
Paul Pilch University of Boston Cavin-1 
pEGFP-N1 
pEGFP-C1 
C-eGFP K 
(182) 
N-eGFP K 
Gunter 
Schmidtke 
Universität Konstanz UBE1 pcDNA3.1 HA A (183) 
Cam 
Patterson 
Division of Cardiology 
University of North 
Carolina 
Hsc70 pcDNA3.1 Myc A (184) 
Eric Wanker 
Max-Delbrück 
Centrum                    
für mol. Medizin 
Vcp/p97 pTC10 Flag A (185) 
Pier Paolo Di 
Fiore 
University of Milan EPS15L1 pcDNA1 HA A (186) 
Paul van 
Bergen en 
Henegouwen 
Utrecht University EPS15L1 pcDNA3 Myc A (187) 
Elisabetta 
Citterio 
Netherlands cancer 
centre 
USP5 pcDNA3.1 Myc A (188) 
Philip A. 
Robinson 
University of Leeds UCHL1 ? HA A (189) 
Anne-Marie 
Pendergast 
Duke University            
Medical Center 
Abi2 ? eYFP K (190) 
Laboratory Stocks 
Puromycin pBabe - P - 
SOCS3 pcDNA3.1(+) Flag A - 
Antibiotic resistance (A
R
): A= ampicillin; K=kanamycin; P=puromycin. 
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2.2 Methods 
2.2.1 Cell culture  
Murine embryonic fibroblasts stably expressing a puromycin-resistance and 
(His)6+biotin-tagged Ub (HBUb) transgene or puromycin-resistance transgene 
alone were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) foetal bovine serum (FBS), 1mM L-glutamine and 
100U/ml penicillin, 100µM streptomycin, and 4µg/ml puromycin.  For 
experiments requiring stable isotopic labelling of amino acids in cell culture 
(SILAC), the same cells were maintained in either SILAC DMEM (R6K6) or control 
SILAC DMEM (R0K0) supplemented with 10% (v/v) dialysed calf serum (dCS), 
100U/ml penicillin, 100µM streptomycin,  and 4µg/ml puromycin.   
 
Plat-E retroviral packaging cells were maintained in DMEM supplemented with 
10% (v/v) FBS, 100U/ml penicillin, 100µM streptomycin, 1µg/ml puromycin, 
10µg/ml blasticidin, and 1mM glutamine.  
 
HEK293 cells were maintained in DMEM supplemented with 10% (v/v) FBS, 
100U/ml penicillin, 100µM streptomycin, and 1mM glutamine.  
 
All cell lines were maintained at 37°C in a humidified 5% (v/v) CO2 atmosphere.  
Passaging of cells was performed at ~80% confluency by washing cells in tissue 
grade PBS followed by incubation with trypsin or cell dissociation buffer for 2-3 
minutes at room temperature (RT) after which the reaction was neutralised via 
the addition of fresh media. Cells were finally resuspended via gentle pipetting 
before transferring to 10-12ml of fresh media.  
2.2.2 Preparation of puromycin resistant murine embryonic fibroblasts 
2.2.2.1 Production of retrovirus for stable transduction of MEFs 
Plat-E retroviral packaging cells were seeded on 10cm dishes to be 80% confluent 
the following day when cells were transfected with the relevant plasmid vector 
using Lipofectamine 2000 transfection reagent as per manufacturer’s 
instructions. Briefly, on the day of transfection, either DNA (20µg) or 
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Lipofectamine 2000 reagent (60µl) were added to Optimem serum-free media 
(1.5ml) and mixed thoroughly via gentle pipetting prior to the individual 
solutions being mixed together, again via gentle pipetting. The solution was then 
incubated for 15 minutes at room temperature to allow formation of lipid-DNA 
complexes. During this time, the target cells were washed twice with Optimem 
before addition of the necessary transfection volume of Optimem (15ml). The 
Lipofectamine 2000 reagent-DNA-Optimem solution was then added to the target 
cells in a drop-wise fashion and mixed via gentle rocking. Cells were incubated 
at 37°C for 3 hours to allow transfer of DNA into the target cells after which 
time the transfection media was replaced with growth media containing no 
antibiotics before incubating overnight (O/N) at 37°C. Retrovirus-containing 
media was collected following two sequential incubation periods, one of 24 
hours at 37°C and a second of 24 hours at 32°C at which point the retrovirus-
containing media was stored at -80°C to maintain stability. 
2.2.2.2 Production of puromycin resistant MEFs via retroviral transduction 
MEFs were seeded in 10cm dishes to be 40% confluent the following day for 
transduction with retrovirus-containing media (section 2.2.2.1). At this time, the 
media was refreshed with 2ml DMEM supplemented with 10% (v/v) FCS, 1mM 
glutamine, and the cells transduced with the addition of 10µg/ml polybrene and 
2ml of retrovirus-containing media. After 12 hours, the media was replaced with 
DMEM supplemented with 10% (v/v) FBS, 1mM L-glutamine and 100U/ml 
penicillin, 100µM streptomycin, and 1µg/ml puromycin. Individual puromycin 
resistant clones were picked in 50µl of media and expanded sequentially in 24 
well plates, 6cm dishes, and T75 flasks. 
2.2.3 Plasmid DNA preparation and quantification 
Expression DNA plasmids were either received from donors in solution, as filter-
paper spots, or prepared from glycerol laboratory stocks. Donated plasmids 
(Table 2.0) were first amplified by transforming XL1-Blue E.coli via heat pulse 
treatment.  Briefly, 50µl of cells were aliquoted into pre-cooled microfuge tubes 
before the addition of 50ng of DNA and incubation on ice for 15 minutes. The 
mixture was then heat-shocked for 90 seconds in a 42°C water bath followed by 
recovery on ice for 2 minutes. The cells were then allowed to recover for a 
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further 45 minutes in a 37°C shaker following the addition of 450µl pre-heated, 
37°C, Luria Bertani (LB) broth (1% (w/v) bactotryptone, 0.5% (w/v) yeast 
extract, 1% (w/v) sodium chloride) with no selection antibiotic. Cells were then 
concentrated by centrifugation at 1000g for 5 minutes after which the volume of 
LB-broth was reduced to 100µl. The cells were then resuspended, spread onto 
dry LB-agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v), 1.5% 
(w/v) agarose) plates supplemented with the relevant selection antibiotic 
(ampicillin, 50µg/ml; kanamycin, 10µg/ml) and allowed to proliferate overnight 
in a 37°C incubator. The following day, the plates were either stored at 4°C or a 
starter-culture was prepared by picking off a single colony and inoculating 5ml 
of selection LB-broth that was incubated for 8 hours at 37°C with shaking. In the 
case of laboratory stocks, 5ml of LB supplemented with the relevant selection 
antibiotic was inoculated with a stab from a glycerol stock and incubated for 8 
hours at 37°C with shaking. 
 
The plasmid DNA was extracted from the starter-culture using a Wizard Plus 
miniprep DNA purification system (Promega) following the manufacturer’s 
instructions or further amplified for a maxiprep DNA extraction procedure. In 
the latter case, the full 5ml starter-culture was used to inoculate 250ml of 
selection LB-broth that was incubated for a further 16 hours at 37°C with 
shaking. The plasmid DNA was then extracted using a maxiprep DNA purification 
system (Qiagen) following the manufacturer’s instructions. 
 
DNA yields were measured using a NanoDrop™ 1000 Spectrophotometer. 
Absorption of ultraviolet light by DNA peaks at 260nm whereas that of protein 
peaks at 280nm. Absorption measurements were performed directly on 2µl of 
eluted DNA in either distilled H2O (dH2O) or TE buffer (1M Tris-HCl pH7.5, 0.25M 
EDTA) with the same solvent also being used as reference. Purity of nucleic acids 
was assessed from the resulting 260nm/280nm (protein contamination) and 
260nm/230nm (chemical contamination e.g. phenol, EDTA) ratios where a value 
greater than 1.8 and >2.0 respectively is deemed to be of sufficiently high 
purity. 
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2.2.4 MTT assay 
Cell death or apoptosis can be caused by unexpected side effects resulting from 
drug treatment or transgene overexpression. Cell survival can be assessed via a 
cell viability assay such as the MTT assay (191). Briefly, yellow MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent is converted to 
purple formazan crystals upon reduction within the mitochondria of living cells. 
Formazan concentration, measured as a function of its absorbance at 590nm, is 
directly related to the cell density and therefore a good indicator of viability. 
Proliferation of each cell line was compared to controls consisting of a dish 
containing no cells (blank) and cells pre-killed with 50% (v/v) DMSO for one hour.  
Since the mitochondria are no longer functioning, the reduction of MTT and 
therefore a colour change cannot take place. 
 
WT, WT HBUb, SOCS3-/- HBUb and SOCS3-/- MEFs were seeded in 12 well plates at 
a density of 5x104 cells/well so that they would be ~60-70% confluent the next 
day. After this time, the media was refreshed and MTT reagent (100µM) directly 
added to cells before incubating at 37°C for 3 hours. The media was then 
removed and cells lysed with 500µl of neat DMSO, which also solubilises the 
formazan crystals. Proliferation was assessed by measuring the absorbance of 
200µl aliquots of DMSO-solubilised crystals at 590nm.  
2.2.5 Cell preparation and harvesting 
2.2.5.1 Preparation of tissue culture dishes 
Most cells adhere and grow on untreated tissue culture dishes without difficulty. 
Where adherence is a problem such as in the case of HEK293 cells which weakly 
adhere to untreated dishes, a coating can be applied to strengthen the cell-
plastic interaction e.g. poly-D-lysine. The overall positive charge provided by the 
amino group of the lysine side chain increases the electrostatic interaction with 
the negatively charged plasma membrane of the HEK293 cells. Here, cell 
attachment was enhanced by briefly washing the dishes with neat aqueous poly-
D-lysine and leaving to dry following the removal of all residual solution. 
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2.2.5.2 Harvesting for cell characterisation 
MEFs grown on the appropriately sized dishes were placed on ice and washed 
twice with ice cold tissue culture grade PBS before harvesting with the addition 
of an appropriate volume (50µl, 6-well plate; 250µl, 6cm diameter dish; 500µl, 
10cm diameter dish) of RIPA buffer (50mM HEPES pH 7.4, 150mM sodium 
chloride, 1% (v/v) Triton x100, 0.5% (v/v) sodium deoxycholate, 0.1% (w/v) SDS, 
10mM sodium fluoride, 5mM EDTA, 10mM sodium phosphate, 0.1mM PMSF, 
10µg/ml benzamidine, 10µg/ml soybean trypsin inhibitor, 2% (w/v) EDTA-free 
complete protease inhibitor cocktail). Cell lysis was completed by incubating for 
one hour at 4°C with rotation. Supernatant, (~45µl, 6-well plate; ~230µl, 6cm 
diameter dish; ~450µl, 10cm diameter dish) was then isolated, taking care not to 
disturb the pellet, following centrifugation at 21000g for 15 minutes at 4°C. 
2.2.5.3 Harvesting for tandem affinity purification 
MEFs grown on the appropriately sized dishes were placed on ice and washed 
twice with ice cold tissue culture grade PBS before harvesting with the addition 
of an appropriate volume (250µl, 6cm diameter dish; 500µl, 10cm diameter dish; 
1ml, 20cm diameter dish) of lysis buffer A (8M urea, 300mM NaCl, 50mM 
NaH2PO4, 0.5% (v/v) NP-40, pH 8.0) supplemented with 1mM PMSF. Lysate was 
sonicated for three 10 second pulses, with a 10 second rest phase, at 40% 
amplitude with a 2mm diameter stepped micro-tip (150µl-1ml) or 6mm tapered 
micro-tip (>5ml) to fragment the precipitated DNA. Supernatant (~230µl, 6cm 
diameter dish; ~450µl, 10cm diameter dish) was then isolated, taking care not to 
disturb the pellet, following centrifugation at 21000g for 30 minutes at RT.  
2.2.5.4 Harvesting for co-immunoprecipitation 
HEK293 cells grown on the appropriately sized, poly-D-lysine-treated dishes were 
placed on ice and media completely removed. Since certain treatments i.e. H2O2 
exacerbate cell dissociation, cells were harvested in ice cold PBS which was 
removed following centrifugation at 1000g for 5 minutes at 4°C and replaced 
with an appropriate volume (250µl, 6cm diameter dish; 500µl, 10cm diameter 
dish) of  co-immunoprecipitation buffer (50mM HEPES, pH 7.4, 120mM NaCl, 
5mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, supplemented with 
                                                                                                                                                                                                                                                      69
phosphatase inhibitors 5mM NaF, 1mM Na3VO4, and protease inhibitors 10µg/ml 
benzamidine, 0.1mM PMSF, 10µg/ml soybean trypsin inhibitor, 2% (w/v) EDTA-
free complete protease inhibitor cocktail). Cells were resuspended via gently 
pipetting and lysis completed by incubating for one hour at 4°C with rotation. 
Supernatant (~230µl, 6cm diameter dish; ~450µl, 10cm diameter dish) was 
isolated, taking care not to disturb the pellet, following centrifugation at 21000g 
for 15 minutes at 4°C. 
2.2.5.5 Harvesting for peptide array 
HEK293 cells grown on 10cm diameter, poly-D-lysine-treated dishes were placed 
on ice and the media completely removed. Cells were harvested in ice cold PBS 
which was removed following centrifugation at 1000g for 5 minutes at 4°C. Cell 
lysates were prepared to be highly concentrated by lysing cells in a small volume 
(250µl/10cm diameter dish) of peptide array buffer (50mM HEPES, pH 7.4, 
150mM NaCl, 5mM EDTA, 1% (v/v) Triton X-100, supplemented with phosphatase 
inhibitors 5mM NaF, 1mM Na3VO4, and protease inhibitors 10µg/ml benzamidine, 
0.1mM PMSF, 10µg/ml soybean trypsin inhibitor, 2% (w/v) EDTA-free complete 
protease inhibitor cocktail).  This allowed the concentration of the detergent 
Triton X-100 to be diluted, prior to incubation with the peptide array, with TBS-
Tween (50mM Tris pH 7.5, 150mM NaCl, 0.05% (v/v) Tween-20) to below 0.05% 
preventing it from effecting interactions. 
2.2.6 Protein quantification by bicinchoninic acid assay 
The bicinchoninic acid (BCA) assay (192) is an accurate, sensitive, stable 
technique for quantification of proteins i.e. high tolerance to non-ionic 
detergent and salts usually found in buffers. It is based on the coupling of two 
reactions, the reduction of alkaline Cu2+ to Cu1+ (biuret reaction) by peptide 
bonds and the formation of a purple complex between Cu1+ and two molecules of 
BCA. The intensity of the purple complex, measured as a function of its 
absorbance at 630nm (A630), is directly proportional to the amount of protein in 
solution and as such, is a good indicator of protein concentration. 
 
Protein standards (0.0 to 2.0µg/µl) of bovine serum albumin (BSA) prepared in 
the appropriate lysis buffer along with appropriate dilutions of protein lysate in 
                                                                                                                                                                                                                                                      70
lysis buffer (total volume, 10µl) were arranged on a 96 flat-well plate. A 200µl 
1:50 dilution of copper sulphate (4% (v/v)) to BCA reagent (1% (w/v) 4,4 
dicarboxy-2,2 biquinoline disodium salt, 2% (w/v) sodium carbonate anhydrous, 
0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% 
(w/v) sodium bicarbonate, pH 11.25) was then added to each well before 
incubating at RT for the appropriate time period until a linear standard curve (r2 
~ 0.98) standard curve was produced. Absorption measurements were taken at 
630nm using a POLARstar OPTIMA (BMG LabTech) microplate reader. Protein 
concentrations were quantified using POLARstar OPTIMA MARS data analysis 
package v.1.20 and GraphPad Prism v.4. 
2.2.7 Tandem affinity purification 
Tandem affinity purification (TAP) (174) is a facile strategy to achieve high 
levels of purity necessary for post-analysis via LC-MS/MS. General TAP strategies 
involve the production of a fusion protein where a TAP tag is attached to the N- 
or C-terminus of the protein of interest. Employing multiple structurally distinct 
tags theoretically allows for the selection of specific complexes and the removal 
of others. TAP strategies typically involve two purification stages allowing 
reduction of non-specific purification and contaminants. It has been shown that 
using the HBUb-tag system the second purification step can achieve a 6-fold 
reduction in non-specific purification over the first (175).  The majority of TAP 
strategies allow purification under native conditions but this leaves the majority 
of post-translational modifications (PTMs) vulnerable. The HBUb tag (168,175) is 
able to facilitate purification under extreme denaturing conditions (8M urea/6M 
guanidinium chloride) thus protecting PTMs, in this case, ubiquitinated proteins 
from deubiquitinases (DUBs) and reduce background from non-specifically bound 
proteins and ubiquitin binding proteins which bind ubiquitin but are not 
themselves ubiquitinated. The tight binding of biotin to streptavidin (Kd=10
-15M) 
also facilitates very stringent wash conditions to further reduce background via 
the removal of all non-covalently associated proteins. Overall, TAP using the 
HBUb tag provides high purity and low background from non-specifically bound 
proteins facilitating the detection of proteins, even those in low abundance.   
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2.2.7.1 Preparation of NTA-Ni2+-Sepharose beads 
The appropriate volume of nitrilotriacetic acid (NTA)-Ni2+-Sepharose beads was 
aliquoted and the supernatant removed using a Hamilton syringe following 
centrifugation at 500g for 30 seconds. The pellet was washed, to remove the 
ethanol storage media, in 5 bead volumes of autoclaved distilled water and 
rotated for 3 minutes at RT. Following centrifugation at 500g for 30 seconds at 
RT, the supernatant was removed using a Hamilton syringe and the process 
repeated with buffer A (8M urea, 300mM NaCl, 50mM NaH2PO4, 0.5% (v/v) NP-40, 
pH 8.0) supplemented with 1mM PMSF and 10mM imidazole to reduce non-
specific binding. Finally, one bead volume of buffer A was added to the beads to 
produce a 50% (v/v) bead slurry. 
2.2.7.2 Preparation of streptavidin-Sepharose beads 
The appropriate volume of streptavidin-Sepharose beads was aliquoted and the 
supernatant removed using a Hamilton syringe following centrifugation at 500g 
for 30 seconds. The pellet was then re-suspend and washed, to remove the 
ethanol storage media, in 5 bead volumes of elution buffer (8M urea, 200mM 
NaCl, 50mM NaH2PO4, 2% (w/v) SDS, 10mM EDTA, 100mM Tris, pH 8.0) 
supplemented with 1mM PMSF. Following centrifugation at 500g for 30 seconds, 
the supernatant was removed using a Hamilton syringe and the process 
repeated. Finally, one bead volume of elution buffer was added to beads the 
beads to produce a 50% (v/v) bead slurry. 
2.2.7.3 Nickel affinity chromatography 
Soluble protein lysates were prepared in buffer A supplemented with 1mM PMSF. 
Lysates were equalised to 1mg/ml and incubated with 30µl of 50% (v/v) Ni2+-
NTA-Sepharose beads per milligram of protein and rotated overnight at RT. 
Optimisation experiments were performed in microfuge tubes whereas for 
scaled–up experiments the larger volumes (~400ml) of lysates were aliquoted to 
15ml conical tubes. The next day, the flow-through was removed following 
centrifugation at 100g for 1 minute. The beads were then washed sequentially, 
once with 20 bead volumes of buffer A (8M urea, 300mM NaCl, 50mM NaH2PO4, 
0.5% (v/v) NP-40, pH 8.0) supplemented with 1mM PMSF and 10mM imidazole 
and twice with 20 bead volumes of buffer B (8M urea, 300mM NaCl, 50mM 
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NaH2PO4, 0.5% (v/v) NP-40, pH 6.3) supplemented with 10mM imidazole and 1mM 
PMSF. The supernatant was then removed with a Hamilton syringe following 
centrifugation at 100g for 1 minute. Elution was performed in two steps. Bound 
proteins were eluted from the Ni2+-NTA-Sepharose beads with 5 bead volumes of 
elution buffer (8M urea, 200mM NaCl, 50mM NaH2PO4, 2% (w/v) SDS, 10mM EDTA, 
100mM Tris, 500mM imidazole, pH 8.0) supplemented with 1mM PMSF. The 
supernatant was then isolated following centrifugation at 100g for 1 minute and 
the process repeated.  
2.2.7.4 Streptavidin affinity purification 
Eluate from nickel affinity chromatography was directly added to 10µl of 50% 
(v/v) streptavidin-Sepharose beads per milligram of initial protein lysate and 
rotated overnight at RT.  The next day, the flow-through was removed following 
centrifugation at 100g for 1 minute. The beads were then washed sequentially, 
twice with 25 bead volumes of buffer C (8M urea, 200mM NaCl, 2% (w/v) SDS, 
100mM Tris, pH 8.0) and twice with 25 bead volumes of buffer D (8M urea, 1.2M 
NaCl, 0.2% (w/v) SDS, 100mM Tris, 10% (v/v) ethanol, 10% (v/v) isopropanol, pH 
8.0). In each case, the supernatant was removed following centrifugation at 
100g for 1 minute. After the final wash, the supernatant was removed using a 
Hamilton syringe. Elution was performed using two methods.  
 
Method one: optimisation of experimental strategy: 
 
For SDS-PAGE analysis of eluate, bound proteins were eluted from the 
streptavidin-Sepharose beads via the addition of one bead volume of 12% (w/v) 
SDS sample buffer (50mM Tris, PH 6.8, 10% glycerol (v/v), 12% (w/v) SDS, 0.02% 
(w/v) bromophenol blue, 1.6mg/ml dithiothreitol (DTT)) and heating to 95°C for 
5 minutes. The supernatant was then isolated, using a Hamilton syringe, 
following centrifugation at 100g for 1 minute. 
 
Method two: LC-MS/MS: In-gel trypsin digestion 
 
Optimum sample preparation following SDS-PAGE fractionation for LC-MS/MS 
requires the use of thin, narrow lane pre-cast gels (see section 2.2.9.2). This 
requirement reduces acrylamide levels and trypsin volume resulting in improved 
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digest efficiency. The main caveat is that the gels have small wells and thus 
small loading volumes (25µl). To increase probability of detecting low-abundant 
proteins, a large initial volume (~40ml) of protein lysate was prepared and so a 
large volume (~2ml) of eluate was produced that needed to be concentrated to 
~25µl before SDS-PAGE fractionation. SDS sample buffer is not compatible with 
protein concentration spin-columns. Bound proteins were eluted from the 
streptavidin-Sepharose beads via the addition of one bead volume of aqueous 
biotin (50mM) and heating to 95°C for 5 minutes. The supernatant was then 
isolated, using a Hamilton syringe, following centrifugation at 100g for 1 minute. 
2.2.8 Immunoblot analysis 
Soluble protein lysates were fractionated via SDS-PAGE on 8, 10, or 12% (w/v) 
resolving gels (see below). Fractionated proteins were transferred to a 
nitrocellulose membrane and blocked for 1 hour at RT or overnight at 4°C with 
5% (w/v) dried milk powder (Marvel) in TBS-Tween (10mM Tris pH 7.6, 150mM 
NaCl, 0.1% (v/v) Tween-20). Proteins were detected with specific primary 
antibody followed by the corresponding horseradish peroxidase (HRP)-conjugated 
antibody (Table 2.1). Membranes were incubated overnight with primary 
antibody in 5% (w/v) dried milk powder in TBS-Tween. Membranes were 
incubated with secondary antibody for 1 hour at RT in 5% (w/v) dried milk 
powder in TBS-Tween. Membranes were then submerged in TBS-Tween and 
washed three times for ten minutes with shaking. Proteins were visualised using 
enhanced chemiluminescence using ECL Western Blotting Substrate (Pierce). 
Excess TBS-Tween was removed and membranes were incubated in 2ml of ECL 
Western Blotting Substrate for 1 minute. Excess substrate was removed before 
developing using medical x-ray film (Kodak) and an X-OMAT 2000 processor 
(Kodak).  
 
Resolving gel: 12%: 28% (v/v) dH20, 25% (v/v) Buffer 1 (1.5M Tris pH 8.8, 0.4% 
(w/v) SDS), 6.5% (v/v) 50% (v/v) glycerol, 0.32% (v/v) APS (0.3mg/ml), 0.08% 
(v/v) TEMED, 40% (v/v) 30% (v/v) bis/tris acrylamide. 
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Resolving gel: 10%: 34% (v/v) dH20, 25% (v/v) Buffer 1 (1.5M Tris, pH 8.8, 0.4% 
(w/v) SDS), 6.5% (v/v) 50% (v/v) glycerol, 0.32% (v/v) APS (0.3mg/ml), 0.08% 
(v/v) TEMED, 33.4% (v/v) 30% (v/v) bis/tris acrylamide. 
 
Resolving gel: 8%: 41% (v/v) dH20, 25% (v/v) Buffer 1 (1.5M Tris, pH 8.8, 0.4% 
(w/v) SDS), 6.5% (v/v) 50% (v/v) glycerol, 0.32% (v/v) APS (0.3mg/ml), 0.08% 
(v/v) TEMED, 26.7% (v/v) 30% (v/v) bis/tris acrylamide; 
 
Stacking gel: 25% (v/v) Buffer 2 (0.5M Tris, pH 6.8, 0.4% (w/v) SDS), 1% (v/v) 
APS (0.3mg/ml), 0.1% TEMED, 12% (v/v) 30% (v/v) bis/tris acrylamide)  
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Table 2.1: Primary and secondary antibodies 
 
Antibody 
Reactivity
Linked Species Supplier Cat.no Dilution
Poly-His 
(HHHHHH)
- Mouse Sigma-Aldrich H1029 1:1000
Poly-His 
(HHHHHH)
- Rabbit Cell Signaling 2365 1:1000
HA (YPYDVPDYA) - Rabbit Sigma-Aldrich F3165 1:1000
MYC                   
(9e10, 
EQKLISEEDL)
- Mouse In-House - 1:1000
Flag  (DYKDDDDK) - Mouse Sigma-Aldrich F3165 1:2000
IκBa - Rabbit Cell Signaling 4812 1:1000
pIκBa - Mouse Cell Signaling 9246 1:1000
SOCS3 - Goat
Santa Cruz 
Biotechnology
sc-7009 1:1000
GFP - Goat/Sheep In-House - 1:2000
Ub - Mouse
Santa Cruz 
Biotechnology
sc-8017 1:1000
K48-Ub - Rabbit Millipore 05-1307 1:1000
pTyr (4G10) - Goat Millipore 05-321x 1:1000
PTRF (cavin-1) - Rabbit Abcam ab48824 1:1000
Streptavadin HRP Rabbit
Pierce Thermo 
Scientific 
21134 1:500
Rabbit HRP Goat Sigma-Aldrich A6154 1:1000
Mouse HRP Goat Sigma-Aldrich A4416 1:1000
Goat HRP Rabbit Sigma-Aldrich A5420 1:2000
Mouse
IRDYE 
800CW
Donkey Licor 926-32212 1:2500
Rabbit
IRDYE 
680LT
Goat Licor 926-68021 1:2500
Secondary Antibodies
Primary Antibodies
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2.2.9 Sample processing pre-LC-MS/MS analysis 
2.2.9.1 Concentration of Eluate 
Eluate was concentrated using Amicon 10K Ultra-2 Centrifugal Filter Devices 
(Millipore) as per manufacturer’s instructions. Briefly, the eluate was 
transferred into the device before centrifugation using a fixed angle rotor at 
7500g for 40 minutes at RT. Immediately after, the flow-through was removed 
and the concentrated protein eluted by centrifugation for 2 minutes at 1000g 
after which the sample (~25µl) was isolated to a fresh microfuge tube.  
2.2.9.2 SDS-PAGE and gel slice extraction 
Concentrated protein (Section 2.2.9.1) was fractionated following the addition 
of 5µl 4x NuPage LDS sample buffer (Invitrogen) using NuPAGE 4-12% Bis-Tris Gel 
1.0mm x 10 well (Invitrogen) on an XCell SureLock Mini-Cell (Invitrogen) using 
NuPAGE MOPs SDS Running Buffer (Invitrogen) as per manufacturer’s 
instructions. During fractionation, the dye front was only allowed to progress for 
2cm into the resolving gel so to reduce acrylamide levels thus improving in-gel 
digestion efficiency. Protein bands were visualised using a Coomassie-based 
staining solution InstantBlue (Expedion). A single lane was then segmented on a 
clean glass plate, under reduced-keratin/contaminant conditions using a fresh 
scalpel, into ~3mm slices before being transferred individually to fresh 
microfuge tubes and stored at -80°C before further processing. Care was taken 
to remove all unstained regions from each 3mm section to further reduce 
acrylamide levels.    
2.2.9.3 In-gel trypsin digestion 
SDS-PAGE fractionated proteins must be extracted from the acrylamide gel and 
trypsin digested prior to LC-MS/MS. Gel pieces were first washed in 500µl 
(100mM) ammonium bicarbonate for 30 minutes on a shaker before disposing of 
wash and repeating with 500µl, 50% (v/v) acetonitrile/ammonium bicarbonate 
(100mM). The samples were then reduced with the addition of 150µl (100mM) 
ammonium bicarbonate and 10µl (45mM) DTT followed by incubation at 60°C for 
30 minutes in a heating block. Samples were allowed to cool to RT before 
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alkylation using 10µl (100mM) iodoacetamide followed by incubation in the dark 
at RT for 30 minutes. The solvent was then discarded and the gel pieces washed 
in 500µl, 50% (v/v) acetonitrile/ammonium bicarbonate (100mM) for 1 hour on a 
shaker after which the wash was discarded. The gel pieces were then shrunk by 
treating with 50µl acetonitrile for 10 minutes after which the solvent was 
discarded and the gel pieces dried using a vacuum centrifuge for 1 hour. A 
sufficient quantity (~20µl) of trypsin suspended in 1ml ammonium bicarbonate 
(25mM) was used to rehydrate each gel piece. A further amount of trypsin, in 
10µl volumes, was added if the initial volume was absorbed by the gel slice. This 
continued until the gel piece reverted to its initial fully rehydrated size. Finally, 
a sufficient amount of ammonium bicarbonate (25mM) was added to just cover 
the gel piece. The protein was then allowed to digest overnight at 37°C.  
 
The following day, gel pieces were isolated via brief centrifugation after which 
the supernatant was transferred to a fresh 96 well plate without disturbing the 
gel pieces. Residual digested protein was then extracted by treating the gel 
piece with 20µl, 5% (v/v) formic acid for 20 minutes at RT with shaking followed 
by the addition of 40µl acetonitrile for a further 20 minutes with shaking at RT. 
Following brief centrifugation, the supernatant was pooled with the initial 
supernatant on a 96 well plate. Finally, extracts were dried using a SpeedVac 
centrifugal evaporator. Samples were then stored at -20°C prior to MALDI-TOF. 
Due to different requirements of the Orbitrap Velos LC-MS/MS, dried samples 
were first resuspended in a sufficient volume of dH20 (10µl) beforehand.   
2.2.9.4 Reduced-keratin work environment 
Accurate MS analysis can be limited by keratin contamination. Keratins are the 
main components of skin, hair, and nails which makes it the most abundant 
contaminant under normal laboratory conditions. Keratin contamination 
becomes significant during MS when attempting to assess proteins with low 
abundance. As such, it is vital that contamination is kept to a minimum.  
 
For all experimental stages leading up to MS, simple steps were made to reduce 
keratin contamination. All work, where possible, was performed in a biological 
safety cabinet (BSC) that was quarantined and cleaned with ethanol and water 
prior to use. All equipment and reagents contained in paper/lint-free packaging 
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were sprayed with ethanol prior to use within the BSC. Where necessary, 
reagents such as lysis buffer were prepared in the BSC and filter sterilised using 
0.45µm filters (Sartorius Stedim Biotech) prior to use.  Reagent contamination, 
when outside of BSC i.e. during pH adjustment, was reduced by using facemasks 
and minimising the time reagent containers were left uncovered.  Clothing, 
being a high source of keratin, was covered with lab coat and disposable clean-
room sleeve protectors along with powder-free nitrile gloves to minimise 
contamination from hands and wrists.  
2.2.10 Mass spectrometry data quantitation and analysis 
2.2.10.1 Mascot Daemon 
An MS/MS ion search was performed using Mascot daemon v2.2 using the mus 
musculus SwissProt protein database (SwissProt_56.6.fasta). Raw mass 
spectrometry data (.raw) from the Orbitrap Velos Fourier Transform Mass 
Spectrometer (FTMS), operated by William Mullen (University of Glasgow, 
Proteomics Biomarkers and Systems Medicine), was searched for monoisotopic 
peaks (z=2+ and 3+) with a MS peptide tolerance of 5ppm and a MS/MS tolerance 
of 0.05Da. Peptides with a charge greater than one was chosen to enable 
differentiation from simple, non-peptide ions. A maximum of one missed trypsin 
cleavage site was allowed per peptide to account for non-cleavage of Arg or Lys 
dipeptides, interspersed dipeptides, and cases where either peptide precedes a 
proline residue. To account for mass variations of peptides due to PTMs, a set of 
common variable and fixed modifications were chosen to improved peptide 
sequencing and identification. Variable modifications, i.e. those which might 
only occur following treatment or under certain cellular conditions, included 
phosphorylation (S, T, and Y), a remnant of ubiquitin cleavage, GlyGly (K), and 
SILAC labels 13C6-arginine (R6) and 13C6-lysine (K6). The alkylating agent 
iodoacetamide was used during in-gel trypsin digestion to prevent oxidation of the 
SH group of cysteine residues via S-carbamidomethylation. 
Carbamidomethylation along with oxidation of methionine was set as fixed 
modifications i.e. those which are expected to occur as a result of processing. 
    
Data from a hybrid quadrupole time of flight mass spectrometer (QTOF), 
operated by Richard Burchmore (University of Glasgow, Sir Henry Wellcome 
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Functional Genomics Facility), has a lower resolution and accuracy. Raw mass 
spectrometry data (.wiff) from the QTOF was searched using a peptide tolerance 
of 1.2Da and a MS/MS tolerance of 0.6Da. All other settings remained 
unchanged. 
2.2.10.2 MaxQuant 
Post-MS data analysis will be performed using MaxQuant v.1.1.1.36 (170) (Figure 
2.0), a freely available software package that was designed for SILAC-based 
studies. The software includes its own peptide search engine, Andromeda (193) 
and operates as a stand-alone, PC-based module. Briefly, MaxQuant takes raw 
MS data from which it extracts peak information, and performs quantitation of 
SILAC peptide pairs (170). Data, combined with a set of user defined 
parameters, are then submitted to the peptide search engine Andromeda (193) 
after which peptides are assigned to proteins. The parameters defined are 
important as they can increase the stringency of the search, increase confidence 
in protein identification, and simplify analysis. However, with any automated 
proteomics software package, it is also possible to negatively influence protein 
identification e.g. reducing minimum peptide length, and so default settings 
were used where possible. Table 2.2 outlines additional MaxQuant settings used, 
all others settings were unchanged from their default state. The parameters that 
were altered enabled the software to account for detection of low abundant 
proteins (identification using single unique peptide), specification of the SILAC 
isotopes, and variability of mass i.e. due to phosphorylation (S, T, and Y), 
ubiquitination (GlyGly, trypsin remnant), oxidation (Met, in vitro processing) and 
carbamidomethylation (iodoacetamide alkylation prior to trypsin digestion).     
 
Peptide identification is based on the comparison the MS/MS sequenced peptides 
with peptides from true and modified/reverse peptide databases (International 
protein index (IPI), Uniprot) (170).  This analysis produces a posterior error 
probability (PEP) for each peptide. The smaller the PEP, the more certain is the 
identification of the peptide (170). Proteins are ‘identified’ by a process of 
peptide assignment.  Peptides are assigned to all proteins in which they are 
found but are accepted to belong to proteins with the most identified peptides 
(Razor peptides). At least a single unique peptide is necessary for confident 
protein identification.  Proteins are accepted based on the protein PEP, the 
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product of the individual peptide PEPs, which is limited by the false discover 
rate (FDR) which is set at 1% as a default (170). Protein SILAC ratios are 
calculated as the median of the SILAC ratios of unique or unique and razor 
peptides based on the stringency required (170). These ratios are then 
normalised to account for differences in protein abundance. Finally, MaxQuant 
outputs data into several tab-delimited text files that can be manipulated by 
standard software packages i.e. Excel.    
2.2.10.3 Analysis for raw mass spectra 
Raw mass spectra were manually assessed using either Xcalibur v.2.1, Thermo 
Scientific (Orbitrap Velos FTMS) or Analyst v.1.2, Applied Biosystems (QTOF). 
Visual inspection allowed assessment of correct peak assignment, SILAC ratios, 
and the possibility of conversion of 13C6-arginine to 
13C6-proline. The latter is 
assessed by the detection satellite peaks that are offset from heavy labelled 
monoisotopic peaks, relating to proline-containing peptides, by multiples of 5Da. 
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Figure 2.0: Quantitative proteomics using MaxQuant 
MaxQuant (170) takes raw MS data from which it extracts peak information, and 
performs quantitation of SILAC peptide pairs. Data, combined with a set of user defined 
parameters, is then submitted to the peptide search engine Andromeda (193) after 
which peptides are assigned to proteins. Peptide identification is based on the 
comparison the MS/MS sequenced peptides with peptides from true and 
modified/reverse peptide databases.  Proteins are accepted based on a posterior error 
probability (PEP), the product of the individual peptide PEPs, which is limited by the 
false discover rate (FDR) which is set at 1%. Protein SILAC ratios are calculated as the 
median of the SILAC ratios of selected peptides. Finally, MaxQuant outputs data into 
several tab-delimited text files that can be manipulated by standard analysis software 
packages i.e. Excel. Adapted with permission from (193). Copyright (2011) American 
Chemical Society. 
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Table 2.2: MaxQuant modified settings 
Most parameters used were unchanged from their default state. Parameters presented 
here were altered to account for specific experimental conditions. 
  
Parameter Value Comment
Version 1.1.1.36 MaxQuant version used.
SILAC isotope Arg6, Lys6 Heavy SILAC isotopes
Quantification: Use only 
unmodified peptides and
TRUE
Modified peptides are rare and variable. Using least 
modified peptides improves accuracy of protein 
quantitation.
Modifications included in 
protein quantification
Oxidation (M);                              
Acetyl (Protein N-term);             
Phospho (STY);                      
GlyGly (K)
Accounts for more probable experimentally induced 
modifications.
Peptides used for protein 
quantification
Unique and razor
Peptides that match several proteins but are assigned 
to the most abundant and thus most probable protein.
Min. ratio count 1
At least one SILAC-paired peaks used to calculate the 
SILAC ratio.
Re-quantify TRUE
Forces MaxQuant to search for SILAC paired peaks 
where none were previously detected. If peaks are 
found then they are used to quantify the missing 
peptide pair. However, this often this results in the 
quantification of the background, which should be very 
low. In this way, a SILAC ratio is returned which should 
be a good estimation of the different amounts of the 
protein in the heavy and light samples 
Fasta file ipi.MOUSE.v3.80.fasta A database of 59534 protein entries.
First search fasta file mouse.first.search.fasta A reduced database use for MaxQuant calibration .
Labelled amino acid 
filtering
FALSE
Enables MaxQuant to improved us of R6K6 SILAC 
labelling.
Variable modifications
Oxidation (M);                                              
Acetyl (Protein N-term);                                 
GlyGly (K);                                                  
Phospho (STY)
Experimentally induced modifications that could impact 
peptide identification.
Fixed modifications Carbamidomethyl (C) Modifications that arise due to sample processing.  
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2.2.11 Production of SOCS3 L189A Mutant 
2.2.11.1 Primer design and synthesis for site directed mutagenesis 
Primers, (forward, 5’-tcc acc gtg gcc acc gcc cag cat ctt tgt cg-3’, reverse, 5’-cg 
aca aag atg ctg ggc ggt ggc cac gtt gga-3’) were designed to produce an L189A 
mutation of the B/C-box within the SOCS3 SOCS-box. This mutation disrupts the 
essential leucine residue and prevents interaction with elonginC thus blocking E3 
ligase function (194) (Figure 2.1).  
 
In brief, primers were designed to be 25 bases in length with the mutation 
centred with 10-15 bases each side. Primers had a GC content greater than 40%, 
terminated with a GC and had a melting temperature greater or equal to 78°C 
where: 
 
 
Tm = 81.5 + 0.41(%GC) – (675/N) - %mismatch 
 
 
N = Primer length in bases 
%GC and %mismatch are whole numbers 
 
The final design verified using an online tool (Agilent) available at: 
(https://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&Su
bPageType=ToolQCPD&PageID=15). 
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Figure 2.1: Mutation of the SOCS-box disrupts the SOCS3-elonginBC 
interaction  
An L189A mutation of the B/C-box within the SOCS3 SOCS-box disrupts an 
essential leucine residue (Panel A) and prevents interaction with elonginC and 
thus blocks E3 ligase function (194) (Panel B). Primers were designed (Section 
2.2.11.1) and site-directed mutagenesis performed on SOCS3-cDNA as described 
(Section 2.2.11.2). The mutation was confirmed via DNA sequencing (Section 
2.2.11.3) and by co-immunoprecipitation (Panel B, section 6.2.1.1).  
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2.2.11.2 Site-directed mutagenesis 
Site-directed mutagenesis was performed using a Quikchange II Site-Directed 
Mutagenesis kit as per manufacturer’s instructions. Briefly, reaction components 
(reaction buffer, dsDNA template, primers, dNTP mix, ddH2O, and DNA 
polymerase) were mixed and the reaction allowed to proceed for 18 
temperature cycles (95°C, 30 seconds; 55°C, 1 minute; 68°C, 6 minutes) 
following an initial 30 second extended melting period 95°C. Non-mutated, 
methylated DNA was then digested for 1 hour with the restriction enzyme Dnp I 
prior to nick repair and amplification of mutated dsDNA via the transformation 
of XL1-Blue super-competent cells. Mutant-DNA transformed-cells along with 
mutagenesis (pWhitescript) and transformation (pUC18) controls were spread on 
separate LB–ampicillin (50µg/ml) agar plates containing 80µg/ml X-gal and 20mM 
IPTG. Colonies were allowed to proliferate for 16 hours at 37°C before isolation 
of transformed colonies prior to mini or maxiprep DNA purification and 
sequencing.  
2.2.11.3 Sequencing of plasmids 
Before and after site-directed mutagenesis, candidate SOCS3-FLAG plasmids 
were sequenced using the DNA sequencing service provided by 
www.dnaseq.co.uk based at the University of Dundee. Sequencing was 
performed across the open reading frame (ORF) using T7 
(TAATACGACTCACTATAGGG, forward) and SP6 (AGCTATTTAGGTGACACTATAG, 
reverse) primers that were provided by www.dnaseq.co.uk. The quality of 
sequencing was visually evaluated using Chromas lite by assessing the intensity 
and separation of individual base peaks. The location of the epitope tag, the 
identity, and species of the encoded SOCS3 protein was verified via an NCBI 
BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
2.2.12 Transfection 
HEK293 cells seeded at 80% confluency on poly-D-lysine-coated dishes were 
transfected with 2µg to 8µg of DNA using Lipofectamine 2000 Reagent (Life 
Technologies, UK) as per manufacturer’s instructions. Briefly, either DNA or 
Lipofectamine 2000 reagent were added to Optimem serum-free media and 
mixed thoroughly via gentle pipetting prior to the individual solutions being 
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mixed together, again via gentle pipetting. The solution was then incubated for 
15 minutes at room temperature to allow formation of lipid-DNA complexes. 
During this time, the target cells were washed twice with Optimem before 
addition of the necessary transfection volume of Optimem. The Lipofectamine 
2000 reagent-DNA-Optimem solution was then added to the target cells in a 
drop-wise fashion and mixed via gentle rocking. Cell were incubated at 37°C for 
3 hours to allow transfer of DNA into the target cells after which time the 
transfection media was replace with growth media. Cells were then allowed to 
proliferate for 24 hours at 37°C before the media was refreshed. After a further 
24hrs at 37°C, the cells were harvested (Section 2.2.5).   
2.2.13 Co-immunoprecipitation  
2.2.13.1 Sepharose beads 
Co-immunoprecipitation was performed using 40µl of 50% slurry (v/v) of Protein 
G Sepharose beads (Sigma).  Prior to use, beads were washed twice in 1ml lysis 
buffer (50mM HEPES, pH 7.4, 120mM NaCl, 5mM EDTA, 10% (v/v) glycerol, 1% 
(v/v) Triton x-100, supplemented with phosphatase inhibitors 5mM NaF, 1mM 
Na3VO4, and protease inhibitors 10µg/ml benzamidine, 0.1mM PMSF, 10µg/ml 
soybean trypsin inhibitor, 2% (w/v) EDTA-free complete protease inhibitor 
cocktail), which was completely removed using a Hamilton syringe following 
centrifugation at 300g for 30 seconds. Beads were resuspended in 100µl 2% (v/v) 
IgG free BSA as a blocking agent and incubated for 1-4 hours with rotation at 
4°C. Soluble protein lysates prepared in lysis buffer were equalised to 1mg/ml 
was incubated with 40µl pre-equilibrated protein G beads at 4°C with rotation 
for one hour to remove non-specifically binding proteins. Recovered, pre-cleared 
lysate was added to 50µl of pre-equilibrated protein G Sepharose beads 
suspended in 100µl 2% (v/v) IgG free BSA plus an optimised volume of the 
relevant antibody and incubated overnight at 4°C with rotation. Beads were 
isolated following centrifugation at 300g for 30 seconds. Recovered beads, 
bound to antibody and protein, were washed three times using 1ml of lysis 
buffer, the final wash was removed using a Hamilton syringe. Protein complexes, 
from both pre-clear and antibody-bound beads, were eluted in 40µl of 12% (w/v) 
SDS sample buffer supplemented with DTT by incubating at 67°C for 30 minutes 
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followed by a further 5 minutes at 95°C. Supernatant was collected using a 
Hamilton syringe following centrifugation at 300g for 30 seconds and prepared 
for western blot analysis.   
2.2.13.2 Pre-conjugated anti-Flag M2-agarose beads 
Co-immunoprecipitation was performed using 40µl of pre-conjugated anti-Flag 
M2-agarose beads (Sigma). The protocol shown in section 2.2.13.1 was repeated 
without pre-clearing of cell lysates. 
2.2.14 Denatured immunoprecipitation of ubiquitinated proteins 
To ensure precipitation of the ubiquitinome was unaffected by DUBs or 
uncontaminated by ubiquitin binding proteins or non-specifically bound proteins, 
a non-denaturing immunoprecipitation was performed on denatured cell lysates.  
 
HEK293 cells were seeded on poly-D-lysine-treated dishes to achieve ~80% 
confluency the following day. Cells were transfected as previously described 
(Section 2.2.12) with cDNA constructs for Ub-HA and combinations of candidate 
SOCS3 substrates, SOCS3, and components the E3 ubiquitin ligase scaffold 
(cullin5, Rbx2, elonginB, and elonginC). Cells were treated with MG132 (6µM) for 
2 hours prior to harvesting so to protect ubiquitinated proteins from degradation 
and then washed twice with ice cold PBS and scrapped into 0.1 ml of denaturing 
lysis buffer (50mM sodium HEPES, pH 7.5, 100mM sodium chloride, 1mM N-
ethylmaleimide, 2% (w/v) SDS, 0.1mM PMSF, 10µg/ml soybean trypsin inhibitor, 
10µg/1ml benzamidine, and 2% (w/v) EDTA-free complete protease inhibitor 
mix). The samples were then incubated at 95°C for 5 min before sonicating for 
three 10-second pulses, with a 10-second rest phase, at 40% amplitude with a 
2mm diameter stepped micro-tip (150µl-1ml). To prevent denaturing the 
precipitating antibody, the denaturing lysis buffer was diluted with 0.9 ml lysis 
buffer containing sufficient Triton X-100 and sodium deoxycholate to give final 
concentrations of 1% (w/v) and 0.5% (w/v) respectively. Insoluble material was 
removed by centrifugation at 21000g for 5 minutes at 4°C and soluble fractions 
(~990µl) equalised for protein content volume prior to incubation for overnight 
at 4°C with rotation with 30µl of 50% slurry (v/v) monoclonal (HA-7) anti-HA 
agarose beads or 50µl of 50% slurry (v/v) protein G Sepharose plus 4µl (200ug) 
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anti-PTRF antibody. As negative controls, immunoprecipitation was also 
performed using either 30µl of 50% (v/v) slurry of pre-conjugated Flag M2 
agarose beads or 40µl of 50% (v/v) slurry of protein G Sepharose beads and 4µl of 
MYPT1. Recovered proteins were isolated following centrifugation at 1000g for 1 
minute at 4°C and washed three times with 1ml non-denaturing lysis buffer 
(50mM sodium HEPES, pH 7.5, 100mM sodium chloride, 1.1% (v/v) Triton X-100, 
0.6% (w/v) sodium deoxycholate, 1mM N-ethylmaleimide, 0.1mM PMSF, 10µg/ml 
soybean trypsin inhibitor, 10µg/1ml benzamidine, and 2% (w/v) EDTA-free 
complete protease inhibitor mix) prior to elution in 40µl of 12% (w/v) SDS sample 
buffer at 67°C for 30 minutes. Samples were then fractionated by SDS-PAGE and 
recovery of proteins visualised via immunoblotting. 
2.2.15 Peptide array  
2.2.15.1 CelluSpot synthesis of peptide array and overlay 
It is predicted that the SOCS3-substrate interaction and subsequent 
ubiquitination of the substrate is dependent on the SOCS3-SH2 domain. As such, 
SOCS3 substrates are expected to be tyrosine-phosphorylated. Known tyrosine-
phosphorylated peptides from potential SOCS3 substrates, identified from the 
proteomics screen (Section 5), were extracted using 
http://www.phosphosite.org (last accessed: 1-10-12).  A Peptide array was 
produced using phosphorylated forms of these peptides (Table 2.3) via the 
CelluSpot system.  
 
Peptide arrays were produced by Dr George Baillie (University of Glasgow, 
Institute of Cardiovascular and Medical Sciences) as described (195). Briefly, 
using an automated system, cellulose-conjugated peptides are synthesised and 
spotted onto a coated microscope slide producing a 3-dimensional layer of 
peptides. This system increases binding capacity as compared with monolayer 
peptide arrays (Section 2.2.15.2) and improves detection of weak interactions by 
providing a greater number of peptides in a given area.   
 
Interactions between SOCS3 and tyrosine-phosphorylated peptides were 
identified by overlaying the peptide array with SOCS3-Flag, in its native state. 
SOCS3-Flag was detected using a Flag-specific antibody followed by an IR-tagged 
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secondary antibody. Any interaction between SOCS3 and a peptide was visualised 
using a LI-COR Odyssey Sa system. Briefly, before overlaying with SOCS3-Flag, 
the peptide arrays were moistened using TBST (50mM Tris pH 7.5, 150mM NaCl, 
0.1% Tween 20) and blocked, to prevent non-specific interactions, in 3ml of 
TBST containing 5% (w/v) BSA for 4 hours at room temperature. CelluSpot 
peptide arrays are sensitive to mechanical stress and so to address this 
limitation and to reduce volumes of solutions used, all incubations were 
performed in 4-well dishes (Thermo-Scientific). Peptide arrays were overlaid 
with cell lysates (500µg/ml) diluted in a total volume of 2.5ml with TBST 
containing 0.5% (w/v) BSA and protease inhibitors (10µg/ml benzamidine, 0.1mM 
PMSF, 10µg/ml soybean trypsin inhibitor, 2% (w/v) EDTA-free complete protease 
inhibitor cocktail). Following three, ten minute washes in TBST with rocking, the 
peptide array was incubated with the primary, anti-FLAG (mouse), antibody 
diluted in TBST containing 1% (w/v) BSA overnight at 4°C with rocking. The 
peptide arrays were then washed three times for five minutes in TBST before 
incubating with the secondary, anti-mouse 800-IRdye (donkey) antibody diluted 
in TBST containing 1% (w/v) BSA for 45 minutes at RT. Due to the sensitivity of 
IR-tagged antibodies, this incubation period was performed in the dark. The 
SOCS3-peptide interactions were visualised using a LI-COR Odyssey Sa system. As 
a control, the same procedure was replicated in parallel using GFP-containing 
cell lysates. 
2.2.15.2 SPOT synthesis of peptide array and overlay 
It is predicted that the SOCS3-substrate interaction and subsequent 
ubiquitination of the substrate is dependent on the SOCS3-SH2 domain. As such, 
SOCS3 substrates are expected to be tyrosine-phosphorylated. Using peptides 
from candidate SOCS3 substrates previously found to interact significantly 
(p<0.05, one-tailed, paired t-test) with SOCS3, a peptide array was produced 
using phosphorylated or non-phosphorylated forms of these peptides (Table 2.4). 
Candidate SOCS3 substrate peptides were produced by automatic SPOT synthesis 
on Whatman 50 cellulose membranes by the Baillie laboratory as described 
(196).  
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The array was first overlaid with an anti-SOCS3 antibody as a control to assess 
background before being stripped and overlaid with purified SOCS3 protein. 
Interactions between SOCS3 and peptides were identified by overlaying the 
peptide array with purified Trx-polyhis-tagged SOCS3 (Sino Biological Inc.) in its 
native state. Trx-polyhis-SOCS3 was detected using a SOCS3-specific antibody 
followed by an IR-tagged secondary antibody. Any interaction between SOCS3 
and a peptide was visualised using a LI-COR Odyssey Sa system.   
 
The array was first bathed in pure ethanol before washing in TBST (50mM Tris pH 
7.5, 150mM NaCl, 0.1% Tween 20) for 5 minutes and then blocked, to prevent 
non-specific interactions, in 3ml of TBST containing 5% (w/v) BSA for 4 hours at 
RT. Blocking and overlaying was performed in sealed bags. The array was washed 
briefly in TBST before incubating with the primary, anti-SOCS3 antibody diluted 
in TBST containing 1% (w/v) BSA overnight at 4°C with rocking. The peptide 
arrays were then washed three times for five minutes in TBST before incubating 
with the secondary, 680-IRdye antibody diluted in TBST containing 1% (w/v) BSA 
for 45 minutes at RT. Due to the sensitivity of IR-tagged antibodies, this 
incubation period was performed in the dark. The SOCS3-peptide interactions 
were visualised using a LI-COR Odyssey Sa system. The array was then stripped in 
stripping buffer (Tris-Cl 62mM pH6.8, DTT 20mM, SDS 2% (w/v)) at 70ºC for 30 
minutes before washing  three times for ten minutes in TBST. The array was then 
bathed in pure ethanol, washed in TBST and blocked as before prior to 
overlaying O/N with purified Trx-polyhis-tagged SOCS3 (10µg/ml) diluted in a 
total volume of 2.5ml with TBST containing 0.5% (w/v) BSA and protease 
inhibitors (10µg/ml benzamidine, 0.1mM PMSF, 10µg/ml soybean trypsin 
inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail). Following 
three, ten minute washes in TBST with rocking, the peptide array was incubated 
with the primary, anti-SOCS3, antibody diluted in TBST containing 1% (w/v) BSA 
overnight at 4°C with rocking. The peptide arrays were then washed three times 
for five minutes in TBST before incubating with the secondary, 680-IRdye 
antibody diluted in TBST containing 1% (w/v) BSA for 45 minutes at RT. Due to 
the sensitivity of IR-tagged antibodies, this incubation period was performed in 
the dark. The SOCS3-peptide interactions were visualised using a LI-COR Odyssey 
Sa system. 
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Table 2.3: Peptide array of tyrosine-phosphorylated peptide from candidate 
SOCS3 substrates     
Peptide(s) of candidate proteins are listed in tabular form while the layout of peptides 
spotted in duplicate onto the CelluSpot array are presented below. Controls are 
highlighted in bold. 
Sequence Sequence
1 Eps15L (1) V-D-P-A-pY-T-G-R-V-G-A 36 Hsc73(1) L-G-T-T-pY-S-C-V-G-V-F
2 Eps15L (2) K-Q-G-F-pY-V-A-L-R-L-V 37 Hsc73(2) T-T-P-S-pY-V-A-F-T-D-T
3 Eps15L (3) S-L-E-Q-pY-D-Q-V-P-D-G 38 Hsc73(3) V-Q-V-E-pY-K-G-E-T-K-S
4 Ube1 (1) D-E-G-L-pY-S-R-Q-L-Y-V 39 Hsc73(4) T-K-S-F-pY-P-E-E-V-S-S
5 Ube (2) S-R-Q-L-pY-V-L-G-H-E-A 40 Hsc73 (5) I-A-E-A-pY-L-G-K-T-V-T
6 Ube1 (3) R-R-C-V-pY-Y-R-K-P-L-L 41 Tubb5 (1) K-N-S-S-pY-F-V-E-W-I-P
7 Ube1 (4) V-L-G-P-pY-T-F-S-I-C-D 42 Tubb5 (2) P-T-G-T-pY-H-G-D-S-D-L
8 Ube1 (5) N-F-S-D-pY-I-R-G-G-I-V 43 Tubb5 (3) N-E-A-L-pY-D-I-C-F-R-T
9 Cavin-1 (1) K-V-M-I-pY-Q-D-E-V-K-L 44 Usp5 (1) L-S-G-E-pY-S-K-P-V-P-E
10 Cavin-1 (2) D-H-V-V-pY-A-R-S-K-T-A 45 Usp5 (2) E-L-L-E-pY-E-E-K-K-R-Q
11 Sqstm1 (1) V-C-P-D-pY-D-L-C-S-V-C 46 FAK (1) A-A-A-pY-L-D-P-N-L-N
12 Sqstm1 (2) D-T-I-Q-pY-S-K-H-P-P-P 47 FAK (2) L-N-F-F-pY-Q-Q-V-K-S-D
13 Impdh2 A-P-G-E-pY-F-F-S-D-G-I 48 FAK (3) V-K-S-D-pY-M-L-E-I-A-D
14 Histone 3.1 (1) K-P-H-R-pY-R-P-G-T-V-A 49 FAK (3) K-K-S-N-pY-E-V-L-E-K-D
15 Histone 3.1 (2) E-I-R-R-pY-Q-K-S-T-E-L 50 FAK (4) L-I-D-G-pY-C-R-L-V-N-G
16 Histone 3.1 (3) A-C-E-A-pY-L-V-G-L-F-E 51 FAK (5) E-T-D-D-pY-A-E-I-I-D-E
17 Abi2 (1) V-P-N-D-pY-V-P-S-P-T-R 52 FAK (6) E-E-D-T-pY-T-M-P-S-T-R
18 Abi2 (2) A-I-Y-D-pY-T-K-D-K-E-D 53 FAK (7) H-Q-G-I-pY-M-S-P-E-N-P
19 Abi2 (3) L-F-D-S-pY-T-N-L-E-R-V 54 FAK (8) G-L-S-R-pY-M-E-D-S-T-Y
20 Abi2 (4) R-V-A-D-pY-C-E-N-N-Y-I 55 FAK (9) E-D-S-T-pY-Y-K-A-S-K-G
21 Abi2 (5) R-H-S-P-pY-R-T-L-E-P-V 56 FAK (10) D-S-T-Y-pY-K-A-S-K-G-K
22 Abi2 (6) G-S-L-P-pY-R-R-P-P-S-I 57 FAK (11) S-R-P-G-pY-P-S-P-R-S-S
23 Abi2 (7) V-V-A-I-pY-D-Y-T-K-D-K 58 FAK (12) N-Q-H-I-pY-Q-P-V-G-K-P
24 Psma6 (1) D-P-A-G-pY-Y-C-G-F-K-A 59 FAK (13) P-A-D-S-pY-N-E-G-V-K-L
25 Psma6 (2) P-A-G-Y-pY-C-G-F-K-A-T 60 FAK (14) N-D-K-V-pY-E-N-V-T-G-L
26 Psma6 (3) E-G-R-L-pY-Q-V-E-Y-A-F 61 FAK (15) L-A-Q-Q-pY-V-M-T-S-L-Q
27 Rps3 (1) D-P-V-N-pY-Y-V-D-T-A-V 62 Krt18 (1) F-S-T-N-pY-R-S-L-G-S-V
28 Rps3 (2) E-S-L-R-pY-K-L-L-G-G-L 63 Krt18 (2) Q-A-P-S-pY-G-A-R-P-V-S
29 Actn4 (1) M-V-D-pY-H-A-A-N-Q-S 64 Krt18 (3) A-A-S-V-pY-A-G-A-G-G-S
30 Actn4 (2) S-M-G-D-pY-M-A-Q-E-D-D 65 Krt18 (4) R-L-A-S-pY-L-D-R-V-R-S
31 Actn4 (3) V-S-S-F-pY-H-A-F-S-G-A 66 Krt18 (5) D-W-S-H-pY-F-K-I-I-E-D
32 Actn (4) V-A-E-K-pY-L-D-I-P-K-M 67 Krt18 (6) V-E-A-R-pY-A-L-Q-M-E-Q
33 Actn (5) E-L-I-E-pY-D-K-L-R-K-D 68 pY759gp130 S-T-V-Q-pY-S-T-V-V-H-S
34 Eps15 (1) N-F-S-A-pY-P-S-E-E-D-M 69 Y759gp130 S-T-V-Q-Y-S-T-V-V-H-S
35 Eps15 (2) Q-I-S-T-pY-E-E-E-L-A-K
Protein (Peptide) Peptide
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Table 2.4: Peptide array of tyrosine-/non-phosphorylated peptides from 
candidate SOCS3 substrates     
Peptides from candidate SOCS3 substrates previously found to interact significantly 
(p<0.05, one-tailed, paired t-test) were produced by automatic SPOT synthesis on 
Whatman 50 cellulose membranes. Peptide(s) of candidate proteins are listed in tabular 
form. Controls are highlighted in bold. 
 
Sequence Sequence
1 pY759gp130(+) S-T-V-Q-pY-S-T-V-V-H-S 26 Hsc73(1)(-) L-G-T-T-Y-S-C-V-G-V-F
2 pY759gp130(-) S-T-V-Q-Y-S-T-V-V-H-S 27 Hsc73(2)(+) T-T-P-S-pY-V-A-F-T-D-T
3 Eps15L (2) (+) K-Q-G-F-pY-V-A-L-R-L-V 28 Hsc73(2)(-) T-T-P-S-Y-V-A-F-T-D-T
4 Eps15L (2) (-) K-Q-G-F-Y-V-A-L-R-L-V 29 Hsc73 (5)(+) I-A-E-A-pY-L-G-K-T-V-T
5 Ube (2)(+) S-R-Q-L-pY-V-L-G-H-E-A 30 Hsc73 (5)(-) I-A-E-A-Y-L-G-K-T-V-T
6 Ube (2)(-) S-R-Q-L-Y-V-L-G-H-E-A 31 Tubb5 (1)(+) K-N-S-S-pY-F-V-E-W-I-P
7 Ube1 (4)(+) V-L-G-P-pY-T-F-S-I-C-D 32 Tubb5 (1)(-) K-N-S-S-Y-F-V-E-W-I-P
8 Ube1 (4)(-) V-L-G-P-Y-T-F-S-I-C-D 33 Tubb5 (3)(+) N-E-A-L-pY-D-I-C-F-R-T
9 Impdh2(+) A-P-G-E-pY-F-F-S-D-G-I 34 Tubb5 (3)(-) N-E-A-L-Y-D-I-C-F-R-T
10 Impdh2(-) A-P-G-E-Y-F-F-S-D-G-I 35 pY759gp130(-) S-T-V-Q-Y-S-T-V-V-H-S
11 Histone 3.1 (3)(+) A-C-E-A-pY-L-V-G-L-F-E 36 pY759gp130(+) S-T-V-Q-pY-S-T-V-V-H-S
12 Histone 3.1 (3)(-) A-C-E-A-Y-L-V-G-L-F-E 37 FAK (2)(+) L-N-F-F-pY-Q-Q-V-K-S-D
13 Abi2 (3)(+) L-F-D-S-pY-T-N-L-E-R-V 38 FAK (2)(-) L-N-F-F-Y-Q-Q-V-K-S-D
14 Abi2 (3)(-) L-F-D-S-Y-T-N-L-E-R-V 39 FAK (4)(+) L-I-D-G-pY-C-R-L-V-N-G
15 Abi2 (4)(+) R-V-A-D-pY-C-E-N-N-Y-I 40 FAK (4)(-) L-I-D-G-Y-C-R-L-V-N-G
16 Abi2 (4)(-) R-V-A-D-Y-C-E-N-N-Y-I 41 FAK (5)(+) E-T-D-D-pY-A-E-I-I-D-E
17 Psma6 (1)(+) D-P-A-G-pY-Y-C-G-F-K-A 42 FAK (5)(-) E-T-D-D-Y-A-E-I-I-D-E
18 Psma6 (1)(-) D-P-A-G-Y-Y-C-G-F-K-A 43 FAK (8)(+) G-L-S-R-pY-M-E-D-S-T-Y
19 Psma6 (2)(+) P-A-G-Y-pY-C-G-F-K-A-T 44 FAK (8)(-) G-L-S-R-Y-M-E-D-S-T-Y
20 Psma6 (2)(-) P-A-G-Y-Y-C-G-F-K-A-T 45 FAK (9)(+) E-D-S-T-pY-Y-K-A-S-K-G
21 Psma6 (3)(+) E-G-R-L-pY-Q-V-E-Y-A-F 46 FAK (9)(-) E-D-S-T-Y-Y-K-A-S-K-G
22 Psma6 (3)(-) E-G-R-L-Y-Q-V-E-Y-A-F 47 Krt18 (5)(+) D-W-S-H-pY-F-K-I-I-E-D
23 Rps3 (2)(+) E-S-L-R-pY-K-L-L-G-G-L 48 Krt18 (5)(-) D-W-S-H-Y-F-K-I-I-E-D
24 Rps3 (2)(-) E-S-L-R-Y-K-L-L-G-G-L 49 pY759gp130(+) S-T-V-Q-pY-S-T-V-V-H-S
Protein (Peptide) Protein (Peptide)
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2.2.16 Substrate degradation assay 
The stability of candidate SOCS3 substrates is expected to be reduced in the 
presence of SOCS3. Inhibition of protein synthesis will enable the time-
dependent degradation of SOCS3 targets to be detected.  Emetine, an 
irreversible inhibitor of protein synthesis, which acts by binding to and blocking 
the translocation of the 40S ribosomal unit (197,198), will be used for this 
purpose.    
 
HEK293 cells were seeded at 36x105 cells in poly-D-lysine-treated 10cm dishes 
for ~80% confluency the following day. Cells were then transfected as described 
(Section 2.2.12) with cavin-1 (24µg) cDNA plasmid. After 24 hours cells were 
split equally into 6 well plates and allowed to proliferate for a further 24 hours. 
Cells were then treated with emetine (100µM) with or without MG132 (6µM) or 
chloroquine (100mM) for 0-10 hours prior to harvesting using the co-
immunoprecipitation protocol (section 2.2.5.4). Samples were then equalised for 
protein concentration prior to fractionation by SDS-PAGE and degradation 
assessed via immunoblotting. 
 
2.3 External services 
Biomers, DM: 
www.biomers.net   Primer synthesis 
 
DNASeq, UK:    
www.dnaseq.co.uk  DNA sequencing 
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3.0 Characterisation of experimental cell lines 
3.1 Introduction 
Inflammation is a protective yet potentially damaging process that requires tight 
regulation. Dysregulation can lead to several disorders that are initiated by a 
state of low-grade chronic inflammation including atherosclerosis and 
rheumatoid arthritis (26,130). The concomitant occurrence of inflammatory 
diseases with obesity is thought to result from the chronically elevated secretion 
of adipocytokines such as IL6 from adipose tissue (5,199).  
 
IL6 exerts its effect via the activation of the JAK/STAT and ERK pathways via its 
cognate receptor, gp130 (Figure 1.2). Cytokine-receptor ligation initiates STAT-
driven gene transcription of several IL6-dependent genes including SOCS3. 
SOCS3, which is present at low basal levels, is rapidly induced following IL6 
stimulation and negatively regulates IL6 signalling via several mechanisms. 
STAT1/3 activation is prevented by the direct binding of SOCS3 to the catalytic 
domain of JAKs via the N-terminal KIR, SH2, and ESS domains (123). ERK 
activation is dependent on the activation of pY759-gp130-bound SHP2. As such, 
ERK signalling is inhibited by competition from SOCS3 that also binds pY759 
(55,200). SOCS1 similarly regulates JAK/STAT signalling in response to IFNγ and 
has also been shown to direct proteasomal degradation of tyrosine-
phosphorylated JAK2 (87). JAK2 is mono-ubiquitinated in unstimulated cells but 
becomes polyubiquitinated and degraded following tyrosine phosphorylation 
(Y1007) and subsequent association with SOCS1 (87). It is also possible that SOCS3 
might similarly regulate JAK1 (73) but this has yet to be demonstrated directly. 
The study found that in response to LIF, pJAK1 accumulated to greater levels in 
SOCS3 SOCS-box knockout (SOCS3∆SB/∆SB) embryonic stem cells compared to WT. 
Turnover of JAK1 was not assessed. 
 
Similar to SOCS1, SOCS3  regulates the polyubiquitin-dependent proteasomal 
degradation of signalling intermediates by acting as the specificity factor within 
an ECS-type E3 ubiquitin ligase (86). SOCS3 has been shown to regulate the 
ubiquitin-dependent proteasomal degradation of focal adhesion kinase (FAK)-1 
(10), insulin receptor substrate (IRS)-1/2 (9), sialic-acid-binding immunoglobulin-
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like lectin (SIGLEC)-7 (12), and CD33 (11). Furthermore, SOCS3 has also been 
shown to regulate lysosomal routing of the G-CSF receptor via ubiquitination of 
the juxtamembrane residue K632 (8,201). However, the full spectrum of SOCS3-
dependently ubiquitinated targets is currently unknown.  
 
SOCS3 is also induced by elevated cAMP levels mediated by EPAC (70) and PKA-
independent ERK activation (118). SOCS3 is currently one of two cAMP-inducible 
E3 ubiquitin ligases to be identified (202). It is hypothesised that since SOCS3 is 
inducible via several routes including the JAK/STAT pathway (55,55,70), toll-like 
receptors (51), and cAMP(70), the pool of SOCS3-ubiquitinated targets may vary 
depending on the route of SOCS3 induction. Cyclic AMP has long been recognised 
an important inhibitor of inflammatory signalling (115). Thus, uncovering new 
targets of cAMP/EPAC1’s effects might provide potential therapeutic approaches 
for treating multiple inflammatory disorders. 
 
The aim of this study was to compare ubiquitinomes from WT and SOCS3-/-MEFs. 
By this approach, it should be possible to identify substrates ubiquitinated by 
SOCS3 following its cAMP-dependent induction in WT but not SOCS3-/- MEFs. To 
capture the ubiquitinome, an N-terminally-(His)6+biotin-tagged form of ubiquitin 
(HBUb) (168,175,203) was expressed in both cell lines. This tag enables tandem 
affinity purification of the ubiquitinome under highly denaturing conditions (8M 
urea). This environment will contribute to the protection of the ubiquitinome 
from DUBs, which cleave polyubiquitin chains to monomers for recycling. 
Furthermore, the strong interaction between the HBUb tag and streptavidin 
beads (KD=10
-15M) allows stringent wash conditions to produce a sample 
minimally contaminated by non-specifically bound proteins. Such characteristics 
make the HBUb tag ideal for analysis of the ubiquitinome via mass spectrometry.  
3.2 Experimental cell lines and strategy 
MEFs were chosen as an experimental model due to their tractability and 
robustness with regards to retroviral transduction. Furthermore, their longevity 
and ability to grow quickly in large numbers supports their use for this study. 
Moreover, although not physiologically relevant, it was thought that these cells 
would allow identification of specific targets of SOCS3 with minimal effort. 
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Isolation of the ubiquitinome was facilitated by HBUb-tagged ubiquitin. Cell lines 
that stably express the HBUb transgene (WT HBUb, SOCS3-/- HBUb) were 
produced via retroviral transduction of a HBUb-expressing plasmid (168) 
(donated by Prof. Peter Kaiser, University of California at Irvine). A control 
puromycin resistant cell line that stably expresses the puromycin-resistance 
plasmid vector pBabe-puro was also produced via the same method (Section 
2.2.2).  
 
To evaluate the suitability of control MEFs (WT and SOCS3-/-) and HBUb-
expressing MEFs (WT HBUb and SOCS3-/- HBUb) as experimental models, the cells 
were fully characterised. Control and experimental MEFs need to fulfil several 
key requirements before qualifying as suitable experimental models. First, to 
prevent a toxic reaction to transgene expression, HBUb expression was assessed 
by its effect on cell viability (Section 3.3.1). Second, for accurate relative 
quantification, reduced data processing, and simplified data analysis following 
MS analysis, the HBUb transgene should be expressed at equivalent levels in WT 
HBUb and SOCS3-/- HBUb MEFs. Furthermore, it is expected that, for normal cell 
function, endogenous ubiquitin is also expressed at equivalent levels in all cell 
lines (Section 3.3.2). Third, HBUb, which is co-expressed with endogenous 
ubiquitin, should not impact K48-linked polyubiquitination or formation of other 
well-characterised polyubiquitin chains such as K63-linked chains. To do so 
would potentially generate aberrant results. Therefore, HBUb transgene 
expression should not interfere with common ubiquitin-dependent signalling 
pathways such as the NFκB pathway (Section 3.3.3). Fourth, SOCS3 induction 
should not be affected by transgene expression thus WT and WT HBUb MEFs 
should express SOCS3 at equivalent levels while SOCS3-/- HBUb MEFs and SOCS3-/- 
control MEFs should not express SOCS3 (Section 3.3.4).  
 
In addition, the sensitivity of detection of ubiquitylated, tyrosine-
phosphorylated SOCS3 substrates will be enhanced via the used of the protein 
tyrosine phosphatase inhibitors sodium orthovanadate and hydrogen peroxide. 
Since these chemicals can be toxic, optimum concentration and incubation 
periods were assessed (Section 3.3.5).  
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In summary, I aimed to examine the possibility of potential adverse effects as a 
consequence of permanent or temporary cellular alterations i.e. SOCS3 
knockout, transgene expression, or treatments. Presented here are the strategy, 
procedure, and results of those characterisation experiments. 
3.3 Results and discussion 
3.3.1 HBUb expression does not impact cell viability 
The impact of HBUb expression on cell viability was assessed via an 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Section 
2.2.4) (191). Cell density is estimated from the reduction of MTT to formazan 
that has a maximum absorbance at 590nm. MTT reduction can only occur in the 
mitochondria of live cells and so absorbance is directly proportional to live cell 
density and thus cell proliferation. The concentration of MTT (100µM) had 
previously been optimised by colleagues. Proliferation of each cell line was 
compared to controls consisting of a dish containing no cells (blank) and cells 
pre-killed with 50% (v/v) DMSO for one hour. Optimum DMSO incubation time had 
been previously assessed via a time course (data not shown) where cells were 
treated with 50% DMSO from 0 to 4 hours. The effectiveness of DMSO to promote 
cell death was confirmed by viewing rounded-up cells under a light microscope 
and via an MTT assay (results not shown). 
 
The MTT assay was performed as described (Section 2.2.4). No significant 
difference was observed (p>0.05, t-test) in proliferation between the WT and 
WT HBUb (Figure 3.1) or between SOCS3-/- and SOCS3-/- HBUb MEFs. 
Furthermore, there was no significant difference (p>0.05, t-test) in proliferation 
between WT HBUb and SOCS3-/- HBUb MEFs (Figure 3.1). These data suggested 
that overexpression of the HBUb transgene and/or SOCS3 knockout had no 
significant negative effect on cell viability.  
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Figure 3.1: Impact of HBUb expression on cell viability 
Cells were seeded at a density of 5x104 cells/well in 12 well plates and allowed to 
proliferate. After 24 hours incubation at 37ºC, the media was refreshed before MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent (100µM) was 
directly added to cells followed by a further incubation period of 3 hours. Negative 
controls included a dish containing no cells (blank) and cells pre-killed with 50% (v/v) 
DMSO for one hour. Media was removed and cells lysed with 500µl of DMSO which also 
solubilises the formazan crystals. Proliferation was assessed by measuring the 
absorbance of 200µl aliquots of DMSO-solubilised formazan crystals at 590nm. An 
averaged result from three experiments is shown. Results are presented as mean values 
±SEM for n=3 experiments. 
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3.3.2 HBUb transgene and endogenous ubiquitin are expressed at 
comparable levels in control and experimental cell lines  
Isolation of the ubiquitinome is aided by HB-tagged ubiquitin which enables 
purification under highly denaturing conditions (175).  Under this condition, the 
recovered sample will be minimally contaminated by ubiquitin binding proteins 
and non-specifically bead-bound proteins. Importantly, the ubiquitinome will be 
preserved due to the inactivation of DUBs.  For accurate relative quantification 
of HBUb-modified proteins and to reduce the likelihood of producing false-
positives in subsequent SILAC analysis, cell lines should express the HBUb 
transgene at equivalent levels. This requirement is not completely essential 
since variations in expression can be taken into account and the data sets 
manipulated accordingly. However, data manipulation might increase data 
processing time and potentially add further error into the data set if performed 
incorrectly. Therefore, to ensure comparable expression levels, several WT and 
SOCS3-/- HBUb-expressing clones were compared. Furthermore, all cell lines 
should express endogenous ubiquitin at equivalent levels.    
 
Cells grown to confluency in 10cm dishes were treated with 6µM MG132 for 2 
hours to preserve the ubiquitinome from proteasomal degradation. Cell lysates 
were prepared and equalised prior to fractionation by SDS-PAGE and expression 
levels of ubiquitin and HBUb assessed via immunoblotting using either an anti-
ubiquitin antibody for detection of total ubiquitin levels or an anti-polyhistidine 
antibody, which detects the hexahistidine domain within the HB-tagged ubiquitin 
(Figure 3.2). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
housekeeping gene, was used as a loading control and detected using an anti-
GAPDH antibody.    
 
The ubiquitinome is the subset of the proteome that is mono-, multi-, or 
polyubiquitinated with chains of various lengths. As such, a range of mass shifts 
would be expected for each ubiquitinated protein generating a smear pattern 
following visualisation via immunoblotting (175). Consistent with this, smears 
were detected along with high molecular weight ubiquitin signals suggesting a 
functional ubiquitin and HBUb tag (Figure 3.2). Ubiquitin expression was found  
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Figure 3.2: HBUb transgene and endogenous ubiquitin are expressed at 
comparable levels in control and experimental cell lines  
WT HBUb, SOCS3-/- HBUb, WT, and SOCS3-/- MEFs were grown to confluency after which 
the media was refreshed before treating with vehicle (DMSO, 1:1000) or MG132 (6µM), 
to enrich for ubiquitinated proteins, for 2 hours prior to harvesting. Soluble protein 
lysates were equalised to 40µg before SDS-PAGE fractionation. Expression of total 
ubiquitin or HBUb was assessed by immunoblotting with specific anti-Ub (Panel A) or 
anti-polyhistidine antibody (Panel B) respectively. GAPDH antibody was used as a 
loading control (Panel C). 
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to be comparable between WT and SOCS3-/- MEFs and also between WT HBUb 
and SOCS3-/- HBUb MEFs (Figure 3.2, panel A). Only the experimental cell lines 
expressed HB-tagged ubiquitin and did so at approximately equivalent levels 
(Figure 3.2, panel B). Detection of ubiquitin and HBUb was enhanced following 
MG132 treatment suggesting that both moieties were being incorporated into 
K48-linked polyubiquitin chains and contributing to ubiquitin-dependent 
proteasomal degradation. Furthermore, GAPDH was detected at equivalent 
levels for all samples thereby confirming equivalent gel loading (Figure 3.2, 
panel C). This data suggests that it will be possible to make direct comparisons 
between the ubiquitinomes isolated from experimental (WT HBUb and SOCS3-/- 
HBUb) or control lines (WT and SOCS3-/- MEFs) enabling accurate relative 
quantification without the need for additional data manipulation. 
3.3.3 HBUb transgene expression does not impair polyubiquitin chain 
formation and function 
Ubiquitin is a 76 amino-acid protein, which is thought to be involved in the 
regulation of most cellular events. Covalent attachment of mono-, multi-, or 
polyubiquitin chains provides a diverse set of signals from which signalling 
pathways can be fine-tuned. Polyubiquitination involves the formation of an 
isopeptide bond between the ε-amino-group-lysine on target proteins and the C-
terminal glycine residue (G76) of ubiquitin by the individual actions of E1 
activating, E2 conjugating, and E3 ligase proteins (Section 1.4, figure 1.6). 
Ubiquitin has seven lysine residues K6, K11, K27, K29, K33, K48, and K63 (98) 
and all can be used to form polyubiquitin chains although most is known about 
the K48- and K63-linked moieties. K48-linked chains are the most understood 
and direct proteasomal degradation (98) whereas K63-linked chains can function 
as scaffolds and activators of ubiquitin-interacting domain-bound complexes 
(16).  However, recent studies suggest that all non-K63-polyubiquitin chains 
might have a role in targeting proteins to the proteasome (138). 
 
While the HBUb tag has been used several times to successfully isolate 
polyubiquitinated proteins (168,175,203), it is approximately 18kDa, which is a 
substantial increase in size over endogenous ubiquitin (8kDa). As such, it may 
potentially disrupt certain ubiquitin-mediated events. The N-terminal 
attachment of the HB tag to ubiquitin suggests that mono-/multi-ubiquitination 
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would be unaffected although the tag could still disrupt the interaction with the 
components of the ubiquitin cascade or ubiquitin binding proteins. 
Polyubiquitination could be similarly affected. Furthermore, co-expression of the 
HBUb transgene and endogenous ubiquitin would be expected to produce 
polyubiquitin chains incorporating both moieties. As such, steric hindrance, as a 
consequence of the HB tag, could potentially disrupt the activation/association 
of ubiquitin binding proteins.  
 
SOCS3 is known to regulate proteasomal degradation of several substrates (9-12) 
and so detection of these SOCS3 targets depends on their K48-linked 
polyubiquitination. However, due to the potentially multifunctional role of 
SOCS3 (8), the involvement of other forms of ubiquitin conjugation cannot be 
completely ruled-out. As such, expression of the HBUb transgene should not 
impact K48-linked polyubiquitination or other forms of ubiquitin conjugation.  
 
The NFκB pathway relies on both K48- and K63-linked polyubiquitin chains for 
full activation (16) (Section 1.4, figure 1.7) and as such was deemed a suitable 
model for assessing the impact of HBUb transgene expression on polyubiquitin 
chain formation and function. In response to pro-inflammatory cytokines (TNFα) 
or as a result of bacterial infection (LPS), NFκB-dependent gene transcription is 
initiated to regulate cell survival and apoptosis (16). Under basal conditions, 
NFκB is prevented from entering the nucleus by NFκB inhibitor α (IκBα) which 
binds NFκB. NFκB is released by IκBα following a complex cascade of 
phosphorylation and ubiquitination eventually leading to the proteasomal 
degradation of IκBα and translocation of NFκB to the nucleus.  Different stimulus 
initiates distinct sequences of events that eventually activate NFκB, although in 
each case many ubiquitin mediated events such as protein 
localisation/activation and proteasomal degradation are common (16).  Given 
the importance of ubiquitin regulated events, disruption by the HBUb tag could 
impair several signalling pathways resulting in the generation of spurious results.   
As such, the NFκB pathway, specifically IκBα degradation, will be employed to 
assess the impact of HBUb expression on this well-defined ubiquitin-dependent 
pathway.  
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To assess the impact of HBUb transgene expression on the formation of 
functional polyubiquitin chains, the effects of LPS on IκBα levels and 
phosphorylation were investigated. WT, WT HBUb, SOCS3-/-, and SOCS3-/- HBUb 
MEFs grown to confluency in 6-well plates were treated with 1µg/ml of LPS for 
0-90 minutes to activate the NFκB pathway. Cells were then lysed and IκBα 
phosphorylation and degradation assessed using phospho-specific anti-IκBα and 
specific anti-IκBα antibodies respectively (Figure 3.3). 
 
Treatment with LPS led to an accumulation of pIκBα Ser32 that peaked after 15 
minutes. Subsequently, IκBα levels decreased to a minimum level after 30 
minutes (Figure 3.3). Consistent with IκBα being a gene target of NFκB, total 
IκBα was seen to increase after this time. For all cell lines, phosphorylation 
preceded degradation, which peaked at 15 and 30 minutes respectively. 
Moreover, the same pattern of shifts in IκBα phosphorylation and degradation 
was observed for each cell line over three experiments (Figure 3.4). These 
results suggest that IκBα regulation by LPS is fully functional. 
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Figure 3.3: The K48- and K63-polyubiquitin-dependent NFκB pathway in not 
affected by HBUb transgene expression 
WT, WT HBUb, SOCS3-/-, and SOCS3-/- HBUb MEFs were grown to confluency in 6-well 
plates after which the media was refreshed before treating with LPS (1µg/ml) for the 
indicated time intervals prior to harvesting. Soluble protein lysates were equalised to 
40µg before SDS-PAGE fractionation. Phosphorylation and degradation of IκBα was 
assessed by immunoblotting with specific anti-pIκBα or anti-IκBα antibody respectively. 
GAPDH was used as a loading control. Results representative of n=3 experiments. 
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Figure 3.4 LPS-dependent activation of the NFκB pathway results in 
significant phosphorylation and degradation of IκBα 
Basal pIκBα Ser32 or IκBα levels (untreated cells, time = 0) were compared with pIκBα 
or IκBα levels at a time period corresponding to either maximum phosphorylation (15 
minutes) or degradation (30 minutes) respectively. Phosphorylation was measured as a 
percentage of maximum whereas degradation was measured as a percentage of 
unstimulated levels. Results are presented as mean values ±SEM for n=3 experiments. 
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3.3.4 SOCS3 can be induced in WT but not SOCS3-/- MEFs by forskolin, LPS 
and IL6/IL6R 
SOCS3 is present in cells at low basal levels, due to its removal via proteasomal 
degradation, but levels are quickly elevated following its induction. SOCS3 is 
inducible via several different routes including, but not limited to, cytokines 
(IL1, IL6, LIF, OSM, IFNγ, TNF, EPO, and prolactin), chemo-attractants (IL8, N-
formyl-Met-Leu-Phe), bacterial components (LPS, unmethylated CpG DNA), and 
the intracellular second-messenger cAMP. Since this study is concerned with 
understanding specific cAMP/EPAC1 effects of SOCS3, forskolin was used as the 
primary stimulus. Via distinct, cAMP-independent mechanisms, the pro-
inflammatory cytokine IL6 and the Gram-negative bacteria cell membrane 
component and endotoxin, LPS, were used as controls because of their 
availability and ability to strongly induce SOCS3 (70,158). All three stimuli 
induce SOCS3 through distinct routes; forskolin elevates cAMP via direct 
activation of adenylyl cyclase, while IL6 induces the dimerisation of the receptor 
gp130 leading to STAT-mediated gene transcription (Section 1.2). LPS induces 
SOCS3 via NFκB-dependent gene transcription (Section 1.4).  
 
This study relies on cAMP-induced SOCS3 to tag proteins with K48-linked HBUb 
chains, thus enabling SOCS3-dependently HBUb-modified proteins to be 
detectable in WT but not SOCS3-/- MEFs. It is therefore important that prior 
manipulation of the cells e.g. retroviral transformation, should not influence 
SOCS3 induction. As such, SOCS3 induction should be comparable between both 
WT and WT HBUb MEFs in response to all stimuli. Conversely, SOCS3-/- and 
SOCS3-/- HBUb MEFs should not express SOCS3. All cells lines were grown to 
confluency in 10cm dishes after which the media was refreshed and treated for 
two hours with forskolin (50µM), IL6/IL6R (5ng/ml, 25ng/ml) or LPS (1µg/ml) 
with or without the proteasome inhibitor MG132 (6µM) to prevent SOCS3 
degradation. Soluble protein lysates were equalised before SDS-PAGE 
fractionation and immunoblotting.  
 
SOCS3 was observed to be inducible to comparable levels with each stimulus in 
WT and WT HBUb MEFs (Figure 3.5). Moreover, for each WT cell line, forskolin 
was observed to be the strongest inducer of SOCS3 followed by IL6 and LPS 
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(Figure 3.6). Furthermore, consistent with the fact that SOCS3 is regulated via 
proteasomal degradation, SOCS3 could only be detected upon treatment with 
the proteasome inhibitor MG132. SOCS3 was not inducible in either SOCS3-/- or 
SOCS3-/- HBUb MEFs following the same treatments as compared with the WT 
control (Figures 3.5). In conclusion, this data suggests that prior manipulation of 
cells did not impact three distinct routes of SOCS3 induction in WT or WT HBUb 
MEFs. Furthermore, MG132 treatment is necessary to maximise SOCS3 
accumulation. The use of MG132 will also be necessary to prevent SOCS3-
dependent substrate degradation and thus enable isolation of sufficient protein 
for mass spectromeric analysis. Moreover, since the SOCS3-/- cell lines are unable 
to express SOCS3, SOCS3-dependent ubiquitination of substrates should only 
occur in WT HBUb and SOCS3-/- HBUb MEFs.  
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Figure 3.5: SOCS3 is induced to similar levels by forskolin, LPS or IL6/IL6R 
in WT but not SOCS3-/- MEFs 
WT, WT HBUb, SOCS3-/-, and SOCS3-/- HBUb MEFs were grown to confluency before 
treating with either forskolin (50µM), IL6/IL6R (5ng/ml, 25ng/ml) or LPS (1µg/ml) with 
or without MG132 (6µM) along with the relevant vehicle control (ethanol, 1:100; DMSO 
1:1000) for two hours prior to harvesting. Soluble protein lysates were equalised to 40µg 
before SDS-PAGE fractionation. SOCS3 induction was assessed by immunoblotting with 
specific anti-SOCS3 antibody. GAPDH was used as a loading control. 
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Figure 3.6: SOCS3 is significantly induced to comparable levels by forskolin, 
LPS or IL6/IL6R in WT but not SOCS3-/- MEFs 
WT, WT HBUb, SOCS3-/-, and SOCS3-/- HBUb MEFs were grown to confluency before 
treating with either forskolin (50µM), IL6/IL6R (5ng/ml, 25ng/ml) or LPS (1µg/ml) with 
or without MG132 (6µM) along with the relevant vehicle control (Ethanol, 1:100; DMSO 
1:1000) for two hours prior to harvesting. Soluble protein lysates were equalised before 
SDS-PAGE fractionation. SOCS3 induction was assessed by immunoblotting with anti-
SOCS3 antibody. GAPDH was used as a loading control. Immunoblots from three 
independent experiments were analysed using Total Lab v.2009 software. SOCS3 
induction was measured as a percentage of maximal stimulation. SOCS3 induction was 
normalised to GAPDH loading control. Results are presented as mean values ±SEM for 
n=3 experiments. *** = p<0.001, ** = p<0.01, * = p<0.05 with respect to vehicle (One-way 
ANOVA with Bonferroni post test) . 
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3.3.5 Impact of hydrogen peroxide and sodium orthovanadate on global 
tyrosine phosphorylation, K48-specific ubiquitination, and SOCS3 induction. 
Cellular tyrosine-phosphorylated proteins, which are expected to include 
potential SOCS3 substrates, are kept at very low basal levels due to the action of 
protein tyrosine phosphatases (PTPs) (204). Sodium orthovanadate (Na3VO4), a 
tyrosine phosphatase inhibitor, enables the accumulation of tyrosine-
phosphorylated proteins. It does so by acting as a reversible competitive 
inhibitor that binds to the active site of PTPs via its negatively charged 
tetrahedral Na3VO4 (VO4
3-) region. Thus, Na3VO4 treatment will potentially 
enable accumulation of tyrosine-phosphorylated SOCS3 substrates and extend 
the period of time over which SOCS3 substrates are marked for interaction and 
subsequent ubiquitination by SOCS3. It is hoped that increasing the abundance of 
SOCS3-ubiquitinated proteins via this route will increase the chance of their 
detection via LC-MS/MS.  
 
It has been demonstrated that in combination with hydrogen peroxide (H2O2), 
the effects of Na3VO4 can be amplified 6-10 fold (204) in a cell-specific and time-
dependent manner. H2O2 increases cellular uptake of vanadate by the oxidation 
of orthovanadate to its more cell permeable form pervanadate. The H2O2, 
Na3VO4 combination was initially tested on rat hepatoma Fao, HL-60, BC3H-1 
myoblasts and myocytes (204), others (205) and more recently with HeLa cells  
to elucidate the regulation of EGFR by PTPs (206). Its effects on MEFs, 
specifically its effects on SOCS3 induction and the ubiquitin pathway, are 
unknown. It was speculated that since H2O2 has multiple non-specific effects 
such as being an insulin mimetic (204) as well as a PTP inhibitor, it might also 
adversely affect these pathways. Na3VO4 in combination with H2O2 was therefore 
tested on MEFs to see if a similar increase in tyrosine-phosphorylated proteins 
could be achieved without impacting either SOCS3 induction or the ubiquitin 
pathway. Due to the cellular toxicity of H2O2, concentration and incubation 
periods were optimised for increased global tyrosine phosphorylation but without 
loss of cells through apoptosis and disruption to K48-specific ubiquitination. 
 
WT MEFs were grown to confluency before treating and harvesting cell lysates. 
To assess optimum H2O2 concentration, cells were treated with increasing, 
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indicated concentrations of H2O2 for 2 hours at fixed concentrations of Na3VO4 
(1mM) and MG132 (6µM) (Figure 3.7, panel A). To assess optimum H2O2 
incubation period, cells were treated with H2O2 (0.2mM), Na3VO4 (1mM), and 
MG132 (6µM) for 0 to 120 minutes prior to harvesting (Figure 3.8, panel B). 
Soluble protein lysates prepared in 8M urea buffer were then equalised and 
fractionated by SDS-PAGE. Global tyrosine phosphorylation and K48-specific 
ubiquitination was assessed using specific anti-phosphotyrosine antibody (4G10) 
and anti-K48-Ub antibodies respectively. 
 
Increasing concentrations of H2O2 in combination with Na3VO4 had a dramatic yet 
equivalent effect on global tyrosine phosphorylation compared to vehicle or 
MG132 alone (Figure 3.7, panel A). Furthermore, a concentration of H2O2 greater 
than 1.5mM resulted in a reduction in K48-specifc ubiquitination. Similarly, no 
difference was detected in global tyrosine phosphorylation over the increasing 
incubation periods (Figure 3.7, panel B). Reduced K48-specifc ubiquitination was 
also seen following longer incubation periods with H2O2. Moreover, H2O2 
concentrations above 0.2mM and incubation periods longer than 60 minutes 
resulted in excessive cell death (data not shown). As such, the lower 
concentration and incubation period of 0.2mM and 30 minutes respectively were 
used in subsequent experiments. Since MEFs are to be treated for 2 hours with 
forskolin, MG132, and Na3VO4, H2O2 treatment was performed for the final 30 
minutes of this 2-hour period. 
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Figure 3.7: Impact of H2O2 concentration or treatment period on global 
tyrosine phosphorylation and K48-specific ubiquitination 
WT MEFs were seeded at a density of 5x105 cells/10cm dish and grown to confluency 
before enriching for ubiquitinated proteins with MG132 (6µM) and tyrosine-
phosphorylated proteins with sodium orthovanadate (Na3VO4) and hydrogen peroxide 
(H2O2) for the indicated times and concentrations prior to harvesting.  A. Cells were 
treated for two hours with increasing, indicated concentrations of H2O2 with fixed 
concentrations of Na3VO4 (1mM) and MG132 (6µM). B. Cells were treated with H2O2 
(0.2mM), Na3VO4 (1mM), and MG132 (6µM) for increasing, indicated periods of time prior 
to harvesting. Soluble protein lysates prepared in 8M urea buffer were equalised to 50µg 
and SDS-PAGE fractionated in an equal volume of 12% (w/v) SDS sample buffer. Global 
tyrosine phosphorylation and K48-specific ubiquitination was assessed using specific 
anti-K48-Ub antibody and anti-phospho-tyrosine antibody (4G10). GAPDH was used as a 
loading control. 
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Using the optimised conditions for H2O2, the impact on SOCS3 induction was 
assessed (Figure 3.8). WT MEFs were grown to confluency before treating with 
the indicated drug combinations to enrich for ubiquitinated proteins (MG132, 
6µM), phosphorylated proteins (Na3VO4 ,1mM), and to induce SOCS3 (Forskolin, 
50µM) for two hours prior to harvesting. The cells were also treated with or 
without H2O2 (0.2mM) for the final 30 minutes of this two-hour period. Soluble 
protein lysates prepared in 8M urea buffer were equalised and fractionated by 
SDS-PAGE. Global tyrosine phosphorylation, K48-specific ubiquitination and 
SOCS3 induction was assessed using specific anti-K48-Ub antibody, anti-
phosphotyrosine antibody (4G10), and anti-SOCS3 antibody.  
 
A combination of Na3VO4 and H2O2 produced a detectable increase in global 
tyrosine phosphorylation compared to Na3VO4 alone (Figure 3.8, panel A, lane 4 
vs. lane 5). Consistent with being a proteasome inhibitor and thus protecting 
ubiquitinated substrates from degradation, an increase in K48-specific 
ubiquitination (Figure 3.8, panel B, lane 1-2 vs. lanes 3-8) and SOCS3 (Figure 3.8, 
panel C, lane 1-2 vs. lanes 3) were observed. K48-specific ubiquitination was 
unaffected by Na3VO4 and H2O2. Treatment with Na3VO4 and H2O2 or Na3VO4 
alone, resulted in a 35% reduction in forskolin-induced SOCS3 expression. Given 
the significant enrichment of tyrosine-phosphorylated proteins, it was thought 
that this trade-off was acceptable. These data suggest that neither formation of 
K48-linked polyubiquitin chains nor the induction of SOCS3 is adversely effected 
by Na3VO4 and H2O2 treatment.  
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Figure 3.8: Impact of H2O2 concentration or treatment period on global 
tyrosine phosphorylation and K48-specific ubiquitination 
WT MEFs were seeded at a density of 5x105 cells/10cm dish and grown to confluency 
before treating with the indicated drug combinations to enrich for ubiquitinated 
proteins with MG132 (6µM), tyrosine-phosphorylated proteins with sodium 
orthovanadate (Na3VO4) (1mM), and SOCS3 induction with forskolin (50µM) for two-hours 
prior to harvesting. The cells were also treated with or without hydrogen peroxide 
(H2O2) (0.2mM) for the final 30 minutes. Soluble protein lysates prepared in 8M urea 
buffer were equalised to 50µg and fractionated by SDS-PAGE. Global tyrosine 
phosphorylation, K48-specific ubiquitination and SOCS3 induction was assessed using 
specific anti-K48-Ub antibody, anti-phosphotyrosine antibody (4G10), and anti-SOCS3 
antibody. GAPDH was used as a loading control. 
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3.4 Conclusions 
Here, I aimed to characterise the experimental cell lines and assess any adverse 
effects imparted by the expression of the HBUb transgene, SOCS3 knockout, or 
planned treatments. It was demonstrated that cell viability was not 
compromised by expression of the HBUb transgene (Section 3.3.1). HBUb 
transgene expression was also unable to affect the NFκB pathway, specifically 
IκBα degradation and Ser32 phosphorylation, in response to LPS (Section 3.3.3). 
The reliance of this pathway on both K48- and K63-linked polyubiquitination 
(16), suggests that polyubiquitin chain formation and function are unaffected. 
Ubiquitin has seven lysine residues K6, K11, K27, K29, K33, K48, and K63 (98) 
and all can be used to form polyubiquitin chains. Although not tested, this result 
may also be applicable to less understood polyubiquitin chain formats. 
Furthermore, SOCS3 was induced to comparable levels by three distinct stimuli 
in WT but not SOCS3-/- cell lines (Section 3.3.4). These data increases confidence 
in the likelihood that the cell lines are unaffected by retroviral transduction and 
transgene expression. Moreover, the inability of SOCS3-/- MEFs to respond to 
three SOCS3-inducing stimuli confirmed that these cells are true SOCS3 
knockouts.  
 
Besides transgene expression, treatments with known toxic and off-target 
effects such as H2O2 could adversely affect cell lines. H2O2 was shown to impact 
K48-specific polyubiquitination and induce apoptosis at high concentrations or 
when used for extended periods of time (Section 3.3.5). Following optimisation 
experiments a concentration (0.2mM) and incubation period (30 minutes) were 
identified that resulted in maximum enrichment of tyrosine-phosphorylated 
proteins without affecting cell viability, K48-specific polyubiquitination, or 
induction of SOCS3. All other treatments had been previously optimised within 
the laboratory and all cell lines responded as expected.   
 
To simplify data analysis following mass spectrometric processing of the isolated 
ubiquitinome, the HBUb transgene was required to be expressed at equivalent 
levels. This was subsequently demonstrated for WT HBUb and SOCS3-/- MEFs 
(Section 3.3.2). In addition, endogenous ubiquitin was also expressed at 
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comparable levels supporting previous data suggesting that cells are unaffected 
by prior manipulation.      
 
To summarise, where expected, all cells lines respond identically to all 
treatments. In addition, where not already optimised, treatments were modified 
for maximum effectiveness.  Furthermore, differences as a consequence of 
genetic manipulation i.e. HBUb-transgene expression and SOCS3 knockout 
produced predicable results and did not adversely affect key cellular functions. 
In conclusion, these cells lines are suitable experimental models for this project. 
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4.0 Experimental strategy 
4.1 Introduction 
SOCS3 regulates several pathways in part by acting as a specificity factor for an 
ECS-type E3 ubiquitin ligase complex (9-12). E3 ligases do not recognise a 
consensus ubiquitinylated sequence. Furthermore, SOCS3 does not ubiquitinate 
all its binding partners (162). Therefore, analysis of SOCS3 protein-protein 
interactions via microarray, immunoprecipitation, or GST pull-down is 
insufficient for identification of SOCS3-dependently ubiquitinated substrates. 
Direct analysis of the ubiquitinome is necessary. Differentially SILAC-labelled, 
tandem affinity purified ubiquitinomes of WT MEFs and SOCS3-/- MEFs each 
expressing epitope-tagged forms of ubiquitin were compared using mass 
spectrometry following cAMP-mediated SOCS3 induction (Section 1.5, figure 
1.11). Using this approach, proteins modified by SOCS3 with the epitope-tagged 
form of ubiquitin should be enriched in WT MEFs but not SOCS3-/- MEFs. The 
details of this methodology was previously discussed (Section 1.5). Here, the aim 
is to validate and optimise the proposed experimental strategy. The finalised 
strategy should achieve the following: 
 
• Full SILAC labelling of the proteome. 
• Specific isolation of the HBUb-modified ubiquitinome via TAP. 
• Discrimination of WT HBUb and SOCS3-/- HBUb-isolated ubiquitinomes 
following SILAC. 
• An enriched ubiquitinome of sufficient purity and quantity for subsequent 
mass spectromeric analysis.  
 
Doing so should allow the strategy to be exploited for the identification of 
SOCS3-dependently ubiquitinated substrates. 
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4.2 Optimisation of experimental strategy  
This study employs a three-step experimental strategy of SILAC, TAP, and mass 
spectrometry. Each step was separately assessed and optimised to ensure 
complete labelling of the proteome, isolation of the ubiquitinome, and capture 
of sufficient material for downstream MS analysis.   
 
Several groups have successfully applied a similar experimental strategy as 
proposed here. Thus, each TAP stage was optimised using a published protocol 
e.g. (168) as a starting point. First, maximum incorporation of SILAC isotopes 
depends on incubation period and purity of the SILAC media. Complete 
incorporation has been reported over five cell doublings (163) however, this is 
dependent on the  use of  dialysed serum to avoid contamination from the 
natural isotope. Given that dialysed serum may affect cell proliferation (163), 
complete isotope incorporation was assessed along with the impact of dialysed 
serum-supplemented SILAC media on MEFs (Section 4.3.2). Second, volumes of 
beads for both Ni2+ and streptavidin affinity chromatography were optimised for 
maximum and specific recovery of HBUb-modified proteins with minimal loss 
over the two-step process (Section 4.3.1.1-3, 4.3.1.6-9). Importantly, because of 
the interaction with SOCS3, SOCS3-dependently ubiquitinated proteins were 
expected to be tagged with K48-linked polyubiquitin chains and as such, specific 
enrichment of this ubiquitin moiety is essential. Furthermore, a potential 
problem identified by Tagwerker et al (175,203) was failure of streptavidin 
affinity chromatography due to reduced availability of cellular/active biotin (D-
biotin) in HeLa cells. However, supplementation of growth media with biotin 
prevented the saturation of in vivo biotinylation by excessive HBUb-tag 
expression. The necessity for biotin supplementation in MEFs and its potential 
impact on prior stages of TAP was therefore examined (Section 4.3.1.4-5). Third, 
while optimisation of TAP can be performed on a small scale, isolation of 
sufficient material for MS analysis requires scaling-up of the experimental 
strategy. As such, the optimum amount of starting material was assessed that 
enabled enrichment of sufficient HBUb-modified proteins prior to MS. Finally, 
individually optimised, scaled-up procedures were combined to demonstrate 
specificity and compatibility with the requirements of mass spectromeric 
analysis (Section 4.4.0). 
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4.3 Results and discussion 
4.3.1 Optimisation of tandem affinity purification 
4.3.1.1 Optimisation of Ni2+ bead volume to maximise recovery of HBUb-
modified proteins 
Tandem affinity purification first employs nickel affinity chromatography to 
isolate HBUb-modified proteins via the interaction of Ni2+ with the hexahistidine 
tag. To estimate the minimum bead volume necessary to maximise recovery of 
HBUb-modified proteins, a titration of the Ni2+-NTA-Sepharose beads was 
performed. 
 
WT HBUb MEFs were grown to confluency before enriching for ubiquitinated 
proteins with MG132 (6µM) for two hours prior to harvesting. Soluble protein 
lysates prepared in 8M urea buffer were equalised to 1mg/ml. Ubiquitinated 
proteins were isolated with 20, 30, 40, or 50µl of 50% (v/v) Ni2-NTA-Sepharose 
bead slurry and the recovery of HBUb-modified proteins assessed via 
immunoblotting using anti-ubiquitin and anti-polyhistidine antibodies. 
 
A volume of 30µl of 50% (v/v) Ni2+-NTA-Sepharose bead slurry was found to be 
sufficient for optimal purification of HBUb-modified proteins with no 
improvement detected upon increase in bead volume (Figure 4.0). However, 
only a weak signal was obtained using the anti-polyhistidine antibody (Figure 
4.0, panel B). While this might suggest that the HBUb-tag was not being 
incorporated into polyubiquitin chains, it was later attributed to lack of antibody 
specificity; the use of a more specific streptavidin-HRP antibody produced a 
similar smear to the total anti-ubiquitin antibody (Figure 4.2, panel B).  
Specificity of purification is highlighted by the absence of GAPDH in the eluate.  
GAPDH (Figure 4.0, panel C), which has not been reported to be ubiquitinated 
(207), was present in lysates and subsequently lost in the flow-through and wash 
stages.  
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Figure 4.0: Optimisation of Ni2+ bead volume to maximise recovery of HBUb-
modified proteins 
WT HBUb MEFs were grown to confluency before enriching for ubiquitinated proteins 
with MG132 (6µM) for two hours prior to harvesting. Soluble protein lysates prepared in 
8M urea buffer were equalised to 1mg/ml before nickel affinity chromatography using 
the indicated volumes of 50% (v/v) slurry of Ni2+-NTA-Sepharose beads. Purified HBUb-
modified proteins were fractionated by SDS-PAGE using the indicted percentages of 
lysate/input (L), flow-through (FT), and eluate (E). Recovery of HBUb-modified proteins 
was assessed by immunoblotting with anti-ubiquitin (panel A) and anti-polyhistidine 
antibody (Panel B). GAPDH was used as a loading control (Panel C). 
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4.3.1.2 Biotin supplementation is essential for detection of HBUb-modified 
proteins and does not impact Ni2+ affinity chromatography. 
The HBUb-tag has a 75 amino acid biotinylation signal peptide (BIO) which can 
be covalently linked via Lys41 to the carboxyl group of biotin by endogenous 
biotin ligases (175). Tagwerker et al (175,203) reported a failure of streptavidin 
affinity chromatography due to reduced availability of cellular biotin in HeLa 
cells following excessive HBUb expression. This problem was resolved following 
supplementation of growth media with biotin (1µM). D-biotin, the active isomer, 
is an essential co-factor for several carboxylases involved in fatty acid synthesis 
as well as amino acid and energy metabolism (208). Tagwerker et al reported no 
impact on cell viability and likewise, HBUb expression did not affect cell viability 
in this study (Section 3.3.1). As such, the effect of biotin supplementation on 
cell viability was not pursued. The necessity for biotin supplementation for the 
biotinylation, isolation, and detection of HBUb-modified proteins was assessed 
via a biotin titration experiment.   
 
WT HBUb MEFs were grown to confluency in media supplemented with biotin (0, 
0.25, 0.5, 1, and 2µM) before enriching for ubiquitinated proteins with MG132 
(6µM) for two hours prior to harvesting cells. HBUb-modified proteins were then 
isolated using 30µl of 50% (v/v) Ni2+-NTA-Sepharose bead slurry and biotinylation 
assessed by probing blots with streptavidin-HRP.  
 
While equivalent levels of ubiquitinated proteins were detected in all lysates 
(Figure 4.1, panel A), significant levels of biotinylated proteins could only be 
detected in biotin-supplemented lysates (Figure 4.1, panel B, lane 1 vs. lanes 2-
5). This confirms that biotin supplementation is essential for detection and thus 
biotin-dependent capture of HBUb-modified proteins. Furthermore, increasing 
the biotin concentration did not improve the detection of biotinylated proteins. 
Given that no optimum concentration could be identified, the same biotin 
concentration (1µM) as suggested by Tagwerker et al (175) was used throughout.  
 
To ensure Ni2+ affinity chromatography was unaffected by biotin 
supplementation, using optimised conditions, Ni2+ affinity chromatography was 
repeated in the presence or absence of biotin. While ubiquitinated/HBUb-
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modified proteins were eluted in each case (Figure 4.2, panel A), biotinylated 
proteins could only be detected in the presence of biotin (Figure 4.2, panel B). 
Variations in the eluate of ubiquitinated proteins (Figure 4.2, panel A) are 
assumed to be a consequence of inaccurate preparation of initial protein lysates. 
This is supported by levels of the GAPDH loading control. As before, the 
specificity of purification was highlighted by the absence of GAPDH in the 
eluate. This data suggests that biotinylation does not negatively affect Ni2+ 
affinity chromatography and that biotin supplementation will be essential for 
streptavidin affinity chromatography. 
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Figure 4.1: Biotin supplementation is essential for biotin-dependent 
detection of HBUb-modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media of the indicated 
concentrations before enriching for ubiquitinated proteins with MG132 (6µM) for two 
hours prior to harvesting in an 8M urea buffer. Soluble protein lysates were 
fractionation by SDS-PAGE and the abundance of ubiquitinated and HBUb-modified 
proteins assessed by immunoblotting with anti-ubiquitin antibody (Panel A) and 
streptavidin-HRP respectively (Panel B). GAPDH was used as a loading control (Panel C). 
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Figure 4.2: Biotin supplementation does not impact nickel affinity 
chromatography 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in 8M urea buffer were equalised to 1mg/ml before 
nickel affinity chromatography using 30µl of 50% (v/v) slurry of Ni2+-NTA-Sepharose 
beads. Recovered HBUb-modified proteins were fractionated by SDS-PAGE using 
indicated percentages of lysate/input (L), flow-through (FT), and eluate (E). Recovery 
of biotinylated, HBUb-modified proteins was assessed by immunoblotting using anti-
ubiquitin antibody (Panel A) and streptavidin-HRP (Panel B). GAPDH was used as a 
loading control (Panel C). 
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4.3.1.3 Nickel affinity chromatography specifically recovers HBUb-modified 
proteins  
Nickel affinity chromatography relies on the strong (µM) interaction between Ni2+ 
and the hexahistidine tag.  Given that this epitope is uncommon in nature, 
specific recovery HBUb-modified protein is expected. As such, HBUb-modified 
proteins should only be recovered from WT HBUb and SOCS3-/- HBUb MEFs but 
not WT or SOCS3-/- MEFs. Furthermore, loss of HBUb-modified proteins should be 
minimised over several wash stages.  
 
To evaluate binding and loss of target protein, Ni2+ affinity chromatography was 
repeated as in section 4.3.1.2 with the inclusion of samples taken from all pre-
elution wash steps. Following incubation with Ni2+-NTA-Sepharose beads, there 
was minimal loss of HBUb-modified protein detected in flow-through and wash 
stages (Figure 4.3, panel B). This suggests that the Ni2+ beads were saturated 
with HBUb-modified proteins and that the Ni2+-hexahistidine interaction was not 
disrupted by washing. Interestingly, a large amount of ubiquitinated protein was 
lost in the flow-though (Figure 4.3, panel A). This suggests that the HBUb-tag is 
not being completely incorporated into polyubiquitin chains i.e. incomplete 
labelling of the ubiquitinome. This result might be a consequence of preferential 
incorporation of WT ubiquitin or reduced availability of the HBUb tag.  Given 
that WT HBUb and SOCS3-/- HBUb MEFs should express and incorporate the HBUb-
tag similarly, this result should have minimal impact.  
 
To evaluate specific recovery of HBUb-modified proteins, Ni2+ affinity 
chromatography was performed using both experimental and control MEFs. While 
HBUb-modified proteins were isolated from WT HBUb and SOCS3-/- HBUb MEFs, 
no HBUb-modified proteins were recovered from WT or SOCS3-/- MEFs (Figure 
4.4, panel B/E). WT HBUb and SOCS3-/- HBUb MEFs were not assessed for equal 
expression of the HBUb tag prior to this experiment. As such, the difference in 
isolation of HBUb-modified proteins is expected to be a consequence of a 
variation in HBUb expression. Furthermore, a similar loss of ubiquitinated 
proteins was detected (Figure 4.4, panel A/D, flow-through (FT)) as discussed 
above while only minimal loss of HBUb-modified protein was detected (Figure 
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4.4, panel B/E, flow-through (FT)). These results suggest that nickel affinity 
chromatography is specific for the recovery of HBUb-modified proteins.  
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Figure 4.3: Nickel affinity chromatography specifically recovers HBUb-
modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in an 8M urea buffer were equalised to 1mg/ml before 
nickel affinity chromatography using 30µl of 50% (v/v) slurry of Ni2+-NTA-Sepharose 
beads. Purified HBUb-modified proteins were fractionated by SDS-PAGE along with the 
indicated percentages of lysate/input (L), flow-through (FT), wash stage (W1, W2, W3), 
and eluate (E). Recovery of ubiquitinated and HBUb-modified proteins was assessed by 
immunoblotting using anti-ubiquitin antibody (Panel A) and streptavidin-HRP (Panel B) 
respectively. GAPDH was used as a loading control (Panel C). 
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Figure 4.4: Nickel affinity chromatography specifically recovers HBUb-
modified proteins 
SOCS3-/- and SOCS3-/- HBUb (Left panel) and WT HBUb and WT MEFs (Right panel) were 
grown to confluency in biotin supplemented media (1µM) before enriching for 
ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. Soluble 
protein lysates prepared in 8M urea buffer were equalised to 1mg/ml before incubating 
with 30µl (50% (v/v) slurry) of Ni2+-NTA-Sepharose beads overnight at 4°C with rotation. 
HBUb-modified proteins, recovered in 12% (v/v) SDS buffer following heating treatment 
at 95°C for 5 minutes, were fractionated by SDS-PAGE. Gels were loaded with input 
(I/P), flow-through (FT) and eluate (E) with the indicated percentages. Recovery of 
HBUb-modified proteins was assessed by immunoblotting with anti-ubiquitin antibody 
(Panel A/D) and streptavidin-HRP (Panel B/E). GAPDH was used as a loading control 
(Panel C/F).  
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4.3.1.4 Optimisation of streptavidin bead volume to maximise recovery of 
HBUb-modified proteins. 
The final stage of tandem affinity purification strategy employs streptavidin 
affinity chromatography to isolate HBUb-modified proteins via the strong 
interaction (Kd=10
-15M) of streptavidin with the biotinylated signal peptide (BIO) 
of the HBUb-tag. To estimate the minimum bead volume necessary for the 
maximum recovery of HBUb-modified proteins, a titration was performed.  
 
WT HBUb MEFs were grown to confluency before enriching for ubiquitinated 
proteins with MG132 (6µM) for two hours prior to harvesting. Soluble protein 
lysates prepared in 8M urea buffer were equalised to 1mg/ml. Ubiquitinated 
proteins were then purified with 5, 10, or 15µl of 50% (v/v) streptavidin-
Sepharose bead slurry. Biotinylated proteins were eluted from the streptavidin-
Sepharose beads by heat treatment at 95°C in 12% (w/v) SDS sample buffer for 5 
minutes after which the recovery of HBUb-modified, biotinylated proteins was 
assessed following SDS-PAGE and immunoblotting with anti-ubiquitin antibody 
and streptavidin-HRP. 
 
While the recovery of biotinylated protein increased with streptavidin-Sepharose 
bead volume, little improvement was noticed with a volume greater than 10µl 
(Figure 4.5). Furthermore, although ubiquitinated proteins were lost in the flow-
through, no biotinylated protein could be detected. This suggests the specific 
isolation of biotinylated proteins. Furthermore, specificity of purification was 
highlighted by the absence of GAPDH in the eluate.  GAPDH, which has not been 
reported to be biotinylated (207), was present in lysate and subsequently lost in 
the flow-through and wash stages. These results indicate that 10µl of 50% (v/v) 
streptavidin-Sepharose bead slurry is sufficient for maximum recovery of HBUb-
modified proteins. 
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Figure 4.5: Streptavidin-Sepharose bead optimisation to maximise recovery 
of HBUb-modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in an 8M urea buffer was equalised to 1mg/ml before 
streptavidin affinity chromatography using indicated volumes of 50% (v/v) slurry of 
streptavidin-Sepharose beads. Biotinylated proteins were eluted by heating the beads in 
50µl of 12% (w/v) SDS sample buffer for 5 minutes at 95°C. Eluate (E) was isolated using 
a Hamilton syringe following centrifugation.  Recovered biotinylated proteins were 
fractionated by SDS-PAGE using the indicated percentages of lysate/input (L) and flow-
through (FT).  Recovery of HBUb-modified, biotinylated proteins was assessed by 
immunoblotting using anti-ubiquitin antibody (Panel B) and streptavidin-linked-HRP 
(Panel A). GAPDH was used as a loading control (Panel C). 
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4.3.1.5 Streptavidin affinity chromatography specifically recovers HBUb-
modified proteins  
Streptavidin affinity chromatography relies on the strong interaction between 
streptavidin and biotin.  As such, specific recovery HBUb-modified protein is 
expected with minimal loss over several wash stages. To evaluate binding, loss, 
and recovery of HBUb-modified proteins, streptavidin affinity chromatography 
was repeated as in section 4.3.1.4 under optimised conditions with the inclusion 
of samples taken from all pre-elution wash steps. 
 
While ubiquitinated proteins are lost in the flow-through (Figure 4.6, panel A), 
minimal loss of HBUb-modified, biotinylated proteins are detected in the same 
fraction suggesting specific isolation of these proteins (Figure 4.6, panel B). 
Furthermore, HBUb-modified proteins are detected in eluate but not in the wash 
stages suggesting that the strong interaction between streptavidin and biotin 
prevents any disruption by washing. Seeing as nickel affinity chromatography 
was not performed beforehand, any biotinylated protein detected in the flow-
through might be endogenously biotinylated protein or, if the streptavidin-
Sepharose beads are completely saturated, HBUb-modified protein. Specificity 
of purification was highlighted by the absence of GAPDH in the eluate.  GAPDH, 
which has not been reported to be biotinylated (207), is present in lysate by 
subsequently lost in the flow-through. 
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Figure 4.6: Streptavidin bead optimisation to maximise recovery of HBUb-
modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in an 8M urea buffer were equalised to 1mg/ml before 
streptavidin affinity chromatography using 10µl (50% (v/v) slurry) of streptavidin-
Sepharose beads. Biotinylated proteins were eluted by boiling the beads in 50µl of 12% 
(w/v) SDS sample buffer for 5 minutes at 95°C. Recovered biotinylated proteins (E) 
were fractionated by SDS-PAGE along with the indicated percentages of input (I/P) and 
flow-through (FT). Recovery of HBUb-modified, biotinylated proteins was assessed by 
immunoblotting using an anti-ubiquitin antibody (Panel A), and streptavidin-linked-HRP 
(Panel B). GAPDH was used as a loading control (Panel C). 
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4.3.1.6 Specificity of TAP for the specific recovery of K48-linked poly-HBUb-
modified proteins 
SOCS3 regulates ubiquitin-mediated proteasomal degradation of several 
substrates (9,10,12). As such, detection of SOCS3 targets depends on their K48-
linked polyubiquitination. Due to the complexity of the ubiquitin system, 
multiple polyubiquitin chain variants are expected to be isolated along with the 
target K48-linked polyubiquitin chains. It has been demonstrated separately 
(Section 4.3.1.3 and 4.3.1.5) that nickel and streptavidin affinity 
chromatography specifically isolate HBUb-modified proteins. However, the 
efficiency of HBUb isolation when both are performed in sequence has not been 
tested.  Furthermore, the abundance of K48-linked polyubiquitin chains is 
unknown. To evaluate this, both stages of TAP were performed in sequence and 
the abundance of isolated K48-linked HBUb-modified proteins assessed following 
SDS-PAGE via immunoblotting using anti-K48-ubiquitin antibody. 
 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) 
before enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior 
to harvesting. Soluble protein lysates prepared in 8M urea buffer were equalised 
to 1mg/ml before nickel affinity chromatography using 30µl (50% (v/v) slurry) of 
Ni2+-NTA-Sepharose beads followed by streptavidin affinity chromatography using 
10µl (50% (v/v) slurry) of streptavidin-Sepharose beads. Recovery of K48-linked 
HBUb-modified proteins was assessed following SDS-PAGE by immunoblotting 
with anti-K48-linked ubiquitin antibody, anti-ubiquitin antibody, and 
streptavidin-HRP. 
  
Over the course of the TAP procedure, endogenously biotinylated and non-HBUb 
modified proteins are lost in the flow-through (Figure 4.7, panel A/B) whereas 
biotinylated, HBUb-modified proteins are retained within the eluate (Figure 4.7, 
panel C). Furthermore, HBUb-modified proteins are highly enriched following the 
final stage of TAP. Specificity of purification was highlighted by the absence of 
GAPDH in the eluate.  GAPDH, which has not been reported to be ubiquitinated 
or biotinylated (207), is present in the lysate but subsequently lost in the flow-
through.  
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Figure 4.7: Tandem affinity purification recovers K48-linked poly-HBUb-
modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in 8M urea buffer were equalised to 1mg/ml before 
nickel affinity chromatography using 30µl (50% (v/v) slurry) of Ni2+-NTA-Sepharose beads 
followed by streptavidin affinity chromatography using 10µl (50% (v/v) slurry) of 
streptavidin-Sepharose beads. Purified proteins were fractionated by SDS-PAGE along 
with the indicted percentages of input (I/P), flow-through (FT), and eluate (E). Specific 
recovery of K48-linked HBUb-modified proteins was assessed by immunoblotting with 
anti-K48-linked ubiquitin antibody (Panel A), anti-ubiquitin antibody (Panel B), and 
streptavidin-HRP (Panel C). GAPDH was used as a loading control (Panel D). 
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Compared to total ubiquitin levels, a reduced level of K48-linked poly-HBUb-
modified proteins was detected (>50%) (Figure 4.7, panel A). This might suggest 
reduced specificity of the K48-specific antibody or that multiple polyubiquitin 
chain variants are present. If the latter is true, no impact on relative 
quantitation and SOCS3 target identification is expected since WT HBUb and 
SOCS3-/- HBUb MEFs would be equally affected. 
4.3.1.7 Tandem affinity purification specifically recovers HBUb-modified 
proteins 
TAP has previously been demonstrated to isolate HBUb–modified proteins 
(Section 4.3.1.6). However, if purification is specific then HBUb-modified 
proteins would be recovered from WT HBUb and SOCS3-/- HBUb MEFs but not WT 
and SOCS3-/- MEFs. To ensure this specificity, TAP was repeated using both 
experimental and control cell lines.  
 
While biotinylated, HBUb-modified proteins were recovered from WT HBUb and 
SOCS3-/- HBUb MEFs, no protein was recovered from WT or SOCS3-/- MEFs (Figures 
4.8 and 4.9, panel A vs. E in each case). This suggests that TAP is specific for the 
isolation of HBUb modified proteins. Following nickel affinity chromatography, 
high levels of ubiquitinated and/or biotinylated proteins were lost in the flow-
through (Figures 4.8 and 4.9, panel B/C in each case). This was previously 
attributed to incomplete labelling of the ubiquitinome due to inadequate HBUb 
expression. This might also be applicable here, however the loss of HBUb-
modified proteins in the flow-through (Figure 4.8 and 4.9, panel A in each case) 
suggests that the nickel beads are saturated. Moreover, this result might also be 
explained by loss of endogenously biotinylated proteins. However, a similar loss 
is not seen for the WT MEFs and given that biotinylated proteins are rare (~4-6 in 
eukaryotes), such an intense signal would not be expected. As such, this data 
supports the former explanation of bead saturation. As with previous findings 
(Figure 4.7), reduced levels of K48-linked poly-HBUb-modified proteins are 
detected compared with total levels of polyubiquitinated proteins suggesting 
that multiple polyubiquitin chain variants are present. Furthermore, in all cases, 
the specificity of the procedure is supported by the absence of GAPDH in the 
eluate. GAPDH, which has not been reported to be ubiquitinated or biotinylated 
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(207), is present in lysate by subsequently lost in the flow-through.  These 
results indicate that TAP specifically isolates HBUb-modified proteins. 
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Figure 4.8: Specificity of TAP for the recovery of K48-linked poly-HBUb-
modified proteins from WT or WT HBUb MEFs 
Control (Right panel) or experimental (Left Panel) MEFs were grown to confluency in 
biotin-supplemented media (1µM) before enriching for ubiquitinated proteins with 
MG132 (6µM) for two hours prior to harvesting. Soluble protein lysates prepared in 8M 
urea buffer were equalised to 1mg/ml before nickel affinity chromatography using 30µl 
(50% (v/v) slurry) of Ni2+-NTA-Sepharose beads followed by streptavidin affinity 
chromatography using 10µl (50% (v/v) slurry) of streptavidin-Sepharose beads. Purified 
proteins were fractionated via SDS-PAGE along with the indicted percentages of input 
(I/P), flow-through (FT), and eluate (E). Specific recovery of K48-linked HBUb-modified 
proteins was assessed by immunoblotting with anti-K48-linked-ubiquitin antibody 
(Panels B/F), anti-ubiquitin antibody (Panels C/G), and streptavidin-HRP (Panels A/E). 
GAPDH was used as a loading control (Panels D/H). 
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Figure 4.9: Specificity of TAP for the recovery of K48-linked poly-HBUb-
modified proteins from SOCS3-/- HBUb MEFs  
Control (Right panel) or experimental (Left panel) MEFs were grown to confluency in 
biotin-supplemented media (1µM) before enriching for ubiquitinated proteins with 
MG132 (6µM) for two hours prior to harvesting. Soluble protein lysates prepared in 8M 
urea buffer were equalised to 1mg/ml before nickel affinity chromatography using 30µl 
(50% (v/v) slurry) of Ni2+-NTA-Sepharose beads followed by streptavidin affinity 
chromatography using 10µl (50% (v/v) slurry) of streptavidin-Sepharose beads. Purified 
proteins were fractionated via SDS-PAGE along with the indicted percentages of input 
(I/P), flow-through (FT), and eluate (E). Specific recovery of K48-linked HBUb-modified 
proteins was assessed by immunoblotting with anti-K48-linked-ubiquitin antibody 
(Panels B/F), anti-ubiquitin antibody (Panels C/G), and streptavidin-HRP (Panels A/E). 
GAPDH was used as a loading control (Panels D/H). 
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4.3.2 Optimisation of stable isotope labelling of amino acids in cell culture 
4.3.2.1 SILAC media supplemented with dialysed serum does not affect cell 
viability  
SILAC can achieve almost 100% incorporation of the labelled isotope. However, 
this is partly dependent on the purity of the SILAC media. As such, the use of 
dialysed serum is essential, although its use could potentially impact cell 
proliferation, adherence, and thus viability. This is not expected to be an issue 
since dialysed serum has been used with MEFs in other studies (209) although it 
must be considered as a potential obstacle and will need to be tested. The 
impact of dialysed serum on cell viability was assessed via an MTT assay (191).  
 
WT MEFs were first expanded in either DMEM or SILAC control media and then 
seeded at 5x104 cells per well in 24-well plates and incubated overnight in either 
1ml SILAC control R0K0 media supplemented with 10% (v/v) dialysed foetal 
bovine serum, 100U/ml penicillin, 100µM streptomycin, and 4µg/ml puromycin 
or Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) 
foetal bovine serum, 100U/ml penicillin, 100µM streptomycin, 1mM L-glutamine, 
and 4µg/ml puromycin. The MTT assay was then performed as previously 
described (Section 2.2.4).   
 
No significant difference in proliferation was detected between the two growth 
media suggesting that the WT MEFs can tolerate SILAC control media containing 
dialysed serum (Figure 4.10).  
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Figure 4.10: SILAC media supplemented with dialysed serum does not affect 
cell viability 
WT MEFs were seeded at a density of 5x104 cells per well (24-well plates) and incubated 
overnight in either 1ml SILAC control R0K0 media supplemented with 10% (v/v) dialysed 
foetal bovine serum, 100U/ml penicillin, 100µM streptomycin, and 4µg/ml puromycin or 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) foetal bovine 
serum, 100U/ml penicillin, 100µM streptomycin, 1mM L-glutamine, and 4µg/ml 
puromycin.  The next day, control cells were treated with 50% (v/v) DMSO-media at 
37°C for two hours. A blank well containing only culture media was included as a further 
control. MTT (100µM) was then directly added to each well and incubated at 37°C for 
three hours after which the media was removed and cells lysed with DMSO which also 
solubilises the formazan crystals. Proliferation was assessed by measuring the 
absorbance of 200µl aliquots of DMSO-solubilised crystals at 590nm. Results are 
presented as mean values ±SEM for n=3 experiments (One-way ANOVA with Bonferroni 
post test). 
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4.3.2.2 SILAC can achieve full incorporation into MEF proteome over five 
days 
SILAC essentially enables the production of two separate proteomes 
distinguishable by a mass shift imparted by a stable isotope of a suitable amino 
acid.  Complete labelling of the proteome means that each natural amino acid 
i.e. 12C6-arginine and 
12C6-lysine is replace by its heavy isotope. Full 
incorporation is dependent on the purity of the SILAC media and incubation 
period. It has been demonstrated  for HEK293 cells that five cell doublings 
equating to five days of cell proliferation is sufficient to achieve complete 
incorporation (163). Furthermore, the metabolism of arginine to proline, which 
complicates relative quantitation of peptide abundance, can be prevented by 
supplementation media with proline (200mg/L) (169). To determine if full 
incorporation could be accomplished in MEFs over the same time period and 
without conversion of 13C6-arginine to 
13C5-proline, a time course was performed. 
WT MEFs were seeded appropriately so that they would achieve confluency after 
2 or 5 days. During this time, cells were grown in either SILAC media (R6K6, 
where 6 relates to the mass shift of 6Da) or control media (R0K0). Soluble 
protein lysates were equalised prior to SDS-PAGE fractionation and Coomassie 
staining. A single gel slice per time-point was extracted and submitted for in-gel 
trypsin digestion and LC-MS/MS. Proteins contained in each gel slice were 
identified from the subsequent raw data using the Mascot search engine as 
described (Section 2.2.10.1). Incorporation was assessed using the returned 
Mascot data by manual inspection of the mass spectra using Analyst QS v.1.1, 
Applied Biosystems. 
 
Peptides incorporating stable isotopes of arginine or lysine should produce 
monoisotopic peaks that are shifted, relative to the natural species, by 6Da. Due 
to the doubly charged nature of the selected peptide (AGFAGDDAPR, alpha-
cardiac actin [Mus musculus]) this shift is reduced to 3Da (Figure 4.11). 
However, this shift is more than adequate to discriminate heavy and light 
peptides. Furthermore, peaks relating to the natural isotope are reduced to the 
level of background over five days and incorporation from this spectra is 
estimated to be 95% (Figure 4.11, panel C). Furthermore, due to the natural 
abundance (1.1%) of the heavy isotope of 12C, 13C, two further peaks are 
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produced relating to the presence of 1 or 2 13C that have replaced the natural 
species. These peaks are similarly affected by the charge status of the peptide 
and are therefore staggered by multiples of 0.5Da to the right of the 
monoisotopic peak.  
 
In cases where 13C arginine has been converted into 13C proline, peptides that 
contain proline will have an additional mass shift of 5Da, 2.5Da for a doubly 
charged peptide, for each proline residue present. As such, a monoisotopic peak 
would be expected at m/z=494.3Da. This peak is not seen (Figure 4.11, panel C) 
suggesting that arginine to proline conversion is undetectable. Furthermore, 
contamination of 13C-labelled amino acids with 12C would produce minor peaks 
shifted by 1Da (0.5Da) to the left of the monoisotopic peak. A weak peak is seen 
in both labelled and unlabelled spectra suggesting that this is background.   
 
A second example (Figure 4.12) shows the same result. However, in this case, 
due to a missed cleavage, the peptide is doubly labelled with a C-terminal 
arginine and lysine. Such an artefact is common and is taken into account by 
MaxQuant which can manage up to three labelled amino-acids per peptide (170). 
Furthermore, miscleavages can also occur in the presence of an N-terminal 
proline which prevent trypsin digestion thus producing similar artefact (167). 
Peaks at around 456.3Da (Figure 4.12, panel B/C) probably relate to a partially 
labelled peptide and as such would be left unmatched to a light peptide. Such 
an artefact might lead to the SILAC ratio being underestimated. However, this 
can be overcome by incubating cells in SILAC media for a longer time period. In 
this case labelling was estimated to be 77% with the reduction attributable to 
partial labelling.      
 
This data suggests that the over five days, SILAC achieves a high level of 
incorporation that enables discrimination of differentially labelled peptides. 
However, an extended period of SILAC labelling would be recommended. 
Furthermore, although the estimation of isotope incorporation is understandably 
inaccurate, 95% coverage would be sufficient to determine the significance of 
variations in peptide abundance.  
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Figure 4.11: Incorporation of SILAC isotope 13C6-Arg  
WT HBUb MEFs were seeded at various densities to allow proliferation to confluency 
after 2 or 5 days. Control (R0K0) (Panel A) or SILAC (R6K6) (Panels B/C) media was 
introduced to MEFs previously adapted to control media at the initial time point and 
allowed to proliferate. Soluble protein lysates were prepared using an 8M urea-based 
lysis buffer after the indicated time points. Following SDS-PAGE fractionation, gel slices 
were prepared and submitted for in-gel trypsin digestion and LC-MS/MS. The peaks 
shown are the doubly charged peaks of the peptide AGFAGDDAPR, assigned to the 
protein alpha-cardiac actin [Mus musculus] by the Mascot search engine as described 
(Section 2.2.10.1). This peptide, which contains a single C-terminal arginine, has an 
observed mass of 488.2756kDa, an experimental mass of 974.5367kDa, and a calculated 
mass of 975.4410kDa. Panel C shows the complete incorporation of 13C6-Arg in the 
peptide at day 5. 
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Figure 4.12: Incorporation of SILAC isotope 13C6-Arg/Lys  
WT HBUb MEFs were seeded at various densities to allow proliferation to confluency 
after 2 or 5 days. Control (R0K0) (Panel A) or SILAC (R6K6) (Panels B/C)  media was 
introduced to MEFs previously adapted to control media at the initial time point and 
allowed to proliferate. Soluble protein lysates were prepared using an 8M urea-based 
lysis buffer after the indicated time points. Following SDS-PAGE fractionation, gel slices 
were prepared and submitted for in-gel trypsin digestion and LC-MS/MS. The peaks 
shown are the triply charged peaks of the peptide CDVDIRK, assigned to the protein 
alpha-cardiac actin [Mus musculus] by the Mascot search engine as described (Section 
2.2.10.1). This peptide, which contains a double labelled C-terminal arginine and lysine, 
has an observed mass of 453.2102kDa , an experimental mass of 904.4058kDa, and a 
calculated mass of 904.4436kDa. Panel C shows the complete incorporation of 13C6-
Arg/Lys in the peptide at day 5. 
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4.3.3 Optimisation of sample preparation required for detection LC-MS/MS 
4.3.3.1 Optimisation of preparation of raw material for LC-MS/MS  
The complexity of the proteome is reduced by TAP and so less protein will be 
available for subsequent analysis. Furthermore, smaller proteins are generally 
more abundant and thus produce more peptides while large proteins are less 
abundant and produce fewer peptides. These limitations are important 
considerations for performing confident protein identification, which 
recommends the assignment of at least two unique peptides. However, where 
peptides are in low abundance and difficult to analyse i.e. phosphopeptides, a 
single peptide often suffices (179). Evidently, the isolation and identification of 
low abundance proteins is improved with higher quantities of proteins i.e. µg 
amounts. As such, the initial raw material used should be scaled-up so that a 
sufficient quantity of protein can be isolated following TAP. As a general rule, if 
proteins can be detected with Coomassie stain (R250), which is sensitive down to 
0.1µg of protein, then this quantity is sufficient for MS analysis. To assess the 
quantity of initial raw material necessary to isolate sufficient HBUb-modified 
protein following TAP for MS analysis, a titration was performed.   
 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) on 
5, 10, 15, or 20x10cm dishes before enriching for ubiquitinated proteins with 
MG132 (6µM) for two hours prior to harvesting. Soluble protein lysates prepared 
in 8M urea buffer were pooled and equalised to 1mg/ml before nickel affinity 
chromatography using 30µl (50% (v/v) slurry) of Ni2+-NTA-Sepharose beads per 
milligram of initial protein. This was followed by streptavidin affinity 
chromatography using 10µl (50% (v/v) slurry) of streptavidin-Sepharose beads per 
milligram of initial protein. The final eluate was then fractionated by SDS-PAGE 
and recovered proteins visualised using Coomassie stain (R250). 
 
The initial quantity of protein used for TAP ranged from 5 to 30mg. Subsequent 
isolation and detection of HBUb-modified protein increased with the number of 
10cm dishes used (Figure 4.13). Furthermore, in each case, a smear pattern 
typical of polyubiquitinated protein was produced. The use of 20x10cm dishes 
produced the strongest signal where the majority of the proteins were present in 
the 2-4µg range although higher molecular weight proteins exceeded this range. 
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Strong bands detected around 150kDa and 25kDa are thought to be non-
specifically purified proteins whereas bands below 20kDa might correspond to 
free HBUb, which has a predicted molecular mass of around18kDa. These results 
suggest that the use of 20x10cm dishes enables sufficient material to be isolated 
following TAP. However, for improved confidence of detection of proteins across 
the full mass range, a greater amount is recommended.  
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Figure 4.13: Optimisation of sample preparation required for detection LC-
MS/MS 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) on 5, 10, 
15, or 20x10cm dishes before enriching for ubiquitinated proteins with MG132 (6µM) for 
two hours prior to harvesting. Soluble protein lysates prepared in 8M urea buffer were 
pooled and equalised to 1mg/ml before nickel affinity chromatography using 30µl (50% 
(v/v) slurry) of Ni2+-NTA-Sepharose beads per milligram of initial protein. This was 
followed by streptavidin affinity chromatography using 10µl (50% (v/v) slurry) of 
streptavidin-Sepharose beads per milligram of initial protein. The eluate was then 
fractionated by SDS-PAGE and recovered proteins visualised using Coomassie stain 
(R250). 
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4.3.3.2 The streptavidin-biotin interaction can be disrupted with an aqueous 
biotin solution and elevated temperature 
The biotin-streptavidin interaction is one of the strongest non-covalent 
interactions in nature (Kd=10
-15M). So far, optimisation of TAP has employed SDS 
buffer and elevated temperatures to elute HBUb-modified proteins from 
streptavidin beads. Furthermore, a large volume (>1ml) of eluate was isolated 
following TAP in the previous section (4.3.3.2). A result of this, a large 2mm, 
18x16cm gel with merged wells was necessary to enable the loading of such a 
large volume. This is not ideal since the strength of the signal was weakened as 
it was spread over a large area. In-gel trypsin digestion is an optimised method 
of peptide generation for MS commonly performed at the University of Glasgow. 
Efficient in-gel trypsin digestion is achieved by reducing the volume of 
acrylamide to a minimum. As such, a small, thin (1mm) gel with narrow lanes 
(10-well) is recommended.  Given that such gels (Invitrogen, NuPAGE 4-12% Bis-
Tris Gel), have a capacity of around 30µl/well, the TAP eluate must be 
concentrated prior to SDS-PAGE fractionation. However, SDS-based sample 
buffer is not compatible with standard protein concentration spin columns. 
Therefore, a different elution strategy is necessary. Current literature offers 
several potential solutions including elution with excess free biotin (210), water 
(211), and low salt (211). Furthermore, other commercially available 
streptavidin bead providers advise other methods such as low (0.1%) SDS and 
glycine-HCL, pH 2.5. However, these conditions might be specific for the 
products for which they were designed. Here, these elution strategies are 
individually tested or combined with the aim to produce a high yielding elution 
buffer.  
 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) 
before enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior 
to harvesting. Soluble protein lysate prepared in an 8M urea buffer was 
equalised to 1mg/ml before streptavidin affinity chromatography. Biotinylated 
proteins were eluted in one bead volume of 0.1% (w/v) SDS sample buffer or the 
indicated concentration of biotin diluted in either H2O or a low salt buffer (LSB; 
10mM HEPES, 1% (v/v) Igepal CA-630, 0.1% (w/v) SDS, 5mM EDTA) followed by 
incubation at 95°C for 5 minutes. Additionally, elution was performed using one 
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bead volume of glycine-HCL (0.1M, pH2.5) at RT for 5 minutes prior to isolation 
of supernatant. Captured biotinylated proteins were fractionated by SDS-PAGE 
and recovery assessed using streptavidin-linked-HRP.  
 
While biotin-supplemented H20 or low salt buffers (LSB) have comparable elution 
efficiency, both glycine-HCL and low SDS buffer failed to elute (Figure 4.14). As 
demonstrated by Holmberg et al (211) salt, even in low concentrations can 
stabilise the streptavidin-biotin interaction preventing release of biotinylated 
molecules. In this case, excess biotin is assumed to be the key disrupting agent. 
Elution from the streptavidin beads (300nmol biotin/ml binding capacity) was 
not affected by increasing concentrations of biotin over a 5-30mM range. This 
suggests that the minimum concentration (5mM) of biotin used combined with 
elevated temperature was sufficient to out-compete bound HBUb-modified 
proteins. These data suggest that an aqueous biotin solution combined with brief 
elevated temperature is sufficient to elute biotinylated proteins from 
streptavidin beads. Moreover, the chosen solution is compatible with 
commercially available protein concentration spin columns.   
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Figure 4.14: Optimisation of streptavidin bead elution strategy for the 
recovery of HBUb-modified proteins 
WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting. 
Soluble protein lysates prepared in an 8M urea buffer were equalised to 1mg/ml before 
streptavidin affinity chromatography using 10µl (50% (v/v) slurry) of streptavidin-
Sepharose beads. Biotinylated proteins were eluted by heating the beads for 5 minutes 
at 95°C in one bead volume of 0.1% (w/v) SDS sample buffer or the indicated 
concentration of biotin diluted in either H2O or a low salt buffer (LSB; 10mM HEPES, 1% 
(v/v) Igepal CA-630, 0.1% (w/v) SDS, 5mM EDTA). Elution was also performed by 
incubating beads with glycine-HCL (0.1M, pH2.5) at RT for 5 minutes. Recovered 
biotinylated proteins were fractionated by SDS-PAGE along with the indicated 
percentage of input (I/P). Recovery of HBUb-modified, biotinylated proteins was 
assessed following transfer onto nitrocellulose membrane using streptavidin-HRP.  
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4.4 Scaled-up tandem affinity purification specifically enriches sufficient 
HBUb-modified protein for MS analysis. 
The previous sections (4.3.1–4.3.3) have specified requirements for initial 
sample preparation, affinity chromatography, and pre-MS conditioning. When 
combined in to a single protocol, it is expected that not only are HBUb-modified 
proteins captured and recovered with high yield, but that this sample can then 
be concentrated and detected via Coomassie stain. This would confirm the 
effectiveness of the experimental strategy. Using these optimised conditions 
TAP, protein concentration and SDS-PAGE fractionation were performed in 
sequence. WT and WT HBUb MEFs were grown to confluency in biotin-
supplemented media (1µM) on 20x10cm dishes before enriching for ubiquitinated 
proteins with MG132 (6µM) for two hours prior to harvesting. Soluble protein 
lysates prepared in 8M urea buffer were pooled and equalised to 1mg/ml before 
nickel and streptavidin affinity chromatography using optimised conditions. 
Eluted proteins were concentrated using Amicon, Ultra-2 centrifugal filter 
device (Molecular weight cut-off (MWCO)=10kDa) after which the recovered 
sample was fractionated via SDS-PAGE and recovered proteins visualised using 
Coomassie stain or streptavidin-HRP.  
 
While proteins were isolated from WT HBUb MEFs, none could be detected using 
WT MEFs (Figure 4.15). Furthermore, a smear showing an enrichment of high 
molecular mass proteins is detected which is typical of polyubiquitinated 
proteins. The yield of HBUb-modified proteins is comparable to that seen 
previously (Section 4.3.3.1, figure 4.13, panel A) however, use of a gradient gel 
with narrow lanes has improved fractionation and signal strength.  The bands of 
lowest molecular mass (Figure 4.15, panel A, lanes 1 and 2) are thought to be 
non-specific since they appear in both WT and WT HBUb eluate whereas those 
found below 25kDa only in the WT HBUb lane are predicted to correspond to free 
HBUb or Ub-HBUb oligomers. Specificity of the procedure is supported by the 
streptavidin visualisation (Figure 4.15, panel B). While HBUb-proteins are highly 
enriched in WT HBUb MEFs (Figure 4.15, panel B, lane 1), only a weak non-
specific band can be detected for WT MEFs (Figure 4.15, panel B, lane 2). These 
data confirm that using this procedure, a sufficient quantity of HBUb-modified 
protein can be isolated for MS-analysis. 
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Figure 4.15: Scaled-up tandem affinity purification specifically enriches 
sufficient HBUb-modified protein for MS analysis  
WT and WT HBUb MEFs were grown to confluency in biotin-supplemented media (1µM) 
on 20x10cm dishes before enriching for ubiquitinated proteins with MG132 (6µM) for two 
hours prior to harvesting. Soluble protein lysates prepared in 8M urea buffer were 
pooled and equalised to 1mg/ml before nickel affinity chromatography using 30µl (50% 
(v/v) slurry) per milligram of initial protein of Ni2+-NTA-Sepharose beads followed by 
streptavidin affinity chromatography using 10µl (50% (v/v) slurry) per milligram of initial 
protein of streptavidin-Sepharose beads. Eluted proteins were concentrated using 
Amicon, Ultra-2 centrifugal filter device after which the recovered sample was 
fractionated via SDS-PAGE and proteins visualised using Coomassie stain (R250) (Panel A) 
or streptavidin-HRP (Panel B).  
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4.5 Conclusions 
Here, the aim was to assess and optimise the experimental strategy. It was 
shown that SILAC was able to label the proteome without adversely affecting 
cell viability (Section 4.3.2). The method used to assess incorporation was not 
ideal. Even though proteins with a long half-life were chosen, analysis of single 
peptides does not reflect the efficiency of SILAC to label the whole proteome. 
Moreover, I was able to perform a search for either labelled or unlabelled 
peptides, from cells SILAC-labelled for five days, using the Mascot search engine 
(data not shown). While labelled peptides were in abundance, no unlabelled 
peptides could be detected. This result suggested full incorporation of the stable 
isotope into the proteome. A more informative approach would be to assess the 
whole proteome. This can be achieved by a comparison of the proteomes 
extracted from single cell type, differentially labelled via SILAC. If full 
incorporation has been achieved then SILAC ratios for each peptide should equal 
1± error. This analysis requires software such as MaxQuant or Mascot Distiller 
however, only the former was available the time. Furthermore, samples were 
analysed using a QTOF MS, the output of which (.wiff) is not compatible with 
MaxQuant. Moreover, I was not able to convert this file to the required format.  
As such, an Orbitrap mass spectrometer, which is supported by MaxQuant, would 
be required. In addition, although the same analysis should be possible with 
MSQuant, the predecessor to MaxQuant, MSQuant requires data extracted from a 
now defunct web browser (IE6). As such, I was not able to analyse the data as I 
would have liked. Giving that these samples should still be available, repeating 
the analysis on an Orbitrap could be performed belatedly.  
 
Tandem affinity purification was shown to be specific and enriched HBUb-
modified proteins giving a high yield that was sufficient for analysis by MS. 
Furthermore, it was found that biotin supplementation was essential for 
streptavidin affinity chromatography (Sections 4.3.1 and 4.33).  It was 
interesting to find that, during nickel affinity chromatography and to a lesser 
extent, streptavidin affinity chromatography, a large amount of ubiquitinated 
protein was being lost in the flow-through (Section 4.3.1.7, figure 4.8). 
Importantly, this also included loss of K48-linked ubiquitin. This was in contrast 
to that of HBUb-modified protein, which was highly enriched, in the final eluate 
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while only a minimal amount was lost in the previous steps. This was surprising 
since the bead volume had been previously optimised. This might suggest that 
bead volume was insufficient or that expression of the HBUb tag varied 
significantly between HBUb-expressing clones resulting in reduced availability of 
the HBUb tag i.e. incomplete labelling of the ubiquitinome. This would require 
optimisation be repeated for each clone used, which was not done due to time 
restrictions. Furthermore, the increase in size of HB-tagged ubiquitin (18kDa) 
over the endogenous moiety (8kDa) might make the HBUb-tag incompatible with 
a specific set of E3 ligases. This would result in preferential incorporation of 
endogenous ubiquitin and produce an endogenous ubiquitin-tagged 
subpopulation that would be lost during affinity chromatography.  Although WT 
and SOCS3-/- cell lines would be affected equally, this limitation might 
potentially reduce the probability of detecting low abundant SOCS3-dependently 
ubiquitinated targets. 
 
To maximise the isolation of K48-linked polyubiquitin chains, a potential solution 
might be to express a K48-only mutant form of HBUb. This might reduce the 
recovery of polyubiquitin chain variants and potentially improve detection of 
SOCS3 targets. K48-only ubiquitin mutants have been used previously to identify 
the specificity of E3 ligases (212). However, stable overexpression of a K48-only 
mutant might have adverse effects that impact cell function and thus the use of 
ubiquitin mutants was not pursued.  
 
Important for MS-analysis is the scaling-up of raw materials and reagents. 
Comparable results were obtained using scaled-up conditions as compared to 
initial small-scale reactions (Section 4.4). Furthermore, 20x10cm dishes were 
shown to enable TAP isolation of a sufficient quantity of HBUb-modified protein 
for MS analysis. However, detection/identification of proteins can be improved 
following analysis of more peptides. Moreover, given the loss of ubiquitinated 
protein seen during affinity chromatography it was decided to use 20x15cm 
dishes.  
 
The choice to use in-gel trypsin digestion required the development of an elution 
strategy that would be compatible with standard protein concentration methods. 
It was found that an aqueous biotin solution combined with a period of elevated 
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temperature was sufficient to disrupt the streptavidin-biotin interaction (Section 
4.3.3). The use of heat is concerning due to the sensitivity of urea to heat. With 
heat and time, urea decomposes to isocyanate which carbamylates the N-
terminus of proteins or side chains of basic amino acids lysine and arginine. 
Carbamylation of protein side chains increases their mass and thus the mass of 
the protein/peptide. Although this modification can be accounted for during 
post-MS analysis, it might reduce the number of proteins identifiable and also 
increase database search time. However, both issues can be overcome by using 
fresh urea buffers and keeping the temperature below 37ºC. Since the chosen 
elution method still relies on elevated temperatures, streptavidin beads should 
be washed with a non-urea based wash buffer several times and excess buffer 
removed prior to elution. With hindsight, elution efficiency should have been 
assessed for a range of temperatures and as such further reduce the risk of 
disrupting peptide modifications. Another possible strategy would be to use 
avidin beads which have a lower affinity (Kd = 10
-8M) for biotin than streptavidin 
and would therefore require milder elution conditions (2mM D-biotin in PBS at 
room temperature). However, this might result in a reduced yield and limit the 
ability to capture low abundant proteins. Furthermore, wash conditions would 
need to be less stringent which would increase background.    
 
In conclusion, while not without its limitations, the optimised experimental 
strategy enables the almost complete labelling of the proteome and the specific 
enrichment of HBUb-modified proteins with a high yield. Importantly, for the 
detection of proteasome-degraded proteins, a large proportion of isolated 
ubiquitin chains are K48-linked. The data generated in this section suggests that 
using this strategy, it should be possible to capture sufficient quantity of HBUb-
modified proteins and identify potential SOCS3-dependently ubiquitinated 
substrates via mass spectromeric analysis.    
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5.0 Identification of SOCS3-dependently ubiquitinated substrates 
5.1 Introduction 
Optimisation of the experimental strategy confirmed the specific enrichment of 
a differentially-labelled, HBUb-modified ubiquitinome (Section 4.0). Once 
performed under optimised conditions, the samples produced were processed for 
LC-MS/MS analysis. This involved tryptic digestion of proteins and fractionation 
by reverse-phase liquid chromatography, after which co-eluting peptides were 
ionised and their abundance and m/z analysed by mass spectrometry. The most 
abundant peptides (top ten) from this first scan are selected for fragmentation 
and sequencing via a second round of MS to produce an MS/MS spectra. Following 
the analysis of this raw data by proteomics software packages e.g. MaxQuant 
and Mascot, proteins were identified from the MS-sequenced peptides. 
MaxQuant, the primary software package used in this study, is designed 
specifically for SILAC-labelling experiments. As such, it quantifies SILAC ratios of 
the identified proteins from assigned peptides. Using this strategy, I aimed to 
identify SOCS3-dependently ubiquitinated proteins enriched in WT but not in 
SOCS3-/- MEFs.     
 
MS is a very sensitive technique and thus vulnerable to variations such as 
electronic noise, miss-calibration or calibration drift. These variations can 
drastically alter the output over multiple samples or experimental repeats.  In 
combination with sample variations, unbiased comparisons of experimental data 
can be compromised (213). To ensure confidence in data acquisition, several 
biological and technical repeats are recommended. Unfortunately, cost 
constraints make this unfeasible. As such, only two biological repeats were 
performed with reverse SILAC labelling being performed on the repeat 
experiment to account for any impact of SILAC. Post-MS data analysis was 
performed using the free quantitative proteomics software MaxQuant (Section 
2.2.10.2) (170).  
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5.1.1 Strategy to identify potential SOCS3-dependently ubiquitinated 
substrates 
In order to identify potential SOCS3-dependently ubiquitinated substrates a 
differentially SILAC-labelled, TAP-isolated ubiquitinome was captured using the 
previously optimised experimental strategy (Section 4.0). Samples generated via 
this process were submitted for in-gel trypsin digestion (Section 2.2.9.3) and LC-
MS/MS (Section 2.2.10). While automated data analysis is a typically black-box 
procedure, increased confidence in returned results can be achieved by using 
multiple analysis software packages or search engines (180,214). Raw MS data 
was therefore assessed using both MaxQuant/Andromeda (170,180,193) and 
Mascot (180) search engines. While Mascot simply returns a list of identified 
proteins based on analysis of peptide sequences, MaxQuant can return a list of 
proteins based not only on peptide sequence analysis but also on quantitative 
analysis of their SILAC ratios. As such, using Mascot, I aimed to identify proteins 
present in WT but not SOCS3-/- MEFs, whereas using MaxQuant, I aimed to 
identify proteins that are enriched in WT but not in the SOCS3-/- MEFs. A protein 
which is significantly enriched (log2(normalised H/L)>1 or log2(normalised L/H)>1 
for reverse labelling experiment) would signify a potential SOCS3 substrate.  
 
Additionally, based on user-defined parameters, both programs can consider 
PTMs, thus ubiquitination (GlyGly, trypsin remnants) and tyrosine 
phosphorylation sites may be identified.  Such evidence may support the protein 
as a SOCS3 target and would also facilitate further studies e.g. mutational 
analysis.  However, since PTMs are sometimes difficult to detect due to the low 
abundance or loss during sequence fragmentation (179), this data might not be 
retrievable.   
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5.2 Results and discussion  
5.2.1 Selection of HBUb-expressing MEF clones 
As previously discussed (Section 3.0), the HBUb transgene should be expressed at 
comparable levels to simplify quantitation of MS data. As such, prior to further 
investigation, several WT and SOCS3-/- HBUb-expressing clones were assessed for 
comparable HBUb expression. Doing so would ensure that any changes in 
expression occurring during the experimental process could be monitored and 
accounted for.  
 
Lysates of MEF clones were prepared as described (Section 2.2.5.3), equalised 
prior to SDS-PAGE fractionation and expression of the HBUb transgene and SOCS3 
analysed by immunoblotting (Figure 5.0). 
 
Expression of the HBUb transgene varied among the MEF clones (Figure 5.0, 
panel A). However, SOCS3-/- HBUb clone 8 and WT HBUb clone 17 expressed the 
HBUb transgene at comparable levels (Figure 5.0, panel A, small arrows). 
Furthermore, SOCS3 was expressed in WT but not SOCS3-/- MEFs confirming that 
the clones were correctly assigned (Panel B, large arrow). Moreover, WT HBUb 
clone 17 showed the highest SOCS3 expression. As such, SOCS3-/- HBUb clone 8 
and WT HBUb clone 17 were selected for further experimentation. 
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Figure 5.0: Selection of HBUb expressing clones 
WT HBUb and SOCS3-/- MEFs were grown in biotin-supplemented media (1µM) before 
enriching for ubiquitinated proteins with MG132 (6µM) for two hours prior to harvesting 
as described (Section 2.2.5.3). Soluble protein lysates were the equalised and 
fractionated by SDS-PAGE. Expression of the HBUb-transgene and SOCS3 was assessed 
using streptavidin-HRP (Panel A) and anti-SOCS3 antibody (Panel B). GAPDH was used as 
a loading control (Panel C). A large arrow indicates SOCS3 while small arrows indicate 
WT and SOCS-/- MEF clones used for further experimentation.  
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5.2.2 Preparation of differentially SILAC-labelled, TAP-isolated ubiquitinome 
for mass spectrometry  
Using SOCS3-/- HBUb clone 8 and WT HBUb clone 17, the previously optimised 
experimental strategy (Section 1.5, figure 1.11) was performed. In addition, 
small adjustments were made to improve SILAC labelling and the recovery of the 
ubiquitinome. This involved a period of pre-SILAC labelling during cell expansion 
and the use of 20x15cm tissue culture dishes. It was previously demonstrated 
that SILAC media supplemented with dialysed serum does not affect cell viability 
(Section 4.3.2.1) and so longer incubation periods were not expected to be an 
issue. Briefly, prior to seeding cells into dishes, cells were adapted to dialysed 
serum-supplemented control (R0K0) media while being expanded in T150 flasks 
as before. After reaching ~80% confluency, cells that were to be heavy labelled 
were passaged into SILAC media (R6K6) while unlabelled cells were passaged 
into control (R0K0) media. Cells were then allowed to expand to ~80% 
confluency (5-7 days) after which time they were seeded into 20x15cm dishes at 
a density (1:5) sufficient to achieved confluency over 5 days. As such, SILAC 
labelling was performed for double the time previously assessed during 
optimisation and should therefore achieve greater incorporation of the SILAC 
isotope. To reduce workload, forward (WT HBUb=R6K6/heavy media, SOCS3-/- 
HBUb=R0K0/light control media) and reverse (WT HBUb=R0K0/light control 
media, SOCS3-/- HBUb=R6K6/heavy media) labelling experiments were performed 
separately. Furthermore, for the same reason, treatment (MG132 (6µM), Na3VO4 
(1mM), forskolin (50µM) for two hours plus H2O2 (0.2mM) for the final 30 
minutes) and harvesting (Section 2.2.5.3) of the WT HBUb and SOCS3-/- HBUb 
cells were also performed separately. Harvested cells were then flash-frozen 
using dry ice and methanol before storing at -80ºC prior to further processing.   
 
Using this approach, the forward labelling experiment produced a total of 170mg 
(From WT HBUb=86.4mg; SOCS3-/- HBUb=135mg) of protein following 
equalisation and mixing. The reverse labelling experiment produced a total of 
400mg (From WT HBUb = 340.6mg; SOCS3-/- HBUb=237.4 mg) of protein following 
equalisation and mixing.  
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Prior to mixing cell lysates and further processing, expression of the HBUb 
transgene was re-evaluated. Cell lysates were equalised prior to fractionation by 
SDS-PAGE and expression of the HBUb transgene and SOCS3 induction were 
analysed by immunoblotting (Figure 5.1). The HBUb transgene was expressed to 
comparable levels in cell lysates from forward and reverse labelling experiments 
(Figure 5.1, panel A). Furthermore, SOCS3 was induced in WT HBUb but not 
SOCS3-/- HBUb MEFS (Figure 5.1, panel B, arrow).  
 
After equalisation and mixing of cell lysates, tandem affinity purification 
(Section 2.2.7) and protein concentration (Section 2.2.9.1) was performed.  The 
generated TAP eluate was fractionated by SDS-PAGE (Section 2.2.9.2) prior to 
preparing gel slices (Section 2.2.9.2) for in-gel trypsin digestion (Section 
2.2.9.3). Following Coomassie staining of the TAP eluate from forward and 
reverse labelling experiments, a high molecular weight smear typical of 
ubiquitinated proteins was detected (Figure 5.2). This suggests that sufficient 
material was recovered for mass spectrometric analysis. Additionally, unmixed 
cell lysates from the same experiments showed comparable Coomassie staining 
suggesting that cell lysates were correctly equalised prior to mixing and TAP. 
This is important since incorrect equalisation could adversely affect data by the 
generation of false-positives during quantitation.  
 
Finally, in-gel trypsin-digested (Section 2.2.9.3) samples were submitted for LC-
MS/MS using an Orbitrap Velos Fourier transform mass spectrometry (FTMS), 
operated by William Mullen (University of Glasgow, Proteomics Biomarkers and 
Systems Medicine). Retrieved spectrometric data was then automatically 
analysed using Mascot and MaxQuant. Using the generated information, raw mass 
spectra was also manually assessed using the Orbitrap control and monitoring 
software Xcalibur v2.1 (Thermo Scientific).  
 
 
                                                                                                                            162 
 
250 
50 
37
75
Mr (kDa)
25
Streptavidin-HRP
Protein Lysates 
(50µg)
IB: GAPDH
WT 
HBUb
SOCS3
-/-
HBUb
Forward 
SILAC 
labelling
IB: SOCS3
Reverse 
SILAC 
labelling
A
C
B
WT 
HBUb
SOCS3
-/-
HBUb
 
 
 
Figure 5.1: Evaluation of HBUb transgene expression and SOCS3 induction 
prior to TAP and MS 
WT HBUb and SOCS3-/- HBUb MEFs were SILAC-labelled as described (Section 5.2.2). 
Prior to harvesting (Section 2.2.5.3), MEFs were treated with MG132 (6µM), Na3VO4 
(1mM), and forskolin (50µM) for two hours. Cells were treated with H2O2 (0.2mM) for the 
final 30 minutes. Soluble protein lysates were then equalised and fractionated by SDS-
PAGE. HBUb-transgene and SOCS3 expression were assessed using streptavidin-HRP 
(Panel A) and anti-SOCS3 antibody  (Panel B) respectively. GAPDH was used as the 
loading control (Panel C). Arrow indicates SOCS3. 
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Figure 5.2: Fractionation of concentrated SILAC-labelled, TAP-isolated 
HBUb-modified proteins prior to MS 
WT HBUb and SOCS3-/- HBUb MEFs were SILAC-labelled as described (Section 5.2.2). 
Prior to harvesting (Section 2.2.5.3), MEFs were treated with MG132 (6µM), Na3VO4 
(1mM), and forskolin (50µM) for two hours and with H2O2 (0.2mM) for the final 30 
minutes. After equalisation and mixing of cell lysates, tandem affinity purification 
(Section 2.2.7) and protein concentration (Section 2.2.9.1) was performed and the 
generated sample fractionated by SDS PAGE (Section 2.2.9.2). Recovery of HBUb-
modified proteins was assessed via Coomassie staining. The concentrated TAP eluate 
from forward labelled (Left panel) and reverse labelled (Right panel) experiments are 
compared with equalised, unmixed cell lysates from the sample experiment. 
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5.2.3 Data analysis   
5.2.3.1 Mascot-based protein identification and mass spectra analysis of raw 
MS data 
Potential SOCS3-dependently ubiquitinated targets are expected to be enriched 
in WT HBUb MEFs but not SOCS3-/- HBUb MEFs. To identify the presence of these 
proteins, raw MS data from the forward SILAC-labelled experiment was searched 
using the Mascot search engine as described (Section 2.2.10.1). Prior to MS, the 
SDS-PAGE-fractionated TAP eluate was sectioned into several manageable gel 
slices and then processed and analysed separately (Section 2.2.9.2). As such, the 
Mascot search engine returned several lists of identified proteins with each set 
corresponding to a specific gel slice/mass range. Furthermore, separate searches 
were performed for proteins containing only labelled or unlabelled peptides. 
Peptides detectable in heavy-labelled WT HBUb MEFs but not light-labelled 
SOCS3-/- HBUb MEFs were extracted from the returned results (Table 5.0). A 
total of 73 proteins were identified to be exclusively from heavy labelled WT 
HBUb MEFs. Several of these proteins were identified in multiple mass ranges, a 
characteristic typical of polyubiquitinated species (Table 5.0, dark grey boxes). 
Supporting this observation, many of these proteins had an expected mass much 
lower than the mass range from which they were extracted e.g. cavin-1 (PTRF, 
O54724) a protein with a predicted mass of ~44kDa was detected in gel slice 
corresponding to a mass range of 75-100kDa(Table 5.0, protein 47, light grey 
box). Importantly, a known SOCS3-dependently ubiquitinated substrate FAK1 was 
identified (Table 5.0, protein 43, bold, light grey box). Furthermore, a 
component of the SOCS3-E3 complex, cullin5 (Table 5.0, protein 52, bold, light 
grey box) was also identified.  
 
Using returned Mascot search data, mass spectra from selected peptides were 
manually assessed. Selected peptides included a protein detected in WT HBUb 
MEFs and SOCS3-/- HBUb MEFs, pyruvate kinase i.e. a probable non-SOCS3 
substrate (Figure 5.3), the known SOCS3 substrate FAK1 (Figure 5.4), and a 
potential SOCS3 substrate, cavin-1 (Figure 5.5). Spectra were assessed for the 
presence of peaks relating to heavy or light-labelled species. Doing so would 
confirm that proteins have been identified as being exclusively from the heavy-
labelled WT HBUb MEFs i.e. they do not have a light-labelled peptide equivalent.  
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Furthermore, the conversion of 13C6-arginine to 
13C6-proline was assessed which 
if present, is expected to produce satellite peaks shifted by 5Da from the mono-
isotopic peak.    
 
Analysis of the spectra for pyruvate kinase (Figure 5.3, panel A, arrows indicate 
monoisotopic peaks), detected two sets of peaks relating to doubly charged 
peptides with a C-terminal arginine (Figure 5.3, panel B1/2). The nature of the 
charge meant that the observed mass was half that of the expected mass. The 
laddered peaks to the right of the monoisotopic peaks related to the 
incorporation of naturally present 13C (~1.1% of total). The observed 
monoisotopic peaks were separated by 3Da suggesting that this shift is due to 
the SILAC isotope.  Furthermore, these peaks were of similar intensity i.e. a 
SILAC ratio ~1.  Additionally, the conversion of 13C6-arginine to 
13C5-proline could 
not be detected since no significant peaks were visible at the expected location 
of 779.8Da i.e. 2.5Da to the right of the heavy-labelled monoisotopic peak. 
These data confirmed that the protein was present in both differentially labelled 
cells and is therefore not expected to be a substrate of SOCS3. Furthermore, this 
data did not seem to be affected by 13C5-proline contamination suggesting that 
SILAC ratios can be accurately calculated from the monoisotopic peaks.   
 
In contrast to pyruvate kinase, the spectra of the known SOCS3 substrate FAK1 
(10) (Figure 5.4, panel A, arrows indicate monoisotopic peaks), detected a single 
doubly charged monoisotopic peak. This protein was identified via a search using 
the SILAC label as a fixed modification and is therefore expected to be a heavy-
labelled peptide. No peak corresponding to a doubly-charged light-labelled 
peptide was detected at the predicted location of 578.3Da i.e. 3Da to the left of 
the heavy-labelled monoisotopic peak. As such, the SILAC ratio could not be 
estimated. This data confirmed that the protein was correctly identified as being 
present in only heavy-labelled cells. However, in contrast to pyruvate kinase 
which was identified from several high-scoring peptides (data not shown), FAK1 
was identified from a single peptide with a low score. This resulted in a protein 
score of 866/595 for pyruvate kinase (Figure 5.3, panel B1/2) as opposed to 26 
for FAK1 (Figure 5.4, panel B), although this result is still above the limit of 19 
set by the significance threshold (p<0.05). As such, while being exclusively found 
in WT HBUb MEFs, the peptide might still be incorrectly assigned. 
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Cavin-1 was identified from several low-scoring peptides (Figure 5.5, panel B, 
full peptide list not shown) with a protein score of 21. An intense peak at 
449.11Da prevented clear analysis of the spectra (Figure 5.5, panel A). However, 
a single doubly charged monoisotopic peak was identified (Figure 5.5, panel A, 
arrows indicate monoisotopic peaks). This protein was identified by a search 
using the SILAC label as a fixed modification and is therefore expected to be a 
heavy labelled peptide. However, no peak corresponding to a doubly-charged 
light-labelled peptide was detected at the predicted location of 448.74Da i.e. 
3Da to the left of the heavy-labelled monoisotopic peak. As such, the SILAC ratio 
could not be estimated. This data confirmed that the protein was correctly 
identified as being present in only heavy-labelled cells and as such might be a 
potential SOCS3 substrate. 
 
The Mascot search engine performed peptide assignment while considering 
modifications due to phosphorylation and ubiquitination. However, for the data 
presented, no modifications were identified. Furthermore, analysis of mass 
spectra allowed checks to be made with regards to peptide assignment and 
proline contamination. Moreover, from the peak intensities of SILAC-paired 
peaks of individual peptides, a SILAC ratio can be estimated. For example, 
pyruvate kinase had a SILAC ratio of ~1 whereas FAK1 and PTRF/cavin-1 would 
have had a much higher/significant SILAC ratio if the corresponding light peaks 
were visible. However, this project is aims to identify specifically enriched 
proteins from calculated SILAC ratios. Such analysis must consider all peptides of 
a single protein simultaneously. The Mascot search engine cannot perform this 
analysis.  As such, protein identified by Mascot might not be detected as being 
significantly enriched when all peptides are considered. For these reasons, 
MaxQuant data analysis was used as the primary tool for identifying potential 
SOCS3 substrates.  Furthermore, this approach might be able to account for 
SILAC-paired peaks where the light peak is of low intensity such as in the case of 
FAK1 and cavin-1.         
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Table 5.0: Mascot analysis of the forward SILAC-labelling experiment    
Using the Mascot Daemon server (v2.2), raw MS data from the forward SILAC-labelled 
experiment was searched using Mascot search engine as described (Section 2.2.10.1). 
Separate searches were performed for labelled and unlabelled peptides. Protein 
identifications with a significant score (p<0.05) were accepted.Peptides detectable only 
in heavy-labelled WT HBUb MEFs were extracted from the returned results. Dark grey 
boxes indicate proteins found in several mass ranges. Light grey boxes indicate proteins 
of interest.  
 
Gene 
Name
Uniprot 
accession 
number
Expected 
Size    
(kDa)
Gene 
Name
Uniprot 
accession 
number
Expected 
Size       
(kDa)
1 Trim27  Q62158 58.5 39 Psmc1 P62192 49.2
2  Sfi1 Q3UZY0 144.0 40 Impdh1 P50096 55.3
3 Lats2 Q7TSJ6 115.5 41 Aarsd1 Q3THG9 45.0
4 Ywhah P68510 28.2 42 Ttll12 Q3UDE2 74.0
5  Actr1a P61164 42.6 43 Ptk2/FAK1 P34152 23-123
6 Actr2 P61161 44.8 44 Tbc1d15 Q9CXF4 76.5
7 Trap1 Q9CQN1 80.2 45  Tubb2a Q7TMM9 49.9
8  Fasn P19096 272.4 46 Plod3 Q9R0E1 84.9
9  Tert O70372 128.0 47  Ptrf/Cavin-1 O54724 44.0
10  Fads2 Q9Z0R9 52.4 48 Exosc3 Q7TQK4 29.5
11  Derl2 Q8BNI4 27.6 49 Fam132a Q8R2Z0 33.3
12 Maged1 Q9QYH6 85.7 50 Ssbp1 Q9CYR0 17.3
13 Kel Q9EQF2 81 51 Zc3hav1 Q3UPF5 88-107
14  Radil Q69Z89 52-121 52 Cul5 Q9D5V5 91.0
15 Peo1 Q8CIW5 33-77 53  Anxa1 P10107 38.7
16 Polr1a O35134 194.1 54  Prkaa1 Q5EG47 63.9
17 Cd2ap Q9JLQ0 70 55 Ccdc50 Q810U5 30-35
18  Mllt10 O54826 113.0 56 Wbp2 P97765 28.0
19  Tubb2a Q7TMM9 49.9 57 Stxbp1 O08599 68.0
20 Maged1 Q9QYH6 85.7 58 Ube2n P61089 17.1
21 Rrp1 P56183 50.0 59 Psma6 Q9QUM9 27.4
22 Usp5 P56399 95.8 60 Tert O70372 128.0
23 Fam63b Q6PDI6 39-66 61 Actr1a P61164 42.6
24 Krt18 P05784 47.5 62 Actr2 P61161 44.8
25 Eps15 P42567 64-98 63  Mllt10 O54826 113.0
26 Mbtps1 Q9WTZ2 117.5 64 Eral1 Q9CZU4 48.2
27  Tubb2a Q7TMM9 49.9 65 Peo1 Q8CIW5 33-77
28  Eps15l1 Q60902 75-99 66 Kel Q9EQF2 81
29 Tert O70372 128.0 67  Radil Q69Z89 52-121
30 Rps3 P62908 26.7 68 Polr1a O35134 194.1
31  Psmd2 Q8VDM4 100.2 69 Cd2ap Q9JLQ0 70.4
32 Trap1 Q9CQN1 80.2 70  Derl2 Q8BNI4 27.6
33 Cep135 Q6P5D4 133.3 71 Krt18 P05784 47.5
34  Mllt10 O54826 113.0 72 N4bp2l2 Q8JZS6 54-66
35 Hgs Q99LI8 86.0 73 Rps4x P62702 29.6
36 Tuba1b P05213 50.2
37 Nsfl1c Q9CZ44 29-40
38 Rabgef1 Q9JM13 56.9
Gel slice/ 
Mass range 
(kDa)
30 - 40
Gel slice/ 
Mass 
range 
5 75 - 100
5 75 - 100
1 >>250
2 > 250
3 150 - 250
4 100 - 150
6 ~60 - 75
7 ~40 - 75
8
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Figure 5.3: Spectra of pyruvate carboxylase, a protein detectable in 
differentially labelled WT HBUb and SOCS3-/- HBUb MEFs  
Using the Mascot Daemon server (v2.2), raw MS data from the forward SILAC-labelled 
experiment was searched using Mascot search engine as described (Section 2.2.10.1). 
Separate searches were performed for labelled and unlabelled peptides. Proteins 
containing peptides detectable in heavy-labelled WT HBUb and light-labelled SOCS3-/- 
MEFs were extracted from the returned results. Spectra of peptides from identified 
proteins were manually analysed using Xcalibur 2.1 (Thermo Scientific). A. Mass spectra 
of pyruvate carboxylase. B. Selected data returned by the Mascot search engine. B1. 
Unlabelled peptide search. B2. Labelled peptide search. Arrows indicate locations of 
monoisotopic peaks of heavy or light-labelled peptides. Ions score is -10*Log(P), where P 
is the probability that the observed match is a random event. Individual ions scores > 19 
indicate identity or extensive homology (p<0.05). 
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Figure 5.4: Spectra of a known SOCS3-dependently ubiquitinated substrate, 
FAK-1, detectable in heavy-labelled WT but not light-labelled SOCS3-/- MEFs 
Using the Mascot Daemon server (v2.2), raw MS data from the forward SILAC-labelled 
experiment was searched using Mascot search engine as described (Section 2.2.10.1). 
Separate searches were performed for labelled and unlabelled peptides. Proteins 
containing peptides detectable only in heavy-labelled WT HBUb MEFs were extracted 
from the returned results. Spectra of peptides from proteins identified by this search 
were manually analysed using Xcalibur 2.1 (Thermo Scientific). A. Mass spectra of FAK1. 
B. Selected data returned by the Mascot search engine. Arrows indicate 
locations/expected locations of monoisotopic peaks of heavy or light labelled peptides 
respectively. Ions score is -10*Log(P), where P is the probability that the observed 
match is a random event. Individual ions scores > 19 indicate identity or extensive 
homology (p<0.05). 
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Figure 5.5: Spectra of a potential SOCS3-dependently ubiquitinated 
substrate, PTRF (cavin-1) detectable in heavy-labelled WT but not light-
labelled SOCS3-/- MEFs 
Using the Mascot Daemon server (v2.2), raw MS data from the forward SILAC-labelled 
experiment was searched using Mascot search engine as described (Section 2.2.10.1). 
Separate searches were performed for labelled and unlabelled peptides. Proteins 
containing peptides detectable only in heavy-labelled WT HBUb MEFs were extracted 
from the returned results. Spectra of peptides from proteins identified by this search 
were manually analysed using Xcalibur 2.1 (Thermo Scientific). A. Mass spectra of 
PTRF/cavin-1. B. Selected data returned by the Mascot search engine. Arrows indicate 
locations/expected locations of monoisotopic peaks of heavy or light-labelled peptides 
respectively. Ions score is -10*Log(P), where P is the probability that the observed 
match is a random event. Individual ions scores > 19 indicate identity or extensive 
homology (p<0.05). 
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5.2.3.2 MaxQuant: identification of potential SOCS3 substrates using SILAC 
ratios calculated using raw MS data 
Raw MS data from both forward and reverse SILAC-labelling experiments were 
analysed using MaxQuant as described (Section 2.2.10.2 and Table 2.2). The 
subsequent ProteinGroups.txt results table generated by MaxQuant was manually 
assessed. Detected contaminants were removed and proteins arranged by their 
log2-transfomed, normalised SILAC ratios (Figure 5.6, Tables 5.1 and 5.2). SILAC 
ratio is taken as H/L for the forward-labelling experiment (WT HBUb=heavy, 
SOCS3-/- HBUb=light) and L/H for the reverse (WT HBUb=light, SOCS3-/- 
HBUb=heavy). 
 
Analysis of both forward and reverse experiments produced a similar pattern of 
SILAC ratio distributions (Figure 5.6). However, while several proteins were 
found significantly enriched (log2 (normalised SILAC ratio) > 1 i.e. a two fold 
increase) in the forward experiment, only one was found in the reverse 
experiment. Most proteins had an unvarying SILAC ratio (-1 > log2 (normalised 
SILAC ratio) < 1) suggesting that they were detectable in WT HBUb and SOCS3-/- 
HBUb MEFs. Several proteins were found enriched in SOCS3-/- HBUb MEFs (log2 
(normalised SILAC ratio) < -1) and as such might be a consequence of the 
deletion of SOCS3.  For example, if there is a case where SOCS3 ubiquitinates 
another E3 ligase, then substrates of this E3 might be enriched in the 
differentially-labelled SOCS3-/- MEFs. These extra data may contribute to the 
identification of further SOCS3 substrates. While these proteins might be of 
interest in the future, they were not considered here.    
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Figure 5.6: Value-ordered plots of log2-transformed normalised SILAC ratios 
from forward and reverse SILAC-labelled experiments 
Raw MS data was analysed using MaxQuant as described (Section 2.2.10.2 and Table 
2.2). Detected contaminants were removed and proteins arranged by their log2-
transfomed, normalised SILAC ratios. A. Forward-labelling experiment. B. Reverse 
labelling experiment. Proteins with a log2 SILAC ratio greater that 1 i.e. a two fold 
increase, is considered significant. 
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Selections of identified proteins with the highest SILAC ratios from forward and 
reverse experiments are presented in Table 5.1 and 5.2. Seventy-six proteins 
were identified overall in the forward-labelling experiment, and using 
normalised SILAC ratios, 15 were found to be significantly enriched (Table 5.1, 
double line indicates cut-off). Most of these proteins were identified from 
multiple unique peptides, with a high sequence coverage and a low PEP score 
(FDR<1%). Furthermore, multiple SILAC-paired peaks were used to calculate the 
SILAC ratio (Ratio H/L count). As such, these characteristics increased 
confidence in protein assignment. Interestingly, several proteins found using 
Mascot were also identified using MaxQuant e.g. cavin-1. However, a known 
SOCS3-dependently ubiquitinated substrate FAK1 or the SOCS3 E3 component 
cullin5 were not detected. This might be a consequence of the mode of SOCS3 
induction i.e. forskolin and being a non-SOCS3 substrate respectively. In 
contrast, in the reverse experiment, while having slightly improved peptide 
identification characteristics, only 56 proteins were identified with only a single 
protein identified as being significantly enriched in the WT HBUb MEFs (Table 
5.2, Maged1, protein 1). Furthermore, Maged1 was previously identified (Table 
5.1, protein 17) as an unvarying protein. As such, Maged1 was not considered as 
a potential SOCS3 substrate. Additionally, while a few ubiquitinylated lysine 
residues were identified in both experiments, no phosphorylated residues could 
be found. 
 
While the SILAC ratios are disappointing, many proteins were identified in both 
forward and reverse experiments. Out of 76 proteins found in the forward 
labelling experiment, 44 (out of 56) were found in the reverse experiment 
(Tables 5.1 and 5.2, bold, full list not shown). Ten of these 48 proteins were 
found to be significantly enriched in the forward labelling experiment. Over 
these two experiments, while similar arrays of proteins were identified, the 
SILAC ratios were not replicated. This is indicative of experimental error 
although the source of this error is not apparent. A comparison of the total ion 
chromatograms (TIC, the summed ion intensities of each mass spectrum plotted 
against time) of both experiments showed a more intense signal was produced 
for the reverse experiment as indicated by the normalised level (NL) (Figure 5.7, 
lower panel vs. upper panel). Furthermore, extracted spectra contained more 
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complex/improved peak information (data not shown). This is supported by the 
improved sequence coverage and ratio H/L count (Table 5.2 vs. Table 5.1). 
    
Ubiquitin was detected in both forward (Table 5.1, dark grey box, protein 34) 
and reverse experiments (Table 5.2, dark grey box, protein 34). This allowed the 
quality of the data to be assessed. For the forward-labelled experiment, 
ubiquitin was indentified using 16 unique peptides and an 88% sequence 
coverage whereas the reverse used 10 unique peptides and 85.6% sequence 
coverage. Furthermore, MaxQuant was able to identify six out of seven 
ubiquitinated lysine residues in the forward experiment whereas only two were 
identified in the reverse.  Importantly, for both cases, the log2-transformed 
normalised SILAC ratios were approximately zero indicating that ubiquitin/HBUb 
was expressed to comparable levels in WT HBUb and SOCS3-/- HBUb MEFs. 
Furthermore, it also suggests the complete incorporation of the SILAC label. As 
such, it can be concluded that the data from both experiments is of similar 
quality.  
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Table 5.1:  MaxQuant analysis of forward labelling experiment    
MS data was analysed using MaxQuant as described (Section 2.2.10.2). Proteins were 
arranged by their log2-transfomed, normalised SILAC ratio. Proteins in bold were also 
found in the reverse-labelling experiment. Light grey/dotted boxes indicate proteins 
investigated further (Section 6.0). Dark grey box indicates ubiquitin. 
 
Gene 
Names
Uniprot 
Accession 
Number
Unique 
Sequence 
Coverage 
[%]
PEP
Log2 
Normalised 
H/L ratio
Ratio 
H/L 
Count
GlyGly 
(K)      
Site
1 Usp5 P56399 4 4 5.6 1.52E-09 2.66 4.28 2.10 5
2 Eps15l1 Q60902-1 1 1 1.2 9.62E-11 2.37 3.75 1.91 1
3 Uchl1 Q3TCH2 1 1 8 0.00263 2.69 3.74 1.90 1
4 Ube1 Q02053 9 9 10.9 3.43E-44 1.96 3.22 1.69 8
5 Ccdc113 Q8C5T8 1 1 3.4 0.107 1.86 3.04 1.60 2 145
6 Psmd2 Q8VDM4 3 3 4.2 4.68E-14 1.90 2.80 1.49 9
7 Smt3h1 Q9Z172-1 1 1 10.9 7.99E-06 3.41 2.72 1.45 3
8 Cavin-1 O54724 5 5 15.8 1.26E-48 4.05 2.58 1.37 6
9 Sqstm1 Q64337-1 8 8 32.6 4.29E-85 3.62 2.50 1.32 14
10 Impdh P24547 4 4 8.1 9.22E-14 3.49 2.26 1.18 4
11 Abi2 Q6AXD2 1 1 3.3 0.001494 3.11 2.25 1.17 1
12 H3.3a P84244 3 3 12.7 7.62E-05 3.28 2.24 1.16 7
13 Hgs Q99LI8 2 2 2.6 0.001888 1.38 2.20 1.14 1
14 Rps3 P62908 2 2 10.3 2.97E-08 1.29 2.06 1.04 2
15 Fam63b Q6PDI6-1 1 1 2.5 0.000195 1.48 1.99 1.00 1
16 Vcp Q01853 11 11 16.7 2.17E-36 1.16 1.92 0.94 11
17 Maged1 Q571N9 1 1 1.4 2.74E-06 2.74 1.75 0.81 2
18 Hsc70 P63017 19 19 37.8 3.47E-123 1.92 1.59 0.67 46
19 Hist1h2bp Q8CGP2-2 2 2 13 0.008093 2.28 1.56 0.64 2
20 Ube2n P61089 1 1 5.4 8.59E-10 2.69 1.56 0.64 1
21 Vim P20152 8 8 17.8 8.42E-20 1.81 1.39 0.48 15
22 Eps15 P42567-1 2 2 3 2.34E-15 0.86 1.37 0.45 2
23 Ttn A2ASS6-1 1 1 0 0.16482 1.89 1.36 0.45 1 4963
24 Psmc1 P62192 2 2 9.3 0.001057 2.12 1.33 0.42 2
25 Rad23b P54728 3 3 5.3 0.000183 1.99 1.31 0.39 11
26 H2a.x P27661 3 1 13.3 8.77E-20 2.69 1.31 0.39 8
27 Ccdc50 Q810U5-1 1 1 3.9 3.28E-09 1.44 1.29 0.36 1
28 Rabgef1 Q9JM13 4 4 8.1 5.96E-08 1.52 1.24 0.31 3
29 Hsp90aa1 P07901 10 3 5.2 3.66E-54 1.02 1.23 0.30 5
30 Tbc1D15 Q9CXF4 3 3 4.9 1.89E-08 1.57 1.22 0.29 3
31 Hsp90ab1 Q71LX8 11 1 1.5 2.53E-57 1.29 1.20 0.27 28
32 Nsfl1c Q9CZ44-3 6 6 20.2 3.32E-32 2.01 1.19 0.26 6
33 Hsp90ab1 P11499 11 1 1.4 5.73E-53 1.34 1.17 0.22 4
34 Ubc P0CG50 16 16 88 4.02E-176 1.92 1.16 0.21 561
6;11;29; 
33;48;63
35 Anxa1 Q3US43 1 1 3.1 0.007636 1.26 1.15 0.21 1
36 Rps10 P63325 5 5 30.9 4.74E-20 1.76 1.12 0.17 8
37 Pcna Q9CZD6 3 3 9.9 1.80E-08 1.29 1.09 0.13 3
38 Stam P70297 1 1 1.8 0.006177 1.22 1.01 0.02 1
39 Pgam1 Q9DBJ1 3 3 14.6 0.000212 1.30 0.99 -0.01 3 5
40 Psmd4 O35226-2 1 1 4.5 1.60E-20 1.55 0.93 -0.10 1
Peptides/
Unique
Ratio H/L / 
Normalised 
H/L
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Table 5.2:  MaxQuant analysis of reverse labelling experiment    
MS data was analysed using MaxQuant as described (Section 2.2.10.2). Proteins were 
arranged by their log2-transfomed, normalised SILAC ratio. Proteins in bold were also 
found in the forward-labelling experiment. Light grey/dotted boxes indicate proteins 
investigated further (Section 6.0). Dark grey box indicates ubiquitin. 
Gene 
Names
Uniprot 
Accession 
Number
Unique 
Sequence 
Coverage 
[%]
PEP
Log2 
Normalised 
L/H ratio
Ratio 
H/L 
Count
GlyGly  
(K)         
Site
1 Maged1 Q9QYH6 3 3 4.4 2.07E-06 0.48 0.49 1.03 8
2 Rps3 P62908 3 3 14 5.29E-06 0.72 0.76 0.39 7
3 Actg1 Q9QZ83 8 1 5.3 5.55E-37 0.78 0.77 0.38 6
4 Psmd4 O35226-2 2 2 7.1 0.0001434 0.79 0.78 0.35 5
5 Hsp90ab1 P11499 10 8 14.8 1.94E-25 0.78 0.80 0.33 51
6 Impdh P24547 7 7 16.2 1.08E-10 0.80 0.81 0.31 15
7 Hsc70 P63017 15 15 27.7 3.12E-78 0.84 0.84 0.25 53
8 Pcx Q3T9S7 46 46 50.6 0 0.85 0.86 0.22 334
9 Usp5 P56399 7 7 11.9 2.57E-12 0.78 0.87 0.21 13
10 Acta P68134 8 1 4.2 9.40E-38 0.90 0.87 0.21 11
11 Rpl18 P35980 2 2 11.7 0.0008755 0.88 0.87 0.21 8
12 Pcna P17918 3 3 11.1 0.0007213 0.91 0.88 0.19 5
13 Smt3h1 Q9Z172-1 1 1 10.9 2.83E-08 0.89 0.89 0.16 5
14 Hist1h2bp Q8CGP02 1 1 9.7 0.017583 0.90 0.91 0.13 3
15 Pk3 P52480-1 3 3 6.6 3.49E-05 0.93 0.92 0.13 15
16 Rps20 P60867 1 1 9.2 0.0064067 0.91 0.92 0.12 4
17 Rad23b P54728 2 2 4.3 0.0009927 0.86 0.93 0.10 5
18 Rps7 D3YWP6 3 3 14.9 0.0002335 0.95 0.94 0.08 7
19 Psmc2 P46471 1 1 2.3 0.001442 0.98 0.97 0.04 1
20 Nsfl1c Q9CZ44-3 4 4 14.8 5.59E-09 0.99 0.97 0.04 8
21 Lamr1 P14206 2 2 7.1 0.0033983 0.97 0.97 0.04 2
22 Ldh1 Q3TCI7 2 2 7.5 2.93E-05 0.99 0.98 0.03 7
23 Eps15 P42567-1 5 5 7.4 6.83E-38 0.96 0.98 0.03 5
24 Psmd2 Q8VDM4 4 4 6.9 3.86E-10 0.96 0.99 0.01 14
25 Eef1a P10126 5 5 11.5 1.13E-15 1.00 0.99 0.01 40
26 Cct8 P42932 2 2 3.6 0.0004716 0.98 0.99 0.01 5
27 H2a.x Q3THW5 3 3 20.2 9.91E-06 0.94 1.00 0.01 8
28 Rps10 P63325 3 3 23 2.28E-09 1.02 1.02 -0.03 13
29 Nono Q99K48-1 3 3 5.3 2.90E-06 1.02 1.03 -0.04 7
30 Rpl3 D3YZ47 2 2 5 0.0022049 1.04 1.03 -0.04 4
31 Ccng2 O08918 1 1 2.3 0.01304 1.09 1.03 -0.05 3 262
32 Sqstm1 Q64337-1 4 4 15.2 7.49E-33 1.06 1.04 -0.06 14
33 Mcca Q99MR8 14 14 24.1 1.04E-27 1.07 1.05 -0.07 19
34 Ubc P0CG50 10 10 85.6 8.29E-124 1.08 1.06 -0.08 392 11;48
35 H3.3a P84244 2 2 8.8 0.0021028 1.06 1.08 -0.11 8
36 Pcca Q91ZA3 11 11 19.3 1.36E-34 1.11 1.08 -0.12 29
37 Rpl7 P14148 1 1 3.9 0.0058481 1.16 1.10 -0.13 1
38 Vcp Q01853 17 17 28.8 1.40E-70 1.02 1.11 -0.15 28
39 Ddx2b P10630-2 2 2 5.4 0.0015976 1.11 1.11 -0.16 5
40 Ube1 Q02053 9 9 11.8 6.56E-22 1.09 1.13 -0.18 21
41 Cavin-1 O54724 5 5 15.1 2.45E-08 1.18 1.15 -0.20 11
Peptides/
Unique
Ratio H/L / 
Noramlised 
H/L
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Figure 5.7: Total ion chromatogram from forward and reverse-labelled 
experiments 
Representative total ion chromatograms (TIC), the summed ion intensities of each mass 
spectrum plotted against time, of forward (Upper panel) and reverse (Lower panel) 
labelled experiments using Xcalibur v2.1 (Thermo Scientific). Data was obtained under 
the same conditions using an Orbitrap Velos Fourier Transform Mass Spectrometer 
(FTMS), operated by William Mullen (University of Glasgow, Proteomics Biomarkers and 
Systems Medicine).  
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5.3 Conclusions 
Using Mascot and MaxQuant I aimed to identify protein specifically enriched in 
the WT HBUb but not SOCS3-/- HBUb MEFs. In doing so, I might be able to identify 
SOCS3-dependently ubiquitinated substrates. Using Mascot, it was possible to 
identify proteins present in only WT HBUb MEFs or in WT HBUb and SOCS3-/- 
HBUb MEFs. The repeated identification of several proteins in different gel 
slices/mass ranges suggested that these proteins were ubiquitinated with several 
different lengths of polyubiquitin-chain. Furthermore, using the approach, a 
known SOCS3-dependently ubiquitinated substrate, FAK1, was identified. 
However, it was not detected in the subsequent MaxQuant analysis suggesting 
that it was not sufficiently enriched, perhaps due to the mode of SOCS3 
induction or incorrectly assigned by Mascot due to the method of identification 
i.e. single low scoring peptide. In contrast, other proteins such as cavin-1 were 
found using MaxQuant.  
 
Using the data returned by Mascot I was also able to manually assess the raw 
mass spectra of pyruvate kinase, which was detected in WT HBUb and SOCS3-/- 
HBUb MEFs i.e. a probable non-SOCS3 substrate, FAK1, and a potential SOCS3 
substrate, cavin-1. It was shown that these proteins were correctly assigned 
from the presence of heavy and/or light peaks and from an estimation of the 
SILAC ratio. Additionally, analysis of mass spectra found that there was no 
detectable contamination from 13C6-arginine to 
13C6-proline conversion.  
 
The aim of the project was to analyse the enrichment of proteins in a specific 
cell type facilitated by SILAC. This was not possible using Mascot.  MaxQuant was 
designed specifically for SILAC studies and so it was used as the primary tool for 
identifying potential SOCS3 substrates. Seventy-six proteins were found in the 
forward-labelled experiment whereas only 56 were found in the reverse. 
Furthermore, a large proportion (44 proteins) of these proteins was detected in 
both experiments. However, only 15 proteins were found to be significantly 
enriched (log2(normalised H/L)) in the WT HBUb MEFs.  
 
Interestingly, SOCS3 itself was not identified using either Mascot or MaxQuant. 
This might be considered surprising given that SOCS3 has been shown to be 
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degraded concomitantly with its substrates, suggesting autoubiquitination 
(11,12). As such, SOCS3 might have been expected to be isolated during TAP of 
the ubiquitinome. It may be possible that the experimental context prevented 
autoubiquitination i.e. cAMP-dependent SOCS3 induction and/or 
phosphorylation-dependent inhibition following Na3VO4/H2O2 treatment. If this is 
the case then this too would have contributed to the low numbers of proteins 
detected. Alternatively, MaxQuant and/or its quantitation parameters might also 
be responsible. For quantification purposes, a single SILAC ratio was required 
(Table 2.2, minimum ratio count= 1). Since SOCS3 was absent in the SOCS3-/- 
MEFs, no SILAC-paired peaks (clearly visible for pyruvate kinase, figure 5.3) 
would have been detected and thus not reported by MaxQuant. As such, this too 
would have contribute to the low number of proteins detected since SOCS3-
ubiquitnated substrates would only be detected in one cell type, no SILAC-paired 
peaks detected and so no SILAC ratio would be calculated or protein reported. 
This might explain why FAK1 was detected using Mascot but not MaxQuant i.e. 
undetectable SILAC pair.  However, this is not the case here, at least in the 
forward experiment, since several proteins were enriched in the presence but 
not absence of SOCS3 while others such as ubiquitin had the expected character. 
The detection of these proteins might be a consequence of using the MaxQuant 
“re-quantify” option, which forces MaxQuant to look for peaks pairs.  If peaks 
are found then they are used to quantify the missing peptide pair. However, this 
often this results in the quantification of the background, which should be very 
low. In this way, a SILAC ratio is returned which should be a good estimation of 
the different amounts of the protein in the heavy and light samples (Sara 
Zanivan, personal communication). Supporting this, if MaxQuant was presenting 
a reduced list of proteins, due to undetectable SILAC-paired peaks, since the 
Mascot search did not rely on SILAC-paired peaks, a larger protein list would 
have been expected to have been generated by Mascot. This was not the case. 
However, a better approach might have been to assess the down-regulation of 
the proteins in cell lysates in the presence or absence of SOCS3 (215). In 
contrast, this project analysed the enhancement of ubiquitination in the 
presence of SOCS3.   
 
The selection of the stable isotopes used for SILAC might have contributed to the 
small number of proteins detected. Here, both arginine and lysine imparted the 
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same mass shift of 6Da, which would make differentially-labelled, unique 
peptides with similar mass indistinguishable. However, such a scenario can be 
accounted for using MaxQuant. To increase the amount of information gained 
from MS, SILAC isotopes with different masses could have been used e.g. 
13C6
15N2-lysine (K8) and 
13C6
15N4-arginine (R10). In addition to the use of different 
SILAC isotopes, it would also have been preferable to have performed both 
experiments at the same time. Since this was not the case, the concentrated 
TAP eluates (Figure 5.2) were run on separate gels and a different number of gel 
slices/samples were prepared for each experiment. In doing so I was not able to 
use additional functionality provided by MaxQuant, “match between runs” (216). 
This allows peptide identities to be combined from each run and increase the 
number of proteins identified. However, to do so with non-equivalent gel slices 
would result in the increased generation of false positives.    
 
Through analysis of ubiquitin, forward and reverse-labelled experiments seemed 
to be of similar quality. This was because in both cases ubiquitin was identified 
with a similar number of unique peptides with high sequence coverage and low 
PEP values. Furthermore, log2-transformed normalised SILAC ratios were both 
approximately zero which likely suggests that ubiquitin/HBUb tag was expressed 
at comparable levels and that incorporation of the SILAC label was near 
complete.  However, more ubiquitin-modified lysine residues of ubiquitin were 
identified in the forward compared to the reverse-labelling experiment. This 
might be a consequence of less unique peptides of ubiquitin being analysed (10 
vs.16, Ubc, Table 5.1 vs. Table 5.2) in the reverse experiment and that PTMs can 
be lost during MS/MS fragmentation and sequencing (179).   
 
The precise identification of ubiquitin is not surprising since it is highly 
expressed in both cell types in the form of the HBUb-transgene. In fact, 
overexpression of the HBUb-transgene might also be responsible for the small 
number of proteins identified. During MS analysis, the top most abundant 
peptides are selected for MS/MS sequencing (William Mullen, personal 
communication). As such, low abundant peptides might be lost due to the over 
abundant ubiquitin peptides. MS analysis does account for this in that upon 
detection of a peptide, it is ignored for a period of ten seconds before it is 
accepted again. During this period, less abundant peptides would be analysed. 
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However, where peptides are overabundant or where contamination is an issue, 
samples can be re-analysed using exclusion tables listing these unwanted 
peptides/ions. Doing so enables low abundant peptides to be assessed thus 
increasing the data set. This type of MS run could be performed here but it was 
found to be financially unfeasible. 
 
Even so, while similar arrays of proteins were identified, the full range of 
proteins and their SILAC ratios were much lower in the reverse compared to the 
forward-labelling experiments. The detection of fewer proteins was not 
expected given that significantly more protein was used in the reverse 
experiment (400mg) compared to the forward (170mg). Furthermore, this 
translated to an enhanced total ion chromatogram (TIC, the summed ion 
intensities of each mass spectrum plotted against time) being produced for the 
reverse experiment as indicated by the normalised level (NL) (Figure 5.7, lower 
panel vs. upper panel). Moreover, extracted spectra from this TIC contained 
more complex/improved peak information (data not shown). As such, increased 
numbers of peptides and SILAC-paired peaks were available for protein 
identification and calculation of the SILAC ratio (Table 5.2 vs. Table 5.1). This 
suggests that the data generated by MaxQuant, following the reverse 
experiment, was more accurate. However, in some cases, small improvements 
were seen to dramatically affect the SILAC ratio. This is indicative of 
experimental error although the source of this error is not apparent. Reverse 
SILAC was performed to assess its impact on results. However, following analysis 
of ubiquitin, this is not thought to be the issue. Alternatively, a reduced protein 
list might have been generated due to the way MaxQuant identifies proteins. 
Peptides are assigned to all proteins in which they are found but are accepted to 
belong to proteins with the most identified peptides (Razor peptides). The use of 
these peptides for quantitation might have adversely affected the SILAC ratio. 
While quantitation was performed using unique and razor peptides, using only 
unique peptide might have lead to an improved result. Additionally, urea can 
decompose over time and when heated to produce isocyanate which 
carbamylates (H2NCO) the N-terminus of proteins or side chains of basic amino 
acids lysine and arginine. As such, fresh buffers were used and TAP beads 
washed with non-urea buffer prior to elution to avoid additional protein 
modifications. However, such a modification might still have taken place. Since 
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MaxQuant was did not consider the extra mass shift (43Da), a reduced list of 
proteins might have been generated.         
 
In conclusion, it was decided that while the reverse SILAC experiments seemed 
more accurate, they were also un-useable being of limited information. As such, 
only data from the forward-labelled experiments were further pursed. From this 
experiment, only proteins significantly elevated in the WT HBUb MEFs were 
selected for further validation (Table 5.1). This included cavin-1, which was 
identified by both Mascot (Table 5.0) and MaxQuant (Table 5.1) searches.  
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6.0 In vitro verification of candidate SOCS3 substrates 
6.1 Introduction 
In its role as a regulator of intracellular cell signalling, SOCS3 acts in part as a 
specificity factor for an E3 ubiquitin ligase. The main body of the E3 consists of 
the scaffold protein cullin5 that binds to the adaptor protein complex of 
elonginB and elonginC via its N-terminus and to the RING finger-containing 
protein Rbx2 via its C-terminus (86,194). Rbx2 binds a ubiquitin-charged E2 
conjugation protein that facilitates the transfer of ubiquitin to the substrate. 
SOCS3 binds to this larger complex via its C-terminal SOCS-box motif that 
interacts with the elonginBC heterodimer. The SOCS3-dependent E3 is thought to 
bind tyrosine-phosphorylated substrates via a centrally located SH2 domain. In 
support of this, known substrates of SOCS3 are tyrosine-phosphorylated prior 
ubiquitination (9-12). However, SOCS3 has three defined N-terminal domains, 
the KIR, ESS, and SH2 domains that cannot be ruled-out as potential sites of 
interaction. The main function of the E3 complex seems to be to regulate 
proteasomal degradation of substrates via K48-linked polyubiquitination. 
However, SOCS3 has also been implicated in the ubiquitin-mediated lysosomal 
routing and degradation of the G-CSF receptors (8,201). As such, potentially 
wider roles for SOCS3 likely exist.    
 
Global proteomics screening for SOCS3-dependently ubiquitinated targets was 
previously carried out (Section 5.0). However, due to limitations of all screening 
methodologies, a proportion a false-positives is expected and as a result, 
verification of individual substrates must be performed. Basic validation can be 
performed by demonstrating a protein-protein interaction. This can be achieved 
via several methods, including but not limited to, yeast-2-hybrid, fluorescence 
resonance energy transfer (FRET), co-immunoprecipitation, GST-pull-down, 
protein-microarray, and peptide array. Furthermore, these techniques can be 
elaborated via the addition of mutations, PTMs, and by varying conditions to 
improve stringency and selectivity.  Ultimately, protein interactions result in 
functional outcomes and investigations require function-dependent assays. In the 
case of SOCS3, substrates are expected to be degraded in a polyubiquitin-
dependent fashion via the 26S proteasome (9-12). As such, SOCS3 substrates 
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would be affected by a mass-shift detectable via immunoblotting, as well as a 
reduced half-life in the presence but not absence of SOCS3. Furthermore, the 
impact of SOCS3 should be investigated using well-characterised substrate-
dependent effects (see below). Finally, interdependency can be further 
investigated by using small molecule and peptide inhibitors as well as siRNA 
knockdown or gene knockout and rescue experiments.   
6.1.1 Cavin-1: a potential SOCS3-dependently ubiquitinated substrate 
Cavin-1 (Polymerase 1 and transcript release factor, PTRF) (217) is one of a 
family of four proteins cavin-1-4 (218). While cavin-1-3 are expressed at high 
levels in endothelial cells, adipocytes, fibroblasts, and epithelial cells, cavin-4 is 
restricted to cardiac and skeletal muscle (219,220). While a three-dimensional 
structure for any of the cavins has yet to solved, common features include 
leucine-zipper motifs, PEST domains, and phospho-regulatory sites (219,221). 
Prototypical member cavin-1 is 392 amino acids in length, giving a predicted 
mass of 43kDa. However, following SDS-PAGE fractionation it is commonly 
detected at 50-60kDa (219), such a shift is characteristic of multiple PTMs. 
Furthermore, five truncated isoforms of 47, 43, 30, 25, and 15 kDa are 
commonly detected (219,222). Aboulaich et al (222) showed that while cavin-1 
contains three PEST sites, these domains could only be detected in the full-
length but not truncated forms of cavin-1 suggesting that the latter are the 
consequence of proteolytic-mediated degradation.   While cavin-1 has previously 
been shown to function within the nucleus as a polymerase I transcript release 
factor (223), it also abundant on the cytosolic face of the plasma membrane 
where it functions as an adaptor protein involved in the formation of caveolae, 
flask shaped invaginations within the plasma membrane. Cavin-1 aggregates into 
large oligomeric complexes along with other family members (219). It is thought 
that this complex makes several weak interactions with phosphatidylserine (PS) 
thus strengthening its association with the components of caveolae at the 
plasma membrane. As such, altering the lipid environment might regulate the 
association of the cavin complex with the PM. Caveolae are involved in 
endocytosis, cholesterol homeostasis, and sequestration of cell signalling 
mediators for efficient signalling but also for signal ablation, as reviewed in 
(224). Interestingly, caveolae sequester several PEST domain-containing 
proteins, including cavin-1 and all its truncated forms (222). 
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Figure 6.0: Cavin-1, caveolin-1, and the formation of caveolae  
A. Caveolae are 50-100nm flask shaped invaginations within the plasma 
membrane (PM). Adapted with permission from (218). Caveolin-1 (Cav-1), an 
integral membrane protein that forms the main structural component of 
caveolae, is sequestered into caveolae by cavin-1, a peripheral membrane 
protein located on the cytoplasmic face of the PM. Caveolin-2, which is 
dependent on caveolin-1 for PM-localisation, forms a heterodimer with caveolin-
1 and supports the structural and scaffold role of caveolin-1.  Cavin-2 is thought 
to sequester cavin-1 to the plasma membrane and modulate caveolae structure 
since overexpression of cavin-2 results in the formation of elongated caveolae 
(225). Cavin-3 drives vesicle formation and is involved intracellular microtubule 
trafficking (225).  B. Domain structure of cavin-1. PEST, Pro-Glu-Ser-Thr-rich 
regions; LR, Leu rich region; NLS, nuclear localisation sequence.  Adapted with 
permission from (219). 
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However, the truncated forms are not detected in the nucleus or cytosol 
suggesting that proteolysis may occur in situ.  
 
Caveolins are a family of three proteins (caveolin-1-3) which serve as the main 
structural components of caveolae. As such, ectopic expression of caveolin-1 or 
caveolin-3 is usually sufficient to form caveolae (226). Whereas caveolin-1 and 2 
are widely expressed, caveolin-3 is limited to striated muscle (224). Cavin-1 is 
thought to sequester caveolin-1 to caveolae and regulates location and stability 
of caveolin-1 by preventing lateral motion and lysosomal degradation (227). 
Expression of cavin-1 and caveolin-1 are tightly linked such that overexpression 
of cavin-1 results in a concomitant increase in caveolin-1. Genetic deletion of 
cavin-1 in mice leads to impaired caveolae formation and loss of stability of all 
three caveolins (226). As such, it could be hypothesised that any effect on cavin-
1 expression might similarly affect caveolin-1.  
 
Caveolin-1 is critical in regulating inflammatory signalling (218), regulates 
vascular permeability via sequestration and inhibition of eNOS and its 
dysregulation has been linked to enhanced AKT and ERK1/2 signalling resulting in 
several cardiovascular phenotypes (228-230). For example, while caveolin-1 KO 
mice models are viable, they develop pulmonary hypertension and cardiac 
hypertrophy (225). However, it is not known if the same is true for cavin-1 KO 
mice, which have a lipodystrophic phenotype i.e. high circulating triglyceride 
levels, reduced adipose tissue mass, glucose intolerance, and hyperinsulinaemia 
(226). This phenotype is believed to stem from the impaired triglyceride uptake 
and storage by adipocytes due to the lack of caveolae (226).  Caveolin-1 also 
enhances COX-2 degradation and controls integrin signalling (231-233). 
Interestingly, caveolin-1 has been described as a novel regulator of cytokine 
signalling due to its ability to inhibit prolactin-induced STAT5 signalling via a 
conserved pseudo-kinase domain (234) similar to that of SOCS1/3. Caveolin-1 has 
also been shown to regulate innate immunity by being protective against 
infection by maintaining a balance between host response and cytokine-
dependent tissue damage (235). It was found that compared to WT mice, 
caveolin-1 knockout mice infected with the respiratory pathogen Pseudomonas 
aeruginosa had elevated levels of inflammatory cytokines (IL6, TNFα) as a result 
of sustained JAK/STAT and NFκB signalling within lung tissue (235). Furthermore, 
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increased ROS production was noted along with decreased survival and 
phagocytic ability of alveolar macrophages (235). Additionally, in adipocytes, 
caveolin-1-binding is thought necessary for full activation of the insulin receptor 
β while tyrosine phosphorylation of caveolin-1 results in endocytosis of the 
activated insulin receptor (236). In contrast to its protective effects, caveolin-
1/caveolae are thought to regulate the transcytosis of LDL in blood vessels 
resulting in the accumulation of pro-atherogenic lipids in the sub-endothelial 
space, which is important for lesion formation (Section 1.13) (237). As such, loss 
of caveolin-1 has been suggested to be protective against atherosclerosis (237). 
Recently, cavin-1 has been found to be downregulated, due to epigenetic 
silencing, in breast cancer (238). Since cavin-1 is crucial for caveolae formation, 
it is thought that it might function as a tumour suppressor by attenuating 
downstream signalling events (238). Furthermore, cavin-1 has also been found to 
be downregulated in both adenocarcinoma and squamous cell carcinoma 
compared to healthy tissue (239). The same has previously been found in 
prostate cancer cell lines PC3 and LNCaP (240). Moreover, expression of cavin-1 
has been demonstrated to inhibit cell migration in PC3, DU145, and NIH-3T3 cells 
and that loss of cavin-1 leads to increased migration and matrix 
metalloprotease-9 production (241). This suggests that cavin-1 might be 
important in the development and progression of several forms of cancer.  
 
Caveolin-1 and presumably cavin-1 might therefore be critical in cardiovascular 
disease, diabetes, breast cancer, and inflammation. Furthermore, cAMP-induced 
SOCS3 might serve to negatively regulate several pro-inflammatory signalling 
pathways. As such, cavin-1 is an ideal candidate for SOCS3-dependent 
regulation. However, SOCS3 is up-regulated in several chronic inflammatory 
disorders and obesity (159). In such a case, in might be hypothesised that levels 
of cavin-1 and caveolin-1 would be reduced, resulting in an up-regulation of 
eNOS and loss of insulin signalling and as such, contribute to a metabolic 
syndrome. However, loss of caveolin-1 might be protective. Effectively targeting 
SOCS3 levels might therefore be therapeutically beneficial.  
6.1.2 Hsc70: a potential SOCS3-dependently ubiquitinated substrate 
Heat shock proteins (HSPs) are well-defined protein chaperones that upon 
induction e.g. by heat, ischemia, or oxidative stress, bind unfolded proteins to 
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improve stability or mark them for degradation via the ubiquitin-proteasome 
pathway or autophagy. Furthermore, HSPs are also involved in protein synthesis 
and trafficking (242) and other roles are increasingly being found.  
 
Hsc70, a member of the largest heat shock protein family Hsp70, is 
constitutively and ubiquitously expressed and has been linked to EC health and 
homeostasis. Hsc70 knockout is embryonic lethal and Shiota et al (243) showed 
that siRNA-mediated knock-down results in ~40% EC cell death over 48 hours. 
Shiota et al also demonstrated the importance of Hsc70 as a regulator of 
angiogenesis via its action upon the PI3K/Akt signalling pathway. Inhibition (non-
specific) or siRNA-mediated knockdown of Hsc70 was able to block VEGF-
mediated HUVEC cell migration by inhibition of PI3K transcription, which blocked 
phosphorylation of Akt and its downstream effector eNOS. Furthermore, siRNA 
silencing of Hsc70 blocked EC migration and tube formation in vitro (243). As 
such, Hsc70 might be important in recovery from vascular insufficiency 
(ischaemia) and tumourigenesis.  A further role for Hsc70 in tumourigenesis was 
described in a study by Ding et al (244) where it was found that Hsc70 regulates 
agonist-induced (CXCL12) endocytosis of the chemokine receptor CXCR4 in 
HEK293 cells. Furthermore, siRNA knockdown of Hsc70 reduced endocytosis of 
endogenous CXCR4 and inhibited CXCL12-induced chemotaxis in U87 glioma 
cells. Thus, Hsc70 may similarly regulate other receptors (244,245).  If Hsc70 is a 
potential SOCS3-dependently ubiquitinated target, then overexpression of SOCS3 
might prevent metastasis of these neural tumour cells. In some cancers, loss of 
SOCS3 due to promoter hypermethylation can lead to uncontrolled IL6 signalling 
which can support tumourigenesis due the proliferative and anti-apoptotic 
effects of IL6 (246). Regulation of Hsc70 by SOCS3 might therefore be a novel 
mechanism by which a loss of SOCS3 contributes to tumourigenesis. 
6.1.3 Experimental strategy 
SOCS3 has been demonstrated to regulate the polyubiquitination and subsequent 
degradation of several proteins (9-12). As such, proteins identified in this study 
via a proteomics screen are also hypothesised to be similarly regulated. A 
prerequisite for substrate polyubiquitination is an interaction with SOCS3. Co-
immunoprecipitation was used as the preliminary assay to assess protein-protein 
interactions. 
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Prior to SOCS3-substrate interaction, substrates are expected to be tyrosine-
phosphorylated (9-12). While the role of tyrosine-phosphorylation can be 
investigated during co-immunoprecipitation experiments, peptide arrays enable 
the identification of important residues and protein domains. Furthermore, 
peptides can be fabricated with or without PTMs and thus interactions are 
unaffected by either basal phosphorylation or unanticipated modifications.  
SOCS3 binds tyrosine-phosphorylated substrates via a well-defined SH2-domain 
with the consensus binding sequence (S/A/V/Y/F) – Φ – (V/I/L) – Φ – (H/V/I/Y), 
where Φ is a hydrophobic residue (78). Furthermore, tyrosine-phosphorylated 
residues of potential substrates are available online at protein databases such as 
phosphosite.org.  While these sites might not be comprehensive, they do act as a 
starting point.  Furthermore, the dependency on other protein domains can be 
investigated using full-length peptide arrays of both SOCS3 and any candidate 
substrate.  Peptide arrays are commonly fabricated on-site by the Baillie 
laboratory. As such, they offer an efficient and cost effective technique to 
assess SOCS3-substrate interactions in vitro. 
 
Until recently, proteasome-mediated degradation was thought to be a K48-
polyubiquitin-dependent process (137). However, evidence now suggests that all 
non-K63 polyubiquitin chains might contribute to proteasomal degradation 
(138,247). Nevertheless, K48-polyubiquitin chains are the most abundant form of 
polyubiquitin-chain linkage in mammals (247) and so might serve as the major 
signal that drives proteasomal degradation. As such, isolation of 
polyubiquitinated candidate substrates in the presence but not absence of SOCS3 
would support the substrate as a target of SOCS3. This could be achieved via in 
vitro ubiquitination assays using purified proteins. Using this technique, results 
would be unaffected by non-SOCS3-dependent E3 ligases or other modifying 
proteins.  Others (11) have successfully performed ubiquitination reactions in 
situ following transfection and overexpression of the necessary components. In 
both cases, isolation of the substrate or ubiquitinome can be performed via 
immunoprecipitation. Given the availability of cDNA constructs, the latter 
technique was preferred.  
 
While immunoprecipitation might detect enhanced ubiquitination in the 
presence of SOCS3, polyubiquitin-chain specificity directs functional outcome. In 
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this case, SOCS3 substrates are predicted to be degraded. The presence of K48-
linked ubiquitination can be assessed using polyubiquitin-chain-specific 
antibodies. However, the definitive test is to show degradation of the substrate 
in the presence but not absence of SOCS3. I decided to perform this assay in situ 
following transfection of the relevant components into WT HEK293 cells. 
Rescuing degradation via inhibition of the proteasome would add further 
supporting evidence to the hypothesis.      
 
Using these techniques, I aimed to show that potential substrates not only 
interacted with SOCS3 but also identify which protein domains and/or residues 
were important. Furthermore, I aimed to show that following interaction, 
substrates were subsequently ubiquitinated in a SOCS3-dependent manner. 
Additionally, the availability of cDNA constructs meant that only a proportion of 
the potential SOCS3 substrates were assessed (Table 5.1, light grey/dotted 
boxes). However, only a selection is presented here including cavin-1 and Hsc70 
(Table 5.1, light grey boxes). 
6.2 Results and discussion 
6.2.1 Optimisation of experimental conditions  
6.2.1.1 Optimisation of co-immunoprecipitation assay 
SOCS3 substrate verification was initially performed using a co-
immunoprecipitation assay. If potential SOCS3 substrates interact with SOCS3, 
then SOCS3 is expected to specifically isolate the substrate from a complex 
mixture of proteins present in cell lysates. Antibody-antigen complexes can have 
strong binding affinities although the range of affinities can be wide (Kd=10
-5 to 
10-12M). However, due to the transient nature of many intracellular protein-
protein interactions, their binding affinities might be lower. As such, 
experimental conditions must be optimised to support the detection of these 
protein interactions. Given that SOCS3-substrate interactions are the only 
interactions being investigated, repeated manipulation of co-
immunoprecipitation conditions is not expected, a single condition should be 
sufficient. To assess selection of co-immunoprecipitation conditions, the SOCS-
box-dependent interaction between SOCS3 and the elonginBC-cullin5 scaffold 
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(Kd=10
-7M) (86) was used as a model system. Furthermore, specificity of this 
interaction was tested using a SOCS3-L189A SOCS-box mutant that cannot bind 
components of the E3 ligase (194). Importantly, SOCS3 is expected to interact 
with SOCS3-dependently ubiquitinated substrates via its SH2 domain (9-12). As a 
more stringent examination of reaction conditions, the interaction between 
SOCS3 and FAK1 (10), a known SOCS3-dependently ubiquitinated substrate was 
assessed. It was thought that if SOCS3 could precipitate all proteins under a 
single experimental condition then it should similarly precipitate candidate 
substrates.  
 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, 
cullin5, elonginB-myc, and elonginC cDNA constructs in the indicated 
combinations (Figure 6.1). To evaluate the impact of tyrosine phosphorylation on 
protein-protein interactions, cells were treated with or without Na3VO4 (1mM) 
for 2 hours and H2O2 (0.2mM) for the final 15 minutes prior to harvesting. Soluble 
protein lysates were prepared and co-immunoprecipitation performed as 
described (Section 2.2.13) using pre-conjugated Flag M2 agarose beads. 
Recovered protein complexes were fractionated by SDS-PAGE and analysed by 
immunoblotting.  
 
ElonginB and cullin5 were precipitated in the presence but not absence of SOCS3 
(Figure 6.1, panel F/G lane 2 vs. 3 and 5 vs. 6) thus confirming the suitability of 
the conditions for this interaction. The interaction of SOCS3 with E3 ligase 
components has been reported to be disrupted by JAK2-mediated tyrosine 
phosphorylation at Y204 and Y221 within the SOCS-box  and the subsequent 
disruption was found to have a destabilising effect on SOCS3 (100). Importantly, 
cullin5 and elonginB were precipitated at comparable levels before and after 
PTP inhibition suggesting that elevating global levels of tyrosine-phosphorylation 
in this manner does not affect formation of the E3 ligase complex. Furthermore, 
no impact on SOCS3 expression levels was detected. Interestingly, levels of 
SOCS3 are reduced when not co-expressed with the E3 components suggesting 
that this interaction is stabilising (Figure 6.1, panel B/E lane 1 vs. 3 and 4 vs. 6).  
 
To demonstrate the specificity of the SOCS3-elonginB-cullin5 interaction, the 
previous experiment was then repeated using the SOCS3-L189A SOCS-box 
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mutant, which has been shown to be defective in binding E3 scaffold proteins 
(194). PTP inhibitors were not used here due to the previous experiment showing 
them to be redundant. SOCS3 but not SOCS3-L189A precipitated elonginB and 
cullin5 indicating the specificity of the SOCS3-E3 interaction (Figure 6.2, panel 
D/E, lane 4 vs. 5). Furthermore, this data confirmed that conditions used for co-
immunoprecipitation were adequate to preserve interactions between these 
proteins.  Although cullin5 was detected in immunoprecipitates, expression in 
cell lysates was masked by non-specific bands and was therefore not presented 
here.  
 
Co-immunoprecipitation conditions were more stringently tested by repeating 
the previous experiments using FAK1, a known SOCS3-dependently ubiquitinated 
substrate(10). FAK1 was precipitated to high levels in the presence but not 
absence of SOCS3 (Figure 6.3, panel E, lane 1 vs. 3). Although the cells were not 
treated with PTP inhibitors, probing with anti-pY antibody detected a strong 
band with the same mass as that predicted for FAK1 (115kDa) (Figure 6.3, panel 
A) suggesting that basal levels of tyrosine phosphorylation are sufficient for the 
interaction. Furthermore, the absence of this band in the singly transfected cells 
suggests that interaction with SOCS3 might preserve tyrosine phosphorylation 
and prolong the FAK1-SOCS3 interaction.  
 
These data confirm that co-immunoprecipitation conditions are sufficient to 
preserve the protein-protein interactions tested. These conditions were then 
used to demonstrate an interaction between SOCS3 and its candidate substrates.   
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Figure 6.1: The impact on tyrosine phosphorylation on the interaction 
between SOCS3 and the E3 scaffold proteins elonginB and cullin5 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, cullin5, 
elonginB-myc, and elonginC cDNA constructs in the indicated combinations. Soluble 
protein lysates were prepared and co-immunoprecipitation performed as described 
(Section 2.2.13) using 30µl of 50% (v/v) slurry of pre-conjugated Flag M2 agarose beads. 
Recovered protein complexes were fractionated by SDS-PAGE and analysed by 
immunoblotting using anti-SOCS3 (Panel B/E), anti-cullin5 (Panel G), and anti-myc 
antibody (Panel C/F). Global tyrosine phosphorylation was assessed using anti-
phosphotyrosine antibody (4G10) (Panel A) while GAPDH was used as a loading control 
(Panel D). 
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Figure 6.2: The impact of the SOCS3-L189A SOCS-box mutation on its 
interaction with the E3 ligase components elonginB and cullin5 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, SOCS3-
L189A-Flag, cullin5, elonginB-myc, and elonginC cDNA constructs in the indicated 
combinations. Soluble protein lysates were prepared and co-immunoprecipitation 
performed as described (Section 2.2.13) using 30µl of 50% (v/v) slurry of pre-conjugated 
Flag M2 agarose beads. Recovered protein complexes were fractionated by SDS-PAGE 
and analysed by immunoblotting using anti-SOCS3 (Panel A/C), anti-cullin5 (Panel E), 
and anti-myc antibody (Panel B/D).  
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Figure 6.3: SOCS3 precipitates known SOCS3-dependently ubiquitinated 
substrate FAK1 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag and FAK1-
myc cDNA constructs in the indicated combinations. Soluble protein lysates were 
prepared and co-immunoprecipitation performed as described (Section 2.2.13) using 
30µl of 50% (v/v) slurry of pre-conjugated Flag M2 agarose beads. Recovered protein 
complexes were fractionated by SDS-PAGE and analysed by immunoblotting using anti-
SOCS3 (Panel C/F) and anti-myc antibody (Panel B/E). Global tyrosine phosphorylation 
was assessed using anti-phosphotyrosine antibody (4G10) (Panel A) while GAPDH was 
used as a loading control (Panel D). 
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6.2.1.2 Optimisation of denatured immunoprecipitation assay 
SOCS3 is expected to ubiquitinate its candidate substrates. Therefore, an 
enhanced ubiquitin signal is expected in the presence but not absence of SOCS3 
following isolation of the ubiquitinome or candidate substrate via 
immunoprecipitation. To reduce background from ubiquitin-interacting proteins, 
candidate-binding proteins, and preserve ubiquitin chains from DUBs, 
immunoprecipitation will be performed on denatured cell lysates. Furthermore, 
isolation of the ubiquitinome will be facilitated by the use of HA-tagged 
ubiquitin (Ub-HA) and pre-conjugated anti-HA agarose beads. Prior to 
experimentation, the expression of Ub-HA was assessed. Furthermore, the 
volume of anti-HA agarose beads were optimised for maximum recovery of Ub-
HA-modified protein.    
 
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA or GFP 
cDNA constructs using the indicated concentrations (Figure 6.4). Soluble protein 
lysates were then either directly fractionated by SDS-PAGE (Figure 6.4, left 
panel) or denatured immunoprecipitation was performed as described (Section 
2.2.14) (Figure 6.4, right panel). Captured proteins were fractionated by SDS-
PAGE and recovery or expression of ubiquitinated proteins analysed by 
immunoblotting. 
 
Ub-HA was highly expressed in a dose-dependent manner with 4µg per 6cm 
diameter dish giving the strongest signal (Figure 6.4, panel A). However, Ub-HA 
was significantly expressed compared to the control using a lower concentration 
of 2µg. Recovery of Ub-HA using anti-HA agarose beads increased in a dose-
dependent manner with no improvement gained above 30µl (50% (v/v) slurry) 
(Figure 6.4, Panel C). These data suggest that 2-4µg per 6cm diameter dish of 
cDNA construct is sufficient to express detectable Ub-HA and that 30µl (50% 
(v/v) anti-HA agarose beads is optimal for recovery of Ub-UA-tagged proteins.   
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Figure 6.4: Expression of Ub-HA and optimisation of denaturing co-
immunoprecipitation 
HEK293 cells were transfected as described (Section 2.2.12) using the indicated 
amounts of Ub-HA or GFP cDNA constructs per dish. The ubiquitinome was preserved by 
treating with MG132 for 2 hours prior to harvesting. Samples were equalised before 
fractionated by SDS-PAGE and expression of the tagged moieties assessed by 
immunoblotting using an anti-HA antibody (Panel A). GAPDH was used as a loading 
control (Panel B). Additionally, denatured immunoprecipitation was performed as 
described (Section 2.2.14) using 30µl of 50% slurry (v/v) monoclonal (HA-7) anti-HA 
agarose beads or as a control, 30µl of 50% (v/v) slurry of pre-conjugated Flag M2 
agarose beads. Captured ubiquitinated proteins were fractionated by SDS-PAGE and 
recovery assessed by immunoblotting using anti-HA antibody (Panel C). 
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6.2.2 A SOCS3-Hsc70 interaction could not be confirmed via co-
immunoprecipitation 
Hsc70 (Section 6.1.2) was identified in the proteomics screen (Section 5.0) with 
a log2 normalised SILAC ratio of 0.67 (Table 5.1). Although not significant, a 
miscommunication led it being verified here. Optimised experimental conditions 
for co-immunoprecipitation (Section 6.2.1.1) were used to assess an interaction 
between Hsc70 and SOCS3. If Hsc70 is a substrate of SOCS3, then Hsc70 is 
expected to be precipitated in the presence but not absence of SOCS3.   
 
HEK293 cells were transfected as previously described (Section 2.2.12) with 
SOCS3-Flag, Hsc70-myc, Hsc70-GFP, and FAK1-myc cDNA constructs in the 
indicated combinations (Figure 6.5). Tyrosine phosphorylation was preserved by 
treating cells with Na3VO4 (1mM) for 2 hours and H2O2 (0.2mM) for the final 15 
minutes prior to harvesting. Soluble protein lysates were prepared and co-
immunoprecipitation performed as described (Section 2.2.13) using 40µl of 50% 
(v/v) slurry of protein G Sepharose beads and 10µl of anti-SOCS3 antibody. 
Recovered protein complexes were fractionated by SDS-PAGE and analysed by 
immunoblotting.  
 
While Hsc70 was precipitated in the presence of SOCS3, it was also precipitated 
in its absence (Figure 6.5, H/I lanes 5 vs. 6 and 7 vs. 8). This result was 
replicated using an anti-Flag antibody (data not shown). This suggests the 
isolation of Hsc70 was not due to cross-reactivity of the precipitating antibody 
but because of Hsc70 binding non-specifically to the protein G Sepharose beads. 
As such, performing the reciprocal experiment i.e. using GFP, myc, or Hsc70–
specific precipitating antibodies would also be vulnerable to the same effect. It 
was decided that a peptide array might provide a more definitive result (Section 
6.2.5). As such, no further co-immunoprecipitation experiments were performed 
using Hsc70. 
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Figure 6.5: A SOCS3-Hsc70 interaction could not be confirmed via co-
immunoprecipitation 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, Hsc70-
myc, Hsc70-GFP, and FAK1 cDNA constructs in the indicated combinations. Tyrosine 
phosphorylation was preserved by treating cells with Na3VO4 (1mM) for 2 hours and H2O2 
(0.2mM) for the final 15 minutes prior to harvesting. Soluble protein lysates were 
prepared and co-immunoprecipitation performed as described (Section 2.2.13) using 
40µl of 50% (v/v) slurry of protein G Sepharose beads and 10µl of anti-SOCS3 antibody. 
Recovered protein complexes were fractionated by SDS-PAGE and precipitation analysed 
by immunoblotting using anti-GFP (Panel C/I), anti-myc (Panel B/D/G/H), and anti-Flag 
antibody (Panel J). GAPDH was used as a loading control (Panel F). 
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Figure 6.5: A SOCS3-Hsc70 interaction could not be confirmed via co-
immunoprecipitation
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6.2.3 SOCS3 can precipitate cavin-1 but not Abi2 
Cavin-1 (Section 6.1.1) and Abi2 were identified in the proteomics screen 
(Section 5.0) with significant log2 normalised SILAC ratios of 1.37 and 1.17 
respectively (Table 5.1). Optimised experimental conditions for co-
immunoprecipitation (Section 6.2.1.1) were used to assess an interaction 
between cavin-1 or Abi2 and SOCS3.  
 
HEK293 cells transfected as previously described (Section 2.2.12) with SOCS3-
Flag, Abi2-GFP, cavin-1-GFP cDNA constructs in the indicated combinations 
(Figure 6.6). To evaluate the impact of tyrosine phosphorylation on protein-
protein interactions, cells were treated with or without Na3VO4 (1mM) for 2 
hours and H2O2 (0.2mM) for the final 15 minutes prior to harvesting. Soluble 
protein lysates were prepared and co-immunoprecipitation performed as 
described (Section 2.2.13) using 40µl of 50% (v/v) slurry of protein G Sepharose 
beads and 10µl of anti-SOCS3 antibody. Recovered protein complexes were 
fractionated by SDS-PAGE and assessed by immunoblotting. 
 
Cavin-1 was precipitated in the presence but not absence of SOCS3 (Figure 6.6, 
panel E, lane 7 vs. 8) whereas Abi2 could not be precipitated (Figure 6.6, panel 
E, lane 5 vs. 6). While a weak signal for cavin-1 was detected in the absence of 
SOCS3, this signal is significantly enhanced in its presence. Furthermore, this 
enhancement is not due to variations in cavin-1 expression (Figure 6.6, panel B, 
lane 7 vs. 8). This data suggest that cavin-1 specifically interacts with SOCS3. 
Interestingly, cavin-1 is detected as three separate bands (Figure 6.6, panel E, 
lane 2) but only the top bands seems to be precipitated. The lower bands might 
be proteolysed fragments that have been previously detected in caveolae by 
other groups (219,222) suggesting that only full-length cavin-1 interacts with 
SOCS3.       
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Figure 6.6:SOCS3 precipitates potential substrate cavin-1 but not Abi2 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, Abi2-GFP, 
cavin-1-GFP cDNA constructs in the indicated combinations. Tyrosine phosphorylation 
was preserved by treating cells with Na3VO4 (1mM) for 2 hours and H2O2 (0.2mM) for the 
final 15 minutes prior to harvesting. Soluble protein lysates were prepared and co-
immunoprecipitation performed as described (Section 2.2.13)  using 40µl of 50% (v/v) 
slurry of protein G Sepharose beads and 10µl of anti-SOCS3 antibody. Recovered protein 
complexes were fractionated by SDS-PAGE and precipitation analysed by 
immunoblotting using anti-GFP (Pane B/E, arrow indicates cavin-1) and anti-Flag 
antibody (Panel C/F, arrow indicates SOCS3). Global tyrosine phosphorylation was 
assessed using anti-phosphotyrosine antibody (4G10) (Panel A) while GAPDH was used as 
a loading control (Panel D). 
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SOCS3 substrates are predicted to be tyrosine-phosphorylated prior to 
interacting with the SOCS3-SH2 domain. To further explore the dependence on 
the SOCS3-cavin-1 interaction on tyrosine-phosphorylation, the previous 
experiment was repeated by reducing basal levels of tyrosine-phosphorylation by 
incubating in cells in serum free medium overnight prior to treating with or 
without PTP inhibitors (Figure 6.7).  
 
Although cavin-1 was precipitated in the presence and absence of PTP inhibitors 
(Figure 6.7, panel E, lane 5 vs. 7), a much weaker signal was detected following 
treatment with PTP inhibitors. Although Na3VO4 specifically targets PTPs, H2O2 
also has off-target effects such as acting as an insulin mimetic (204).  In this role 
it has been shown to increase phosphorylation of serine residues (248). However, 
since its effects have not been fully characterised, its effects on global 
phosphorylation cannot be predicted. As such, it is possible that serine, 
threonine, or tyrosine-phosphorylation of either SOCS3 or cavin-1 may be 
responsible for disrupting the interaction. Interestingly, these same disrupting 
conditions were used to isolate cavin-1 during the proteomics screen (Section 
5.0). In this case, a weak signal might have been compensated for by 
ubiquitination and stabilisation of cavin-1 following MG132-mediated proteasome 
inhibition.  
 
All known SOCS3-dependently ubiquitinated substrates are tyrosine-
phosphorylated prior to interacting and being ubiquitinated by SOCS3 (9-12). As 
such, the SOCS3-SH2 domain was predicted to be involved in binding cavn-1. 
However, it might bind at other locations such as the KIR, ESS, SOCS-box, or at a 
novel uncharacterised site. The SOCS3 SOCS-box is an unstructured domain that 
becomes organised following binding, via a mainly hydrophobic interaction, to 
the E3 components elonginB and elonginC (77). As such, this trimer must be 
formed prior to binding cullin5 (77). SOCS3-L189A carries a mutation within the 
most conserved domain within the SOCS family, the B/C-box. It is thought that if 
SOCS3-L189A cannot bind elonginBC then the region will remain unstructured 
and should be unable to interact with other proteins including cavin-1. Due to 
the availability of the SOCS3-L189A mutant, it was used to assess whether the 
SOCS-box had a role in the SOCS3-cavin-1 interaction (Figure 6.8).  Thus, the 
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previous co-immunoprecipitation experiment was repeated to compare 
precipitation of cavin-1 in the presence of WT or the SOCS-box mutant.    
 
Cavin-1 was precipitated equivalently with both WT and SOCS3-L189A mutant 
suggesting that the SOCS-box might not be involved in binding cavin-1 (Figure 
6.8). However, this does not completely rule-out this domain since the mutant 
has only been characterised in relation to the elonginBC interaction.  
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Figure 6.7: Tyrosine-phosphorylation inhibits the cavin-1-SOCS3 interaction 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, cavin-1-
GFP cDNA constructs in the indicated combinations. Cells were treated with or without 
Na3VO4 (1mM) for 2 hours and H2O2 (0.2mM) for the final 15 minutes prior to harvesting. 
Soluble protein lysates were prepared and co-immunoprecipitation performed as 
described (Section 2.2.13) using 40µl of 50% (v/v) slurry of protein G Sepharose beads 
and 10µl of anti-SOCS3 antibody. Recovered protein complexes were fractionated by 
SDS-PAGE and precipitation assessed by immunoblotting using anti-GFP (Panel B/E) and 
anti-Flag antibody (Panel C/F/G, arrow indicates SOCS3). Global tyrosine 
phosphorylation was assessed using anti-phosphotyrosine antibody (4G10) (Panel A) 
while GAPDH was used as a loading control (Panel D). 
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Figure 6.8: SOCS3 and the SOCS3 L189A SOCS-Box mutant precipitates 
cavin-1 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, SOCS3-
L189A-Flag, and cavin-1-GFP cDNA constructs in the indicated combinations. Soluble 
protein lysates were prepared and co-immunoprecipitation performed as described 
(Section 2.2.13) using 40µl of 50% (v/v) slurry of protein G Sepharose beads and 10µl of 
anti-SOCS3 antibody. Recovered protein complexes were fractionated by SDS-PAGE and 
precipitation assessed by immunoblotting using anti-GFP (Panel A/D) and anti-Flag 
antibody (Panel B/E1/2, arrow indicates SOCS3). GAPDH was used as a loading control 
(Panel C).  
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6.2.4 Cavin-1 ubiquitination is enriched in the presence of SOCS3 
SOCS3 is predicted to attach K48-linked polyubiquitin chains to its substrates. As 
such, an increased ubiquitin signal is expected in the presence but not absence 
of SOCS3 following the isolation of the ubiquitinome or candidate substrate by 
immunoprecipitation. To reduce background and preserve polyubiquitin chains 
immunoprecipitation was performed under denatured conditions.     
 
HEK293 cells were transfected as described (Section 2.2.12) with the relevant 
cDNA constructs in the indicated combinations (Figures 6.9-6.13). Soluble 
protein lysates were prepared and denatured immunoprecipitation performed as 
described (Section 2.2.14) (Figures 6.9-6.13). Captured proteins were 
fractionated by SDS-PAGE analysed by immunoblotting. 
 
Following isolation of the ubiquitinome, cavin-1 appears to be highly enriched in 
the presence but not absence of SOCS3 and components of the E3 ligase (Figure 
6.9, panel A/B, lane 6 vs.8, and arrow). Previous data (Figure 6.6, panel E, lane 
2 and 8) showed that cavin-1 was detected as three bands while only the top 
band was precipitated.  However, in this case the signal relating to the bottom 
band is enhanced while other bands are similarly precipitated. As such, this new 
data suggests that SOCS3 can bind full-length and fragmented cavin-1. However, 
there seems to be little difference between these lanes in the levels of high 
molecular weight ubiquitin signal expected of polyubiquitination (small 
differences are indicated by brackets 1 and 3).  This suggests that cavin-1 might 
be mono-ubiquitinated by SOCS3 and polyubiquitinated via another route. 
Alternatively, since cavin-1 is not greatly enriched, the ubiquitin signal might be 
too weak to produce a visible difference. The band (~75kDa) present in the 
control (Figure 6.9, panel A/B, lane 7) is assumed to be non-specific since an 
anti-Flag antibody was used during precipitation. While this antibody would have 
precipitated SOCS3-Flag, the use of denaturing conditions would have prevented 
the isolation of SOCS3-bound proteins.         
 
The same enhancement of cavin-1 was seen with the reciprocal co-
immunoprecipitation experiment (Figure 6.10, panel A/B, lane 5 vs. 7, arrows). 
However, in this case an enhanced polyubiquitin signal was detected in the high 
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molecular faction (Figure 6.10, lane 5 vs. lane 7, bracket 1) in the cavin-1-only 
transfected cells. Interestingly, in the presence of the SOCS3-E3 complex, an 
enhanced polyubiquitin signal was detected around 75kDa i.e. the expected 
mass of cavin-1 (Figure 6.10, lane 5 vs. lane 7, bracket 2). The same variation in 
the ubiquitin smear was seen to a lesser extent previously (Figure 6.9, panel 
A/B, lanes 6 vs. 8, brackets 1-4). It therefore seems that in the presence of 
SOCS3, the ubiquitin smear relating to cavin-1 is shifted to a lower molecular 
fraction. This suggests that SOCS3 might somehow inhibit or negatively regulate 
polyubiquitination of cavin-1, possibly by out-competing other E3 ligases. Given 
that only low molecular weight ubiquitination is enhanced in the presence of the 
SOCS3-E3, cavin-1 might be mono-/multi-ubiquitinated. SOCS3 might therefore 
protect or preferentially ubiquitinate cavin-1 leading to this switch in the 
ubiquitin smear.  As a negative control, the impact of the SOCS3-L189A SOCS-box 
mutant on cavin-1 ubiquitination was assessed.  However, no difference was 
seen in the ubiquitination of cavin-1 compared to the WT (Figure 6.10, panel 
A/B, lanes 7 and 8).  As such, this result supports the role of SOCS3 in protecting 
a certain ubiquitinated form of cavin-1.  
 
The strong smear detected in the control (Figure 6.10, panel A, lane 6) is due to 
the use of an anti-Flag antibody as the control, which resulted in the 
precipitation of ubiquitinated SOCS3-Flag. The same result should also have been 
expected in the previous experiment (Figure 6.9, panel A, lane 7). However, 
given the varying efficiencies of antibodies to precipitate their target (anti-
cavin-1 being less efficient than anti-HA), different exposure times were 
necessary which resulted in the overexposure of the control (Figure 6.10, panel 
A, lane 6). To avoid precipitation of SOCS3, all future experiments employed an 
unrelated antibody, myosin phosphatase-targeting subunit 1 (MYPT1) as the 
control.     
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Figure 6.9: Cavin-1 ubiquitination is enriched in the presence of SOCS3  
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA plus SOCS3-
Flag, cavin-1-GFP, and E3 ligase components cullin5, elonginB-myc, elonginC, and Rbx1-
myc cDNA constructs in the indicated combinations. Soluble protein lysates were 
prepared and denatured immunoprecipitation performed as described (Section 2.2.14). 
Captured ubiquitinated proteins were fractionated by SDS-PAGE and recovery assessed 
by immunoblotting using anti-GFP (Panel A) and anti-HA antibody (Panel B). Where 
possible, protein expression was assessed using anti-SOCS3 (Panel C) and anti-myc 
antibody (Panel D). GAPDH was used as a loading control (Panel E). The greyed-out box 
indicates which lysates were used for the control immunoprecipitation. Arrows indicate 
cavin-1 while brackets indicate variations in the ubiquitin smear. 
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Figure 6.10: Cavin-1 ubiquitination is enriched in the presence of SOCS3  
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA plus SOCS3-
Flag, SOCS3-L189A-Flag, cavin-1-GFP, and E3 ligase components cullin5, elonginB-myc, 
elonginC, and Rbx1-myc cDNA constructs in the indicated combinations. Soluble protein 
lysates were prepared and denatured immunoprecipitation performed as described 
(Section 2.2.14). Captured proteins were fractionated by SDS-PAGE and recovery 
assessed by immunoblotting using anti-HA (Panel A) and anti-GFP antibody (Panel B). 
Where possible, protein expression was assessed using anti-SOCS3 (Panel C), anti-GFP 
(Panel E), and anti-myc antibody (Panel D). GAPDH was used as a loading control (Panel 
F). The greyed-out box indicates which lysates were used for the control 
immunoprecipitation. Arrows indicate cavin-1 while brackets indicate variations in the 
ubiquitin smear. 
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As controls for the previous experiments (Figure 6.9 and 6.10), ubiquitination of 
SOCS3 was assessed in the presence and absence of components of the E3 ligase. 
SOCS3 was found to be highly ubiquitinated in the absence but not the presence 
of the E3 scaffold (Figure 6.11, panel A, lane 3 vs. 4). Furthermore, levels of 
SOCS3 were lower in the presence of the E3 components. However, treatment 
with MG132 is expected to preserve SOCS3 suggesting that loss of SOCS3 might 
be occurring via an alternative route, possibly via a PEST-domain mediated 
route. Ubiquitination of SOCS3 in the absence of the E3 scaffold might suggest 
that ubiquitination occurs due to the presence of endogenous E3 proteins i.e. 
cullin5, elonginBC, and Rbx2 or alternatively by a completely different E3 ligase. 
The lack of ubiquitination in the presence of the E3 complex is perhaps a 
consequence of the unequal expression of its individual components. Since these 
components are required in a 1:1 stoichiometry, varying expression levels might 
result in the formation of several variations of an incomplete complex. As such, 
a reduced ubiquitination signal would be expected. Although the same µg-
amount of cDNA construct was used in each case, expression levels of each 
component was not checked, in part, due to the lack of specific antibodies. 
Plasmids for E3 ligase scaffolds optimised for expression are now commercially 
available and could be an option in the future. It might also be beneficial to 
perform an in vitro ubiquitination assay, using a purified E3 complex, since it 
would be unaffected by alternative routes of ubiquitination.  
 
The reciprocal control immunoprecipitation produced the same result (Figure 
6.12). In this case, the SOCS3-L189A mutant was also included and was seen to 
be ubiquitinated to a higher degree than the WT in the absence of the E3 
scaffold. This suggests that SOCS3 is being ubiquitinated by different E3 ligase 
since, as it was previously shown (Figure 6.2, panel D/E, lanes 4 vs. 5), that 
SOC3-L189A cannot bind elonginB or cullin5. 
 
This control data suggests that the ubiquitinated cavin-1 is enriched in the 
presence of SOCS3. However, SOCS3 is present at reduced levels when expressed 
with components of the E3 ligase. As such, ubiquitinated cavin-1 might be 
expected to be enriched to greater levels in the presence of SOCS3 alone. Of 
course, this would rely on the presence of endogenous E3 ligase components for 
SOCS3-dependent ubiquitination.    
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Figure 6.11: SOCS3 ubiquitination is enriched in the absence of components 
of the E3 ligase   
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA plus SOCS3-
Flag, and E3 ligase components cullin5, elonginB-myc, elonginC, and Rbx1-myc cDNA 
constructs in the indicated combinations. Soluble protein lysates were prepared and 
denatured immunoprecipitation performed as described (Section 2.2.14). Captured 
proteins were fractionated by SDS-PAGE and recovery assessed by immunoblotting using 
anti-SOCS3 (Panel A). Where possible, protein expression was assessed using anti-SOCS3 
(Panel B), and anti-myc antibody (Panel C). GAPDH was used as a loading control (Panel 
D).  
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Figure 6.12: SOCS3 ubiquitination is enriched in the absence of components 
of the E3 ligase   
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA plus SOCS3-
Flag, SOCS3-L189A-Flag, and E3 ligase components cullin5, elonginB-myc, elonginC, and 
Rbx1-myc cDNA constructs in the indicated combinations. Soluble protein lysates were 
prepared and denatured immunoprecipitation performed as described (Section 2.2.14). 
Captured proteins were fractionated by SDS-PAGE and recovery assessed by 
immunoblotting using anti-HA antibody (Panel A). Where possible, protein expression 
was assessed using anti-SOCS3 (Panel B), and anti-myc antibody (Panel C). GAPDH was 
used as a loading control (Panel D). 
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So far, it has been demonstrated that low molecular weight ubiquitination of 
cavin-1 is enriched in the presence but not absence of SOCS3. If SOCS3 was to 
mediate proteasomal degradation of cavin-1 then an enrichment of K48-specifc 
polyubiquitination should be detected. Furthermore, control experiments 
suggest that SOCS3 levels can be enhanced in the absence of the E3 complex. As 
such, cavin-1 immunoprecipitation experiments were performed as before in the 
presence or absence of SOCS3 or SOCS3-L189A. Enrichment of K48-
polyubiquitination was assessed via immunoblotting with K48-polyubiquitin 
chain-specific antibody.   
 
Cavin-1 was again detected to be enriched in the presence but not absence of 
SOCS3 (Figure 6.13, panel B/C1, lane 5 vs. 7/8, and arrows). Furthermore, as 
discussed previously, a switch in the ubiquitin smear is seen. While a high 
molecular weight polyubiquitination signal is detected in the absence of SOCS3 
(Figure 6.13, lane 5 vs. 7, brackets 2 and 4), in its presence, an enhanced signal 
is detected around the expected mass of cavin-1 (Figure 6.13, lane 5 vs. 7/8, 
brackets 3 and 5). The low molecular weight fraction (Figure 6.13, lane 5 vs. 
7/8, brackets 3 and 5) might be attributable to ubiquitinated forms of full-length 
cavin-1 and cavin-1 fragments. Interestingly, K48-specific polyubiquitination is 
also enhanced in the presence of SOCS3 within this same region (Figure 6.13, 
lane 5 vs. 7/8, bracket 1). However, since SOCS3-L189A produces the same 
effect, it suggests that K48-polyubiquitination is via a non-SOCS3 mechanism. 
However, it may support SOCS3 as functioning to protect cavin-1 K48-
polyubiquitination. 
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Figure 6.13: Cavin-1 ubiquitination is enriched in the presence of SOCS3  
HEK293 cells were transfected as described (Section 2.2.12) with Ub-HA plus SOCS3-
Flag, SOCS3-L189A-Flag, and cavin-1-GFP cDNA constructs in the indicated 
combinations. Soluble protein lysates were prepared and denatured 
immunoprecipitation performed as described (Section 2.2.14).  Captured proteins were 
fractionated by SDS-PAGE and recovery assessed by immunoblotting using anti-K48-Ub 
(Panel A), anti-HA (Panel B) and anti-GFP (Panel C1 (long exposure), C2 (short exposure) 
antibody. Where possible, protein expression was assessed using anti-GFP (Panel D), 
anti-SOCS3 antibody (Panel E). GAPDH was used as a loading control (Panel F). The 
greyed-out box indicates which lysates were used for the control immunoprecipitation. 
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6.2.5 Peptide array of tyrosine-phosphorylated peptides from SOCS3 
candidates supports an interaction between SOCS3 and Hsp70 but not 
cavin-1 
SOCS3 is predicted to interact with and ubiquitinate, tyrosine-phosphorylated 
substrates (9-12). Online databases such as phosphosite.org provide access to 
proteins and the identity of their known tyrosine-phosphorylated peptides.  To 
assess the interaction of SOCS3 with candidate substrates identified via a 
proteomics screen (Section 5.0), peptide arrays were fabricated using known 
tyrosine-phosphorylated peptides from these candidates (Section 2.2.15, Table 
2.3). Proteins were selected for peptide array analysis based on their SILAC ratio 
(log2(normalised H/L)>1) and the presence of known tyrosine-phosphorylated 
residues. While purified GST-fusion proteins are typically used for peptide array 
overlays, a quicker approach would be to use cell lysates from cells over-
expressing the protein of interest (249). 
 
HEK293 cells were transfected with SOCS3-Flag, SOCS3-L189A-Flag, or GFP cDNA 
constructs as described (Section 2.2.12). Soluble protein lysates were then 
prepared and the peptide array overlaid and visualised as described (Section 
2.2.15.1).  
 
SOCS3 was found to interact with several tyrosine-phosphorylated peptides 
(Figure 6.14, panel A vs. panel C). Proteins that significantly (p<0.05, paired 
one-tailed t-test) interact with SOCS3 are presented in Table 6.0. Importantly, 
SH2-interacting positive control peptides pY-FAK1 and pY-gp130, but not gp130, 
significantly interacted with SOCS3. Three peptides from Hsc70 significantly 
interacted with SOCS3. Furthermore, the interaction with peptide Hsc70 (1) 
produced the strongest signal over all peptide interactions (Figure 6.14, panel A 
vs. panel C, dashed oval) thus appeared to be specific as other peptides from 
Hsc70 (Figure 6.14, panel A vs. panel C, solid oval) did not interact as strongly. 
Interestingly, SOCS3 did not interact significantly with known tyrosine-
phosphorylated peptides from cavin-1 (Figure 6.14, panel A vs. panel C, solid 
rectangle) supporting previous data suggesting that tyrosine phosphorylation 
inhibits the cavin-1-SOCS interaction (Figure 6.7).  
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Several SOCS3-peptide interactions were preserved when the peptide arrays 
were overlaid with the C-terminal domain SOCS-box mutant, SOCS3-L189A 
(Figure 6.14, panel B vs. panel A) (Table 6.0). Importantly this included several 
peptides from Hsc70. This suggested that these interactions were specific and 
potentially SOCS-box independent. However, since the impact of the L189A 
mutation on non-elonginBC interactions is unknown, it still cannot be completely 
ruled-out. A SOCS-box deletion mutant would give a more informative result. As 
before, SH2-interacting control peptides pY-FAK1 and pY-gp130, but not gp130, 
still significantly interacted with SOCS3-L189A. 
 
So far, SOCS3 has been shown interact with several tyrosine-phosphorylated 
candidate peptides. However, if these interactions are specific and the SOCS3-
substrate interaction is dependent on tyrosine phosphorylation then these 
interactions would be expected to be lost if the PTM was removed. A further 
peptide array was fabricated using peptides that significantly interacted with 
SOCS3, with or without tyrosine phosphorylation. Due to the unavailability of the 
CelluSpot system, the peptide array was fabricated using a different technique 
(Section 2.2.15.2). Furthermore, only a single peptide array was fabricated 
meaning that the array had to be overlaid with the control and then stripped 
before overlaying with SOCS3.  
 
Overlaying the peptide array with the control showed some non-specific 
background, however, the control peptides pY-FAK1, pY-gp130, and gp130 were 
unaffected (Data not shown). Specific interactions were detected when the 
peptide array was overlaid with purified SOCS3. Unfortunately, variations in size 
and intensity were detected between duplicate spots that may be a consequence 
of a non-uniform fabrication process and/or membrane stripping. As such, 
quantitation was not attempted. Repeating the experiment with separate arrays 
for control and SOCS3 overlay and thus avoiding membrane stripping might 
produce more clear results. However, this was not possible due to time 
constraints.   
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Figure 6.14: SOCS3 interacts with several known tyrosine-phosphorylated 
peptides from candidate proteins 
HEK293 cells were transfected as described (Section 2.2.12) with SOCS3-Flag, 
SOCS3-L189A-Flag, or GFP cDNA constructs. Soluble protein lysates were then 
prepared and the peptide array overlaid as described (Section 2.2.15.1) with 
SOCS3-Flag (Panel A), SOCS3-L189A-Flag (Panel B), or GFP-containing cell lysates 
(Panel C). SOCS3-peptide interactions were assessed using anti-Flag primary 
antibody and an 800-IRdye secondary antibody. Interactions were visualized 
using a LI-COR Odyssey system Sa. 
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Table 6.0: SOCS3 interacts with several known tyrosine-phosphorylated 
peptides from candidate proteins  
Peptide arrays spotted with known tyrosine-phosphorylated peptides of candidate 
proteins (Figure 6.14) (Table 2.3) were overlaid with SOCS3, SOCS3-L189A, or GFP 
control. Candidate peptides (Table 2.3) that significantly (p<0.05, paired one-tailed t-
test) interacted with SOCS3 compared to the GFP control and are presented here. 
Moreover, of these interactions, several were preserved following overlaying the array 
with the SOCS3 SOCS-box mutant SOCS3-L189A. Positive controls are highlighted in bold 
while greyed out boxes signify interactions lost following SOCS3-L189A overlay. 
 
     
Array 
Spot 
Peptide Sequence 
SOCS3-FLAG SOCS3-L189A-FLAG 
Protein (Peptide) 
1 V-D-P-A-pY-T-G-R-V-G-A Eps15L (1)   
5 S-R-Q-L-pY-V-L-G-H-E-A Ube (2)   
7 V-L-G-P-pY-T-F-S-I-C-D Ube1 (4)   
13 A-P-G-E-pY-F-F-S-D-G-I Impdh2   
16 A-C-E-A-pY-L-V-G-L-F-E Histone 3.1 (3) Histone 3.1 (3) 
19 L-F-D-S-pY-T-N-L-E-R-V Abi2 (3) Abi2 (3) 
20 R-V-A-D-pY-C-E-N-N-Y-I Abi2 (4)   
24 D-P-A-G-pY-Y-C-G-F-K-A Psma6 (1)   
25 P-A-G-Y-pY-C-G-F-K-A-T Psma6 (2)   
26 E-G-R-L-pY-Q-V-E-Y-A-F Psma6 (3) Psma6 (3) 
28 E-S-L-R-pY-K-L-L-G-G-L Rps3 (2)   
36 L-G-T-T-pY-S-C-V-G-V-F Hsc73(1) Hsc73(1) 
37 T-T-P-S-pY-V-A-F-T-D-T Hsc73(2) Hsc73(2) 
40 I-A-E-A-pY-L-G-K-T-V-T Hsc73 (5) Hsc73 (5) 
41 K-N-S-S-pY-F-V-E-W-I-P Tubb5 (1) Tubb5 (1) 
43 N-E-A-L-pY-D-I-C-F-R-T Tubb5 (3) Tubb5 (3) 
47 L-N-F-F-pY-Q-Q-V-K-S-D FAK (2)   
50 L-I-D-G-pY-C-R-L-V-N-G FAK (4)   
51 E-T-D-D-pY-A-E-I-I-D-E FAK (5) FAK (5) 
54 G-L-S-R-pY-M-E-D-S-T-Y FAK (8)   
55 E-D-S-T-pY-Y-K-A-S-K-G FAK (9)   
66 D-W-S-H-pY-F-K-I-I-E-D Krt18 (5)   
68 S-T-V-Q-pY-S-T-V-V-H-S pY759gp130 pY759gp130 
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6.2.6 SOCS3 specifically interacts with several domains of cavin-1 
While immunoprecipitation has demonstrated an interaction between SOCS3 and 
cavin-1, protein domains or residues necessary for this interaction are unknown. 
Furthermore, apart from protein-sequence-predicted motifs, no further 
structural information about cavin-1 is available. Due to its availability, a 
peptide array was decided to be the most efficient technique to begin 
investigating the interaction. The array was spotted with 25mer, 5 residue 
overlapping peptides of the 392 amino-acid-long cavin-1 (Mus musculus, 
UniProtKB accession number: O54724). SOCS3 would be expected to interact 
with some but not all peptide spots if the SOCS3-cavin-1 interaction was 
specific.       
 
HEK293 cells were transfected with SOCS3-Flag or GFP cDNA constructs as 
described (Section 2.2.12). Soluble protein lysates were then prepared and the 
peptide array overlaid and visualised as described (Section 2.2.15.2). 
  
The LI-COR Odyssey is an efficient methods of visualisation since is has a wider 
linear range of detection than chemiluminescence techniques allowing weak and 
strong signals to be detected on the same membrane. As opposed to enzymatic 
techniques where signal intensity depends of exposure times, the LI-COR system 
allows the signal to be boosted using an intensity setting. A low intensity 
dampens the signal and a high intensity boosts the signal.  Since I was unable to 
predict the high intensity of the SOCS3 overlay, the control and SOCS3 overlay 
were visualised at different intensities. While SOCS3 was visualised with 
intensity=5, the control was visualised with intensity=7. As such, spots detected 
by the control are stronger (x4) than they should be and thus undervalues the 
intensity of the SOCS3 overlay. However, this error has not affected the result 
(Table 6.1). 
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Table 6.1: SOCS3 specifically interacts with several domains of cavin-1   
The peptide array was spotted with 25mer-long, 5 residue overlapping peptides from 
murine cavin-1. Background was detected by probing with an anti-SOCS3 antibody 
(control). SOCS3-peptide interactions were assessed using purified SOCS3. Background 
and specific interactions were visualised using the LI-COR 800-IRdye LI-COR Odyssey Sa 
system. (see text for details) 
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1 1   M-E-D-V-T-L-H-I-V-E-R-P-Y-S-G-F-P-D-A-S-S-E-G-P-E 25
2 6   L-H-I-V-E-R-P-Y-S-G-F-P-D-A-S-S-E-G-P-E-P-T-Q-G-E 30
3 11   R-P-Y-S-G-F-P-D-A-S-S-E-G-P-E-P-T-Q-G-E-A-R-A-T-E 35
4 16   F-P-D-A-S-S-E-G-P-E-P-T-Q-G-E-A-R-A-T-E-E-P-S-G-T 40
5 21   S-E-G-P-E-P-T-Q-G-E-A-R-A-T-E-E-P-S-G-T-G-S-D-E-L 45
6 26   P-T-Q-G-E-A-R-A-T-E-E-P-S-G-T-G-S-D-E-L-I-K-S-D-Q 50
7 31   A-R-A-T-E-E-P-S-G-T-G-S-D-E-L-I-K-S-D-Q-V-N-G-V-L 55
8 36   E-P-S-G-T-G-S-D-E-L-I-K-S-D-Q-V-N-G-V-L-V-L-S-L-L 60
9 41   G-S-D-E-L-I-K-S-D-Q-V-N-G-V-L-V-L-S-L-L-D-K-I-I-G 65
10 46   I-K-S-D-Q-V-N-G-V-L-V-L-S-L-L-D-K-I-I-G-A-V-D-Q-I 70
11 51   V-N-G-V-L-V-L-S-L-L-D-K-I-I-G-A-V-D-Q-I-Q-L-T-Q-A 75
12 56   V-L-S-L-L-D-K-I-I-G-A-V-D-Q-I-Q-L-T-Q-A-Q-L-E-E-R 80
13 61   D-K-I-I-G-A-V-D-Q-I-Q-L-T-Q-A-Q-L-E-E-R-Q-A-E-M-E 85
14 66   A-V-D-Q-I-Q-L-T-Q-A-Q-L-E-E-R-Q-A-E-M-E-G-A-V-Q-S 90
15 71   Q-L-T-Q-A-Q-L-E-E-R-Q-A-E-M-E-G-A-V-Q-S-I-Q-G-E-L 95
16 76   Q-L-E-E-R-Q-A-E-M-E-G-A-V-Q-S-I-Q-G-E-L-S-K-L-G-K 100
17 81   Q-A-E-M-E-G-A-V-Q-S-I-Q-G-E-L-S-K-L-G-K-A-H-A-T-T 105
18 86   G-A-V-Q-S-I-Q-G-E-L-S-K-L-G-K-A-H-A-T-T-S-N-T-V-S 110
19 91   I-Q-G-E-L-S-K-L-G-K-A-H-A-T-T-S-N-T-V-S-K-L-L-E-K 115
20 96   S-K-L-G-K-A-H-A-T-T-S-N-T-V-S-K-L-L-E-K-V-R-K-V-S 120
21 101   A-H-A-T-T-S-N-T-V-S-K-L-L-E-K-V-R-K-V-S-V-N-V-K-T 125
22 106   S-N-T-V-S-K-L-L-E-K-V-R-K-V-S-V-N-V-K-T-V-R-G-S-L 130
23 111   K-L-L-E-K-V-R-K-V-S-V-N-V-K-T-V-R-G-S-L-E-R-Q-A-G 135
24 116   V-R-K-V-S-V-N-V-K-T-V-R-G-S-L-E-R-Q-A-G-Q-I-K-K-L 140
25 121   V-N-V-K-T-V-R-G-S-L-E-R-Q-A-G-Q-I-K-K-L-E-V-N-E-A 145
26 126   V-R-G-S-L-E-R-Q-A-G-Q-I-K-K-L-E-V-N-E-A-E-L-L-R-R 150
27 131   E-R-Q-A-G-Q-I-K-K-L-E-V-N-E-A-E-L-L-R-R-R-N-F-K-V 155
28 136   Q-I-K-K-L-E-V-N-E-A-E-L-L-R-R-R-N-F-K-V-M-I-Y-Q-D 160
29 141   E-V-N-E-A-E-L-L-R-R-R-N-F-K-V-M-I-Y-Q-D-E-V-K-L-P 165
30 146   E-L-L-R-R-R-N-F-K-V-M-I-Y-Q-D-E-V-K-L-P-A-K-L-S-V 170
31 151   R-N-F-K-V-M-I-Y-Q-D-E-V-K-L-P-A-K-L-S-V-S-K-S-L-K 175
32 156   M-I-Y-Q-D-E-V-K-L-P-A-K-L-S-V-S-K-S-L-K-E-S-E-A-L 180
33 161   E-V-K-L-P-A-K-L-S-V-S-K-S-L-K-E-S-E-A-L-P-E-K-E-G 185
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34 166   A-K-L-S-V-S-K-S-L-K-E-S-E-A-L-P-E-K-E-G-D-E-L-G-E 190
35 171   S-K-S-L-K-E-S-E-A-L-P-E-K-E-G-D-E-L-G-E-G-E-R-P-E 195
36 176   E-S-E-A-L-P-E-K-E-G-D-E-L-G-E-G-E-R-P-E-D-D-T-A-A 200
37 181   P-E-K-E-G-D-E-L-G-E-G-E-R-P-E-D-D-T-A-A-I-E-L-S-S 205
38 186   D-E-L-G-E-G-E-R-P-E-D-D-T-A-A-I-E-L-S-S-D-E-A-V-E 210
39 191   G-E-R-P-E-D-D-T-A-A-I-E-L-S-S-D-E-A-V-E-V-E-E-V-I 215
40 196   D-D-T-A-A-I-E-L-S-S-D-E-A-V-E-V-E-E-V-I-E-E-S-R-A 220
41 201   I-E-L-S-S-D-E-A-V-E-V-E-E-V-I-E-E-S-R-A-E-R-I-K-R 225
42 206   D-E-A-V-E-V-E-E-V-I-E-E-S-R-A-E-R-I-K-R-S-G-L-R-R 230
43 211   V-E-E-V-I-E-E-S-R-A-E-R-I-K-R-S-G-L-R-R-V-D-D-F-K 235
44 216   E-E-S-R-A-E-R-I-K-R-S-G-L-R-R-V-D-D-F-K-K-A-F-S-K 240
45 221   E-R-I-K-R-S-G-L-R-R-V-D-D-F-K-K-A-F-S-K-E-K-M-E-K 245
46 226   S-G-L-R-R-V-D-D-F-K-K-A-F-S-K-E-K-M-E-K-T-K-V-R-T 250
47 231   V-D-D-F-K-K-A-F-S-K-E-K-M-E-K-T-K-V-R-T-R-E-N-L-E 255
48 236   K-A-F-S-K-E-K-M-E-K-T-K-V-R-T-R-E-N-L-E-K-T-R-L-K 260
49 241   E-K-M-E-K-T-K-V-R-T-R-E-N-L-E-K-T-R-L-K-T-K-E-N-L 265
50 246   T-K-V-R-T-R-E-N-L-E-K-T-R-L-K-T-K-E-N-L-E-K-T-R-H 270
51 251   R-E-N-L-E-K-T-R-L-K-T-K-E-N-L-E-K-T-R-H-T-L-E-K-R 275
52 256   K-T-R-L-K-T-K-E-N-L-E-K-T-R-H-T-L-E-K-R-M-N-K-L-G 280
53 261   T-K-E-N-L-E-K-T-R-H-T-L-E-K-R-M-N-K-L-G-T-R-L-V-P 285
54 266   E-K-T-R-H-T-L-E-K-R-M-N-K-L-G-T-R-L-V-P-V-E-R-R-E 290
55 271   T-L-E-K-R-M-N-K-L-G-T-R-L-V-P-V-E-R-R-E-K-L-K-T-S 295
56 276   M-N-K-L-G-T-R-L-V-P-V-E-R-R-E-K-L-K-T-S-R-D-K-L-R 300
57 281   T-R-L-V-P-V-E-R-R-E-K-L-K-T-S-R-D-K-L-R-K-S-F-T-P 305
58 286   V-E-R-R-E-K-L-K-T-S-R-D-K-L-R-K-S-F-T-P-D-H-V-V-Y 310
59 291   K-L-K-T-S-R-D-K-L-R-K-S-F-T-P-D-H-V-V-Y-A-R-S-K-T 315
60 296   R-D-K-L-R-K-S-F-T-P-D-H-V-V-Y-A-R-S-K-T-A-V-Y-K-V 320
61 301   K-S-F-T-P-D-H-V-V-Y-A-R-S-K-T-A-V-Y-K-V-P-P-F-T-F 325
62 306   D-H-V-V-Y-A-R-S-K-T-A-V-Y-K-V-P-P-F-T-F-H-V-K-K-I 330
63 311   A-R-S-K-T-A-V-Y-K-V-P-P-F-T-F-H-V-K-K-I-R-E-G-E-V 335
64 316   A-V-Y-K-V-P-P-F-T-F-H-V-K-K-I-R-E-G-E-V-E-V-L-K-A 340
65 321   P-P-F-T-F-H-V-K-K-I-R-E-G-E-V-E-V-L-K-A-T-E-M-V-E 345
66 326   H-V-K-K-I-R-E-G-E-V-E-V-L-K-A-T-E-M-V-E-V-G-P-E-D 350
67 331   R-E-G-E-V-E-V-L-K-A-T-E-M-V-E-V-G-P-E-D-D-E-V-G-A 355
68 336   E-V-L-K-A-T-E-M-V-E-V-G-P-E-D-D-E-V-G-A-E-R-G-E-A 360
69 341   T-E-M-V-E-V-G-P-E-D-D-E-V-G-A-E-R-G-E-A-T-D-L-L-R 365
70 346   V-G-P-E-D-D-E-V-G-A-E-R-G-E-A-T-D-L-L-R-G-S-S-P-D 370
71 351   D-E-V-G-A-E-R-G-E-A-T-D-L-L-R-G-S-S-P-D-V-H-T-L-L 375
72 356   E-R-G-E-A-T-D-L-L-R-G-S-S-P-D-V-H-T-L-L-E-I-T-E-E 380
73 361   T-D-L-L-R-G-S-S-P-D-V-H-T-L-L-E-I-T-E-E-S-D-A-V-L 385
74 366   G-S-S-P-D-V-H-T-L-L-E-I-T-E-E-S-D-A-V-L-V-D-K-S-D 390
75 368   S-P-D-V-H-T-L-L-E-I-T-E-E-S-D-A-V-L-V-D-K-S-D-S-D 392
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SOCS3 interacts with cavin-1 at several regions but most intensely at peptides 
16-24 and two seemingly repeating regions at peptides 42-46 and 52-56. Putative 
domain assignment has been previously established by Aboulaich et al (222), 
Bastiani et al (219), and Hansen et al (221). As such, cavin-1 is predicted to have 
three disordered PEST domains associated with proteolysis, two nuclear 
localisation signals (NLS) and three leucine rich repeats (LRR) which might be 
important for protein-protein interactions and impart structural characteristics. 
SOCS3 seems to interact strongly at an N-terminal region predicted to form a 
coiled-coil/leucine zipper protein-interaction motif as well as with a C-terminal 
domain basic region that is also predicted to contain LRR and NLS motifs.  
 
Ideally, the reciprocal experiment should be performed so that binding sites on 
SOCS3 can also be assessed. Due to time restrictions this has not yet been 
performed. Furthermore, I would also have liked to fabricate several 
SOCS3/cavin-1 sequential and/or single residue mutants to further explore the 
interaction via this technique. These same mutants could also be used for in 
vitro analysis such as co-immunoprecipitation and functional studies.   
6.2.7 Degradation of cavin-1 could not be detected following the inhibition of 
protein synthesis  
The stability of SOCS3 substrates is expected to be reduced in the presence of 
but not absence SOCS3. Inhibition of protein synthesis will enable the time-
dependent degradation of SOCS3 targets to be detected.  Emetine, an 
irreversible inhibitor of protein synthesis that acts by binding to and blocking the 
translocation of the 40S ribosomal unit (197,198), was used for this purpose. 
Prior to performing the degradation experiments, the natural degradation of 
cavin-1, following inhibition of protein synthesis, was assessed via a time-course. 
Furthermore, the action of the proteasome inhibitor MG132 and lysosome 
inhibitor chloroquine was also assessed over the same time course with the aim 
of providing evidence of the route of cavin-1 degradation.     
 
The degradation assay was performed as described (Section 2.2.16). Despite 
seven attempts, time-dependent degradation of cavin-1 could not be 
reproducibly detected (Figure 6.15, panel A). Bands assumed to be cavin-1 did 
vary although not as predicted. In the presence of only the protein synthesis 
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inhibitor (emetine, 100µM), no degradation was detected (Lanes 2-6) while 
degradation was observed in the presence of the inhibitor of proteasome 
(MG132, 6µM) (Lanes 7-10). However, correcting for GAPDH levels (Panel B, 
lanes 11-14), treatment with the lysosomal inhibitor (chloroquine, 100mM) 
appears to protect cavin-1. Given that the emetine-only positive control did not 
show any change in cavin-1, a conclusion cannot be made about its route of 
degradation using this data. Cavin-1 has been detected by other groups as 
several bands, possibly due to a susceptibility to proteolysis (219,222). As such, 
the several lower bands (70-40kDa) detected might relate to cavin-1 fragments. 
Alternatively, since bands were visualised using an anti-PTRF (cavin-1) antibody, 
these bands might equally be endogenous cavin-1. Given that these bands also 
vary unpredictably in intensity, they add extra variability that limits 
interpretation of the data. Cavin-1 has been suggested to have a long half-life 
(220) and performing a longer time-course might produce a more definitive 
result. However, treatment with emetine is toxic and even after 8 hours cell 
death was seen (data not shown). As such, it was decided not to pursue this 
experimental strategy further.  
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Figure 6.15: Degradation of cavin-1 could not be detected following 
inhibition of protein synthesis  
The degradation assay was performed as described (Section 2.2.16). Samples were 
equalised for protein concentration prior to fractionation by SDS-PAGE and degradation 
assessed via immunoblotting with anti-PTRF(cavin-1) antibody (Panel A). GAPDH was use 
as a loading control (Panel B). One of seven experiments.  
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6.3 Conclusions 
Numerous candidate SOCS3-dependently ubiquitinated substrates were identified 
via a proteomics screen (Section 5.0).  Here, the aim was to validate substrates 
via co-immunoprecipitation, analysis of ubiquitination in situ, and peptide array 
analysis. Initial investigations used co-immunoprecipitation experiments to 
demonstrate an interaction between SOCS3 and the candidate substrates. While 
Hsc70 was precipitated, it also interacted non-specifically with the agarose 
beads (Figure 6.5). It was decided that other techniques such as peptide arrays 
and/or functional assays might be more informative. Cavin-1 was the only 
candidate substrate that was found to interact with SOCS3 via this route (Figure 
6.6). Interestingly, this interaction seemed to be disrupted in the presence of 
PTPs inhibitors Na3VO4 and H2O2 (Figure 6.7). This was not expected since the 
SOCS3-dependent E3 is predicted to bind tyrosine-phosphorylated substrates. 
However, due to the off-target effects of H2O2 (204,248), it is possible that the 
interaction is being disrupted by hyper-phosphorylation of other residues. As 
such, the experiment should have been repeated in the absence of H2O2. 
However, it is interesting to note that the condition demonstrated to inhibit the 
interaction was also used to enrich cavin-1 via a proteomics screen. 
 
The interaction between cavin-1 and SOCS3 also seemed to be independent of 
the SOCS3 SOCS-box since WT and the SOCS3-L189A SOCS-box mutant both 
precipitated cavin-1 at comparable levels (Figure 6.8). This is important since 
SOCS3 is required to bind components of the E3 ligase via its SOCS-box motif. 
Any interaction between cavin-1 and the SOCS3 SOCS-box might rule out cavin-1 
as a SOCS3-dependently ubiquitinated substrate.  However, this does not 
completely rule-out this domain since the mutant has only been characterised in 
relation to the elonginBC interaction. A more informative approach would be to 
use a SOCS-box deletion mutant and also to use disrupting or deletion mutations 
of other domains to assess their involvement. Alternatively, this interaction 
could be further explored using full-length peptide arrays of both SOCS3 and 
cavin-1 to map the SOCS3-cavin-1 interacting sites. This may also enable the 
location of potentially disrupting phosphorylated residues. Furthermore, 
mutagenesis or peptide fabrication with or without phosphorylation would 
enable localisation of the individual disrupting residues.       
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It was disappointing to validate only a single candidate via these experiments 
however not all of the top candidates identified from the proteomics screen 
were tested due to the unavailability of cDNA constructs. Furthermore, while 
conditions for co-immunoprecipitation were tested (Section 6.2.1.1), these 
conditions might not be ideal for weakly interacting proteins and as such would 
require modifications of the experimental conditions to reduce stringency. This 
is a major limitation of this strategy and might have led to missed interactions. 
The use of in vivo techniques such as yeast-2-hybrid might be more successful. 
However, while protein tyrosine kinases have been identified in yeast, they are 
not as common as in multi-cellular organisms and so yeast might not convey the 
PTM to non-native proteins (250). Given that the candidate SOCS3 substrate 
protein tyrosine kinases are also unknown, analysis of tyrosine-phosphorylation-
dependent protein-protein interactions via this assay is not possible at this time.  
 
A peptide array spotted with tyrosine-phosphorylated peptides from candidate 
SOCS3 substrates (Figure 6.14) showed that Hsc70 seemed to specifically interact 
with SOCS3 at a specific tyrosine-phosphorylated peptide. Furthermore, the 
array also supported previous data suggesting that tyrosine phosphorylation 
inhibits the SOCS3-cavin-1 interaction. Here, tyrosine-phosphorylated peptides 
from cavin-1 were shown not to significantly interact with SOCS3.  A SOCS3-
cavin-1 interaction was however supported by a full-length peptide array, which 
demonstrated that SOCS3 specifically interacts with several peptides of cavin-1 
(Table 6.1). SOCS3 seems to interact strongly at an N-terminal region predicted 
to form a coiled-coil/leucine zipper protein-interaction motif as well as with a 
C-terminal domain basic region that is also predicted to contain LRR and NLS 
motifs. Such an interaction might lead to disruption of the cavin-complex and/or 
sequestration to the cytoplasm/plasma membrane. SOCS3 can be induced by 
insulin (160) but it is disputed whether cavin-1 translocations from the plasma 
membrane to the nucleus upon insulin signalling (251,252). Binding of SOCS3 to 
the NLS might act to prevent nuclear translocation and sequester cavin-1 to the 
plasma membrane/cytosol. Furthermore, while association with basic regions 
might be predicted to be phosphorylation dependent, the use of E.coli as the 
expression host for the purified SOCS3 suggests that this might not be the case. 
Association at this site might therefore be a consequence of the charge profile of 
SOCS3. Cavin-1-3, and potentially cavin-4, binds phosphatidylserine (PS) 
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(219,221,227) which is thought to strengthen their association with caveolins at 
the plasma membrane (PM). Furthermore, cavin family members accumulate in 
large complexes at the PM suggesting that the cumulative effect of several weak 
interactions with PS might be important. The PS interaction site might be 
predicted to be the basic region which is conserved across all cavin family 
members (221). As such, SOCS3 binding at this site may act to disrupt the cavin 
complex and/or cavin-1 from the PM.  The SOCS3 SOCS-box is unstructured 
domain that only becomes structured upon binding elonginBC via mainly 
hydrophobic interactions (77). As such, the presence of multiple hydrophobic 
LRRs might potentially implicate this region in binding cavin-1.    
 
Analysis of the SOCS3-dependent ubiquitination of cavin-1 produced interesting 
results. Immunoprecipitation of the ubiquitinome resulted in the enrichment of 
ubiquitinated cavin-1 (Figure 6.9). However, the band enriched seemed to relate 
to a cavin-1 fragment.  The reciprocal experiment replicated this result (Figure 
6.10). However, in this case, in the presence of SOCS3-E3 there seemed to be a 
switch in the intensity of the ubiquitin smear from a high to a lower molecular 
weight focused around cavin-1 (~75kDa). The same result was replicated in the 
presence of only SOCS3 i.e. cavin-1 vs. cavin-1 and SOCS3 (Figure 6.13). Here, an 
enrichment of ubiquitinated protein below 75kDa might be attributed to 
ubiquitinated cavin-1 fragments while those above might be ubiquitinated full-
length cavin-1. Interestingly, K48-specific polyubiquitination was also enhanced 
in the presence of SOCS3 within this same region. However, since SOCS3-L189A 
produces the same effect, it suggests that K48-polyubiquitination is via a non-
SOCS3 mechanism. It may however support SOCS3 in the role of protecting cavin-
1 K48-polyubiquitination. These data suggest that SOCS3 might somehow inhibit 
or negatively regulate polyubiquitination of cavin-1, possibly by out-competing 
other E3 ligases. Given that only lower molecular weight ubiquitination is 
enhanced in the presence of the SOCS3-E3, mono-or multi-ubiquitination might 
be involved. However, due to the enhanced detection of K48-polyubiquitination, 
K48-linked dimers or short chains are also a possibility. SOCS3 might therefore 
protect or preferentially ubiquitinate cavin-1 leading to this switch in the 
ubiquitin smear. However, this data does not explain the enrichment of specific 
cavin-1 bands. Aboulaich et al (222) found that cavin-1 contains three PEST 
domains and that it is also acetylated at the N-terminal methionine (Figure 6.9 
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Table 6.1), both of which are associated with protein stability. Since several 
cavin-1 fragments are likely observable in immunoblots (219,222), it might be 
possible that following cleavage of the N-terminal PEST domain, cavin-1 
becomes less susceptible to proteolysis and is bound by SOCS3 which limits 
further proteolysis.  This observation is supported by the full-length cavin-1 
peptide array, which revealed that SOCS3 only weakly interacts with the N-
terminal domain of cavin-1 (Table 6.1). Enrichment of a ubiquitinated, N-
terminally truncated cavin-1 would also suggest that the K48-polyubiquitin-
modified lysine residue is located further upstream. As such, it might be 
concluded that the enhanced ubiquitination signal is a consequence of the 
enrichment of the ubiquitinated cavin-1 fragments. It is not known whether the 
ubiquitin signal is SOCS3-dependent. However, since cavin-1 was found to be 
enriched in the presence but not absence of SOCS3 in the proteomics screen, it 
is expected that SOCS3 has some role in the regulation of cavin-1 ubiquitination.  
 
It is of note that cavin-1 was not substantially enriched via immunoprecipitation. 
The small variations in the ubiquitin smear between test and control lanes have 
made interpretation of the data difficult. This is perhaps a consequence of not 
optimising the volume of the anti-cavin-1 antibody prior to performing 
immunoprecipitation. Optimisation was not performed because of the restrictive 
cost of the cavin-1 antibody, the recommended amount (1/250, ~200µg) for an 
immunoprecipitation was used. Cavin-1 is available as an N- or C-terminally-
tagged GFP construct. As such, more informative results might be possible using 
anti-GFP antibody, which is much cheaper to optimise.   
 
As control for cavin-1 ubiquitination assays, ubiquitination of SOCS3 was assessed 
in the presence or absence of the E3 ligase complex. SOCS3 has been shown to 
be degraded concomitantly with its substrates (11,12) suggesting that formation 
of an E3 ligase complex can destabilise SOCS3.  In support of this, a SOCS3-SOCS-
box deletion mutant or mutation of Lys6 of SOCS3 stabilises the protein (97) by 
disrupting the E3-SOCS3 interaction and by preventing SOCS3 ubiquitination 
respectively. As such, it was predicted that SOCS3 would be ubiquitinated in the 
presence but not absence of the E3 complex. Furthermore, no ubiquitin-
mediated degradation was expected since cells were treated with the 
proteasome inhibitor MG132. However, the opposite ubiquitin profile was 
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detected i.e. SOCS3 was highly ubiquitinated in the absence of the E3 complex 
but less so in its presence. Furthermore, levels of SOCS3 were also reduced in 
the presence of the E3 complex suggesting that degradation took place. 
Components of the E3-complex are required in a 1:1 stoichiometry. Given that 
expression levels of the individual components were not optimised beforehand, 
reduced ubiquitination might be a consequence of incomplete formation of the 
E3-complexes. However, in this event, SOCS3 would have been predicted to be 
stabilised. As such, loss of SOCS3 might be occurring via an alternative route, 
possibly via a PEST-domain mediated route. Contrary to the destabilising effect 
of the E3-complex on SOCS3, disrupting the SOCS3-E3 interaction by tyrosine 
phosphorylation of Y204 and Y221 within the SOCS-box has also been shown to 
destabilise SOCS3 via proteasome mediated degradation (100). Perhaps, while 
unbound to the E3 complex, SOCS3 is vulnerable to phosphorylation or other 
modifying events that might target it for non-proteasome-mediated degradation.  
SOCS3 was also shown to be ubiquitinated in the absence of the E3 complex. This 
was suggested to be via endogenous components of the E3 complex. However, 
the same result was seen using the SOCS3-L189A SOCS-box mutant (Figure 6.12) 
suggesting that SOCS3 is being ubiquitinated by a different E3 ligase. Currently, 
SOCS3 is thought to perform autoubiquitination on the formation of an E3-ligase 
complex and is degraded concomitantly with its substrates (11,12). Furthermore, 
cross-regulation between SOCS family members has been demonstrated (103) 
although this data has been disputed (102). No other E3 that targets SOCS3 is 
known. This data suggests that SOCS3 might be degraded via several mechanisms 
including proteasome and proteolysis-mediated routes.  
 
SOCS3 was predicted to mediate K48-polyubiquitin-directed proteasomal 
degradation of cavin-1. As such, enhanced degradation of cavin-1 was expected 
in the presence of but not absence of SOCS3. The natural degradation of cavin-1 
was first assessed with the aim of detecting a time-point after which cavin-1 is 
significantly degraded as to be detectable via immunoblotting. This time-point 
would be expected to be reduced in the presence of SOCS3. However, the 
natural degradation of cavin-1 could not be adequately detected (Figure 6.15). 
This prevented the functional analysis of SOCS3 using this technique from being 
performed. Co-expressing SOCS3 and cavin-1 might have produced more 
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meaningful data i.e. by potentially reducing the half-life of cavin-1. However, 
this was not done due to time constraints. 
 
The role of SOCS3 in relation to cavin-1 is not understood. These data suggest 
that it might have role in the regulation of cavin-1 ubiquitination. In this role, 
SOCS3 might be induced and bind cavin-1 to regulate is function. Alternatively, 
cavin-1 might sequester SOCS3 to caveolae. Several PEST-domain-containing 
proteins have been found to be enriched in caveolae including cavin-1 and all its 
truncated forms (222). However, these truncated forms are not detected in the 
nucleus or cytosol suggesting that proteolysis occurred in situ. As such, there 
might be a connection between proteolytic regulation and targeting to caveolae 
(222). While SOCS3 was not detected in the same experiment, possibly since it is 
present at low basal levels, SOCS3 does contain a PEST domain and might be 
regulated in a similar fashion. 
 
A further hypothesis is that cavin-1 sequesters SOCS3 to caveolae to support the 
ablation of cytokine and insulin signalling. The insulin receptor and cytokine 
receptors as well as their signalling components, insulin receptor substrate-1 
(IRS-1) and JAK/STAT family members respectively, have been detected in 
caveolae (236,253). Furthermore, caveolin-1 has been described as a novel 
regulator of cytokine signalling due to its ability to inhibit prolactin-induced 
STAT5 signalling via a conserved pseudo-kinase domain (234) similar to that of 
SOCS1/3. Additionally, caveolin-1 knockout mice show prolonged activation of 
STAT3. Thus, caveolin-1 might be necessary for suppression of cytokine signalling 
in caveolae. Interestingly, siRNA knockdown of cavin-1 resulted in a reduction of 
SOCS3 levels (Paul Pilch, Boston University, personal communication) and so 
cavin-1 might therefore regulate SOCS3 stability in a similar way in which it 
regulates caveolin-1 (220). The impact of STAT3 signalling was not pursued but a 
loss of SOCS3 would also be expected to affect STAT3 signalling (70,95). 
Therefore, it might be possible that through stabilisation and/or sequestering to 
caveolae by cavin-1, SOCS3 works in concert with caveolin-1 to suppress 
cytokine signalling. Likewise, since SOCS3 regulates insulin signalling 
(9,159,160), a similar argument could be made. 
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6.4 Future prospects 
SOCS3 is an important negative regulator of pro-inflammatory signalling events 
(130,131). However, SOCS3 has been shown to have context specific effects. As 
such, overexpression of SOCS3 is protective in the case of rheumatoid arthritis 
where it acts to suppress STAT3 signalling (130). However, the specific loss of 
SOCS3 in macrophages allows an IL6-mediated IL10-like anti-inflammatory 
response, possibly by the sustained activation of STAT3 (125).  Due to the polar 
effects of SOCS3, it must be specifically targeted to be therapeutically 
beneficial. Therefore, the impact of SOCS3 on its candidate substrates must be 
assessed in various contexts to be of utility.   
 
Ultimately, the aim would be to devise strategies to specifically target SOCS3 to 
either prolong or suppress its action. Due to the transient nature of SOCS3 
expression, extending its action might be possible via inhibition of its regulators 
i.e. SOCS family members (103) or as yet unidentified E3 ligases or activation of 
cyclic-AMP/inhibition of phosphodiesterases (PDEs). Local delivery of SOCS3 
cDNA via adenovirus or liposomes has already been shown to be successful in the 
treatment of mouse models of rheumatoid arthritis and endotoxic shock 
respectively (130,131). While inhibition of SOCS3 might be useful in certain 
situations i.e. in IL6 mediated inflammatory disorders where sustaining STAT3 
signalling produces an anti-inflammatory response (125), it has not yet been 
explored. However, this might be achieved by the use of peptide or small 
molecule inhibitors aimed at the KIR and SOCS-box domains, although the global 
effect might be undesirable. Since SOCS3 is predicted to specifically interact 
with its substrates, targeting the E3-SOCS3-substrate interface might produce 
specific and desirable physiological effects. To do so would require the full 
understanding of the SOCS3-substrate interaction and its context specific role.     
 
The preliminary experiments performed here have suggested roles SOCS3 in 
relation to cavin-1 while its effects on Hsc70 and other candidate substrates 
have yet to be fully explored.  To further understand the role SOCS3 and its 
impact on its candidate substrates, further experimentation is necessary.  
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6.4.1 Cavin-1 
It was suggested that ubiquitinated cavin-1 C-terminal-domain fragments are 
enriched by SOCS3 leading to an enhanced ubiquitin signal. SOCS3 was 
hypothesised to stabilise this truncated form of cavin-1. I would like to repeat 
the ubiquitination assays using an N-terminal-GFP-SOCS3 construct. If the 
enhanced ubiquitin signal is due to the enrichment of C-terminal-domain cavin-1 
fragments, then a shift in the ubiquitin signal from 75kDa to the lower mass 
(~45kDa) would be expected. Alternatively, the same experiments could be 
performed using a series of cavin-1 N-terminal truncations. Since this data seems 
to dispute the ubiquitination of cavin-1 by SOCS3, in vitro ubiquitination assays 
should also be performed using purified components. Doing so would confirm 
such an event since it would be unaffected by outside agents. 
  
I have also shown that SOCS3 can bind cavin-1 directly using a peptide array 
approach. A reciprocal experiment must now be performed after which, the 
additional information will aid in mutational analysis of either protein to identify 
important structural domains and residues involved in the interaction. 
Furthermore, SOCS3 binding sites on cavin-1 indentified by the peptide array 
suggest a role of SOCS3 in the localisation of cavin-1. It would therefore be of 
interest to perform co-localisation experiments in WT and SOCS3-/- MEFs after 
treating with SOCS3-inducing stimuli. For example, caveolin-1, and presumably 
cavin-1 via its stabilising effect on caveolin-1, regulate several signalling events 
including cytokine (253), insulin (236), and eNOS signalling (254). It is 
hypothesised here that SOCS3 might be sequestered to caveolae in order to 
disrupt the cavin complex or ablate signalling events. Co-localisation 
experiments could therefore be extended to examine the effect of SOCS3 on 
caveolin-1/cavin-1 localisation, caveolae formation, and their impact on 
signalling events.       
6.4.2 Project summary, conclusions, and perspectives 
Using a global proteomics approach, I have been able to identify proteins that 
may potentially be targeted by SOCS3 for ubiquitination (Section 5.0). Of these, 
SOCS3 was found to interact with and regulate the ubiquitination of PTRF/cavin-
1 (Sections 6.2.3, 6.2.4, 6.2.6). However, the mechanism by which SOCS3 
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regulates cavin-1 ubiquitination or its functional outcome is not understood. 
Most candidate substrates (Table 5.1, light grey/dotted box) were not found to 
interact with SOCS3 via a co-immunoprecipitation assay, while cDNA constructs 
were not available for the others.  
 
The limited detection of candidate SOCS3 substrates can be attributed to 
inadequate experimental conditions. With hindsight, improvements could be 
made to all stages of the experimental procedure.  This includes the use of 
different SILAC isotopes (R10K8 vs. R6K6), TAP elution strategy (reduced 
temperature, on-bead trypsin digestion), and MS data analysis. Furthermore, via 
this global proteomics screen, the enhancement of ubiquitination in the 
presence of SOCS3 was analysed.  A better approach might have been to assess 
the stability of the proteome in the presence of SOCS3. This has previously been 
successfully accomplished using a similar experimental approach used here 
(215). Hör et al identified targets of an E3 ligase via MS analysis of isolated, 
SILAC-labelled membrane proteins. A similar study, if performed for SOCS3, 
would require analysis of the entire proteome. Given that down-regulation might 
occur via several mechanisms such as lysosomal and proteome-mediated 
degradation, this approach might have generated too many false-positives and 
was therefore not pursued. However, giving that too few substrates were 
identified using the current approach, this modified technique might be of 
value. Furthermore, following this screen with a secondary stage of high-
throughput analysis i.e. peptide array, yeast-2-hybrid, the list of candidates 
might be sufficiently reduced to generate a list of likely SOCS3 substrates  
 
Given that most candidates have yet to be fully verified, improved validation 
techniques (Section 6.4.1) can be applied. The role of SOCS3-cavin-1 interaction 
can also be further investigated. First, the mode of cavin-1 ubiquitination should 
be clarified. In vitro ubiquitination assays performed in the presence or absence 
of purified SOCS3 and components of the E3-ligase should be sufficient to assess 
if SOCS3 can modify cavin-1. However, immunoprecipitation of a series of cavin-
1 truncations might be able to verify if SOCS3, for whatever reason, binds and 
inhibits further ubiquitination of cavin-1 and potential cavin-1 fragments. The 
latter would suggest a novel role of SOCS3. As previously discussed, cavin-1 may 
act as a scaffold for SOCS3, targeting it to the caveolae so to regulate signalling 
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events. Equally likely is the role of SOCS3 to disrupt cavin complex although it is 
not seen how this could be beneficial. A study of the localisation of SOCS3 and 
cavin-1 could be performed using confocal microscopy and fluorescently labelled 
antibodies upon induction of SOCS3 in WT MEFs. A similar approach has been 
used to demonstrate an interaction between SOCS3 and the insulin receptor 
(160). Furthermore, information gained from full-length peptide arrays might 
enable the fabrication of cavin-1/SOCS3 mutants or peptide inhibitors that can 
be used to disrupt co-localisation and impact functionality. Recently, cavin-1 has 
been found to be downregulated in breast cancer (238), adenocarcinoma and 
squamous cell carcinoma (239), and prostate cancer cell lines PC3 and LNCaP 
(240). Moreover, expression of cavin-1 has been demonstrated to negatively 
regulate cell migration (241). As such, it would be important to assess how 
cavin-1 affects downstream signalling events and the role of SOCS3, if any, in 
these events. Furthermore, enhanced STAT3 signalling is associated with certain 
cancers such as prostate cancer (246) and loss of caveolae, due to loss of 
caveolin-1, increase JAK/STAT signalling (235). It would be of interest to assess 
how cavin-1/SOCS3 impact caveolae signalling. Multiple signalling complexes are 
recruited to caveolae such as gp130, the impact of SOCS3 on specific signalling 
events i.e. IL6, insulin, and eNOS signalling might be elucidated via a 
combination of immunoblotting cell lysates in the presence or absence of 
peptide inhibitors that disrupt the SOCS3-cavin-1 interaction.  
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